




64th ASH[®] Annual Meeting and Exposition


DECEMBER 10 – 13, 2022
NEW ORLEANS, LA



PROGRAM-AT-A-GLANCE



 **DARZALEX[®]**
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro[®]**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units



THERE'S MORE FROM MAIA

Don't miss out on the data
we're rolling out

Visit Booth #429



Scan for
clinical results

janssen 

PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

PROGRAM OF THE 64TH ANNUAL MEETING OF

AMERICAN SOCIETY OF HEMATOLOGY



December 10-13, 2022

Printed in the USA
Copyright © 2022 by the American Society of Hematology, Washington, DC
All rights reserved.



American Society of Hematology

Helping hematologists conquer blood diseases worldwide

ASH® Clinical Practice Guidelines

Evidence-based guidelines covering the prevention, diagnosis, and treatment of blood disorders.

The American Society of Hematology (ASH) Clinical Practice Guidelines support clinicians and their patients with hematologic conditions to make decisions about diagnostic and treatment options based on a systematic review of the best available evidence. The guidelines are published in ASH's open access scientific journal *Blood Advances*.

The guidelines are monitored annually for currency by experts. ASH will revise its guidelines when there is new evidence that could substantially change published recommendations.

Mobile Access to Guidelines and Pocket Guides



ASH Guidelines App: Easily access guideline recommendations from all published guidelines from the convenience of your smartphone or tablet, including complete evidence-to-decision tables.



ASH Pocket Guides App: Get interactive versions of all the Society's clinical pocket guides right on your smartphone. In addition to the pocket guides content, the app includes tools to aid in clinical decision making.

hematology.org/guidelines

Sickle Cell Disease (SCD)

- Stem Cell Transplantation
- Cardiopulmonary and Kidney Disease
- Transfusion Support
- Cerebrovascular Disease
- Management of Acute and Chronic Pain

Venous Thromboembolism (VTE)

- Treatment
- Prophylaxis in Medical Patients
- Prevention in Surgical Patients
- Diagnosis
- Anticoagulation Therapy
- Heparin-Induced Thrombocytopenia (HIT)
- Pregnancy
- Pediatrics
- Cancer
- VTE Guidelines Adapted for Latin America

Anticoagulation in Patients with COVID-19

Immune Thrombocytopenia (ITP)

Von Willebrand Disease (VWD)

- Diagnosis of von Willebrand Disease
- Management of von Willebrand Disease

Acute Myeloid Leukemia (AML)

- Treating Newly Diagnosed Acute Myeloid Leukemia in Older Adults

Coming Soon:

- Thrombophilia
- Acute Lymphoblastic Leukemia in Adolescents and Young Adults
- Amyloidosis

Table of Contents



About ASH

ASH Executive and Program Committees	5
Reviewers of Abstracts and <i>Hematology 2022</i>	8
Corporate Acknowledgements	11
Recipients of Awards	15

Guide to Navigating the Meeting

General Information	21
Diversity, Equity, and Inclusion at ASH	34
Maternal Health at ASH	37
Non-CME Sessions	39

Meeting Schedule

Day-At-A-Glance	41
-----------------	----

Invited Speaker Sessions

General Sessions	65
Special Interest Sessions	67
Trainee Activities (Open to Trainees Only)	75

continued on next page

Table of Contents

continued

Education Program

Education Sessions	81
Education Spotlight Sessions	89
How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)	91

Scientific Program

Scientific Sessions	97
Scientific Symposia	101
Scientific Spotlight Sessions	103
Scientific Workshops	105
ASH Poster Walks	109
Meet the Experts (Ticketed Sessions)	110

Abstract Sessions

Scientific Categories	113
Oral Abstract Sessions	115
Poster Presentations	123

Exhibitors

Satellite Symposia	127
Product Theaters	143
Industry Theaters	147
Company Showcases	149
Exhibitor Directory	151

AMERICAN SOCIETY OF HEMATOLOGY EXECUTIVE COMMITTEE

STAFF LIAISONS:

Martha Liggett, Esq.

E-mail: mliggett@hematology.org

Matthew Gertzog, MBA, CAE

E-mail: mgertzog@hematology.org

LaFaundra Neville-Ingram, CAP

E-mail: Ineville@hematology.org

President: Jane N. Winter, MD

President-Elect: Robert A. Brodsky, MD

Vice President: Mohandas Narla, DSc

Secretary: Cynthia E. Dunbar, MD

Treasurer: Mark A. Crowther, MD

COUNCILLORS:

Belinda Avalos, MD ('22)

Arnold Ganser, MD ('22)

Alison Loren, MD ('23)

Bob Löwenberg, MD, PhD ('23)

Sarah H. O'Brien, MD ('25)

Betty Pace, MD ('24)

Jamile M. Shammo, MD ('24)

Wendy Stock, MD ('25)

PROGRAM COMMITTEE

STAFF LIAISON:

Charles Clayton

E-mail: cclayton@hematology.org

Jane N. Winter, MD ('22) - Chairperson, President

Robert A. Brodsky, MD ('22) - Ex-Officio: President-Elect

Mark A. Crowther, MD ('22) - Ex-Officio: Treasurer

Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary

Mohandas Narla, DSc ('24) - Ex-Officio: Vice President

Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, *Blood*

Catherine M. Bollard, MD ('26) - Liaison, *Blood Advances* Editor-in-Chief

Jennifer R. Brown, MD, PhD ('23) - Liaison, Chair, Committee on Educational Affairs

Adam Cuker, MD ('23) - Liaison, Chair, Committee on Quality

Chancellor E. Donald, MD ('23) - Liaison, Chair, Committee on Practice

Christopher R. Flowers, MD ('22) - Liaison, Chair, Committee on Diversity, Equity and Inclusion

Aaron T. Gerds, MD, MS ('23) - Liaison, Editor-in-Chief, *ASH Clinical News*

Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee

Shaji Kunnathu Kumar, MD ('22) - Liaison, Editor-in-Chief Designee, *The Hematologist*

Ross Levine, MD ('22) - Liaison, Chair, Committee on Scientific Affairs

Laura Michaelis, MD ('22) - Liaison, Editor-in-Chief, *The Hematologist*

Eduardo Magalhães Rego, MD, PhD ('23) - Liaison, Chair, International Members Committee

Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, *Blood*

Mikkael A. Sekeres, MD ('22) - Liaison, Chair, Committee on Communications

Andrew S. Weyrich, PhD ('26) - Liaison, *Blood Advances* Deputy Editor

Ted Wun, MD ('22) - Liaison, Chair, Committee on Training

ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

STAFF LIAISON:

Ana Velarde

E-mail: avelarde@hematology.org

David M. Bodine, PhD ('22) - 2022 Scientific Program Co-Chair

Catherine J. Wu, MD ('22) - 2022 Scientific Program Co-Chair

David Garcia, MD ('22) - Co-Chairperson, 2022 Education Program Co-Chair

Olatoyosi Odenike, MD ('22) - Co-Chairperson, 2022 Education Program Co-Chair

Jean M. M. Connors, MD ('23) - 2023 Education Program Co-Chair

Amy E. DeZern, MD ('23) - 2023 Education Program Co-Chair

Kojo S.J. Elenitoba-Johnson, MD ('23) - 2023 Scientific Program Co-Chair

Elizabeta Nemeth, PhD ('23) - 2023 Scientific Program Co-Chair

Hanny Al-Samkari, MD ('24) - Editor, *Hematology*

Andrew Artz, MD, MS ('22) - Appointed Member

Maria "Ken" E. Figueroa, MD ('22) - Appointed Member

Lynne Kaminer, MD ('22) - Appointed Member

Allison A. King, MD, PhD, MPH ('22) - Appointed Member

Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee

Ann LaCasce, MD ('22) - Appointed Member

Janice W. Lawson, MD ('22) - Appointed Member

Thomas P. Loughran, Jr, MD ('22) - Appointed Member

Jennifer L. McNeer, MD ('22) - Appointed Member

Aaron Tobian, MD, PhD ('22) - Appointed Member

Marcin Wlodarski, MD, PhD ('22) - Appointed Member

2022 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of *Hematology 2022*, the ASH Education Program.

ASH ABSTRACTS COORDINATING REVIEWERS

Inhye E. Ahn	Curtis J. Henry	Kathryn A. Lurain	Richard Rosenquist
Jennifer E. Amengual	Daniel Herranz	Alice Ma	Rebekka K. Schneider
Daria V. Babushok	Marie Alice Hollenhorst	Sham Mailankody	Akshay Sharma
Brandon J. Blue	W. Keith Hoots	Kate A. Markey	Wendy Stock
Niccolo Bolli	Simon Husby	Rossella Marullo	Justin Taylor
Rodrigo T. Calado	Daichi Inoue	Francesco Maura	Tomomi Toubai
Cecelia Calhoun	Julie Irving	Michael Mauro	Peter JM Valk
Raynier Devillier	Tomer Itkin	Jori E. May	Peter van Galen
Bhagirathbhai Dholaria	Sawa Ito	Stephan Mielke	Mireya Paulina Velasquez
Narendranath Epperla	Graham Jackson	Siraj Mithoowani	Valeria Visconte
Karin E. Finberg	Siddhartha Jaiswal	Oreofe O. Odejide	Russell E. Ware
Craig M. Forester	Nisha S. Joseph	Zahra Pakbaz	Julia T. Warren
Ciara L. Freeman	Tapan M. Kadia	Rafal Pawlinski	Justin Watts
Jonathan M. Gerber	Thomas G. Knight	Juliana Perez Botero	Karina Yazdanbakhsh
Nilanjan Ghosh	Robert Kridel	Rachel Phelan	Joanna S. Yi
Renato Luiz Guerino-Cunha	Jatinder K. Lamba	Louise E. Purton	Amer M. Zeidan
Claire Harrison	Ola Landgren	Rachel E. Rau	
Bradley M. Haverkos	Alfred I. Lee	Eduardo M. Rego	

ASH ABSTRACTS REVIEWERS

Zaid Abdel Rahman	Maria Domenica Domenica	Meghan Drayton Jackson	Alexandra Gomez
Mouhamed Yazan Abou-Ismael	Cappellini	Martin Dreyling	Florian Grebien
Roshini S. Abraham	Hetty E. Carraway	Delfim Duarte	Damian J. Green
Maureen Okam Okam Achebe	Caterina Casari	Kieron Dunleavy	Gareth P. Gregory
Diego Adrianzen Herrera	Andre Catic	Urshila Durani	Emma M. Groarke
Aimaz Afrough	Jaroslav Cermak	Claire M. Edwards	Gregory M.T. Guilcher
Josefin Ahnstrom	Wanxing Chai-Ho	Barbara Eichhorst	Guru Subramanian Guru Murthy
Gladstone Airewele	Onyee Chan	Ann-Kathrin Eisfeld	Jonathan A. Gutman
Samer Al Hadidi	Wing C. Chan	Tarec Christoffer Christoffer	Boglarka Gyurkocza
Juan Pablo Alderuccio	Namrata Sonia Chandhok	El-Galaly	Betty K. Hamilton
P-O Andersson	Shanmuganathan	Jean Elcheikh	Alan M. Hanash
Immacolata Andolfo	Chandrakasan	Martin H. Ellis	Jakob Werner Hansen
Pantep Angchaisuksiri	Kenneth S. Charles	Laila Elsherif	Andrew Hantel
Iléana Antony-Debre	Shruti Chaturvedi	Rebecca Epperly	Tanja Nicole Hartmann
Ana G. Antun	Shih-Shih Chen	Bitia Fakhri	Rong He
Daisuke Araki	Roberto Chiarle	Bruno Fattizzo	Michael Heuser
Anthony N. Audino	Dai Chihara	Carmen Fava	Kyle J. Hewitt
Emily C. Ayers	David Coffey	Elisa Fermo	Nobuko Hijiya
Christian Babbs	Jacob Cogan	Kleber Yotsumoto Fertrin	Hideyo Hirai
Talha Badar	Yael C. Cohen	Lorena Lobo Figueiredo-Pontes	Taro Hitosugi
Sherif M. Badawy	Rachel J. Cook	Lucy C. Fox	Peter Hokland
Tamam Bakchoul	Paul Coppo	Ellen Frait	Matthew M. Hsieh
Karen K. Ballen	Stefan Cordes	Matthew J. Frank	Xiao-Jun Huang
Joao T. Barata	Raul Cordoba	Corinne Frere	Krystalyn E Hudson
Roger Belzaira	Jorge E. Cortes	Kathleen Freson	Camelia Iancu-Rubin
Neel S. Bhatt	Christine M. Cserti-Gazdewich	Nico Gagelmann	Hirotu Inaba
Senthil Velan Bhoopalan	Katherine D. Cummins	Radhika Gangaraju	Andrew M. Intlekofer
Alexander G. Bick	Emily K. Curran	Miguel Ganuza Fernandez	Andy Itsara
Amy L. Billett	Charles De Bock	Jacqueline S. Garcia	Samantha Jaglowski
Adam F. Binder	Sofia De Oliveira	Ramon Garcia-Sanz	Sangmoo Jeong
Peter Borchmann	Kim De Veirman	Ulrich Germing	Jill M. Johnsen
Arndt Borkhardt	Susan DeWolf	Mark B. Geyer	Courtney L. Jones
Robert L. Bowman	Michael W. Deininger	Paolo Ghia	Mark Juckett
Erin H. Breese	Roberta Demichelis	Paola Ghione	Moonjung Jung
Yenan T. Bryceson	Marta Derecka	Arnab Ghosh	Swetha Kambhampati
Claudia Lorena Buitrago	Sumana Devata	Alice Giustacchini	Efstathios Kastritis
Jorg Bungert	Benjamin Diamond	James Godfrey	Antonis Kattamis
Ja Min Byun	Richard Dillon	Hartmut Goldschmidt	Kerstin B. Kaufmann
Jo Caers	Chancellor E. Donald	Kandace Gollomp	Dickran Kazandjian

Gina Keiffer
 Saad S. Kenderian
 Michael Keng
 Eugene Khandros
 Miriam Y. Kim
 Sandrina Kinet
 Bérengère Koehl
 Divya Koura
 Motoko Koyama
 Giedre Krenciute
 Vishal Kukreti
 Austin Kulasekararaj
 Anita Kumar
 Shekhar Kumar
 Daisuke Kurotaki
 Catherine Lai
 Bernhard Lammler
 Karilyn T. Larkin
 Sarah Larson
 Elisa Laurenti
 Allison Barz Leahy
 Catherine J. Lee
 Stanley Chun-Wei Lee
 Claudia Lengerke
 Jessica Leonard
 Harry Lesmana
 Sheng Li
 Richard J. Lin
 Andrew H. Lipsky
 Daihong Liu
 Hien D. Liu
 Hongtao Liu
 Qifa Liu
 Kah Poh (Melissa) Loh
 Rui Lu
 Jennifer Kimberly Lue
 Tiago C. Luis
 Troy C. Lund
 Advaita Madireddy
 Silvia Maria Meira Magalhaes
 Nadim Mahmud
 Harry L. Malech
 Luis Enrique Malpica Castillo
 Maksim Mamonkin
 Salomon Manier
 Gabriel N. Mannis
 Kate Manos
 Bridget K. Marcellino
 Enrica Marchi
 Guido Marcucci

Anna E. Marneth
 Maria Paola Martelli
 Thomas Martin
 Matthew J. Matasar
 Masanori Matsumoto
 Kathy McGraw
 Catherine E. McGuinn
 Zoe McQuilten
 Hrishikesh M. Mehta
 Afua Adjeiwaa Mensah
 Maximilian Merz
 Lekha Mikkilineni
 Hanna Mikkola
 Filippo Milano
 Alice S. Mims
 Eliana C. M. Cristina Martins
 Miranda
 Yasushi Miyazaki
 Ghulam Rehman Mohyuddin
 Patrizia Mondello
 Eugenio Montini
 Eugenio Morelli
 Gareth J. Morgan
 Marek Mraz
 Martha-Lena Mueller
 Nicola J. Mutch
 Markus Müschen
 Satish Nandakumar
 Sunita Nathan
 Marquita Nelson
 Andreas Neubauer
 Dang Hai Nguyen
 Florence Nguyen-Khac
 Taiga Nishihori
 Zohra Nooruddin
 Fofulso Joy Ogunbile
 Rebecca L. Olin
 Olalekan O. Oluwole
 Olubusola Oluwole
 Victor M. Orellana-Noia
 Joseph H. Oved
 Sandhya Panch
 Nicki Panoskaltis
 Anna L. Parks
 Sant-Rayn Pasricha
 Freda H. Passam
 Ami B. Patel
 Dilan Anil Patel
 Shyam Ajay Patel
 Melinda Pauly

Fabiana Perna
 Florian Perner
 Aurore Perrot
 Anamarija M. Perry
 Christine L. Phillips
 Yana Pikman
 Sandra Pinho
 Steven W. Pipe
 Nicola Polverelli
 Mortimer Poncz
 Matthew H. Porteus
 Tirthadipa Pradhan-Sundd
 Bethan Psaila
 Ching-Hon Pui
 Dražen Pulanić
 Muna Qayed
 Chittalsinh Raulji
 Patrick M. Reagan
 Michele S. Redell
 Andreas Reiter
 Raffaele Renella
 Suely M. Rezende
 Katy Rezvani
 Joanna Robles
 Lindsey E. Roeker
 Kerry A. Rogers
 Laura Rosinol Dachs
 Adriana Rossi
 Lisa Giulino Roth
 Giovanni Roti
 Alicia Rovo
 Jacob M. Rowe
 Robert Grant Rowe
 Anindita Roy
 Jeremy Rubinstein
 Giovanna Russo
 Sarah C. Rutherford
 Brooke Sadler
 Shella Saint Fleur-Lominy
 Ioanna Sakellari
 Bethany T. Samuelson Bannow
 Mehmet K. Samur
 Takaomi Sanda
 Kristen M. Sanfilippo
 David Sanford
 Veena Sangkhoe
 Santosh L. Saraf
 Jean-Emmanuel Sarry
 Goro Sashida
 Jennifer N. Saultz

Yazeed Sawalha
 Jordan K. Schaefer
 Gary J. Schiller
 Martin Schrappe
 David W. Scott
 Craig D. Seaman
 Bijal D. Shah
 Urvi A. Shah
 Aditi Shastri
 Joseph J. Shatzel
 Sujit Sheth
 Kristin A. Shimano
 Roni Shouval
 Federico Simonetta
 B. Douglas Douglas Smith
 Melody Smith
 Pieter Sonneveld
 Marcel Spaargaren
 Philipp B. Staber
 Tatjana Stankovic
 Robert M. Stern
 Anna Sureda
 Raphael Szalat
 Natasha Szuber
 Ali T. Taher
 Koichi Takahashi
 Aimee C. Tailleu
 Hwei-Fang Tien
 Douglas Tremblay
 Celine M. Vachon
 Karin Vanderkerken
 Cindy Varga
 Ingrid Verhamme
 Luis Mario Villela-Martinez
 Ly P. Vu
 Diane Ward
 Katja C. Weisel
 Kamille West-Mitchell
 Hope P. Wilson
 Nicole Wong Doo
 Gary Woods
 Julia Z. Xu
 Deborah Yallop
 J. Christine Ye
 David T. Yeung
 Musa Yilmaz
 David J. Young
 Joanna Zurko

HEMATOLOGY 2022 REVIEWERS

Anjali S. Advani
 Ranjana Advani
 Cem Akin
 Monzr M. Al Malki
 Aref Al-Kali
 Frederick Appelbaum
 Eugenia Vicky Asare
 K. Scott Baker
 Paul M. Barr
 Nancy L. Bartlett
 Renato Bassan
 Shannon Bates
 Lisa Baumann Kreuziger
 Rafael Bejar
 Jesus G. Berdeja
 Smita Bhatia
 Andrea Biondi

Larissa Bornikova
 Jennifer R. Brown
 Natalie S. Callander
 Gunnar Cario
 Shannon Carpenter
 Marc Carrier
 Giancarlo Castaman
 Eric J. Chow
 Adam D. Cohen
 Claudia S. Cohn
 Nathan T. Connell
 Jorge Cortes
 Charles Craddock
 Stacy E. Croteau
 Adam Cuker
 Corey S. Cutler
 Agnieszka Czechowicz

Anita D'Souza
 Alexey V. Danilov
 Faith E. Davies
 Amy E. DeZern
 Sunny H. Dzik
 Yvonne A. Efebera
 Matthew Ehrhardt
 Toby Andrew Eyre
 Joshua Field
 Courtney D. Fitzhugh
 Christopher R. Flowers
 Annemarie E. Fogerty
 Jacqueline S. Garcia
 James N. George
 Tracy I. George
 Irene M. Ghobrial
 Gerald J. Gleich

Victor R. Gordeuk
 Jed B. Gorlin
 Jason Gotlib
 Erin M. Guest
 Sumit Gupta
 Sandra L. Haberichter
 Claire N. Harrison
 Andreas Hochhaus
 Timothy P. Hughes
 Ibrahim Musa Idris
 Tania Jain
 Andra H. James
 Paula D. James
 Jill M. Johnsen
 Moonjung Jung
 Brad S. Kahl
 Julie Kanter

2022 REVIEWERS

Raj S. Kasthuri
Richard Kaufman
Alok A. Khorana
Adam S. Kittai
Jan-Henning Klusmann
Rami S. Komrokji
John Koreth
Johanna A. Kremer Hovinga
Amrita Y. Krishnan
Michael H. Kroll
Rebecca Kruse-Jarres
Roshni Kulkarni
Kevin H.M. Kuo
John Kuruvilla
David J. Kuter
Andrew T. Kuykendall
Ola Landgren
Alfred I. Lee
Lai Heng Lee
Howard Allen Liebman
R. Coleman Lindsley
Sagar Lonial
Izidore S. Lossos

Kami Maddocks
Paul Mansfield
John O. Mascarenhas
Michael J. Mauro
Eileen Grace Merriman
Reid W. Merryman
Joseph Mikhael
Alice S. Mims
Alison J. Moskowitz
Kasiani C. Myers
Loretta J. Nastoupil
Robert S. Nickel
Omar Niss
Kristen M. O'Dwyer
Adam Jan Olszewski
Monica B. Pagano
Lydia H. Pecker
Kristen M. Pettit
Tycel Jovelle Phillips
Allyson Pishko
Jerald P. Radich
Delphine Rea
Josep-Maria Ribera

Paul G. Richardson
Jacob M. Rowe
Jeffrey E. Rubnitz
Sana Saif Ur Rehman
David A. Sallman
Kristen Sanfilippo
Santosh L. Saraf
Sharon A. Savage
Farzana Sayani
Mikkael A. Sekeres
Nina Shah
Urvi A. Shah
Joseph J. Shatzel
Bronwen E. Shaw
Shalini Shenoy
Nicholas J. Short
Sonali M. Smith
Gerald A. Soff
Stephen R. Spellman
Sarah K. Tasian
Jeffrey W. Taub
Philip A. Thompson
Darrell J. Triulzi

Suzanne Trudel
Lucie M. Turcotte
Geoffrey L. Uy
Emile Van Schaftingen
Sumithira Vasu
Tzu-Fei Wang
Jonathan Webster
Oliver Weigert
Matthew J. Wieduwilt
Tanya Wildes
Raymond Siu Ming Wong
Jennifer C. Yui

2022 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 19, 2022.

2022 ASH Annual Meeting Foundation Run/Walk Supporters

PREMIER

AstraZeneca

Biomea Fusion, Inc

Gilead and Kite Oncology

Global Blood Therapeutics/Pfizer

GSK

ImmunoGen, Inc.

Syndax Pharmaceuticals

LEAD

AbbVie

Seagen Inc.

2022 ASH Annual Meeting Education Supporters

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2022 ASH Annual Meeting:

Hematology 2022: The Education Program

AstraZeneca

GSK

Jazz Pharmaceuticals, Inc.

Merck & Co., Inc.

Novartis Pharmaceuticals

General Education Grant

AbbVie

AstraZeneca

GSK

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Lilly USA, LLC

Merck & Co., Inc.

Novartis Pharmaceuticals

Pfizer Inc.

Syndax Pharmaceuticals Inc.

2022 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 19, 2022.

2022 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

AbbVie
Agius Pharmaceuticals Inc.
Astellas Pharma US, Inc.
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Forma Therapeutics, Inc.
Global Blood Therapeutics/Pfizer Inc.
Graphite Bio
Illumina, Inc.
Imara
Janssen Scientific Affairs, LLC
Kite Pharma Inc.
Novartis Pharmaceuticals
Pharmacyclics LLC
Syneos Health
Vertex Pharmaceuticals Incorporated

2022 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2022 Annual Meeting:

AbbVie ASH Alexa ASH Wellness Studio Theater	Gamida Cell Mobile Device Charging Stations
Astellas Pharma US, Inc. Mobile Device Charging Stations	Gilead and Kite Oncology Internet Stations and Wi-Fi
AstraZeneca Exhibit Hall Aisle Signs Hand Sanitizing Stations	GSK ASH Hotel Door Drop Bag Mobile Device Charging Stations
Daiichi Sankyo, Inc. Hydration Stations Mobile App Mobile Device Charging Stations PosterCast	Janssen Biotech, Inc. Coat and Bag Check Headshot Alley
Eli Lilly and Company Photo Zone and Social Media Wall	ONO Pharma USA, Inc. Protection Kit Stations
	Sanofi ASH Wellness Studio – Yoga Hand Sanitizing Stations

2022 ASH Award Supporters

2022 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 19, 2022.

ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Minority Recruitment Initiative and Scholar Award programs:

AstraZeneca
Bristol Myers Squibb
Janssen Biotech, Inc.
Merck & Co., Inc.
Novartis Pharmaceuticals
Pharmacyclics LLC

2022 ASH Global Initiatives

ASH would like to acknowledge and thank the following companies and foundation for supporting ASH's international consortia:

Consortium on Newborn Screening in Africa

Novartis
PerkinElmer

International Consortium on Acute Leukemia

Torsten Haferlach Leukemia Diagnostics Foundation
Illumina

2022 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy initiatives throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:

PREMIER CIRCLE

Pfizer, Inc.
Regeneron Pharmaceuticals

PARTNER CIRCLE

AstraZeneca
Bristol Myers Squibb
Kite, a Gilead Company
Eli Lilly and Company
Takeda
Vertex Pharmaceuticals

2022 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 19, 2022.

ADVOCATE CIRCLE

Agios Pharmaceuticals

Amgen

Astellas

Genentech

GSK

Janssen Oncology

Merck & Co, Inc.

Pharmacyclics LLC

Sanofi

INSIDER CIRCLE

Atara Biotherapeutics, Inc.

bluebird bio

Graphite Bio

Kura Oncology

Omeros Corporation

Orca Bio

Rigel Pharmaceuticals

2022 ASH Health Equity Collective

The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH's work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:

Daiichi Sankyo

GSK

Janssen Oncology

Novartis

Pfizer, Inc.

Sanofi

Taiho

Vertex Pharmaceuticals

RECIPIENTS OF AWARDS

WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

2022	Irving Weissman	2016	Thalia Papayannopoulou	2010	Volker Diehl
2021	Harvey Lodish	2015	Aaron Marcus	2009	H. Franklin Bunn
2020	Mohandas Narla	2014	Kanti Rai	2008	Robert Kyle
2019	Richard H. Aster	2013	Sir David John Weatherall	2007	Ernest Beutler
2018	Victor Hoffbrand	2012	James George		
2017	Marshall A. Lichtman	2011	David G. Nathan		

ERNEST BEUTLER LECTURE AND PRIZE

2022	John Atkinson and Peter Hillmen	2017	Luigi Naldini and Marina Cavazzana	2012	Bruce R. Blazar and Carl H. June
2021	Margaret Shipp and Stephen Ansell	2016	Hugues de Thé and Zhu Chen	2011	Janet D. Rowley and Brian J. Druker
2020	Courtney DiNardo and Ari Melnick	2015	Alfred Goldberg and Paul Richardson	2010	Barry S. Coller and Joel S. Bennett
2019	Sriram Krishnaswamy and Jeffrey I. Weitz	2014	Michael R. DeBaun and Robert P. Hebbel	2009	Yuet Wai Kan and Thomas Maniatis
2018	Alan D'Andrea and Neal Young	2013	Kenneth Kaushansky and David J. Kuter		

E. DONNALL THOMAS LECTURE AND PRIZE

2022	Bruce Blazar	2011	George Q. Daley	2000	David Ginsburg
2021	Connie Westhoff	2010	Leonard I. Zon	1999	Irving Weissman
2020	Toshio Suda	2009	John E. Dick	1998	Stuart H. Orkin
2019	Philip D. Greenberg	2008	Neal S. Young	1997	Robert Rosenberg
2018	Connie J. Eaves	2007	Hal Broxmeyer	1996	Stanley Korsmeyer
2017	James R. Downing	2006	E. Richard Stanley	1995	Charles Esmon
2016	David Scadden	2005	Rainer Storb	1994	Thomas P. Maniatis
2015	Barbara C. Furie and Bruce Furie	2004	Donald Metcalf	1993	Thomas P. Stossel
2014	Tomas Ganz	2003	Ernest Beutler	1992	Stuart Kornfeld
2013	Katherine A. High	2002	Kenneth Mann		
2012	Timothy J. Ley	2001	Samuel E. Lux, IV		

WILLIAM DAMESHEK PRIZE

2022	Irene Ghobrial	2003	Gary Gilliland	1989	Samuel E. Lux IV
2021	Elizabetha Nemeth	2002	Catherine Verfaillie	1988	Theodore S. Zimmerman
2020	Adolfo Ferrando	2001	Brian Druker	1987	Charles Sherr
2019	Emmanuelle Passegué	2000	David A. Williams	1986	Stuart Orkin
2018	Ross L. Levine	1999	Salvador Moncada	1985	Thomas F. Deuel
2017	Benjamin L. Ebert	1998	J. Evan Sadler	1984	Barbara C. and Bruce Furie
2016	Charles Mullighan	1997	Björn Dahlbäck	1983	Thomas P. Stossel
2015	John Byrd	1996	Kenneth Kaushansky	1982	Janet D. Rowley
2014	Scott Armstrong	1995	James Ihle	1981	Philip W. Majerus
2013	Andrew Weyrich	1994	George J. Broze, Jr.	1979	Yuet Wai Kan
2012	Margaret A. Goodell	1993	Owen Witte	1978	Robert D. Rosenberg
2011	Christoph Klein	1992	Richard D. Klausner	1977	Yale Nemerson
2010	David T. Scadden	1991	Makio Ogawa	1976	Robert I. Weed
2009	Louis M. Staudt	1990	Thalia Papayannopoulou and George Stamatoyannopoulos	1975	Charlotte Friend
2008	Kenneth Anderson			1974	Robert C. Gallo
2007	William Vainchenker				
2006	Riccardo Dalla-Favera				
2005	John Dick				
2004	Ronald Levy				

RECIPIENTS OF AWARDS

ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2022	James Gavin and David Wilkes	2020	Edward J. Benz Jr.	2018	Cage S. Johnson and José A. López
2021	Deepika Darbari	2019	Griffin P. Rodgers	2017	Betty Pace

HENRY M. STRATTON MEDAL

2022	Timothy Ley and Robert Montgomery	2014	Geraldine Schechter and Timothy Springer	2003	Janet Rowley
2021	Kwaku Ohene-Frempong and Denisa Wagner	2013	Nancy Andrews and Elaine Jaffe	2002	George Stamatoyannopoulos
2020	Maria Domenica Cappellini and Michelle Le Beau	2012	Richard Aster and David Ginsburg	2001	Harold R. Roberts
2019	William Allen Eaton and Richard A. Larson	2011	Ching-Hon Pui	2000	H. Franklin Bunn
2018	Brunangelo Falini and Freda K. Stevenson	2010	Sanford Shattil	1999	Helen Ranney
2017	Josef Tomas Prchal and Sherrill J. Slichter	2009	Connie Eaves	1998	Arthur W. Nienhuis
2016	J. Evan Sadler and Ayalew Tefferi	2008	Clara Bloomfield	1997	Rainer Storb
2015	Nancy Speck and Karl Welte	2007	Carlo Croce	1996	Bernard Forget
		2006	Jack Hirsh	1995	David Nathan
		2005	Barry Coller	1994	Titus H.J. Huisman
		2004	Stanley Korsmeyer	1993	Earl W. Davie
				1992	Kenneth G. Mann

HENRY M. STRATTON LECTURE (1970-1991)

1991	Ralph L. Nachman	1983	Eugene P. Cronkite	1975	E. Donnal Thomas
1990	Malcolm Moore	1982	Ernest A. McCulloch	1974	Ernest Beutler
1989	Aaron J. Marcus	1981	Clement A. Finch	1973	Albert S. Gordon
1988	Robert S. Schwartz	1980	Yuet Wai Kan	1972	Oscar D. Ratnoff
1987	Robert C. Gallo	1979	Henry S. Kaplan	1971	H.G. Kunkel
1986	Bernard Babior	1978	William N. Valentine	1970	W.R. Bruce
1985	Vincent DeVita	1977	Thomas A. Waldmann		
1984	Samuel Rapaport	1976	Wendell F. Rosse		

ASH MENTOR AWARD

2022	Michael Caligiuri and Christopher Flowers	2016	Laurence Boxer and Ralph L. Nachman	2010	Mary M. Horowitz and Harvey F. Lodish
2021	Anthony Goldstone and Jonathan Licht	2015	Curt Civin and Craig Kitchens	2009	Arthur Nienhuis and Stuart H. Orkin
2020	Judith Gasson and Wendy Stock	2014	Grover C. Bagby Jr. and John F. DiPersio	2008	George R. Buchanan and Timothy J. Ley
2019	Michael R. DeBaun and Leonard I. Zon	2013	John Adamson and Stanley Schrier	2007	Edward J. Benz Jr and Harold R. Roberts
2018	John E. Dick and Reed E. Drews	2012	Beverly S. Mitchell and Rainer F. Storb	2006	Samuel E. Lux and Deane F. Mosher
2017	Ronald Hoffman and Oliver W. Press	2011	Nancy C. Andrews and Malcolm K. Brenner		

ABSTRACT ACHIEVEMENT AWARDS

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

UNDERGRADUATE STUDENT

Nina Shaver
Georgia Institute of Technology

MEDICAL STUDENT

Varun Sudunagunta, BA
Columbia University

GRADUATE STUDENT

Alexandra Preston
University of Oxford

RESIDENT PHYSICIAN

Lauren Meyer, MD, PhD
University of Washington

POST-DOCTORAL FELLOW

Richard Voit, MD, PhD
Harvard Medical School

ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

Niels Asger Jakobsen, BM, BCh, MRCP
University of Oxford

Anna Santarsieri, MBBS
Cambridge University Hospitals

Shuchi Agrawal Singh, PhD
Cambridge Institute for Medical Research

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Sofia Toribio Castello, MSc
Universidad de Salamanca

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

Chanukya Colonne, MBBS, PhD
University of Sydney

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Carmelo Gurnari, MD
University of Rome

Naomi Kawashima, MD, PhD
Cleveland Clinic Foundation

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Shinpei Harada
Hokkaido University Faculty of Medicine

Yuta Yamada, MD
The University of Tokyo

Takao Yogo, MD
The University of Tokyo

ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Giovanni Marconi, MD
IRCCS Istituto Scientifico

Laura Notarfranchi, MD
University of Parma

JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Aaron Viny, MD
Columbia University

ABSTRACT ACHIEVEMENT AWARDS

MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand's disease.

Sean Quinn, PhD

Children's Hospital of Philadelphia

MINORITY GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based Minority Graduate Student Abstract Achievement Awards to select graduate students to acknowledge the accomplishments of and recruit and retain minority graduate students in the field of hematology.

Kemi Akinnola

Albert Einstein College of
Medicine

Sergio Barajas

Indiana University School of
Medicine

Claudia Cabrera

Washington University in Saint
Louis

Richard Marrero

University of Florida

Nicole Arellano

The University of Chicago

Ariel Blakey

Boston University

Luis Correa

University of Michigan

Carlos Munoz

University of California, San Diego

Ginette Balbin-Cuesta

University of Michigan

Giovanni Botten

The University of Texas
Southwestern

Caroline Kuczynski

Wake Forest School of Medicine

Rolando Vedia

The University of Texas, MD
Anderson Cancer Center

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year's Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Minaam Abbas

Maya Abdallah

Diana Abraham

Faris Abu Za'nouneh

Tareq Abuasab

Puneet Agarwal

Owhofasa Agbedia

Nidhi Aggarwal

Shreya Agrawal

Shuchi Agrawal Singh

Sergio Aguilar

Luis Aguirre

Louise Ahlgren

Salsabil Ahmed

Roberto Aiolfi

Yu Akahoshi

Sumaiya Alam

Haya Al-Ansari

Jean-Baptiste Alberge

Waleed Alduaij

Faris Ali

Stefan Alig

Fatemeh Alikarami

Syeda Ally

Norah Alnegheimish

Anfal Alsadhan

Emmanuela Ambrose

Sarah Aminov

Zhuo-Yu An

Joshua Anil

Annamaria Aprile

Ferran Araujo-Ayala

Christopher Arends

Maare Arffman

Nancy Arthur

Bimarzhan Assatova

Himachandana Atluri

Rebecca Austin

Jonathan Avery

Batia Avni

Shady Awad

Hussein Awada

Franziska Baatz

Rory Bade

Waled Bahaj

Kayla Baker

Natasha Bala

Aria Bales

Somedeb Ball

Suzy Bangudi

Bella Banjanin

Alicia Bao

Daniela Barbieri

Barbara Barion

Marine Baron

Anais Barthe

Anthony Battram

Abdul-Hamid Bazarbachi

Alexandre Bazinet

Nana Adjoa Ben-Crentsil

Josh Bennett

Eduardo Benzi

Daniel Berger

Philipp Berning

Eline Bertrums

Jan Bewersdorf

Rahul Bhansali

Pawan Bhat

Giulia Bianchi

Sarah Bird

Lara Bischof

Hassan Bjeije

Franziska Blaeschke

Joshua Bomsztyk

Christopher Booth

Roisin Borrill

Giovanni Botten

Eileen Boyle

Lisa Brandmeier

Lara Breyer

Jennifer Brown

Maura Bueno

Ayesha Butt

Poojitha Byreddy

Angelo Cabal

Xuan Cai

Martina Calabro

Ismail Can

Lei-Ming Cao

Gabriele Casirati

Gianluca Cavallaro

Laura Ceja Ramirez

Eliska Ceznerova

Mousumi Chakraborty

Courtney Chambers

Reem Chamseddine

Fiorella Charles Cano

Lei Chen

Zhenhua Chen

Chuan Chen

Wanshu Chen

Xiaomin Chen

Qi Chen

Zhaoqi Chen

Manling Chen

Changan Chen

Michelle Chin

Benjamin Chin-Yee

Monika Chojnacka

Fabliha Chowdhury

Anthos Christofides

Yuroou Chu

Bernadette Anne Chua

Jean-Sebastien Claveau

Patricia Colom Diaz

Anna Maria Corsale

Kadriye Cosgun

Amanda Costa

Krysta Coyle

Christina Croussette-Thambiah

Stephanie Crowley

Nataly Cruz-Rodriguez

Xiaojing Cui

Jian Cui

Tyler Cunningham

Gandhar Datar

Ryan Day

Jonathan Day

Fleur De Groot

Alejandro De Janon

Madelon de Jong

A. Vera de Jonge

Romy de Laat-Kremers	Fernando Gil Lopez	Dongxu Jiang	Sarah Lindner
Demi de Winter	Payal Goala	Aisha Jibril	Szumam Liu
Salome Decombis	Max Gordon	Jin Jin	Jiye Liu
Simone Dekker	Jaymeson Gordon	Dylan Jochum	Qiang Liu
Julien Delobel	Erica Gotardo	Isla Johnson	Lawrence Liu
Frederik Denorme	Doriana Gramegna	Astrun Jonsdottir	Feng-Qi Liu
Sara-Maude Desforges	David Granadier	Julia Joo	Xiaoyu Liu
Sai Prasad Desikan	Verena Gress	Maxime Jullien	Yingyue Liu
Aditi Dey	Nora Grieb	Nuzhat Kabir	Min Yen Lo
Francesco Di Meo	Matthew Gromowsky	Radoslaw Kaczmarek	Marissa Locastro
Nicolas Di Siervi	Steven Grover	Ilija Kalashnikov	Alberto Lopez
Daisy Diaz Rohena	Amaliris Guerra	Takahiro Kamiya	Yadith Lopez-Garcia
Danai Dima	Camila Guerrero	Adam Kanack	Matthew Lordo
Mengfei Ding	Annamaria Gulla	Hyndavi Kandala	Kevin Lu
Celia Dobano-Lopez	Elizabeth Gunn	Chiraag Kapadia	Danny Luan
Haojie Dong	Li Guo	Nilesh Kapoor	Sofie Lundgren
Sharlene Dong	Mihir Gupta	Yuta Katai	Xiurui Lv
Julia Driessen	Kristian Gurashi	Alana Keller	Liemei Lv
Mengbao Du	Carmelo Gurnari	Tariq Kewan	Walid Macaron
Meghna Dua	Aishwarya Gurumurthy	Timothy Keyes	Eduardo Magalhaes
Olli Dufva	Sarah Haebe	Faizan Khan	Harinad Maganti
Romane Durand	Karina Hamamoto	Abdullah Khan	Elias Mai
Marti Duran-Ferrer	Yang Han	Abdul Moiz Khan	Catarina Maia
Arda Durmaz	Hailey Harris	Shrijan Khanal	Kamal Mandal
Jibran Durrani	Alice Hart	Reham Khedr	William Mannherz
Ankit Dutta	Sascha Haubner	Wannakorn Khopanlert	Xinjian Mao
Macy Early	Fan He	Joseph Kim	Francisco Marchi
Nathan Eaton	Chunxiao He	Taehyung Kim	Anna Marneth
Jakoba Eertink	Tayla Heavican-Foral	Min Young Kim	Jasmin Martin
Dana Egan-Sherry	Moutaz Helal	Katherine Knorr	Grace McAuley
Theresa Eifert	Andrea Priscila Hernandez Perez	Trine Knudsen	John McClatchy
Irem Eldem	Alberto Hernandez Sanchez	Camille Kockerols	Cameron McDonald-Hyman
Alexandra Elias	Kristina Hinman	Shuhei Koide	Dylan McNally
Hannah Elkus	Dalton Hironaka	Tim Kong	Dino Mehic
Julius Enssle	Michael Hochman	Tiago Koppe	Yihan Mei
Daniel Ermann	Angus Hodder	Charlotte Korst	Ashley Melnick
Carolin Escherich	Jackson Hoesley	Joseph Kramps	Johanna Melo-Cardenas
Isaac Esplin	Fieke Hoff	Frederike Kramer	Jonny Mendoza-Castrejon
Brian Estrella	Davine Hofste op Bruinink	Stefanie Kreutmair	Gao Mengge
Purushoth Ethiraj	Alex Hoover	Benjamin Kroger	Leo Meriranta
Catherine Falkenstein	Hitomi Hosoya	Veronika Kropackova	Nicole Michmerhuizen
Laetitia Faye	Chen-Jen Hsu	Deepak Kumar	Adrian Minson
Jingjing Feng	Xinting Hu	Luisa Ladel	Abu-Sayeeff Mirza
Kyle Ferchen	Shunfeng Hu	Barbara Lam	Jayna Mistry
Christopher Ferreri	Qiu-Sha Huang	Niklas Landberg	Safa Mohamad
Warren Fingrut	Stephanie Hurwitz	Joshua Lara	Razan Mohty
Sydney Fobare	Simon Husby	Sonia Laurie	Florian Moik
Helen Fogarty	Angela Huynh	Corinne Lavasseur	Patrizia Mondello
Cathelijne Fokkema	Jonathan Hyak	Bao Le	Skye Montoya
Raghda Fouda	Daisuke Ikeda	Duy Le	Eugenio Morelli
Lucie Freiman	Raveen Illangeswaran	Shawn Lee	David Moreno
Stephanie Frenz	Anagha Inguva	Jaewoong Lee	Anna Sophia Moret
Mirco Friedrich	Filip Ionescu	Byung-Chul Lee	Takuto Mori
Moritz Furstenuau	Colleen Isabelle	Jamie Lee	Bettina Nadorp
Hope Fury	Takashi Ishida	Camilla Lemvigh	Aishath Naeem
Nico Gagelmann	Chiharu Ishikawa	Lennart Lenk	Keiki Nagaharu
Ashley Galvin	Yuta Ito	Yang Li	Patrice Nasnas
Irene Ganan-Gomez	Zalaya Ivy	Rong Li	Amin Nassar
Saravanan Ganesan	Varun Iyengar	Yizhen Li	Karthik Nath
Ya-Juan Gao	Carine Jaafar	Huihui Li	Suzanne Neppelenbroek
Filip Garbicz	Bruna Jacintho	Na Li	Austin Newsam
Beatriz Garcia-Torre	Othmane Jadi	Emily Liang	Lok Lam Ngai
Andrea Garofalo	Akriti Jain	Huang-Chang Liang	Aithanh Nguyen
Georgina Gener-Ricos	Nikeshan Jeyakumar	Ruiqi Liao	Arman Niknafs
Gaia Gentile	Vishwanath Jha	Elizabeth Lightbody	Masashi Nishikubo
Guido Ghilardi	Zhilian Jia	Keli Lima	Troy Noordenbos

ABSTRACT ACHIEVEMENT AWARDS

Michael Northend	Abigail Rich	Harshini Sriram	Bo Wan
Brittany Notice	Ana Rio-Machin	Karan Srisurapanont	Dandan Wang
Jessica Nunes	Elena Riva	Daniel Srole	Xiujian Wang
Petra Nygren	Troy Robinson	Alexander Stanisic	Shuwen Wang
Anjali Oberoi	Hope Robinson	Sara Stefani	Lisa Wang
Cristiana O'Brien	Luis Gerardo Rodriguez-Lobato	Simon Steiger	Ying Wang
Kevin O'Connor	Margot Roeten	Maximilian Steinhart	Xianhuo Wang
Olisaemeka Ogbue	Lisa Rohrbacher	Dominique Sternadt	Huafeng Wang
Ayobami Olanrewaju	Gabriel Roman Souza	Anna Sternberg	Trisha Wathan
Anne Olazabal Herrero	James Ropa	Carli Stewart	Isabel Weinhaeuser
Jose Oliveira	Milad Rouhimoghadam	Lucille Stuani	Chase West
Olubusola Oluwole	Fernanda Roversi	Robert Stuver	Ethan Whipp
Faustine Ong	Danielle Roy	Shruthi Subramanian	Anna Whitehead
Anna Østergaard	Gordon Ruan	Takeshi Sugio	Kyle Wiatrowski
Jad Othman	Leo Ruhnke	Fumou Sun	Caroline Wiggers
Inge Oudaert	Xianliang Rui	Lu Sun	Alexis Williams
Michael Ozga	David Russler-Germain	Divya Sundar	Katharina Wohlan
Sandeep Padala	Christine Ryan	Arvind Suresh	Henry Wood
Dakshin Padmanabhan	Joseph Saad	Yutaro Suzuki	Faeben Wossenseged
Aswin Pai	Sushree Sahoo	Connor Sweeney	Shang-Chuen Wu
Garima Pandey	Reona Sakemura	Emily Symes	Gongwei Wu
Sun Park	Marianna Salinas	Cristian Taborda	Jin Wu
Kanak Parmar	Nina Samuel	Sabrin Tahri	Ye-Jun Wu
Salma Parvin	Anna Santarsieri	Shuichiro Takahashi	Erik Wu
Erica Pascetti	Martina Sarchi	Erika Tarasco	Zhengrui Xiao
Helene Pasquer	Akihiro Sawa	Lara Tavernari	Tingting Xie
Ruchi Patel	Lama Sawalha	Trisha Tee	Leling Xie
Vivek Patel	Caner Saygin	Elisa Ten Hacken	Jane Xu
Kanisha Patel	Ann-Kristin Schmalter	Phaik Ju Teoh	Jason Xu
Richard Pelzl	Haley Schmidt	Toshiki Terao	Hulya Yilmaz
Claudia Perez Carretero	Walker Schmidt	Jesse Tettero	Tomohiro Yabushita
Megan Perrett	Constanze Schneider	Santiago Thibaud	Noritaka Yada
Luiza Perucci	Tina Schnoeder	Erik Thiele Orberg	Adam Yan
Michael Pfeffer	Joseph Schroers-Martin	Nicole Thomas	Yitong Yang
Lisa Pfeuffer	David Scott	Toby Thomas	Chong Yang
Keir Pickard	Jayla Scott	Rachelle Thompson	Li-Ping Yang
Andrea Piolatto	Yuichiro Semba	Sigrun Thorsteinsdottir	Yanki Yarman
Heribert Playa-Albinyana	Jayastu Senapati	Remi Tilmont	Rashmi Yawalkar
Andrea Poletti	Hajime Senjo	Molly Tokaz	Aditya Yelamali
Grace Power	Julieta Sepulveda Yanez	Lidiane Torres	Takao Yogo
Landon Power	Katie Seu	Kathryn Tringale	Masanori Yoshida
Edward Poynton	Amy Sexauer	Billy Truong	Hongyin Yu
Shravani Prakhya	Rushil Shah	Peter Truong	Tengteng Yu
Alessandra Prezotti	Mohamed Shahin	Jonathan Tsai	Helena Yu
Raja Prince	Haroon Shaikh	Brandon Tse	Haixiang Yu
Jessica Pritchard	Malini Sharma	Sven Turkalj	Yanying Yu
Kemar Prussien	Victoria Shelton	Anudishi Tyagi	Zhuoya Yu
Adnan Qamar	Lilia Shen	Caden Ulschmid	Jessica Zalapa
Jialei Qi	Angela Sheng	Kelsey Uminski	Linda Zhang
Qingyuan Qu	Steven Sher	Socheatraksmey Ung	Yu Zhang
David Qualls	Dalia Sheta	Marc Usart	Quan Zhang
Qurat Ul Ain Qureshi	Lauren Shevell	Bryan Valcarcel	Vida Zhang
Zoya Qureshy	Pedro Silva	Thijs van Bergen	Lei Zhang
Denise Ragusa	Wellington Silva	Niek Van Der Maas	Christine Zhang
Sunnayat Rahman	Martha Sim	Myrthe van Dijk	Jingliao Zhang
Sandeep Raj	Catia Patricia Simoes	Victoria Vardell	Congxiao Zhang
Hannah Raj	Sayantani Sinha	Peyton Venneman	Aobei Zhang
Hari Raman	Vaishnavi Siripurapu	Shangari Vijenthira	Xiaoshuai Zhang
Jyoti Rana	Khanittha Siritham	Ricardo Villanueva	Peng Zhao
Eliot Rapoport	Olivia Sirpilla	Valeria Visconte	Duoduo Zhao
Christian Rausch	Ying Ting Sit	Evangelia Vlachodimtropoulou	Hao Zhao
Kai Rejeski	Surabhi Sivaratnam	Koumoutsea	Yichao Zhou
Kehan Ren	Romanos Sklaventis-Pistofidis	Katharina Waack	Xiang Zhou
Simon Renders	Thomas Smits	Kanako Wakahashi	Xianghui Zhou
Kevin Reyes	Danielle Sohai	Johannes Waldschmidt	Bachisio Ziccheddu

AMERICAN SOCIETY OF HEMATOLOGY 64TH ASH[®] ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 10-13, 2022

GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training and advocacy in hematology. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the

Society's annual meeting, is to facilitate the exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

TWO WAYS TO ATTEND THE 64TH ASH ANNUAL MEETING

ASH is pleased to offer the 64th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in New Orleans or participate from home using ASH's virtual meeting platform. All participants, regardless of location will have access to the virtual meeting platform built for

learning, collaboration, and networking. The platform will connect those in New Orleans with those at home. Access to the virtual platform will begin on December 7, 2022 via annualmeeting.hematology.org.

ASH ANNUAL MEETING HEALTH AND SAFETY PROTOCOLS

We encourage you to monitor the ASH Health and Safety Protocols (www.hematology.org/annual-meeting/safety) online to stay abreast of the latest updates.

VACCINATION

The safety of meeting attendees is ASH's top priority, and we believe the most effective way to ensure the safety of all attendees is for them to be fully vaccinated against COVID-19. Please note that proof of vaccination will be required for all in-person meeting attendees prior to traveling to New Orleans.

For those unable to travel or meet the vaccination requirement, ASH offers several virtual meeting registration options.

PROTECTIVE MASKS

The wearing of protective masks is required of all attendees, ASH staff, and convention center workers, regardless of whether it is required by law at the time of the meeting. Masks must be worn properly (always covering both mouth and nose) except as noted below. The indoor mask requirement applies to the convention center, hotels, shuttle buses, or anywhere an in-person ASH event is being held. Masks are not required outdoors.

Masks may be removed briefly in the following situations:

- When actively eating or drinking
- When speaking at the lectern. Speakers should put their masks back on when not actively presenting or answering a question (i.e., sitting at the head table).
- When being photographed or interviewed on camera by registered media or ASH staff.

In-person attendees will be provided with three KN95 masks in their registration bag to use if they wish, and additional supplies will be available in bins placed throughout the meeting venue.

Attendees who are not properly masked will be refused admittance to ASH sessions and events and may have their badges revoked.

PHYSICAL DISTANCING

Meeting rooms will be set up to accommodate those attendees who prefer more personal space as well as those who prefer to sit closer together.

SANITIZATION

Even though the science shows that COVID-19 transmission is unlikely to occur from touching surfaces touched by multiple persons (i.e., lecterns and internet stations), staff will clean these regularly to promote healthy sanitation overall.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

COVID-19 TESTING

Unlimited, complimentary COVID-19 testing will be available for those who experience symptoms on site and for travelers who must show proof of a recent negative COVID-19 test in order to board their return flight. Testing will be performed by Safe Expo via one testing station within the convention center and one testing station at the Hilton New Orleans Riverside, so that attendees who are symptomatic do not need to return to the convention center to get tested.

Individuals who test positive while on site will not be permitted to continue attending the meeting in person until a negative test is produced and must follow CDC guidance on quarantine and isolation.

ON-SITE QUARANTINE SUPPORT AND TRAVEL RESOURCES

ASH will offer a complimentary Quarantine Support Concierge service to assist any attendees who must quarantine while attending the meeting in New Orleans. Support will include:

- Twice-daily wellness phone calls to check on the individual.

- Assistance with modifying hotel arrangements in New Orleans to extend the check-out date to the end of the quarantine period.
- Assistance with modifying travel arrangements to return home after the quarantine period.
- Coordination with the hotel for the contactless delivery of water, food, beverages, and housekeeping supplies, since housekeeping service will cease.
- Coordination of contactless delivery of other items needed from non-hotel sources (i.e., pharmacy or grocery stores).

INTERNATIONAL ATTENDEES

International attendees should always check current travel restrictions to the U.S. on the Centers for Disease Control and Prevention (CDC) website (<https://www.cdc.gov/coronavirus/2019-ncov/travelers/international-travel-during-covid19.html>) before planning your travel, to make sure you will be able to enter the U.S. In addition, please monitor local regulations at home to ensure that you will be able to return from the U.S.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to live sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2023 but can extend their access by upgrading the subscription to an option with longer access for an additional fee.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription selection at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2023. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee. Registration for the in-person meeting must be done in advance before arriving to the Ernest N. Morial Convention Center. This is a continuation of the new practice instituted last year that requires participants to register online and in advance.

ASH has developed health and safety protocols for the meeting and all participants will be expected to adhere to these protocols. All attendees of the in-person meeting must provide proof that they are vaccinated in order to attend, along with wearing of a protective facial mask. Participants are asked to upload their proof of vaccination to a secure website in advance of travelling to New Orleans. After uploading the proof documentation, a health pass will be issued, and participants will need to show this health pass upon arrival and to pick up their badge and attend the meeting. Full details regarding the health and safety protocols and instructions are available at www.hematology.org/annual-meeting/safety

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The ASH annual meeting virtual access registration packages were designed to give attendees maximum flexibility. Each option below provides access to the meeting's virtual platform including Preview Days that will begin on December 7, 2022. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform. The platform will also include on-demand (recorded) sessions as well as access to networking, exhibits, and more. In-person registrants can upgrade their virtual access to Extended Flexibility or Best Value.

• Real-Time Experience: Access through January 1, 2023

Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.

• Extended Flexibility: Access through February 1, 2023

Provides ongoing access to continue watching on-demand session after the meeting ends. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.

• Best Value: Access through March 1, 2023

Provides maximum flexibility: the ability to participate in all live sessions and networking events during the core dates of the meeting, plus extended access to on-demand content, at the best price per day of access. CME/MOC can be claimed through April 14, 2023 by viewing qualifying sessions on the virtual platform.

GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 27)

Registration Category	In-Person or Real-Time Experience (Virtual access through January 1, 2023)	Extended Flexibility (Virtual access through February 1, 2023)	Best Value (Virtual access through March 1, 2023)
Member (Active and International)	\$800	\$900	\$1,000
Non-Member	\$1,400	\$1,500	\$1,600
ASH Associate or International Member	\$125	\$150	\$175
Resident Member	\$125	\$150	\$175
Graduate/Medical Student Member	\$125	\$150	\$175
Non-Member in Training	\$1,400	\$1,500	\$1,600
Allied Health Professional	\$700	\$800	\$900
Spouse/Guest (in person only)	\$125	NA	NA
Honorary/Emeritus (before 1/1/15)	\$0	\$50	\$100
Honorary/Emeritus (after 1/1/15)	\$125	\$150	\$175
Non-Profit Patient Advocacy Organization Representative (Application for approval is required in advance)	\$0	\$0	\$0

BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

- Member Red
- Non-Member Green
- Associate Member Blue
- International Associate Member Blue
- Non-Member in Training Blue
- Graduate/Medical Student Member Blue
- Resident Member Blue
- Honorary/Emeritus Member White
- Allied Health Professional Purple
- Exhibitor Booth Personnel Black
- Spouses/Guest Yellow
- Media Lime & Blue

BADGES

Badges will not be mailed in advance of the meeting. They will be provided to in-person participants only and will be issued upon arrival and after showing your health pass at registration. ASH reminds in-person participants to bring this health pass with them as it will be needed to obtain the badge. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations. You may pick up your badge at one of two primary registration locations: the Ernest N. Morial Convention Center Great Hall Pre-Function or the Louis Armstrong International Airport baggage claim area. ASH-a-Palooza participants may also pick up their badges at Mardi Gras World on Friday, December 9 only.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ANNUAL MEETING VIRTUAL PLATFORM

Beginning December 7, 2022, the ASH annual meeting will be available to all registered participants at annualmeeting.hematology.org

All registered attendees are encouraged to log in early to get acquainted with the site's navigation. To log into the platform, you

will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the virtual meeting platform, please contact the ASH Customer Relations Department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for international callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

If you have successfully accessed the platform but are having difficulty with one of its features, please use either the online Chatbot, Help, or Contact Us link features within the platform for technical assistance.

PRE-MEETING AND OFFICIAL MEETING DAYS: December 9–13, 2022

There are pre-meeting activities scheduled on Friday, December 9, 2022.

Friday, December 9 **7:00 a.m. - 10:00 p.m. Central time**

- ASH-a-Palooza
- Friday Satellite Symposia
- Scientific Workshops

The 64th ASH Annual Meeting and Exposition schedule will list all times in the Central time zone.

Saturday, December 10

Refer to schedule-at-a-glance and the mobile app for specific session times

Sunday, December 11

Refer to schedule-at-a-glance and the mobile app for specific session times

Monday, December 12

Refer to schedule-at-a-glance and the mobile app for specific session times

Tuesday, December 13

All sessions will occur in the general session room beginning at 8:45 a.m. Central time
The meeting concludes at 2:15 p.m. Central time

All sessions will be presented at the in-person meeting in New Orleans. During the meeting and for the duration of your subscription to the platform, you will be able to access all annual meeting content including:

- Special-Interest Sessions with Q&A
- Special-Interest Sessions
- Education Program and Scientific Program Sessions
- Spotlight Sessions
- Oral Abstract Sessions
- Poster Presentations
- Award Lectures
- Select Friday Satellite Symposia
- Scientific Workshops (until December 16)
- Exhibits and Industry including the Exhibit Hall
- Corporate Presentations (Product Theaters, Industry Theaters, and Company Showcases)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

POST-MEETING EVENTS: December 14–15, 2022

After the official dates of the annual meeting, additional sessions will be held Wednesday and Thursday, December 14–15, including:

- ASH Poster Walks – curated by ASH
- Corporate Poster Walks – hosted and selected by industry company sponsors

BINGE WATCHING—CATCH UP ON CONTENT

Participants will be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting.

SEARCH FOR SESSIONS AND FILL YOUR CALENDAR

SESSION SEARCH AND FILTERS

To help you navigate to the sessions you want to experience, the virtual meeting platform will feature detailed filters that will narrow down available sessions based on your desired areas of interest. Once on the sessions page, choose one or more filters from the left margin to see all sessions on a specific topic (or topics).

To further narrow your search, use the search bar to look for a specific topic.

ADDING SESSIONS TO CALENDAR

When you identify a session of interest, select “Export to Calendar” and choose your preferred calendar application to add an appointment to your personal calendar.

You can also select “Add to My Schedule” to add the session to your virtual meeting schedule of all of your sessions of interest. This schedule can be found in the “Schedule” area of your virtual meeting profile.

The annual meeting mobile application will also allow participants to add sessions to their calendar in the mobile application; these favorited sessions will automatically appear in the “My Favorites” area of your virtual meeting account. Any sessions that you favorite directly on the virtual meeting platform will also appear on your “My Favorites” page.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. For in-person participants, there will be plenty of networking events to maximize your reunion time with colleagues.

ASH's annual meeting virtual platform makes it easy to connect with colleagues in New Orleans and all around the world. All participants can schedule and host video chat meetings with each other, including the ability to schedule these in advance.

ASH COMMUNITY COLLAGE

Visit the ASH Community Collage to view and contribute to the real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Collage will feature a daily leaderboard ranking the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH22, #ASHRunWalk,

#ASHKudos, and #ASHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

CONNECT WITH PARTICIPANTS

From the virtual meeting main page, visit the “Networking” page to find your friends and colleagues, engage in direct instant message chat with them or set up virtual video chats on a one-on-one basis, or organize group discussions for up to 50 people.

WATCH WITH FRIENDS AND COLLEAGUES

A feature unique to the ASH meeting is the ability to watch sessions with other attendees. Invite your mentees, collaborators, or friends to watch together so you can share your thoughts in real time.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in Hall F of the Ernest N. Morial Convention Center.

Speaker Ready Room Hours

- Thursday, December 8 3:00 p.m. – 6:00 p.m.
- Friday, December 9 7:00 a.m. – 9:00 p.m.
- Saturday, December 10 6:30 a.m. – 6:00 p.m.
- Sunday, December 11 6:30 a.m. – 6:00 p.m.
- Monday, December 12 6:00 a.m. – 6:00 p.m.
- Tuesday, December 13 6:30 a.m. – 1:00 p.m.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), ASH policy requires that all meeting session chairs, speakers, and moderators disclose in writing prior to the meeting any financial relationships they may hold with companies in the healthcare and biotechnology industries. Poster presenters are likewise required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. **If bias, actual or perceived, occurs during the presentations, session attendees are encouraged to address**

such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including invited chairs and speakers, and abstract presenters and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity's Board of Directors or advisory committee, and any other financial relationship including Travel Support.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Employ the knowledge gained regarding the diagnosis and treatment of benign and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of 60 AMA PRA Category 1 Credits™.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide AMA PRA Category 1 Credits™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for AMA PRA Category 1 Credits™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of \$30 will be charged for CME certificates. Attendees may complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 64th ASH Annual Meeting must be completed no later than April 14, 2023.

ABIM MOC

Participation in this CME activity enables the attendee to earn up to 60 Medical Knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. You will be asked to submit a reflective statement on how you intend to change your practice based on the knowledge you gained from participation in the meeting. Upon review and approval, your points will be submitted to the ACCME by ASH and will appear in your ABIM Physician Portal within 24 hours. In order to receive ABIM MOC points for the 64th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 14, 2023.

CERTIFICATE OF ATTENDANCE

Non-physicians and other health-care professionals attending the meeting can receive a Certificate of Attendance by completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 10, 2022. The online process of filling out the annual meeting survey must be completed no later than April 14, 2023. There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (<http://ebah.org>). For information about claiming EBAH CME for the 64th ASH Annual Meeting email cme@hematology.org.

QUALIFYING SESSIONS

Physician attendees can claim CME for viewing qualifying live sessions as they are broadcast or after they have concluded. Accredited sessions will be labeled in the print and online meeting materials, as well as in on-site digital signage.

ATTENDEE SERVICES

ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in Hall F of the Ernest N. Morial Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or donate to the ASH Foundation. The following resources are also offered at ASH Central: ASH Health Equity Studio, fASHion boutique for the hematologist with style, ASH Live: Remote Session Viewing, ASH Research Collaborative Kiosk, ASH Store, Collaboration Rooms, Whiteboard Wall, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Health Equity Studio

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution. These micro-sessions will also be available on the virtual meeting platform.

ASH Live: Remote Session Viewing Area

A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session's speakers. **Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.**

ASH Research Collaborative Kiosk

Visit with the ASH Research Collaborative staff and volunteer leaders to learn more about the Data Hub and the Sickle Cell Disease Clinical Trials Network and how your institution might benefit from participation.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness. These micro-sessions will also be available on the virtual meeting platform.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology.org) via the mobile application or the Collaboration Room Help Desk in Hall F to reserve a Collaboration Room.

Collaboration Room Hours

Friday, December 9 7:00 a.m. – 5:45 p.m.
 Saturday, December 10 . . . 7:00 a.m. – 5:45 p.m.
 Sunday, December 11 . . . 7:00 a.m. – 5:45 p.m.
 Monday, December 12 . . . 7:00 a.m. – 5:45 p.m.
 Tuesday, December 13 . . . 7:00 a.m. – 1:45 p.m.

fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, including an ASH-themed soccer jersey to commemorate this year's World Cup, fleece jackets and vests, athletic wear, golf polos, hematology specialty socks, bow and neck ties for men, scarves for women, and warm hats for all. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley

Staffed by professional photographers that provide lighting, a backdrop, and props, Headshot Alley is available for anyone seeking a professional headshot.

Photo Zone

Join the selfie craze and stop by the Photo Zone in ASH Central to take photos in front of New Orleans-themed backgrounds with unique props.

Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Alexa, Ask ASH Meeting

ASH is continuing the use of Amazon's personal-assistant technology, Alexa, to attendees by answering ASH-specific questions. Alexa will be able to connect you with "live"

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

customer service agents that are available to answer questions from their secret Alexa backstage location.

Be sure to start by saying "Alexa, ask ASH Meeting" followed by your question. Here are some example questions you can ask Alexa:

- Alexa, ask ASH Meeting: when do the shuttle buses operate?
- Alexa, ask ASH Meeting: where is ASH Central located?
- Alexa, ask ASH Meeting: does ASH offer child care?

Mobile App

ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2022 annual meeting. The application includes the full text of the abstracts and the manuscripts available in Hematology 2022, the ASH Education Program. The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

The following smartphones are supported: iPhone and Android; the application will also support the iPad and Google tablets.

ASH FOUNDATION DONOR LOUNGE

Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of \$250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in Ma Maison, a meeting space located above the Hall C Lobby Atrium Food Court.

ASH MANAGEMENT OFFICE

The ASH Staff Office is located in Room 238-239 of the Ernest N. Morial Convention Center.

ASH PARK @ THE PLAZA

This year we will make use of three outdoor spaces for ASH Park @ the Plaza. These areas will feature early morning yoga, life-sized games, World Cup viewing on Friday and Saturday, lunch time musical entertainment on Saturday, Sunday and Monday, and lounge furniture. ASH will arrange for seating and tables outdoors for those who wish to remove their protective facial mask while eating meals or visiting with colleagues over coffee.

BUSINESS CENTER

The Ernest N. Morial Convention Center provides full-service business needs for your convenience. The business center is run by UPS and is located in the Hall E lobby of the Ernest N. Morial Convention Center. The business center provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM

ASH has made arrangements with KiddieCorp to provide child care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 23 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and

trained child care specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 18.

For safety reasons, there are some new COVID-19 considerations this year:

- Vaccination is required for all children 6 months of age or older. Please bring your child's vaccine card with you to check them into the child care room.
- ASH will follow the CDC guidance for indoor mask wearing, which means that all children 2 years or older must wear a protective facial mask in order to be enrolled in the indoor child care.
- All staff working in the child care room will also be vaccinated and will wear protective facial masks.

The cost for child care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 18 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 9, through Tuesday, December 13.

The child care room is located in Room 383-385 at the Ernest N. Morial Convention Center.

Child Care Room Hours

Friday, December 9 6:30 a.m. – 7:30 p.m.
 Saturday, December 10 . . 6:30 a.m. – 7:30 p.m.
 Sunday, December 11 . . . 6:30 a.m. – 8:00 p.m.
 Monday, December 12 . . . 6:30 a.m. – 8:00 p.m.
 Tuesday, December 13 . . . 7:30 a.m. – 3:00 p.m.

COAT/BAG CHECK

Check coats for \$2 each and bags for \$3 each at the coat/bag checks located in the Rivergate Room near the Julia Street entrance to the Ernest N. Morial Convention Center and in Hall G Lobby. Electronic items will not be accepted.

Coat/Bag Check Hours

Friday, December 9 7:00 a.m. – 8:30 p.m.
 Saturday, December 10 . . 7:00 a.m. – 8:00 p.m.
 Sunday, December 11 . . . 7:00 a.m. – 8:30 p.m.
 Monday, December 12 . . . 7:00 a.m. – 8:30 p.m.
 Tuesday, December 13 . . . 7:00 a.m. – 3:30 p.m.

FRIENDS OF BILL W.

A meeting room for the Friends of Bill W. is located in Room 203 of the Ernest N. Morial Convention Center.

HEMATOLOGY MEETUPS

To encourage interaction among attendees, "Hematology MeetUp" areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that attendees can coordinate meeting up with each other at a specific location.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

INTERNET STATIONS

Internet Stations are placed throughout the Ernest N. Morial Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 206 of the Ernest N. Morial Convention Center.

NURSING MOTHERS' LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the Ernest N. Morial Convention Center and Hilton New Orleans Riverside. Each nursing mothers' lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is a complimentary refrigerator located in the Child Care Room in Room 383-385 at the Ernest N. Morial Convention Center.

Nursing Mothers' Lounges Locations

Ernest N. Morial Convention Center:

- Hall B Lobby
- Hall H Lobby
- Built Meeting Room in Room 256 Foyer

Hilton New Orleans Riverside:

- Built Meeting Room in Grand Salon Foyer

QUIET ROOMS

Two quiet rooms are located in the Ernest N. Morial Convention Center. Room 211 is designated as the Female Quiet Room and Room 212 is designated as the Male Quiet Room.

PRESS ROOM

The Press Room, open to registered members of the media, is located in Room 256-257 in the Ernest N. Morial Convention Center.

Press Room Hours

- Friday, December 9 9:00 a.m. – 5:00 p.m.
- Saturday, December 10 7:00 a.m. – 6:00 p.m.
- Sunday, December 11 7:00 a.m. – 6:00 p.m.
- Monday, December 12 7:00 a.m. – 6:00 p.m.
- Tuesday, December 13 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS

Centerplate at the Ernest N. Morial Convention Center offers a wide variety of dining options, including cafes in the public lobbies, concessions in the Exhibit Hall, and a food court offering a wide variety of cuisines.

A variety of restaurants are located near the Ernest N. Morial Convention Center. Please stop by the New Orleans Information Desk located in Lobby A at the Ernest N. Morial Convention Center for complimentary restaurant reservation services and more! The desk is open during the following hours:

Friday, December 9 – Monday, December 12

9:00 a.m. - 5:00 p.m.

Tuesday, December 13

9:00 a.m. - 2:30 p.m.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY

To stay safe during your visit to New Orleans, please follow the tips provided below:

- Follow the health and safety protocols implemented by ASH due to COVID-19
- Follow the protocols implemented by hotels, restaurants and transportation companies (taxi, Uber, Lyft)
- Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.
- Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.
- Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.
- When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

- When driving, keep all car doors locked. If taking an Uber or Lyft, verify the car's license plate and have the driver correctly state your name before entering the car.
- Never hand your cell phone to a stranger.

SHUTTLE SERVICE

ASH will be providing complimentary shuttle service for 75 hotels; additionally, 13 hotels are within walking distance of the Ernest N. Morial Convention Center. All passengers on the shuttle service are required to wear a protective facial mask. Staff will be available to remind passengers of this requirement.

Shuttle Locations

Shuttle Routes 1-7

Ernest N. Morial Convention Center Shuttle Hub

Shuttle Routes 8-12

Ernest N. Morial Convention Center Parking Lot G

GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Shuttle Hours

Thursday, December 8 No shuttle service
Friday, December 9 6:30 a.m. – 10:30 p.m.
Saturday, December 10 6:30 a.m. – 9:30 p.m.
Sunday, December 11 6:30 a.m. – 9:30 p.m.
Monday, December 12 6:30 a.m. – 9:30 p.m.
Tuesday, December 13 6:30 a.m. – 3:00 p.m.

Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the Ernest N. Morial Convention Center:

- Cambria New Orleans Downtown Warehouse District
- Courtyard New Orleans Downtown/Convention Center
- Embassy Suites New Orleans Convention Center
- Hampton Inn & Suites New Orleans Convention Center
- The Higgins Hotel New Orleans, Curio Collection by Hilton
- Hilton Garden Inn New Orleans Convention Center
- Hyatt Place New Orleans
- Marriott New Orleans Warehouse Arts District
- The Mercantile Hotel
- Omni Riverfront New Orleans
- Renaissance New Orleans Arts Warehouse District
- Sonesta ES Suites New Orleans Convention Center
- SpringHill Suites New Orleans Downtown/Convention Ctr.

AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes between the Ernest N. Morial Convention Center and Louis Armstrong

International Airport. All passengers on the airport shuttle service are required to wear a protective facial mask. Staff will be available to remind passengers of this requirement.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall G Lobby, of the Ernest N. Morial Convention Center. Tickets cost \$25.

Tickets Sales Hours

Monday, December 12 9:00 a.m. - 7:00 p.m.
Tuesday, December 13 7:00 a.m. - 2:45 p.m.

Shuttle Hours

Monday, December 12 from 12:00 p.m. - 6:00 p.m. on the hour and half hour
Tuesday, December 13 from 9:00 a.m. - 3:00 p.m. on the hour and half hour

Departure Location: Ernest N. Morial Convention Center Shuttle Hub, End of Sidewalk

PARKING

On-site private vehicle parking is available in various lots and garages near the Ernest N. Morial Convention Center. For detailed parking information, visit <https://mccno.com/visitors/getting-here/>.

PUBLIC TRANSPORTATION

The area's public bus system - RTA - has routes servicing the Ernest N. Morial Convention Center with connections to Louis Armstrong International Airport and downtown New Orleans. To plan your journey and obtain the latest fares, visit <https://www.norta.com/>.

A taxi ride from the airport to the Central Business District or French Quarter costs \$36 for up to two passengers. For 3 passengers or more the fee is \$15 per person.

EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 2022 ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls G-J in the Ernest N. Morial Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours

Saturday, December 10 11:00 a.m. – 5:00 p.m.
Sunday, December 11 10:00 a.m. – 5:00 p.m.
Monday, December 12 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY

Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the "ticketed" event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café area located in Hall J.

Lunch Hours

Sunday, December 11 11:00 a.m. – 12:30 p.m.
Monday, December 12 12:00 noon – 1:30 p.m.

ASH BOOTH (#1333) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1333). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, and Company Showcases, which feature new products, research findings, and company overviews presented to small groups of annual meeting attendees (no more than 150) and are located within the Exhibit Hall Theater (Hall J) of the Ernest N. Morial Convention Center. Check the mobile app for the specific theater number you wish to attend; Theaters are numbered one through seven. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

Theater Hours

Saturday, December 10	11:30 a.m. – 12:30 p.m.
	1:30 p.m. – 1:45 p.m.
	3:30 p.m. – 3:45 p.m.
Sunday, December 11	8:00 a.m. – 9:00 a.m.
	11:30 a.m. – 12:30 p.m.
	4:00 p.m. – 4:15 p.m.
Monday, December 12	8:00 a.m. – 9:00 a.m.
	10:15 a.m. – 10:30 a.m.
	12:15 p.m. – 1:15 p.m.

Please see page 143 for detailed Corporate Presentation program information.

POSTER SESSIONS

Poster sessions are held in Hall D of the Ernest N. Morial Convention Center. Receptions are scheduled Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 10

9:00 a.m. – 7:30 p.m. Poster Session I – Viewing
5:30 p.m. – 7:30 p.m. Poster Session I – Presentations

Sunday, December 11

9:00 a.m. – 8:00 p.m. Poster Session II – Viewing
6:00 p.m. – 8:00 p.m. Poster Session II – Presentations

Monday, December 12

9:00 a.m. – 8:00 p.m. Poster Session III – Viewing
6:00 p.m. – 8:00 p.m. Poster Session III – Presentations

SOCIAL EVENTS

POSTER HALL RECEPTIONS

Saturday, December 10 5:30 p.m. – 7:30 p.m.
Sunday, December 11 6:00 p.m. – 8:00 p.m.
Monday, December 12 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2022 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

ASH FOUNDATION RUN/WALK

Sunday, December 11, 2022, 7:00 a.m. – 9:00 a.m.
Corner of Julia Street and Convention Center Blvd.
Start your day in a healthy, fun, and philanthropic way by participating in the ninth annual ASH Foundation Run/Walk before attending the Sunday sessions on December 11. Participants may run or walk through the designed event course along the waterfront in New Orleans, choosing a 3K or 5K route. Not attending the meeting in-person? Don't worry; you too can participate virtually. Proceeds from all individual and group registration fees and individual donations benefit ASH's Global Programs Fund. ASH and the ASH Foundation may opt to designate a portion or all corporate sponsorship revenues associated with the Run/Walk to help support the event's administration cost. Learn more and register at <https://runsignup.com/Race/LA/NewOrleans/ASHFoundationRunWalk>

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MEETING RULES AND REGULATIONS

CODE OF CONDUCT

ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact customerservice@hematology.org as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

PARTICIPATION REQUIREMENTS

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct according to the Code of Conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the Ernest N. Morial Convention Center:

1. I understand and agree that there is inherent risk in participating in any in-person activity and that, due to the circumstances created by COVID-19, there is a heightened degree of personal risk and responsibility. The ASH Annual Meeting is no exception. Although ASH will be taking reasonable legal, prudent, and advisable measures to reduce the risk of virus/illness transmission between people attending the annual meeting, I understand that ASH cannot reduce the level of risk to zero. I acknowledge the risks presented by COVID-19, and the other risks inherent in attending the ASH Annual Meeting and agree to take full personal responsibility for them. I agree that I will not hold anyone else accountable, including ASH, should I become ill or otherwise injured as a result of any act or omission arising out of my decision to attend and participate in the ASH Annual Meeting.
2. **I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE ERNEST N. MORIAL CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY.** I agree, for myself and any heirs, not to sue ASH or the Ernest N. Morial Center or otherwise assert any claim for damages arising out of any illness

(including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.

3. I agree to follow the health and safety protocols established by ASH for the meeting and have read and understand all of these protocols.
4. To the best of my knowledge, I do not have COVID-19 as of this date. I have not tested positive for COVID-19 in the fourteen days prior to the date of this attestation, nor have I experienced any of the following symptoms during that period: fever or chills; cough; shortness of breath or difficulty breathing; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; or diarrhea. If I become symptomatic, I agree that I will get tested for COVID-19 immediately and cease participation in the meeting and all related events. Even if the COVID-19 test results are negative, I will cease participation in the meeting and all related events until I am asymptomatic.
5. I agree that if the COVID-19 test results are positive, I will cease participation in the meeting and follow the Centers for Disease Control and Prevention (CDC) guidelines for quarantining.
6. I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge, since the recipient would not have completed the requirement to show proof of vaccination to ASH before a badge is issued. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

PARTICIPATION OF FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

ANNUAL MEETING DATA COLLECTION

As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:

- American Society of Hematology
 - Privacy Policy (hematology.org/about/privacy-policy)
 - Terms of Service (hematology.org/about/terms-of-service)
- SPARGO (ASH Registration and Housing provider)
 - Privacy Policy (<https://spargoinc.com/privacy-statement>)
- Freeman (Virtual Meeting Platform provider)
 - Privacy Policy (<https://www.freeman.com/privacy-policy/>)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

- Terms of Service (<https://www.freeman.com/terms/>)

Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PROHIBITED SESSION ROOM BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshall.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH's ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

1. Limited Right to Share: Except as provided in Sections A and B.2 of this Policy (hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at <http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode>). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

- **Attribution:** an attendee must give appropriate credit to the original author, and may not in any

way suggest that the original author endorses the attendee or his or her use;

- **Non-Commercial:** an attendee may not use the Meeting Materials for commercial purposes; and
- **No Derivatives:** if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.

DIVERSITY, EQUITY, AND INCLUSION AT ASH®

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care

communities. ASH's efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 64th ASH Annual Meeting to support and strengthen diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ASH HEALTH EQUITY STUDIO

Saturday, Sunday, Monday

Hall F

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

SCIENTIFIC WORKSHOP ON DECENTRALIZED CLINICAL TRIALS

Friday 2:00 p.m. – 5:00 p.m.

275-277

This workshop will convene key stakeholders in the clinical trial enterprise to help define and improve the understanding of decentralized clinical trials (DCTs), including the role of DCTs in hematology and opportunities for future incorporation and engagement. The workshop will also identify successful approaches to DCTs and discuss areas for continued access and improvement of this clinical trial approach for hematologic diseases.

SCIENTIFIC WORKSHOP ON HEMATOLOGY AND AGING

Friday 2:00 p.m. – 5:00 p.m.

278-282

This workshop will be a forum for the presentation of novel research related to the biology of aging and hematologic disorders as it relates to the geriatric population. It will also foster interaction and engagement among aging scientists and investigators conducting research at the interface of hematology and aging and provide opportunities for early career investigators to participate and interact with established leaders in the field of hematology and aging.

SCIENTIFIC WORKSHOP ON EPIDEMIOLOGY: LEVERAGING DIGITAL TECHNOLOGY TO MODERNIZE AND ENHANCE OBSERVATIONAL STUDIES

Friday 2:00 p.m. – 5:00 p.m.

298-299

This workshop will explore methods and examples of studies using artificial intelligence (AI) and machine learning to better capture information efficiently from medical records, histopathological materials, and big data, and use of social media to expand participation and increase representativeness of underserved minorities.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

GRASSROOTS NETWORK LUNCH

Saturday 11:15 a.m. – 12:15 p.m.

St. James Ballroom, Hilton New Orleans Riverside

The ASH Grassroots Network Lunch provides a forum for interested members to learn how they can participate in ASH's advocacy efforts, communicate with Congress and their elected officials, become effective advocates for hematology, and discuss the Society's legislative and regulatory priorities. An overview of the Society's 2022 advocacy accomplishments and a preview of the Society's 2023 advocacy agenda will also be provided.

Given ASH's commitment to policy issues impacting maternal health and hematology, the keynote speaker for this year's event is Veronica Gillispie-Bell, MD, a board-certified obstetrician & gynecologist at Ochsner Health System in New Orleans, LA. She currently serves as the Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner and is the Director of Quality for Women's Services and Medical Director of the Minimally Invasive Center for the Treatment of Uterine Fibroids. Additionally, she is the Medical Director for the Louisiana Pregnancy Associated Mortality Review and Perinatal Quality Collaborative within the Louisiana Department of Health. Dr. Gillispie-Bell will speak to the important connection between hematology and oncology/gynecology and will also provide her perspective regarding ways ASH members can be involved at the state and local levels to impact change aimed at improving health outcomes.

PROMOTING MINORITIES IN HEMATOLOGY: PRESENTATIONS AND RECEPTION

Saturday 6:30 p.m. – 9:00 p.m.

The District Foyer, Hilton New Orleans Riverside

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, Minority Resident Hematology Award, ASH Minority Graduate Award, and the ASH Minority Fellowship Award program participants. A reception will follow the presentations.

LGBTQIA+ COMMUNITY NETWORKING BRUNCH

Sunday 11:15 a.m. – 12:15 p.m.

Gravier AB, Marriott New Orleans Warehouse Arts District

This brunch is an informal community-building and networking event for members of the LGBTQIA+ community attending the meeting. The event is hosted by the ASH Diversity, Equity, and Inclusion (DEI) Programs Subcommittee and aims to create a sense of belonging and allyship and where possible identify opportunities to learn more about the experiences and needs of the community to allow us to have a greater impact in our DEI efforts.

ASH HEALTH EQUITY ROUNDS LUNCH (FOR IN-PERSON PARTICIPANTS)

Sunday 11:30 a.m. – 12:30 p.m.

Cypress, Marriott New Orleans Warehouse Arts District

This series examines the impact of implicit bias and systemic racism in hematology through interactive, case-based discussions, and an interdisciplinary panel that includes hematologists, health equity/public health experts, patients, and patient advocates. Attendees will discuss various disease cases and provocative health equity topics, and participate in experiential learning, breakout sessions, and interactive lectures.

OBSTETRIC MANAGEMENT AND COMPLICATIONS IN SICKLE CELL DISEASE IN HIGH-AND LOW-INCOME COUNTRIES

Sunday 4:30 p.m. – 6:00 p.m.

243-245

Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In a pooled analysis from recent obstetric and hematology studies conducted in low- and middle-income settings, maternal death in women with SCD is approximately 2,393 and 4,300 deaths per 100,000 live births with and without multidisciplinary care, respectively. In comparison, the USA and Northern Europe's general maternal mortality rate is approximately 23.8 and 8 deaths per 100,000 live births, respectively.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

DISABILITY COMMUNITY NETWORKING BREAKFAST

Monday 7:30 a.m. – 9:00 a.m. Gravier EF, Marriott New Orleans Warehouse Arts District

This breakfast is an informal community-building and networking event for members of the disability community attending the meeting. The event is hosted by the ASH Diversity, Equity, and Inclusion (DEI) Programs Subcommittee and aims to create a sense of belonging and allyship and where possible identify opportunities to learn more about the experiences and needs of the community to allow us to have a greater impact in our DEI efforts.

MATERNAL HEALTH IN HEMATOLOGY – CURRENT RESOURCES AND FUTURE ADVOCACY

Monday 10:30 a.m. – 12:00 p.m. Hall E

Maternal morbidity and mortality closely intersect with hematology. In 2021, ASH indicated that the time is right—given greater awareness, as well as attention to health disparities and their intersection with diversity, equity, and inclusion (DEI)—to explore opportunities for the Society to engage in these important public health issues more fully. The session will cover the current efforts, programs, and resources (including but not limited to guidelines), as well as present upcoming plans and opportunities for engagement by the hematology community. Additionally, this session will also touch on the current political climate around the right to maternal healthcare and well-being and ways to be an effective advocate. The session will include case studies highlighting ways to bring attention to hematology and maternal health research and practice issues impacted by public policy decisions.

WOMEN IN HEMATOLOGY NETWORKING DINNER (FOR IN-PERSON PARTICIPANTS)

Monday 7:30 p.m. – 9:30 p.m. Jefferson Ballroom, Hilton New Orleans Riverside

The networking event provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.

MATERNAL HEALTH

Because maternal morbidity and mortality closely intersect with hematology, ASH is committed to supporting the right to maternal health care that addresses hematologic disorders; advocating for access to reproductive health services for all people; and supporting clinicians who serve vulnerable populations, including those at risk of maternal health

conditions. Given the greater awareness of and attention to health disparities, the time is right for ASH to engage fully in these important public health issues. Join us for the following events at the 64th ASH Annual Meeting to help improve maternal healthcare that addresses hematologic disorders.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WHITEBOARD WALL

Saturday, Sunday, Monday

Hall F

Located within ASH Central, the Whiteboard Wall will feature live artists drawing the answers to specific questions that ASH will present to attendees. In-person attendees may watch as the artists bring these answers to life!

There are two Whiteboard Walls this year, one will focus on material health. Questions on the maternal health wall will be:

- What are the key knowledge gaps in maternal health for hematologists?
- What does comprehensive maternal health care look like to you?
- If you had a grant focused on maternal health, what would you research?

GRASSROOTS NETWORK LUNCH

Saturday 11:15 a.m. – 12:15 p.m.

St. James Ballroom, Hilton New Orleans Riverside

The ASH Grassroots Network Lunch provides a forum for interested members to learn how they can participate in ASH's advocacy efforts, communicate with Congress and their elected officials, become effective advocates for hematology, and discuss the Society's legislative and regulatory priorities. An overview of the Society's 2022 advocacy accomplishments and a preview of the Society's 2023 advocacy agenda will also be provided.

Given ASH's commitment to policy issues impacting maternal health and hematology, the keynote speaker for this year's event is Veronica Gillispie-Bell, MD, a board-certified obstetrician & gynecologist at Ochsner Health System in New Orleans, LA. She currently serves as the Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner and is the Director of Quality for Women's Services and Medical Director of the Minimally Invasive Center for the Treatment of Uterine Fibroids. Additionally, she is the Medical Director for the Louisiana Pregnancy Associated Mortality Review and Perinatal Quality Collaborative within the Louisiana Department of Health. Dr. Gillispie-Bell will speak to the important connection between hematology and oncology/gynecology and will also provide her perspective regarding ways ASH members can be involved at the state and local levels to impact change aimed at improving health outcomes.

REPRODUCTIVE AND SEXUAL HEALTH IN SICKLE CELL DISEASE

Sunday 9:30 a.m. – 10:45 a.m.

R06-R09

Reproductive and sexual health challenges associated with sickle cell disease (SCD) are common but under-recognized morbidities. Both males and females with SCD suffer from the disease- or therapy-related challenges impacting negatively on their reproductive and sexual health. Priapism, otherwise rare in the general population, is common among adolescent and adult males with SCD with attendant sequelae of erectile and sexual dysfunctions. Treatment with a disease-modifying agent, hydroxyurea, potentially damages the gonads (testes and ovaries) and could result in infertility. Both SCD and hydroxyurea therapy could damage ovaries, resulting in diminished ovarian reserve and infertility. Curative treatments such as stem cell transplants and gene therapy also pose a significant risk of infertility to both males and females. These challenges have made decision-making on fertility choices difficult for the affected individuals. In this educational session, we will discuss the epidemiology and trends in the management of priapism. We will elaborate on fertility challenges affecting individuals, most especially females, with SCD and provide a template of strategies for engaging patients and their families to guide them in making an informed decision about their treatment choices, mainly as they affect fertility.

MATERNAL HEALTH

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

OBSTETRIC MANAGEMENT AND COMPLICATIONS IN SICKLE CELL DISEASE IN HIGH- AND LOW-INCOME COUNTRIES

Sunday 4:30 p.m. – 5:45 p.m. 243-245

Pregnancy in women with sickle cell disease (SCD) is a life-threatening condition. In a pooled analysis from recent obstetric and hematology studies conducted in low- and middle-income settings, maternal death in women with SCD is approximately 2,393 and 4,300 deaths per 100,000 live births with and without multidisciplinary care, respectively. In comparison, the USA and Northern Europe's general maternal mortality rate is approximately 23.8 and 8 deaths per 100,000 live births, respectively.

MATERNAL HEALTH IN HEMATOLOGY – CURRENT RESOURCES AND FUTURE ADVOCACY

Monday 10:30 a.m. – 12:00 p.m. Hall E

Maternal morbidity and mortality closely intersect with hematology. In 2021, ASH indicated that the time is right—given greater awareness, as well as attention to health disparities and their intersection with diversity, equity, and inclusion (DEI)—to explore opportunities for the Society to engage in these important public health issues more fully. The session will cover the current efforts, programs and resources (including but not limited to guidelines), as well as present upcoming plans and opportunities for engagement by hematology community. Additionally, this session will also touch on the current political climate around the right to maternal healthcare and well-being and ways to be an effective advocate. The session will include case studies highlighting ways to bring attention to hematology and maternal health research and practice issues impacted by public policy decisions.

WOMEN IN HEMATOLOGY NETWORKING DINNER (FOR IN-PERSON PARTICIPANTS)

Monday 7:30 p.m. – 9:30 p.m. Jefferson Ballroom, Hilton New Orleans Riverside

The networking event provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.

NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education's (ACCME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any

presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform, and an up-to-date list of sessions will also be available.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

General Sessions

Best of ASH

Ernest Beutler Lecture and Prize

Late-Breaking Abstracts Session

Plenary Scientific Session

Special Interest Sessions

AI and Machine Learning: A New Frontier in Hematology

ASH Foundation Run/Walk

ASH Health Equity Rounds Lunch

Blood Advances Meet the Editors

Blood Advances Presents: How to Peer Review a Scientific Paper

Blood and Beyond

Blood Presents: How to Get Published in a Peer Review Journal

Disability Community Networking Breakfast

Grassroots Network Lunch

Hemostasis and Thrombosis Community Networking Reception

LGBTQIA+ Community Networking Brunch

Meet the *Blood* Editors

Promoting Minorities in Hematology: Presentations and Reception

Women in Hematology Networking Dinner

Spotlight Sessions

Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)

Sowing the Seeds of Leukemia Before Birth

Non-CME Programs

All sessions in the following programs are not accredited for CME credit:

ASH Poster Walks

ASH Wellness Studio

ASH-a-Palooza

ASH Health Equity Studio

Company Showcases

How I Treat: Bringing Science to Clinical Dilemmas

Industry Theaters

Meet the Scientist

Oral and Poster Abstracts

Product Theaters

Scientific Program

Scientific Symposia

Scientific Workshops

Trainee Activities and Services

Targeting

MLLr

with a covalent inhibitor

Covalency aims to achieve

Higher Selectivity

Deeper Target Engagement

Greater Therapeutic Window

Biomea Fusion is developing an investigational, oral, covalent menin inhibitor (BMF-219) specifically designed for patients with mixed lineage leukemia harboring rearrangements (MLLr). We are a biopharmaceutical company focused on discovering and developing covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. **Visit us at Booth 3342**


To learn more about Biomea Fusion's covalent menin inhibitor (BMF-219) clinical trials, contact us at 1-844-245-0490, clinicaltrials@biomeafusion.com or visit clinicaltrials.gov.



We Aim to Cure™



MEETING SCHEDULE



AMERICAN SOCIETY OF HEMATOLOGY 64TH ASH® ANNUAL MEETING AND EXPOSITION

DAY-AT-A-GLANCE

Thursday, December 8, 2022

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

THURSDAY, DECEMBER 8, 2022

3:00 p.m. – 7:00 p.m. Registration (for in-person participants)
Great Hall Pre-Function

3:00 p.m. – 7:00 p.m. ASH COVID-19 Testing Centers (for in-person participants)
228-230 (Convention Center)
Hilton New Orleans Riverside, Eglington Winton

FRIDAY, DECEMBER 9, 2022

7:00 a.m. – 6:00 p.m. Registration (for in-person participants)
Great Hall Pre-Function

7:00 a.m. – 6:00 p.m. ASH COVID-19 Testing Centers (for in-person participants)
228-230 (Convention Center)
Hilton New Orleans Riverside, Eglington Winton

7:00 a.m. – 10:00 a.m. Satellite Symposia

A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies
VIRTUAL PROGRAM

Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead
Hyatt Regency New Orleans, Celestin EFGH

Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies
Hyatt Regency New Orleans, Elite B

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs
Sheraton New Orleans, Grand Ballroom A/B

Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management
Hyatt Regency New Orleans, Empire CD

Maintaining 'Intensity' for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations
Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B

Myelodysplastic Syndromes 2022: Today and Tomorrow
La Nouvelle Orleans Ballroom AB

Navigating the Frontier of Hematologic Malignancy Therapies
Great Hall A/D

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma
VIRTUAL PROGRAM

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms into Patient Care
Sheraton New Orleans, Rhythms Ballroom

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care
Hyatt Regency New Orleans, Empire B

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
Sheraton New Orleans, Grand Ballroom C

The Sequel to the Targeted Therapy Era in CML: Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans
Sheraton New Orleans, Napoleon C 1-3 + Corridor C/D

The Winning Way with BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing
Hyatt Regency New Orleans, Empire A

9:00 a.m. – 11:00 a.m. 2022 World Cup Soccer Viewing (outside)
ASH Park @ the Plaza 2

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

9:00 a.m. – 12:00 p.m. Training Program Directors Workshop

Marriott New Orleans Warehouse Arts District, Cypress

11:00 a.m. – 2:00 p.m. Satellite Symposia

A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

Hyatt Regency New Orleans, Elite B

Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults

Sheraton New Orleans, Napoleon C 1-3 + Corridor C/D

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)

Hyatt Regency New Orleans, Celestin ABCD

Advances in the Treatment of T-Cell Lymphomas:

A Forum for Data and Case Discussion

Sheraton New Orleans, Rhythms Ballroom

Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias

243-245

An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B

Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow

VIRTUAL PROGRAM

Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA

Hyatt Regency New Orleans, Empire B

Elevating Equity in Caring For Patients With Hematologic Malignancies

Hyatt Regency New Orleans, Celestin EFGH

Expert Illustrations & Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease

217-219

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/ Refractory Disease?

Great Hall B/C

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

Hyatt Regency New Orleans, Empire A

How We Do It™: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow

Sheraton New Orleans, Grand Ballroom DE

Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult

La Nouvelle Orleans Ballroom C

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

343-345

Navigating a Changing Landscape Together:

Gene Therapy for Hemophilia

393-396

Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Integrating Novel Treatment Strategies in the Clinic

Sheraton New Orleans, Grand Ballroom C

Rapidly Evolving Paradigms in Multiple Myeloma:

Applying Current Data in the Clinic

Hyatt Regency New Orleans, Empire CD

State-of-the-Art CMV Care: Experts' Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections

La Nouvelle Orleans Ballroom AB

Taking Stock of the Evolving Treatment

Landscape for Acute GvHD in HSCT

Great Hall A/D

Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient's Lifespan

208-210

Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis

Sheraton New Orleans, Grand Ballroom A/B

12:30 p.m. – 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

ASH Talk Opening Song and Welcome

ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools

ASH Talk #2: The Resilient Trainee

Blood Drops

Blood Buddies

12:30 p.m. – 1:00 p.m. ASH-a-Palooza (Open to Trainees Only)

ASH Talk Opening Song and Welcome

Mardi Gras World, River City Ballroom

1:00 p.m. – 1:20 p.m. ASH-a-Palooza (Open to Trainees Only)

ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools

Mardi Gras World, River City Ballroom

1:00 p.m. – 3:00 p.m. 2022 World Cup Soccer Viewing (outside)

ASH Park @ the Plaza 2

1:30 p.m. – 1:40 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

1:30 p.m. – 2:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

1:50 p.m. – 2:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

2:00 p.m. – 5:00 p.m. Scientific Workshops

Scientific Workshop on Advancing Decentralized Clinical Trials in Hematology
275-277

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS
271-273

Scientific Workshop on Gene Editing in Hematology: Here to Stay
288-290

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
291-292

Scientific Workshop on Hematology and Aging
278-282

Scientific Workshop on Interplay between Coagulation and Malignancy
295-296

Scientific Workshop on Leveraging Digital Technology to Modernize and Enhance Observational Studies
283-285

Scientific Workshop on Myeloid Development
New Orleans Theater AB

Scientific Workshop on Thrombotic Microangiopathies
293-294

Scientific Workshop on Translational Molecular Diagnostics: Genomic Reclassification of Blood Cancer
298-299

2:10 p.m. – 2:30 p.m. ASH-a-Palooza (Open to Trainees Only)

ASH Talk #2: The Resilient Trainee
Mardi Gras World, River City Ballroom

2:40 p.m. – 2:50 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

2:40 p.m. – 3:10 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

3:00 p.m. – 3:10 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

3:00 p.m. – 6:00 p.m. Satellite Symposia

A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B
217-219

A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis
Sheraton New Orleans, Rhythms Ballroom

Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma - What Clinicians Want to Know (Part 2 of a 3-part CME-accredited Symposia Series)
Hyatt Regency New Orleans, Celestin ABCD

Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies
Sheraton New Orleans, Napoleon B 1-3 + Corridor A/B

AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care
Hyatt Regency New Orleans, Elite B

Blazing the Trail to Better Patient Outcomes: Erythroid Maturation Agents in β -Thalassemia
La Nouvelle Orleans Ballroom C

Challenging Cases in Relapsed/Refractory Follicular Lymphoma
Hyatt Regency New Orleans, Empire A

"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
Sheraton New Orleans, Grand Ballroom C

Experts Under the Microscope: Evaluating the Role of Maintenance Therapy in Long-Term Management of AML
343-345

JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy
Hyatt Regency New Orleans, Empire B

Let's Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls
Hyatt Regency New Orleans, Empire CD

Let's Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome
Hyatt Regency New Orleans, Celestin EFGH

Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
208-210

Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
243-245

Navigating New Terrain in Chemotherapy-Induced Anemia: Hem/Onc Perspectives and Evidence-Supported Strategies for Improving Care with Intravenous Iron
393-396

The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management
Sheraton New Orleans, Grand Ballroom A/B

4:35 p.m. – 4:45 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

4:50 p.m. – 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

4:35 p.m. – 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Mardi Gras World, River City Ballroom

5:00 p.m. – 7:00 p.m. Trainee Welcome Reception

Mardi Gras World, Float Den

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

7:00 p.m. – 10:00 p.m. Satellite Symposia

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)
Hyatt Regency New Orleans, Celestin ABCD

Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration
Hyatt Regency New Orleans, Elite B

Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?
Sheraton New Orleans, Grand Ballroom DE

Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes
VIRTUAL PROGRAM

SATURDAY, DECEMBER 10, 2022

7:00 a.m. – 6:00 p.m. Registration (for in-person participants)

Great Hall Pre-Function

7:00 a.m. – 6:00 p.m. ASH COVID-19 Testing Centers (for in-person participants)

228-230 (Convention Center)

Eglinton Winton, Hilton New Orleans Riverside

7:00 a.m. – 7:45 a.m. ASH Wellness Studio

ASH Yoga
 (for in-person participants)
ASH Park @ the Plaza 1

8:00 a.m. – 9:00 a.m. Meet the Experts (Ticketed Sessions) (for in-person participants)

8:30 a.m. – 9:30 a.m. How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)

Can We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes
Hilton New Orleans Riverside, Marlborough A

ITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday
Hilton New Orleans Riverside, Camp

Sickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape
Hilton New Orleans Riverside, Commerce

The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML
Hilton New Orleans Riverside, Canal

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Hall F

9:00 a.m. – 7:30 p.m. Poster Session I - Viewing

Hall D

9:00 a.m. – 9:30 a.m. Coffee Break in Poster Hall (for in-person participants)

Hall D

9:00 a.m. – 9:30 a.m. Health Equity Studio

Defining Inequity and Root Causes of Health Inequity
Hall F

9:00 a.m. – 11:00 a.m. 2022 World Cup Soccer Viewing (outside)

ASH Park @ the Plaza 2

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

Bringing Joy to Your World
Hall F

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

Breathe Well to Feel Well
Hall F

9:30 a.m. – 10:45 a.m. Education Sessions

Autoimmune Hemolytic Anemias (AIHA)
291-292

Controversies in Aggressive NHL
Hall E

JAK/STAT Inhibition and Beyond in Ph Negative MPNs
293-294

Multiple Myeloma: Assessing the Patient and the Disease
Great Hall A/D

9:30 a.m. – 10:45 a.m. Scientific Sessions

Aplastic Anemia, Dysimmunity, and Mutant Clones (Scientific Committee on Bone Marrow Failure)
288-290

Emerging Technologies in Hemostasis (Scientific Committee on Hemostasis)
265-268

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions

114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies
391-392

201. Granulocytes, Monocytes, and Macrophages II
295-296

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Special Populations and Long-term Outcomes in ITP
275-277

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders
271-273

401. Blood Transfusion: Molecular Mechanisms and Novel Therapies
393-396

602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies
353-355

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Vulnerabilities Triggering Mechanisms of Drug Resistance and Sensitivity in Myeloid Neoplasms
343-345

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups
243-245

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia
208-210

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML
220-222

622. Lymphomas: Translational–Non-Genetic: Tumor Microenvironment in Lymphoid Malignancies: Composition, Biology, and Prognostic Significance
New Orleans Theater C

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I
La Nouvelle Orleans Ballroom C

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents
217-219

636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies
260-262

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations
La Nouvelle Orleans Ballroom AB

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
R06-R09

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma
R02-R05

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT
252-254

731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP
278-282

801. Gene Therapies: Addressing Challenges & Opportunities in Pre-clinical Settings
Great Hall B/C

903. Health Services and Quality—Myeloid Malignancies I
388-390

11:00 a.m. – 12:30 p.m. Open Time for Lunch

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ the Plaza 3

11:00 a.m. – 5:00 p.m. Exhibits Open

Hall G-J

11:05 a.m. – 11:15 a.m. ASH Wellness Studio

Money Issues are Burning You Out
Hall F

11:15 a.m. – 11:45 a.m. Health Equity Studio

Recognizing and Addressing Implicit Bias
Hall F

11:15 a.m. – 12:15 p.m. Blood Presents: How to Get Published in a Peer Review Journal

252-254

11:15 a.m. – 12:15 p.m. Blood Presents: How to Get Published in a Peer Review Journal

Hilton New Orleans Riverside, St. Charles Ballroom

11:15 a.m. – 12:15 p.m. Career Development Lunch (Open to Trainees Only)

Hilton New Orleans Riverside, St. James Ballroom

11:20 a.m. – 11:30 a.m. ASH Wellness Studio

One Breath to the Most Kind, Compassionate, and Grateful You!
Hall F

11:30 a.m. – 12:30 p.m. Industry Theaters

Emerging AstraZeneca Hematology Pipeline
(for in-person participants)
Hall J - Theater 5

Investigating the Biological Mechanisms of HR-MDS: Role of the Immune System During Disease
(for in-person participants)
Hall J - Theater 3

Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients With Hematologic Malignancies
(for in-person participants)
Hall J - Theater 7

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

11:30 a.m. – 12:30 p.m. Product Theaters

Are Higher Factor Levels a Rising Consideration When Selecting a Hemophilia Treatment?

(for in-person participants)

Hall J - Theater 6

Data Worth Stopping For: New 5-year Follow-Up Data for an Oral-Based CLL Regimen with a Fixed Treatment Duration

(for in-person participants)

Hall J - Theater 1

Evolving Treatment Expectations in PNH

(for in-person participants)

Hall J - Theater 2

Treatment Options in Relapsed/Refractory Multiple Myeloma: Clinical Studies and Patient Cases

(for in-person participants)

Hall J - Theater 4

11:35 a.m. – 11:45 a.m. ASH Wellness Studio

Fix the Way You Sit

Hall F

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

331. *Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological I*

Great Hall A/D

332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Controversies in Anticoagulation and Venous Thromboembolism*

Great Hall B/C

605. *Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Transcription, Translation, and Epigenetics*

288-290

627. *Aggressive Lymphomas: Clinical and Epidemiological: Treatment of CNS Lymphoma, Neurologic Toxicities, and Relapsed/Refractory DLBCL*

New Orleans Theater C

653. *Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma*

R02-R05

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma*

La Nouvelle Orleans Ballroom AB

905. *Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant*

243-245

12:30 p.m. – 1:30 p.m. Ham-Wasserman Lecture: Leukemogenesis in Infants and Young Children with Trisomy 21

Hall E

1:00 p.m. – 3:00 p.m. 2022 World Cup Soccer Viewing (outside)

ASH Park @ the Plaza 2

1:30 p.m. – 2:00 p.m. Health Equity Studio

Strategies to Overcome Healthcare Disparities

Hall F

1:30 p.m. – 1:45 p.m. Company Showcases

Powering Better Decisions: A Comprehensive Hematopathology Analysis Case Study

(for in-person participants)

Hall J - Theater 6

1:30 p.m. – 2:00 p.m. Coffee Break in Exhibit Hall (for in-person participants)

Hall G-J

1:35 p.m. – 1:45 p.m. ASH Wellness Studio (for in-person participants)

A Simple Way to More Resilience

Hall F

1:45 p.m. – 1:55 p.m. ASH Wellness Studio

Financial Order of Operations

Hall F

2:00 p.m. – 3:00 p.m. Blood Advances Meet the Editors (for in-person participants)

Marriott New Orleans Warehouse Arts District, Julia

2:00 p.m. – 3:15 p.m. Education Sessions

Late Effects of Curative Therapy for Sickle Cell Disease

Hall E

Prophylactic Platelet Transfusions

243-245

Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

Great Hall A/D

Von Willebrand Disease

208-210

Where Are We Headed in Hodgkin Lymphoma?

New Orleans Theater AB

2:00 p.m. – 3:15 p.m. Scientific Sessions

Overcoming T-cell Burnout and Exhaustion (Scientific Committee on Immunology and Host Defense)

271-273

2:00 p.m. – 3:15 p.m. Scientific Symposia

Biology and Translation of NK Cells

293-294

Genetic and Functional Heterogeneity in Megakaryocytes and Platelets

252-254

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

2:00 p.m. – 3:30 p.m. Special Symposium on Quality: Quality Improvement Education and Training

295-296

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions

113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models
275-277

114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment
278-282

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Looking Forward: Novel Therapies and Diagnostic Modalities for Bleeding Disorders
288-290

508. Bone Marrow Failure: Acquired: Biology
260-262

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms
343-345

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK
388-390

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials
265-268

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML
Great Hall B/C

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications
291-292

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III
New Orleans Theater C

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis
217-219

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
R06-R09

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)
R02-R05

703. Cellular Immunotherapies: Basic and Translational I
La Nouvelle Orleans Ballroom C

705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies
La Nouvelle Orleans Ballroom AB

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses
391-392

802. Chemical Biology and Experimental Therapeutics I
353-355

906. Outcomes Research—Myeloid Malignancies II
220-222

3:30 p.m. – 3:45 p.m. Company Showcases

Ultra-low Frequency Variant Detection in AML with Duplex Sequencing Technology
(for in-person participants)
Hall J - Theater 6

3:30 p.m. – 4:00 p.m. Health Equity Studio

Overcoming Lack of Diversity in Clinical Trials
Hall F

3:30 p.m. – 4:00 p.m. Coffee Break in Exhibit Hall (for in-person participants)

Hall G-J

3:35 p.m. – 3:45 p.m. ASH Wellness Studio

Workday Tension Timeout
Hall F

3:45 p.m. – 3:55 p.m. ASH Wellness Studio

Use Your Character Strengths to Get Through Trying Times
Hall F

4:00 p.m. – 5:15 p.m. Education Sessions

Anxiety Provoking Consultations: Mast Cells and Eosinophils
295-296

Are Alternative Donors Now Mainstream in Allogeneic Transplant?
Great Hall B/C

Immunotherapy in Multiple Myeloma
Hall E

Managing Thrombocytopenia in Challenging Situations
243-245

Novel Approaches in MDS
288-290

Update in Hemophilia
291-292

4:00 p.m. – 5:30 p.m. Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan

La Nouvelle Orleans Ballroom AB

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

4:00 p.m. – 5:30 p.m.**Oral Abstract Sessions**

101. *Red Cells and Erythropoiesis, Excluding Iron I*
391-392

508. *Bone Marrow Failure: Acquired: Clinical Studies*
260-262

602. *Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism*
293-294

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML*
388-390

621. *Lymphomas: Translational—Molecular and Genetic: Single Cell, Microenvironment, and Treatment Resistance*
La Nouvelle Orleans Ballroom C

624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma*
278-282

627. *Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL*
New Orleans Theater AB

631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel Therapeutic Targets in MPN and CML*
275-277

632. *Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Disease*
265-268

634. *Myeloproliferative Syndromes: Clinical and Epidemiological: Avant-garde and Traditional Prognostic and Response Assessment in MPNs*
217-219

642. *Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter's Transformation*
R06-R09

651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational*
New Orleans Theater C

703. *Cellular Immunotherapies: Basic and Translational II*
393-396

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT*
Great Hall A/D

721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III*
343-345

723. *Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II*
353-355

905. *Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies*
208-210

906. *Outcomes Research—Myeloid Malignancies I*
220-222

4:00 p.m. – 5:35 p.m.**Scientific Sessions**

JOINT Session: New Tools to Optimize Platelet Transfusion Therapy (Scientific Committee on Megakaryocytes and Platelets & Scientific Committee on Transfusion Medicine)
252-254

JOINT Session: Seed and Soil: The Role of Inflammation in Myeloid Malignancies (Scientific Committee on Myeloid Biology & Scientific Committee on Myeloid Neoplasia)
R02-R05

5:30 p.m. – 7:30 p.m.**Welcome Reception in Poster Hall (for in-person participants)****Hall D****5:30 p.m. – 7:30 p.m.****Poster Session I – Presentations****Hall D**

101. *Red Cells and Erythropoiesis, Excluding Iron: Poster I (1003–1017)*

102. *Iron Homeostasis and Biology: Poster I (1018–1028)*

112. *Thalassemia and Globin Gene Regulation: Poster I (1029–1036)*

113. *Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I (1037–1054)*

114. *Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster I (1055–1083)*

201. *Granulocytes, Monocytes, and Macrophages: Poster I (1084–1098)*

203. *Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1099–1107)*

301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1108–1126)*

311. *Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1127–1138)*

321. *Coagulation and Fibrinolysis: Basic and Translational: Poster I (1139–1146)*

322. *Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1147–1171)*

331. *Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I (1172–1181)*

332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1182–1200)*

401. *Blood Transfusion: Poster I (1201–1208)*

501. *Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1209–1221)*

503. *Clonal Hematopoiesis, Aging and Inflammation: Poster I (1222–1233)*

506. *Bone Marrow Microenvironment: Poster I (1234–1244)*

508. *Bone Marrow Failure: Acquired: Poster I (1245–1257)*

509. *Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1258–1266)*

602. *Myeloid Oncogenesis: Basic: Poster I (1267–1299)*

603. *Lymphoid Oncogenesis: Basic: Poster I (1300–1314)*

604. *Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1315–1340)*

605. *Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1341–1366)*

612. *Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1367–1380)*

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1381–1408)
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1409–1419)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1420–1439)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1440–1460)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1461–1500)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1501–1516)
621. Lymphomas: Translational—Molecular and Genetic: Poster I (1517–1543)
622. Lymphomas: Translational—Non-Genetic: Poster I (1544–1562)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1563–1590)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I (1591–1617)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I (1618–1637)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I (1638–1672)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1673–1688)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1689–1708)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1709–1740)
636. Myelodysplastic Syndromes—Basic and Translational: Poster I (1741–1754)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I (1755–1783)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1784–1796)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (1797–1817)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1818–1855)
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (1856–1914)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I (1915–1940)
701. Experimental Transplantation: Basic and Translational: Poster I (1941–1960)
703. Cellular Immunotherapies: Basic and Translational: Poster I (1961–1992)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I (1993–2021)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I (2022–2043)
711. Cell Collection and Processing: Poster I (2044–2050)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I (2051–2072)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I (2073–2094)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I (2095–2108)
731. Autologous Transplantation: Clinical and Epidemiological: Poster I (2109–2119)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2120–2136)
801. Gene Therapies: Poster I (2137–2151)
802. Chemical Biology and Experimental Therapeutics: Poster I (2152–2165)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I (2166–2183)
901. Health Services and Quality—Non-Malignant Conditions: Poster I (2184–2207)
902. Health Services and Quality—Lymphoid Malignancies: Poster I (2208–2225)
903. Health Services and Quality—Myeloid Malignancies: Poster I (2226–2236)
904. Outcomes Research—Non-Malignant Conditions: Poster I (2237–2259)
905. Outcomes Research—Lymphoid Malignancies: Poster I (2260–2301)
906. Outcomes Research—Myeloid Malignancies: Poster I (2302–2321)

6:30 p.m. – 9:00 p.m. Promoting Minorities in Hematology: Presentations and Reception (for in-person participants)

Hilton New Orleans Riverside, The District Foyer

SUNDAY, DECEMBER 11, 2022

7:00 a.m. – 5:00 p.m. Registration (for in-person participants)

Great Hall Pre-Function

7:00 a.m. – 5:00 p.m. ASH COVID-19 Testing Centers (for in-person participants)

228-230 (Convention Center)

Eglinton Winton, Hilton New Orleans Riverside

7:00 a.m. – 9:00 a.m. ASH Foundation Run/Walk

Convention Center Blvd. and Julia St.

7:30 a.m. – 9:30 a.m. Medical Educators' Symposium

(for in-person participants)

Marriott New Orleans Warehouse Arts District, Cypress

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

8:00 a.m. – 9:00 a.m. Industry Theaters

Gene Therapy for the Hemoglobinopathies: Translating Complex Science to Inform the Physician-Patient Dialogue
(for in-person participants)
Hall J - Theater 1

Sanofi Hematology Clinical Pipeline
Hall J - Theater 5

8:00 a.m. – 9:00 a.m. Product Theaters

A Treatment Option for Patients with Myelodysplastic Syndromes
(for in-person participants)
Hall J - Theater 7

Discussion on the Treatment of Sickle Cell Disease, Moving Beyond Pain as a Primary Target
(for in-person participants)
Hall J - Theater 4

Gene Therapy for Hemophilia B: A look into new advancements
(for in-person participants)
Hall J - Theater 2

Pivotal Phase 3 data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms
(for in-person participants)
Hall J - Theater 6

8:00 a.m. – 9:00 a.m. Meet the Experts (Ticketed Sessions) (for in-person participants)

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Hall F

8:30 a.m. – 9:30 a.m. How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions) (for in-person participants)

Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia - Sunday
Hilton New Orleans Riverside, Marlborough A

Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes.
Hilton New Orleans Riverside, Camp

vWD and Other Bleeding Disorders – Diagnostic Pitfalls and Special Situations
Hilton New Orleans Riverside, Canal

9:00 a.m. – 8:00 p.m. Poster Session II - Viewing

Hall D

9:00 a.m. – 9:30 a.m. Coffee Break in Poster Hall (for in-person participants)

Hall D

9:00 a.m. – 9:30 a.m. Health Equity Studio

Overcoming Disparities in Career Development
Hall F

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

Build a Bigger Brain and Longer Life
Hall F

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

Use Your Character Strengths to Get Through Trying Times
Hall F

9:30 a.m. – 10:45 a.m. Education Sessions

Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets
Great Hall B/C

Maximizing Outcomes in CLL
265-268

Reproductive and Sexual Health in Sickle Cell Disease
R06-R09

9:30 a.m. – 10:45 a.m. Scientific Symposia

Building Dietary Evidence for Hematologic Malignancies - Mechanistic Insights
217-219

Targeting Endogenous Retroelements and Viral Mimicry in Therapy of Hematologic Malignancies
288-290

9:30 a.m. – 11:00 a.m. ASH Guideline Implementation Champions

353-355

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions

113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease
343-345

321. Coagulation and Fibrinolysis: Basic and Translational
293-294

503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models
271-273

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics
260-262

603. Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis
393-396

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia
278-282

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Treatment-related Biomarkers
Hall E

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

618. *Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies*
Great Hall A/D

626. *Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma*
La Nouvelle Orleans Ballroom AB

627. *Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations*
La Nouvelle Orleans Ballroom C

631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations*
275-277

637. *Myelodysplastic Syndromes – Clinical and Epidemiological III*
252-254

652. *Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM)*
New Orleans Theater C

701. *Experimental Transplantation: Basic and Translational: Novel Mechanisms of Acute and Chronic Graft-versus-Host Disease*
391-392

703. *Cellular Immunotherapies: Basic and Translational IV*
388-390

731. *Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis*
220-222

803. *Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology*
208-210

901. *Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias*
291-292

904. *Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras*
295-296

9:30 a.m. – 11:05 a.m. Scientific Sessions

JOINT Session: Cell Competition and Clonal Hematopoiesis (Scientific Committee on Hematopoiesis & Scientific Committee on Stem Cells and Regenerative Medicine)
New Orleans Theater AB

JOINT Session: The Lymphoma Microenvironment and Its Impact on Therapy (Scientific Committee on Lymphoid Neoplasia & Scientific Committee on Transplantation Biology & Cellular Therapies)
R02-R05

10:00 a.m. – 5:00 p.m. Exhibits Open

Hall G-J

11:00 a.m. – 12:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Hall G-J

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ the Plaza 3

11:05 a.m. – 11:15 a.m. ASH Wellness Studio

Coping With Financial Strain and Gain
Hall F

11:15 a.m. – 11:45 a.m. Health Equity Studio

Strategies to Improve Diversity and Inclusion in Healthcare and Industry
Hall F

11:15 a.m. – 12:00 p.m. Meet the *Blood* Editors (for in-person participants)

Marriott New Orleans Warehouse Arts District, Julia

11:15 a.m. – 12:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Trainee Didactic Session: How to Transition from Trainee to Faculty
220-222

Trainee Didactic Session: Writing a Good CV, Portfolio, and Biosketch
217-219

11:15 a.m. – 12:15 p.m. *Blood Advances* Presents: How to Peer Review a Scientific Paper

252-254

11:15 a.m. – 12:15 p.m. LGBTQIA+ Community Networking Brunch

Marriott New Orleans Warehouse Arts District, Gravier AB

11:15 a.m. – 12:30 p.m. ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology

How to Practice Classical Hematology When It's Outside Your Comfort Zone

Hilton New Orleans Riverside, St. James Ballroom

11:20 a.m. – 11:30 a.m. ASH Wellness Studio

Feel Better in Your Body
Hall F

11:30 a.m. – 12:30 p.m. Industry Theaters

Investigating the Function of Tumor Suppressor Proteins in Myelofibrosis (MF) and Myelodysplastic Neoplasms (MDS)
 (for in-person participants)

Hall J - Theater 5

Protection Onboard: A Clinical Approach to Preventing COVID-19 in At-Risk Patients

Hall J - Theater 3

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

11:30 a.m. – 12:30 p.m. Product Theaters

Genentech Lymphoma Product Presentation
(for in-person participants)
Hall J - Theater 4

Kite, The Leader in Cell Therapy: Leading the Way in Large B-Cell Lymphoma Care
(for in-person participants)
Hall J - Theater 7

The Clinical Actionability of ClonoSEQ MRD Assessment in Lymphoid Malignancies
(for in-person participants)
Hall J - Theater 1

Treatment Option in AML
(for in-person participants)
Hall J - Theater 2

What's Next for Patients with Relapsed or Refractory Multiple Myeloma after Multiple Lines of Therapy?
(for in-person participants)
Hall J - Theater 6

11:30 a.m. – 12:30 p.m. ASH Health Equity Rounds Lunch (for in-person participants)

Gender Disparities in Bleeding Disorders
Marriott New Orleans Warehouse Arts District, Cypress

11:35 a.m. – 11:45 a.m. ASH Wellness Studio

Regulate Your Genes for More Energy and Less Inflammation
Hall F

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

101. *Red Cells and Erythropoiesis, Excluding Iron II*
243-245

332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment*
291-292

506. *Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment*
260-262

602. *Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation*
275-277

613. *Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia*
271-273

621. *Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication*
Great Hall B/C

622. *Lymphomas: Translational—Non-Genetic: Translational Research in Lymphoma: Prognostic Biomarkers and Novel Therapeutic Vulnerabilities*
Great Hall A/D

627. *Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL*
R02-R05

637. *Myelodysplastic Syndromes – Clinical and Epidemiological IV*
265-268

653. *Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma*
New Orleans Theater C

722. *Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Critical Advances in GVHD Management*
208-210

904. *Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes*
R06-R09

12:30 p.m. – 1:00 p.m. Health Equity Studio

Defining Inequity and Root Causes of Health Inequity
Hall F

12:30 p.m. – 1:30 p.m. ASH-EHA Joint Symposium: Germline Predisposition and Hereditary Hematopoietic Neoplasia

Hall E

1:30 p.m. – 2:00 p.m. Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award

Hall E

2:00 p.m. – 4:00 p.m. Plenary Scientific Session

Hall E

4:00 p.m. – 4:15 p.m. Company Showcases

AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
(for in-person participants)
Hall J - Theater 6

4:00 p.m. – 4:30 p.m. Health Equity Studio

Recognizing and Addressing Implicit Bias
Hall F

4:00 p.m. – 4:30 p.m. Coffee Break in Exhibit Hall (for in-person participants)

Hall G-J

4:05 p.m. – 4:15 p.m. ASH Wellness Studio

The Greatest Medicine...A True Friend
Hall F

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

4:15 p.m. – 4:25 p.m. ASH Wellness Studio

Fix the Way You Sit
Hall F

4:30 p.m. – 5:45 p.m. Education Sessions

Beyond Routine Frontline Therapy of CML
La Nouvelle Orleans Ballroom C

Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries
243-245

What's New in Indolent Lymphoma
Great Hall B/C

4:30 p.m. – 5:45 p.m. Scientific Sessions

New Therapeutic Targets for Thrombosis That Do Not Cause Bleeding (Scientific Committee on Thrombosis and Vascular Biology)
293-294

4:30 p.m. – 5:45 p.m. Education Spotlight Sessions

Bone Marrow Failure Syndromes: Diagnostic Principles in 2022
260-262

New Horizons for Histiocyte Disorders
275-277

Survivorship in adult patients with lymphoma
Great Hall A/D

4:30 p.m. – 5:45 p.m. Scientific Spotlight Sessions

Platelet Factor 4-Mediated ImmunoThrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)
291-292

4:30 p.m. – 6:00 p.m. ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer

271-273

4:30 p.m. – 6:00 p.m. Blood and Beyond: The Great Influenza: The Epic Story of the Deadliest Plague in History

265-268

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions

201. *Granulocytes, Monocytes, and Macrophages I*
391-392

322. *Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Von Willebrand Disease and Other Congenital and Acquired Bleeding Disorders*
288-290

613. *Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia*
353-355

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Outcomes and New Treatment Strategies in Genetically Adverse Risk and MRD-positive AML*
343-345

623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological IV*
278-282

624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T-cell Malignancies: Clinical and Epidemiological*
393-396

632. *Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TFR, Pregnancy, and Disparities*
388-390

634. *Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs*
217-219

637. *Myelodysplastic Syndromes – Clinical and Epidemiological II*
R06-R09

641. *Chronic Lymphocytic Leukemias: Basic and Translational: Pathogenesis and Transformation*
R02-R05

651. *Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response*
New Orleans Theater AB

652. *Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma*
New Orleans Theater C

701. *Experimental Transplantation: Basic and Translational: Novel Translational Approaches in Transplantation*
208-210

705. *Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas*
Hall E

711. *Cell Collection and Processing I*
220-222

901. *Health Services and Quality—Non-Malignant Conditions: Better, Faster, Stronger: Innovations in Care Delivery, Care Cost, and Healthcare Teams in Classical Hematology*
295-296

4:30 p.m. – 6:30 p.m. Systems-Based Hematology Education and Networking Session

252-254

6:00 p.m. – 8:00 p.m. Poster Hall Reception (for in-person participants)

Hall D

6:00 p.m. – 8:00 p.m. Poster Session II – Presentations

Hall D

101. *Red Cells and Erythropoiesis, Excluding Iron: Poster II (2322–2336)*

102. *Iron Homeostasis and Biology: Poster II (2337–2347)*

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

112. *Thalassemia and Globin Gene Regulation: Poster II (2348–2355)*
113. *Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II (2356–2372)*
114. *Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster II (2373–2400)*
201. *Granulocytes, Monocytes, and Macrophages: Poster II (2401–2415)*
203. *Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2416–2424)*
301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II (2425–2442)*
311. *Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2443–2454)*
321. *Coagulation and Fibrinolysis: Basic and Translational: Poster II (2455–2462)*
322. *Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II (2463–2487)*
331. *Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II (2488–2497)*
332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2498–2517)*
401. *Blood Transfusion: Poster II (2518–2526)*
501. *Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2527–2538)*
503. *Clonal Hematopoiesis, Aging and Inflammation: Poster II (2539–2550)*
506. *Bone Marrow Microenvironment: Poster II (2551–2562)*
508. *Bone Marrow Failure: Acquired: Poster II (2563–2575)*
509. *Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2576–2584)*
602. *Myeloid Oncogenesis: Basic: Poster II (2585–2616)*
603. *Lymphoid Oncogenesis: Basic: Poster II (2617–2631)*
604. *Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2632–2656)*
605. *Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2657–2682)*
612. *Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2683–2696)*
613. *Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2697–2723)*
614. *Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2724–2734)*
615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2735–2755)*
616. *Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2756–2776)*
617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2777–2817)*
618. *Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2818–2834)*
621. *Lymphomas: Translational—Molecular and Genetic: Poster II (2835–2862)*
622. *Lymphomas: Translational—Non-Genetic: Poster II (2863–2881)*
623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (2882–2908)*
624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II (2909–2935)*
626. *Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II (2936–2956)*
627. *Aggressive Lymphomas: Clinical and Epidemiological: Poster II (2957–2991)*
631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (2992–3007)*
632. *Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3008–3027)*
634. *Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3028–3059)*
636. *Myelodysplastic Syndromes—Basic and Translational: Poster II (3060–3072)*
637. *Myelodysplastic Syndromes—Clinical and Epidemiological: Poster II (3073–3100)*
641. *Chronic Lymphocytic Leukemias: Basic and Translational: Poster II (3101–3113)*
642. *Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3114–3134)*
651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3135–3172)*
652. *Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3173–3231)*
653. *Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II (3232–3257)*
701. *Experimental Transplantation: Basic and Translational: Poster II (3258–3276)*
703. *Cellular Immunotherapies: Basic and Translational: Poster II (3277–3309)*
704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II (3310–3339)*
705. *Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II (3340–3360)*
711. *Cell Collection and Processing: Poster II (3361–3367)*
721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II (3368–3390)*
722. *Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II (3391–3412)*
723. *Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II (3413–3426)*
731. *Autologous Transplantation: Clinical and Epidemiological: Poster II (3427–3437)*
732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3438–3455)*
801. *Gene Therapies: Poster II (3456–3470)*
802. *Chemical Biology and Experimental Therapeutics: Poster II (3471–3483)*
803. *Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II (3484–3502)*
901. *Health Services and Quality—Non-Malignant Conditions: Poster II (3503–3526)*
902. *Health Services and Quality—Lymphoid Malignancies: Poster II (3527–3544)*
903. *Health Services and Quality—Myeloid Malignancies: Poster II (3545–3554)*
904. *Outcomes Research—Non-Malignant Conditions: Poster II (3555–3577)*

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

905. Outcomes Research—Lymphoid Malignancies: Poster II (3578–3619)

906. Outcomes Research—Myeloid Malignancies: Poster II (3620–3638)

MONDAY, DECEMBER 12, 2022

7:00 a.m. – 5:00 p.m. Registration (for in-person participants)

Great Hall Pre-Function

7:00 a.m. – 5:00 p.m. ASH COVID-19 Testing Centers (for in-person participants)

228-230 (Convention Center)

Eglinton Winton, Hilton New Orleans Riverside

7:00 a.m. – 7:45 a.m. ASH Wellness Studio

ASH Yoga

ASH Park @ the Plaza 1

7:30 a.m. – 9:00 a.m. Disability Community Networking Breakfast (for in-person participants)

Marriott New Orleans Warehouse Arts District, Gravier EF

8:00 a.m. – 9:00 a.m. Product Theaters

A Breakthrough For Patients: Complement Inhibition In Cold Agglutinin Disease

(for in-person participants)

Hall J - Theater 6

First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More

(for in-person participants)

Hall J - Theater 2

Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies

(for in-person participants)

Hall J - Theater 7

Perspectives on the Treatment of DVT/PE and Reduction in the Risk of Recurrent DVT/PE, Including Patients with Obesity and/or Cancer

(for in-person participants)

Hall J - Theater 5

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL

(for in-person participants)

Hall J - Theater 4

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Hall F

9:00 a.m. – 8:00 p.m. Poster Session III - Viewing

Hall D

9:00 a.m. – 10:00 a.m. E. Donnal Thomas Lecture and Prize: The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics

Hall E

10:00 a.m. – 2:00 p.m. Exhibits Open

Hall G-J

10:00 a.m. – 10:30 a.m. Health Equity Studio

Strategies to Overcome Healthcare Disparities

Hall F

10:00 a.m. – 10:30 a.m. Coffee Break in Exhibit Hall (for in-person participants)

Hall G-J

10:05 a.m. – 10:15 a.m. ASH Wellness Studio

Bringing Joy to Your World

Hall F

10:15 a.m. – 10:25 a.m. ASH Wellness Studio

The Real Purpose of Your Purpose

Hall F

10:15 a.m. – 10:30 a.m. Company Showcases

PICKUP Study: Pneumonia in the ImmunoCompromised – Use of the Karius Test® for the Detection of Undiagnosed Pathogens

(for in-person participants)

Hall J - Theater 6

10:30 a.m. – 11:45 a.m. Education Sessions

Improving Outcomes in ALL

R02-R05

10:30 a.m. – 11:45 a.m. Scientific Sessions

Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias (Scientific Committee on Blood Disorders in Childhood)

343-345

Plasma Cell Dyscrasias: Resistance to Immunotherapy: Mechanisms and Monitoring (Scientific Committee on Plasma Cell Neoplasia)

New Orleans Theater AB

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

10:30 a.m. – 11:45 a.m. Education Spotlight Sessions

Debate: Most/All Patients with Acquired (Immune) Thrombotic thrombocytopenic purpura (TTP) Receive Caplacizumab
295-296

Underrepresented minorities in clinical trials for hematologic malignancies: what's the data on the data?
R06-R09

10:30 a.m. – 12:00 p.m. ASH-FDA Joint Symposium on Newly Approved Drugs I

Great Hall A/D

10:30 a.m. – 12:00 p.m. Maternal Health in Hematology - Current Resources and Future Advocacy

Hall E

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions

114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Organ Function
353-355

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans
278-282

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium
293-294

321. Coagulation and Fibrinolysis: Basic and Translational
291-292

506. Bone Marrow Microenvironment: Extrinsic Regulators of Hematopoiesis
260-262

603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis
208-210

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance
275-277

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: High-risk T-ALL and Prognostic Biomarkers
Great Hall B/C

621. Lymphomas: Translational—Molecular and Genetic: Genomic Characterization
271-273

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Hodgkin Lymphoma: Retrospective Analyses and Prospective Trials
265-268

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Frontline Treatment of Large B-cell Lymphoma
La Nouvelle Orleans Ballroom C

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies and Surrogate Endpoints in ET and PV
217-219

641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers
La Nouvelle Orleans Ballroom AB

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Therapeutic Impact in Multiple Myeloma
New Orleans Theater C

653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions
288-290

705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy
393-396

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease
252-254

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence I
243-245

801. Gene Therapies: Advances in Clinical Gene Therapy for Hematological Disorders
220-222

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Clinical Implication of Artificial Intelligence in Precision Hematology
391-392

905. Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma
388-390

12:00 p.m. – 1:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Hall G-J

12:00 p.m. – 1:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ the Plaza 3

12:05 p.m. – 12:15 p.m. ASH Wellness Studio

Build a Bigger Brain and Longer Life
Hall F

12:15 p.m. – 12:45 p.m. Health Equity Studio

Overcoming Lack of Diversity in Clinical Trials
Hall F

12:15 p.m. – 1:15 p.m. Industry Theaters

A Clinical Overview of Olutasidenib: An Investigational Therapy, Currently Under FDA Review, For the Potential Treatment of Patients with Relapsed/Refractory mIDH1 AML
Hall J - Theater 4

From Science Fiction to Standard of Care: Developing the next wave of Genomic Medicines for Hematology (for in-person participants)
Hall J - Theater 6

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

12:15 p.m. – 1:15 p.m. Product Theaters

An Innovative Treatment Option for Appropriate Patients With cGVHD
(for in-person participants)
Hall J - Theater 7

Darzalex & Darzalex Faspro: A Frontline Treatment Approach for a Variety of Newly Diagnosed Multiple Myeloma Patient Types
(for in-person participants)
Hall J - Theater 5

DLBCL Treatment Landscape Overview for Fellows and APPs
(for in-person participants)
Hall J - Theater 2

**12:15 p.m. – 1:00 p.m. Meet the *Blood* Editors
(for in-person participants)**

Marriott New Orleans Warehouse Arts District, Julia

**12:15 p.m. – 1:15 p.m. ASH Choosing Wisely® Campaign: 2022
ASH Choosing Wisely Champions**

243-245

**12:15 p.m. – 1:15 p.m. Trainee Didactic Sessions (Open to
Trainees Only)**

Trainee Didactic Session: Entrepreneurship
217-219

Trainee Didactic Session: Giving A Scientific Presentation
220-222

12:20 p.m. – 12:30 p.m. ASH Wellness Studio

*Amplify Your Heart Brain for Improved Cognitive
Function and Emotional Stability*
Hall F

12:35 p.m. – 12:45 p.m. ASH Wellness Studio

Feel Better in Your Body
Hall F

1:00 p.m. – 1:30 p.m. Health Equity Studio

Overcoming Disparities in Career Development
Hall F

**1:30 p.m. – 2:30 p.m. Ernest Beutler Lecture and Prize: The
Complement System and Medicine: The
Good, the Bad, the Future**

Hall E

2:30 p.m. – 3:00 p.m. Health Equity Studio

Strategies to Improve Diversity and Inclusion in Healthcare and Industry
Hall F

**2:30 p.m. – 3:00 p.m. Coffee Break in Exhibit Hall (for in-person
participants)**

Hall G-J

2:35 p.m. – 2:45 p.m. ASH Wellness Studio

Straight Spine, Big Smile
Hall F

2:45 p.m. – 4:00 p.m. Education Sessions

Treatment Approaches for the Multiple Myeloma Patient in 2022
Great Hall A/D

Updates in Targeted Therapy in Pediatric Leukemia
343-345

*What is New in Classical Bone Marrow Failure
Syndromes? (focus on management)*
260-262

2:45 p.m. – 4:00 p.m. Scientific Sessions

*Histone Modifications and Chromatin Programs in Clonal Selection and
Cancer Emergence (Scientific Committee on Epigenetics and Genomics)*
275-277

*Morphology in a Genomic World (Scientific Committee on
Hematopathology and Clinical Laboratory Hematology)*
208-210

*Iron and Red Cells: A Co-Dependent Relationship
(Scientific Committee on Iron and Heme)*
265-268

2:45 p.m. – 4:00 p.m. Education Spotlight Sessions

Immunotherapies for myeloid neoplasms: are we ready for primetime?
New Orleans Theater AB

*Point/Counterpoint: The case for/against thrombophilia
testing in many/most adults with unprovoked thrombosis.*
288-290

2:45 p.m. – 4:00 p.m. Scientific Spotlight Sessions

Sowing the Seeds of Leukemia Before Birth
271-273

**2:45 p.m. – 4:15 p.m. Building a Nationwide Sickle Cell Disease
Data Hub and Learning Community**

217-219

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions

112. Thalassemia and Globin Gene Regulation I
220-222

*114. Hemoglobinopathies, Excluding Thalassemia: Clinical
and Epidemiological: Women's and Clinical Issues*
278-282

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies*
353-355

501. *Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental*
252-254

602. *Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution*
293-294

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML*
R02-R05

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML*
295-296

621. *Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology*
388-390

627. *Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome*
La Nouvelle Orleans Ballroom C

637. *Myelodysplastic Syndromes – Clinical and Epidemiological I*
243-245

651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences*
Hall E

652. *Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: New Approaches to MRD Assessment*
Great Hall B/C

721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II*
393-396

732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Results of Large Prospective Studies*
391-392

901. *Health Services and Quality—Non-Malignant Conditions: Level Up! Taking Quality Care to the Next Level in Sickle Cell Disease*
New Orleans Theater C

902. *Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care*
La Nouvelle Orleans Ballroom AB

904. *Outcomes Research—Non-Malignant Conditions: Sickle Cell Care Across the Lifespan*
R06-R09

905. *Outcomes Research—Lymphoid Malignancies: Outcomes in Childhood Leukemia/Lymphoma*
291-292

4:30 p.m. – 5:45 p.m. Education Sessions

Junior Faculty Career Development Education Session
New Orleans Theater AB

Late Effects Monitoring for Survivors of Pediatric Hematologic Malignancies
288-290

Thrombosis Prevention and Treatment
R02-R05

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease
343-345

4:30 p.m. – 5:45 p.m. AI and Machine Learning: A New Frontier in Hematology

Metabolic Regulation and Implications for Red Cells (Scientific Committee on Red Cell Biology)
275-277

4:30 p.m. – 6:00 p.m. ASH Guidelines on AML in Older Adults: Monitoring Emerging Evidence

295-296

4:30 p.m. – 6:00 p.m. ASH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals

265-268

4:30 p.m. – 6:00 p.m. ASH-FDA Joint Symposium on Newly Approved Drugs II

Great Hall A/D

4:30 p.m. – 6:00 p.m. Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

217-219

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions

102. Iron Homeostasis and Biology I
388-390

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP
220-222

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging
393-396

503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts and Biosamples
252-254

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms
353-355

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics
391-392

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations*
New Orleans Theater C

623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II*
R06-R09

624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T- and NK-cell Lymphomas: Prospective Trials and a Retrospective Analysis*
271-273

642. *Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19*
243-245

652. *Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring*
278-282

703. *Cellular Immunotherapies: Basic and Translational III*
La Nouvelle Orleans Ballroom C

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma*
Hall E

721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I*
260-262

902. *Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities*
La Nouvelle Orleans Ballroom AB

905. *Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation*
291-292

4:30 p.m. – 6:05 p.m. Scientific Symposia

Special Symposium on the Basic Science of Hemostasis and Thrombosis
208-210

5:30 p.m. – 8:00 p.m. ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease—Update and Reception (for in-person participants)

Marriott New Orleans Warehouse Arts District, Gravier DEF

6:00 p.m. – 8:00 p.m. Poster Hall Reception (for in-person participants)

Hall D

6:00 p.m. – 8:00 p.m. Poster Session III – Presentations

Hall D

101. *Red Cells and Erythropoiesis, Excluding Iron: Poster III (3639–3653)*

102. *Iron Homeostasis and Biology: Poster III (3654–3664)*

112. *Thalassemia and Globin Gene Regulation: Poster III (3665–3672)*

113. *Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III (3673–3690)*

114. *Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III (3691–3719)*

201. *Granulocytes, Monocytes, and Macrophages: Poster III (3720–3733)*

203. *Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3734–3742)*

301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III (3743–3760)*

311. *Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3761–3773)*

321. *Coagulation and Fibrinolysis: Basic and Translational: Poster III (3774–3781)*

322. *Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III (3782–3806)*

331. *Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III (3807–3816)*

332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (3817–3836)*

401. *Blood Transfusion: Poster III (3837–3845)*

501. *Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (3846–3858)*

503. *Clonal Hematopoiesis, Aging and Inflammation: Poster III (3859–3870)*

506. *Bone Marrow Microenvironment: Poster III (3871–3881)*

508. *Bone Marrow Failure: Acquired: Poster III (3882–3894)*

509. *Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (3895–3902)*

602. *Myeloid Oncogenesis: Basic: Poster III (3903–3935)*

603. *Lymphoid Oncogenesis: Basic: Poster III (3936–3950)*

604. *Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (3951–3976)*

605. *Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (3977–4002)*

612. *Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4003–4015)*

613. *Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4016–4042)*

614. *Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4043–4053)*

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4054–4073)*

616. *Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4074–4094)*

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4095–4134)*

618. *Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4135–4151)*

621. *Lymphomas: Translational—Molecular and Genetic: Poster III (4152–4178)*

622. *Lymphomas: Translational–Non-Genetic: Poster III (4179–4197)*

623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4198–4224)*

624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III (4225–4250)*

626. *Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III (4251–4270)*

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4271–4306)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4307–4323)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4324–4343)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4344–4376)
636. Myelodysplastic Syndromes—Basic and Translational: Poster III (4377–4389)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III (4390–4417)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III (4418–4430)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4431–4451)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4452–4489)
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4490–4549)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III (4550–4575)
701. Experimental Transplantation: Basic and Translational: Poster III (4576–4594)
703. Cellular Immunotherapies: Basic and Translational: Poster III (4595–4626)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4627–4656)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4657–4678)
711. Cell Collection and Processing: Poster III (4679–4685)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III (4686–4707)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4708–4728)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4729–4742)
731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4743–4754)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4755–4772)
801. Gene Therapies: Poster III (4773–4787)
802. Chemical Biology and Experimental Therapeutics: Poster III (4788–4801)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (4802–4819)
901. Health Services and Quality—Non-Malignant Conditions: Poster III (4820–4843)
902. Health Services and Quality—Lymphoid Malignancies: Poster III (4844–4861)
903. Health Services and Quality—Myeloid Malignancies: Poster III (4862–4872)
904. Outcomes Research—Non-Malignant Conditions: Poster III (4873–4895)
905. Outcomes Research—Lymphoid Malignancies: Poster III (4896–4937)
906. Outcomes Research—Myeloid Malignancies: Poster III (4938–4956)

6:30 p.m. – 7:30 p.m. Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Rivergate Terrace

7:30 p.m. – 9:30 p.m. Women in Hematology Networking Dinner

Hilton New Orleans Riverside, Jefferson Ballroom

TUESDAY, DECEMBER 13, 2022

7:00 a.m. – 1:30 p.m. Registration (for in-person participants)

Great Hall Pre-Function

7:00 a.m. – 1:30 p.m. ASH COVID-19 Testing Centers (for in-person participants)

228-230 (Convention Center)

Eglinton Winton, Hilton New Orleans Riverside

8:45 a.m. – 9:00 a.m. Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Hall E

9:00 a.m. – 10:30 a.m. Late-Breaking Abstracts Session

Hall E

11:00 a.m. – 12:30 p.m. Presidential Symposium

Hall E

12:30 p.m. – 2:00 p.m. Best of ASH

Hall E

2:00 p.m. – 2:15 p.m. Business Meeting

Hall E

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WEDNESDAY AND THURSDAY DECEMBER 14-15, 2022

To Be Announced	ASH Poster Walks (virtual platform only)
-----------------	--

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy

VIRTUAL PROGRAM

Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders

VIRTUAL PROGRAM

Platelets from Bench to Bedside

VIRTUAL PROGRAM

The Spectrum of Hemostasis and Thrombosis Research

VIRTUAL PROGRAM

What's Hot in Sickle Cell Disease Research 2022


VIRTUAL PROGRAM

Test your knowledge and earn CME credit at academy.hematology.org



Hematology 2022

AMERICAN SOCIETY of HEMATOLOGY
Education Program™
64th ASH® Annual Meeting and Exposition
December 10-13, 2022



CME/MOC Tests

**EARN UP TO 40 CME CREDITS OR
ABIM MOC POINTS*** by completing two
20-credit exams, one on malignant and the
other on non-malignant hematology.

► Purchase the CME/MOC test at
academy.hematology.org



Hematology 2022 content is at ashpublications.org/hematology



Hematology 2022
review articles from the
Educational Program at the
2022 ASH Annual Meeting.
Each chapter relates to a
different session presented
at the meeting, spanning
the spectrum from basic
discovery and disease
pathogenesis to the clinical
application at the bedside.

***Accreditation and Credit Designation**

The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Hematology designates this enduring material for a maximum of 40 AMA PRA Category 1 Credits™. Physicians who participate in this CME activity but are not licensed in the United States are also eligible for AMA Category 1 PRA Credit™.

***ABIM Maintenance of Certification**

Successful completion of this CME activity enables the participant to earn up to 40 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Notes:




Advancing Discovery. Accelerating Access.

City of Hope is rapidly translating hematologic breakthroughs into lifesaving treatments. With our acquisition of Cancer Treatment Centers of America, we are now one of the largest cancer research and treatment organizations in the country, providing patients with timely access to exceptional care, clinical trials and leading-edge innovation.


Visit us at Booth 1547 to learn more



CityofHope.org/ash22



INVITED SESSIONS



GENERAL SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential

Symposium. Many of the General Sessions also honor distinguished leaders in the field through awards and special lectures.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Ham-Wasserman Lecture

Saturday 12:30 p.m. – 1:30 p.m.
Hall E

Leukemogenesis in Infants and Young Children with Trisomy 21

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speaker:

IRENE ROBERTS, MD, Weatherall Institute of Molecular Medicine, Oxford, England, United Kingdom

SUNDAY

ASH-EHA Joint Symposium

Sunday 12:30 p.m. – 1:30 p.m.
Hall E

Germline Predisposition and Hereditary Hematopoietic Neoplasia

Chairs:

ELIZABETH A. MACINTYRE, PhD, MD, Tour Pasteur Hospital Necker Enfants Malades, Paris, France

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speakers:

CHARLOTTE M. NIEMEYER, MD, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany

LUCY A. GODLEY, MD, PhD, University of Chicago Medical Center, Chicago, IL

Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award

Sunday 1:30 p.m. – 2:00 p.m.
Hall E

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Plenary Scientific Session

Sunday 2:00 p.m. – 4:00 p.m.
Hall E

Chair:

ROBERT A. BRODSKY, MD, President-Elect, American Society of Hematology, Johns Hopkins University, Baltimore, MD

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MONDAY

E. Donnell Thomas Lecture and Prize

Monday 9:00 a.m. – 10:00 a.m.
Hall E

The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speaker:

BRUCE R. BLAZAR, MD, University of Minnesota, Minneapolis, MN

Ernest Beutler Lecture and Prize

Monday 1:30 p.m. – 2:30 p.m.
Hall E

The Complement System and Medicine: The Good, the Bad, the Future

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Speakers:

JOHN ATKINSON, MD, Washington University, Saint Louis, MO
Basic Science

PETER HILLMEN, MD, PhD, St. James's University Hospital, Leeds, United Kingdom
Clinical/Translational Science

TUESDAY

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Tuesday 8:45 a.m. – 9:00 a.m.
Hall E

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

Late-Breaking Abstracts Session

Tuesday 9:00 a.m. – 10:30 a.m.
Hall E

Co-Chairs:

DAVID A. GARCIA, MD, University of Washington, Seattle, WA

OLATOYOSI ODENIKE, MD, University of Chicago, Chicago, IL

Presidential Symposium

Tuesday 11:00 a.m. – 12:30 p.m.
Hall E

What the Hematologist Has Learned from the Pandemic

Chair:

JANE N. WINTER, MD, President, American Society of Hematology, Northwestern University, Chicago, IL

SPECIAL INTEREST SESSIONS

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

ASH Wellness Studio Hall F

7:00 a.m. - 7:45 a.m.	ASH Yoga (ASH Park @ the Plaza 1)
9:05 a.m. - 9:15 a.m.	Bringing Joy to Your World
9:15 a.m. - 9:25 a.m.	Breathe Well to Feel Well
11:05 a.m. - 11:15 a.m.	Money Issues are Burning You Out
11:20 a.m. - 11:30 a.m.	One Breath to the Most Kind, Compassionate, and Grateful You!
11:35 a.m. - 11:45 a.m.	Fix the Way You Sit
1:35 p.m. - 1:45 p.m.	A Simple Way to More Resilience
1:45 p.m. - 1:55 p.m.	Financial Order of Operations
3:35 p.m. - 3:45 p.m.	Workday Tension Timeout
3:45 p.m. - 3:55 p.m.	Use Your Character Strengths to Get Through Trying Times

Health Equity Studio Hall F

9:00 a.m. - 9:30 a.m.	Defining Inequity and Root Causes of Health Inequity
11:15 a.m. - 11:45 a.m.	Recognizing and Addressing Implicit Bias
1:30 p.m. - 2:00 p.m.	Strategies to Overcome Healthcare Disparities
3:30 p.m. - 4:00 p.m.	Overcoming Lack of Diversity in Clinical Trials

Training Program Directors' Workshop

Friday 9:00 a.m. – 12:00 p.m.
Cypress, Marriott New Orleans
Warehouse Arts District (for in-person participants)

Chair:

ALFRED LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

Speakers:

CECELIA CALHOUN, MD, MBA, Yale University, New Haven, CT

ALAN MAST, MD, PhD, Versiti Blood Center of Wisconsin, Milwaukee, WI
Diversity, Equity, and Inclusion

SOO PARK, MD, University of California, San Diego, CA

JOANNE FILICKO-O'HARA, MD, Jefferson University, Philadelphia, PA
Mentorship and Career Development

VALENTINA BAEZ SOSA, MD, MedStar Washington Hospital, Washington, DC

LESLIE ELLIS, MD, MSHPEd, Wake Forest Baptist Hospital, Winston Salem, NC

How the Personal Characteristics of Grit and Resilience Relate to Physician Well-Being

Blood Presents: How to Get Published in a Peer Review Journal

Saturday 11:15 a.m. – 12:15 p.m.
252-254

NANCY BERLINER, MD, Editor-in-Chief, *Blood*, Brigham and Women's Hospital, Boston, MA

ANDREW W. ROBERTS, PhD, MBBS, Deputy Editor-in-Chief, *Blood*, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Grassroots Network Lunch

Saturday 11:15 a.m. – 12:15 p.m.
**St. James Ballroom, Hilton New Orleans
 Riverside**

Chair:

JENNIFER HOLTER CHAKRABARTY, MD, University of
 Oklahoma, Oklahoma City, OK

Speaker:

VERONICA GILLISPIE-BELL, MD, Ochsner Health System,
 New Orleans, LA
*The Intersection of Hematology and
 Gynecology and How to Get Involved*

Blood Advances Meet the Editors

Saturday 2:00 p.m. – 3:00 p.m.
**Julia, Marriott New Orleans Warehouse
 Arts District (for in-person participants)**

Speakers:

MARGARET V. RAGNI, MD, Associate Editor, *Blood
 Advances*, University of Pittsburgh, Pittsburgh, PA
 CONSTANTINE TAM, MBBS, MD, Associate Editor, *Blood
 Advances*, Monash University, Clayton, Victoria,
 Australia

Special Symposium on Quality: Quality Improvement Education and Training

Saturday 2:00 p.m. – 3:30 p.m.
295-296

Chair:

MICHAEL KENG, MD, University of Virginia,
 Charlottesville, VA

Speakers:

JOSE AZAR, MD, Indiana University Simon Cancer
 Center, Indianapolis, IN
Quality Improvement Overview

ASHLEY E. ROSKO, MD, The Ohio State University,
 Columbus, OH

*Quality Improvement Project, Implementing
 Age-Friendly practices in Older Adults
 with Hematologic Malignancies*

RACHAEL F. GRACE, MD, Boston Children's Hospital,
 Boston, MA

*Quality Improvement Project, Immune
 Thrombocytopenia (ITP)*

Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan


Saturday 4:00 p.m. – 5:30 p.m.
La Nouvelle Orleans Ballroom AB


Promoting Minorities in Hematology: Presentations and Reception

Saturday 6:30 p.m. – 9:00 p.m.
**The District Foyer, Hilton New Orleans
 Riverside**

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

ASH Wellness Studio Hall F 	
9:05 a.m. - 9:15 a.m.	Build a Bigger Brain and Longer Life
9:15 a.m. - 9:25 a.m.	Use Your Character Strengths to Get Through Trying Times
11:05 a.m. - 11:15 a.m.	Coping With Financial Strain and Gain
11:20 a.m. - 11:30 a.m.	Feel Better in Your Body
11:35 a.m. - 11:45 a.m.	Regulate Your Genes for More Energy and Less Inflammation
4:05 p.m. - 4:15 p.m.	The Greatest Medicine...A True Friend
4:15 p.m. - 4:25 p.m.	Fix the Way You Sit

Health Equity Studio Hall F 	
9:00 a.m. - 9:30 a.m.	Overcoming Disparities in Career Development
11:15 a.m. - 11:45 a.m.	Strategies to Improve Diversity and Inclusion in Healthcare and Industry
12:30 p.m. - 1:00 p.m.	Defining Inequity and Root Causes of Health Inequity
4:00 p.m. - 4:30 p.m.	Recognizing and Addressing Implicit Bias

Medical Educators' Symposium 

Sunday 7:30 a.m. – 9:30 a.m.
Cypress, Marriott New Orleans Warehouse Arts District

Chair:

SANJAY R. MOHAN, MD, MSCI, Vanderbilt University, Nashville, TN

Speakers:

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT
Burnout and Faculty Engagement

ANISH V. SHARDA, MBBS, Beth Israel Deaconess Medical Center, Boston, MA
Mentorship

SRIKANTH NAGALLA, MBBS, MS, Miami Cancer Institute, Miami, FL
Breakout Session #1: How to Write a Good Test Question

TAMARA DUNN, MD, Stanford University, Stanford, CA
Breakout Session #2: How to Progress in Your Academic Career as a Medical Educator

RAKESH P. MEHTA, MD, Indiana University School of Medicine, Indianapolis, IN
Breakout Session #3: How to Write a Good Letter of Recommendation

LESLIE ELLIS, MS, Wake Forest Baptist Health, Winston Salem, NC
Breakout Session #4: How Do Programs Collect Information and Data

ASH Guideline Implementation Champions

Sunday 9:30 a.m. – 11:00 a.m.
353-355

Moderator:

RACHEL P. ROSOVSKY, MD, MPH, Massachusetts General Hospital, Boston, MA

Speakers:

JORDAN K. SCHAEFER, MD, University of Michigan, Ann Arbor, MI
 WILSON ANDRES VASCONEZ SAMANIEGO, MD, University of Miami/Jackson Memorial Hospital, Miami, FL
 JORI E. MAY, MD, University of Alabama at Birmingham, Birmingham, AL
ASH Guideline Implementation Project

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Meet the *Blood* Editors

Sunday 11:15 a.m. – 12:00 p.m.
Julia, Marriott New Orleans Warehouse Arts District

Speakers:

HELEN E. HESLOP, MD, Associate Editor, *Blood*, Baylor College of Medicine, Houston, TX
 THOMAS L. ORTEL, MD, PhD, Associate Editor, *Blood*, Duke University, Durham, NC

Blood Advances Presents: How to Peer Review a Scientific Paper

Sunday 11:15 a.m. – 12:15 p.m.
252-254 (for in-person participants)

Speakers:

LESLIE S. KEAN, MD, PhD, Associate Editor, *Blood Advances*, Boston Children's Hospital, Boston, MA
 ANDREW WEYRICH, PhD, Deputy Editor, *Blood Advances*, Oklahoma Medical Research Foundation, Oklahoma City, OK

LGBTQIA+ Community Networking Brunch

Sunday 11:15 a.m. – 12:15 p.m.
Gravier AB, Marriott New Orleans Warehouse Arts District

ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology

Sunday 11:15 a.m. – 12:30 p.m.
St. James Ballroom, Hilton New Orleans Riverside

Chair:

CHANCELLOR E. DONALD, MD, Tulane University School of Medicine, New Orleans, LA

Speakers:

JANICE W. LAWSON, MD, Tallahassee Memorial Hospital, Tallahassee, FL
How to Practice Classical Hematology When It's Outside Your Comfort Zone

DAVID GARCIA, MD, University of Washington, Seattle, WA
Justifying the Value of Classical Hematology

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT
Getting Young Hematologists Interested in Classical Hematology

ASH Health Equity Rounds Lunch

Sunday 11:30 a.m. – 12:30 p.m.
Cypress, Marriott New Orleans Warehouse Arts District

Moderator:

JACQUELYN M. POWERS, MD, MSc, Baylor College of Medicine/Texas Children's Hospital, Houston, TX

Speaker:

ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI

Gender Disparities in Bleeding Disorders

PAULA JAMES, MD, Queen's University, Kingston, Ontario, Canada

Gender Disparities in Bleeding Disorders

Blood and Beyond

Sunday 4:30 p.m. – 6:00 p.m.
265-268

Chair:

NANCY BERLINER, MD, Editor-in-Chief, *Blood*, Brigham and Women's Hospital, Boston, MA

Speaker:

JOHN M. BARRY, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, author of *The Great Influenza: The Epic Story of the Deadliest Plague in History* a #1 New York times best seller and named by the National Academies of Science as the year's best book on science.

The Great Influenza: The Epic Story of the Deadliest Plague in History

ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer

Sunday 4:30 p.m. – 6:00 p.m.
271-273

Chair:

MARC CARRIER, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada

Speakers:

MARC CARRIER, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada

Risk Assessment and Prophylaxis

RADHIKA GANGARAJU, MD, University of Alabama, Birmingham, AL

Treatment and Secondary Prevention

ANG LI, MD, MS, Baylor College of Medicine, Houston, TX

Implementation Strategies Regarding Venous Thromboembolism (VTE) in Patients with Cancer

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Systems-Based Hematology Education and Networking Session 

Sunday 4:30 p.m. – 6:30 p.m.
252-254

Chair:

MARC S. ZUMBERG, MD, University of Florida, Gainesville, FL

Speakers:

MICHAEL B. STREIFF, MD, Johns Hopkins Medical Institutions, Baltimore, MD

A Systems-Based Approach to the Prevention and Management of Cancer-Associated Thrombosis

ANNETTE S. KIM, MD, PhD, Brigham and Women’s Hospital, Boston, MA

Avoiding Overuse of Molecular/Genetic Testing Via Systems-Level Interventions

MONDAY

ASH Wellness Studio Hall F 

- 7:00 a.m. - 7:45 a.m. ASH Yoga (ASH Park @ the Plaza 1)
- 10:05 a.m. - 10:15 a.m. Bringing Joy to Your World
- 10:15 a.m. - 10:25 a.m. The Real Purpose of Your Purpose
- 12:05 p.m. - 12:15 p.m. Build a Bigger Brain and Longer Life
- 12:20 p.m. - 12:30 p.m. Amplify Your Heart Brain for Improved Cognitive Function and Emotional Stability
- 12:35 p.m. - 12:45 p.m. Feel Better in Your Body
- 2:35 p.m. - 2:45 p.m. Straight Spine, Big Smile

Health Equity Studio Hall F 

- 10:00 a.m. - 10:30 a.m. Strategies to Overcome Healthcare Disparities
- 12:15 p.m. - 12:45 p.m. Overcoming Lack of Diversity in Clinical Trials
- 1:00 p.m. - 1:30 p.m. Overcoming Disparities in Career Development
- 4:00 p.m. - 4:30 p.m. Strategies to Improve Diversity and Inclusion in Healthcare and Industry

Disability Community Networking Breakfast



Monday 7:30 a.m. – 9:00 a.m.
Gravier EF, Marriott New Orleans Warehouse Arts District

ASH-FDA Joint Symposium on Newly Approved Drugs I

Monday 10:30 a.m. – 12:00 p.m.
Great Hall A/D

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Maternal Health in Hematology - Current Resources and Future Advocacy

Monday 10:30 a.m. – 12:00 p.m.
Hall E

Moderator:

SARAH H. O'BRIEN, MD, Nationwide Children's Hospital, Columbus, OH

Speakers:

JEROME D. WINEGARDEN III, MD, St. Joseph Mercy Hospital Cancer Center/Cancer Research Consortium of West Michigan, National Cancer Institute Community Oncology Research Program, Ann Arbor, MI

Amicus Brief: a Michigan Study

MIKKAEL A. SEKERES, MD, University of Miami, Sylvester Comprehensive Cancer, Miami, FL

Op-ed: a Washington Post Study

DEVA SHARMA, MD, Vanderbilt University Medical Center

Grassroots Advocacy: a Tennessee Study

Meet the Blood Editors

Monday 12:15 p.m. – 1:00 p.m.
Julia, Marriott New Orleans Warehouse Arts District
(for in-person participants)

Speakers:

SELINA M. LUGER, MD, FRCPC, University of Pennsylvania, Philadelphia, PA

IRENE ROBERTS, MD, Weatherall Institute of Molecular Medicine, Oxford, ENG, United Kingdom

ASH Choosing Wisely® Campaign: 2022 ASH Choosing Wisely Champions

Monday 12:15 p.m. – 1:15 p.m.
243-245

Chair:

MARC S. ZUMBERG, MD, University of Florida, Gainesville, FL

Speakers:

JULIA FORTIER, MD, University of Florida, Gainesville, FL

Reducing Unnecessary Pre-Medication Prior to Parenteral Iron Therapy

DAANISH HODA, MD, LDS Hospital, Salt Lake City, UT

Reducing Overtesting and Overdiagnosis of Clostridioides Difficile Infection in the Setting of an HSCT Unit

KAMAL K SAHU, MD, DM, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Implementation of New Electronic Medical Record Algorithm to Streamline the Appropriate Use of Rasburicase

Building a Nationwide Sickle Cell Disease Data Hub and Learning Community

Monday 2:45 p.m. – 4:15 p.m.
217-219

Chair:

ALEXIS A. THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

ALEXIS A. THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Introduction

The Role of a Nationwide SCD Data Hub and Learning Community

Moderated Q&A

CAROLE LANNON, MD, MPH, Cincinnati Children's, Cincinnati, OH

Designing a Nationwide Learning Community

AMANDA M. BRANDOW, DO, MS, Medical College of Wisconsin, Milwaukee, WI

Better Quality Through Better Measurement

VENEE N. TUBMAN, MD, MMSc, Texas Children's Hospital, Houston, TX

Building Your Team to Drive Improvement

ALEXIS A. THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Moderated Panel Q&A

Conclusion

ASH-FDA Joint Symposium on Newly Approved Drugs II

Monday 4:30 p.m. – 6:00 p.m.
Great Hall A/D

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

Monday 4:30 p.m. – 6:00 p.m.
217-219

Chair:

WILLIAM A. WOOD JR., MD, MPH, University of North Carolina, Chapel Hill, NC

Speakers:

WILLIAM A. WOOD JR., MD, MPH, University of North Carolina, Chapel Hill, NC
Introduction

LARS BULLINGER, MD, PhD, Charité University Medicine Berlin, Berlin, Germany

ADAM S. SPERLING, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

JESÚS MARÍA HERNÁNDEZ-RIVAS, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain
Impact of Real-World Evidence on Research and Clinical Care: Priorities from ASH RC DataHub and EU HARMONY Alliance

WILLIAM A. WOOD JR., MD, MPH, University of North Carolina, Chapel Hill, NC
Pandemic Preparedness: Highlighting the Role of Real-World Data Hub Programs

SAMUEL RUBINSTEIN, MD, Vanderbilt University Medical Center, Chapel Hill, NC
Moderated Q&A

KONSTANZE DÖHNER, MD, University Hospital of Ulm, Ulm, Germany

JAN GEISSLER, Acute Leukemia Advocates Network, Bern, Switzerland
HARMONY Alliance: Moving Toward Multicenter Real-World Data Capture in the Hematologic Malignancies in Europe (Patient involvement in big data research)

DONNA S. NEUBERG, ScD, Dana-Farber Cancer Institute, Boston

BRIAN J.P HUNTLY, MB ChB, FRCPath, FMedSci, PhD, University of Cambridge, Cambridge, England, United Kingdom
Building Real-World Research and Collaborative Practice Networks for Malignant Hematology

BINDU KANAPURU, Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

A Regulators View: The Impact of Reliable and Relevant Real-World Data on Measuring Safety and Efficacy

LARS BULLINGER, MD, PhD, Charité University Medicine Berlin, Berlin, Germany
A Call to Action and Collaboration

WILLIAM A. WOOD JR., MD, MPH, University of North Carolina, Chapel Hill, NC
Moderated Q&A

AI and Machine Learning: A New Frontier in Hematology

Monday 4:30 p.m. – 6:00 p.m.
Great Hall B/C

Chair:

AZIZ NAZHA, MD, Incyte, Wilmington, DE

Speakers:

AZIZ NAZHA, MD, Early Drug Development, Incyte, Westlake, OH
AI 101: Why is AI and Machine Learning Important in Hematology?

OLIVIER ELEMENTO, PhD, Weill Cornell Medicine, New York, NY
The Application of Machine Learning in Diagnostic Hematology

ILANA GOLDBERG, PhD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
AI in the Clinic: The Current Translation of Machine Learning Algorithms into Clinical Decision Tools

SHANNON K. McWEENEY, PhD, Oregon Health & Science University, Portland, OR
AI Challenges in Regulatory Approvals and Explicability

ASH Guidelines on AML in Older Adults: Monitoring Emerging Evidence

Monday 4:30 p.m. – 6:00 p.m.
295-296

Chair:

MIKKAEL A. SEKERES, MD, University of Miami, Sylvester Comprehensive Cancer, Miami, FL

Speakers:

LAURA C. MICHAELIS, MD, The Medical College of Wisconsin, Milwaukee, WI
Monitoring and Updating of the ASH AML Guidelines

MARK R. LITZOW, MD, Mayo Clinic, Rochester, MN
Updates on Induction Therapy for Older Adults with AML

KRISTEN MARIE O'DWYER, MD, University of Rochester Medical Center, Rochester, NY
Updates on Post-Remission Therapy for Older Adults with AML

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ASH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals

Monday 4:30 p.m. – 6:00 p.m.
265-268

Chair:

NATHAN T. CONNELL, MD, Brigham and Women's Hospital, Boston, MA

Speakers:

JEAN M. GROW, PhD, Marquette University, Milwaukee, WI

Impact of the VWD Guidelines on Patients

LEONARD A. VALENTINO, MD, National Hemophilia Foundation, New York, NY

Impact of the VWD Guidelines on the Legislative and Policy Agendas

PENNI JO SMITH, MPA, BSN, RN-BC, Primary Children's Hospital, Salt Lake City, UT

Impact of the VWD Guidelines on Allied Health Professionals

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease Update and Reception

Monday 5:30 p.m. – 8:00 p.m.
Gravier DEF, Marriott New Orleans Warehouse Arts District

Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Monday 6:30 p.m. – 7:30 p.m.
Rivergate Terrace

Women in Hematology Networking Dinner

Monday 7:30 p.m. – 9:30 p.m.
Jefferson Ballroom, Hilton New Orleans Riverside

TRAINEE ACTIVITIES

ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience. The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows.

These activities are open only to individuals with a blue trainee badge or received invitation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

FRIDAY

ASH-a-Palooza

Friday 12:30 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

This is ASH's premier trainee event complete with micro-learning sessions, mentorship opportunities, and more! It is only open to trainees wearing a blue badge. ASH Talks are TED Talk style didactic presentations on topical subjects for trainees. Blood Drops are 5-10 minute presentations on various hematology topics that are presented twice. Blood buddies are one-on-one, ten-minute sessions to discuss career tracks and seek advice for faculty members.

ASH Talk Opening Song and Welcome

Friday 12:45 p.m. – 1:00 p.m.
River City Ballroom, Mardi Gras World

Speakers:

RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children's Hospital, Houston, TX
TED WUN, MD, University of California Davis School of Medicine, Sacramento, CA
BECKY ZON, MD, Dana-Farber Cancer Institute, Boston, MA

ASH Talk #1: Learning in a Virtual Space: How trainees can capitalize social media and virtual tools

Friday 1:00 p.m. – 1:20 p.m.
River City Ballroom, Mardi Gras World

Speaker:

ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI

Blood Buddies (In-Person)

Friday 1:30 p.m. – 2:00 p.m., 2:40 p.m. – 3:10 p.m., 4:35 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

Adult Clinical Classical Hematology

GOWTHAMI M. AREPALLY, MD, Duke University Medical Center, Durham, NC

MARC CARRIER, MD, MSc, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada

ANNEMARIE E. FOGERTY, MD, Massachusetts General Hospital, Boston, MA

ALICE MA, MD, University of North Carolina At Chapel Hill, Chapel Hill, NC

ENRICO M. NOVELLI, MD, University of Pittsburgh, Pittsburgh, PA

Adult Clinical Malignant Hematology

HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic, Cleveland, OH

DAVID L. GRINBLATT, MD, NorthShore University HealthSystem, Evanston, IL

MATTHEW ULRICKSON, MD, Banner/MD Anderson Cancer Center, Gilbert, AZ

ALISON R. WALKER, MD, The Ohio State University Medical Center, Powell, OH

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

BMT Peds and Adult

HANY ELMARIAH, MD, MS, Moffitt Cancer Center, Tampa, FL

DEEPA JAGADEESH, MD, Cleveland Clinic, Cleveland, OH

JAMES LABELLE, MD, PhD, University of Chicago, Chicago, IL

KRISTIN M. PAGE, MD, Duke University Medical Center, Durham, NC

Diversity, Equity, and Inclusion (DEI)

LANETTA BRONTÉ-HALL, MPH, MSPH, MD, The Foundation of Sickle Cell Disease Research, Hollywood, FL

PATRICK T. MCGANN, MD, PhD, Children's Hospital Medical Center, Providence, RI

WALLY R. SMITH, MD, Virginia Commonwealth University, Richmond, VA

DEIRDRA R. TERRELL, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Medical Education

TAMARA J. DUNN, MD, Stanford University, Stanford, CA

HIRA LATIF, MD, MedStar Washington Hospital Center, Baltimore, DC

TIFFANY LIN LUCAS, MD, University of California—San Francisco, San Francisco, CA

USHA PEREPU, MBBS, University of Iowa Hospitals and Clinics Program, Iowa City, IA

Medical Student & Residents

MARTHA L. ARELLANO, MD, Winship Cancer Institute of Emory University, Atlanta, GA

ROBERT D. BONA, MD, Frank H. Netter, M.D., School of Medicine at Quinnipiac University, Hamden, CT

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN

MARIA OLIVARES BOUCHER, MD, Albany Medical Center, Albany, NY

LAURA DECASTRO, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

REED E. DREWS, MD, Beth Israel Deaconess Medical Center, Boston, MA

ANNIE IM, MD, University of Pittsburgh Cancer Institute, Pittsburgh, PA

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

MICHAEL LINENBERGER, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA

RAKHI P. P. NAIK, MD, Johns Hopkins Hospital, Baltimore, MD

SANA SAIF UR REHMAN, MD, Washington University School of Medicine, Saint Louis, MO

Pediatric Clinical Classical Hematology

LEILA JEROME CLAY, MD, Johns Hopkins University, St Petersburg, FL

JILL DE JONG, MD, PhD, University of Chicago, Chicago, IL

SEETHAL A. JACOB, MD, MS, Riley Hospital For Children, Indianapolis, IN

JULIE JAFFRAY, MD, MS, Children's Hospital of Los Angeles, Los Angeles, CA

Pediatric Clinical Malignant Hematology

KARA M. KELLY, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

JENNIFER L. MCNEER, MD, University of Chicago, Chicago, IL

ANDREW E. PLACE, MD, PhD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children's Hospital, Houston, TX

PhD/ Lab & Translational Hematology

DAVID M. BODINE, PhD, National Institutes of Health, Bethesda, MD

ANDRES CHANG, MD, PhD, Emory University, Atlanta, GA

RANDAL J. WESTRICK, PhD, Oakland University, Rochester, MI

ISHAC NAZY, PhD, McMaster University, Hamilton, Ontario, Canada

JEREMY P. WOOD, PhD, University of Kentucky, Lexington, KY

Quality Improvement

NATHAN T. CONNELL, MD, Brigham and Women's Hospital, Boston, MA

MARIA I. JUAREZ, MD, Dallas Oncology Consultants, Duncanville, TX

JORDAN K. SCHAEFFER, MD, University of Michigan, Ann Arbor, MI

Blood Drops

Friday	1:30 p.m. – 1:40 p.m., 1:50 p.m. – 2:00 p.m. River City Ballroom, Mardi Gras World
---------------	---

Clinical Research Training Institute (CRTI)

JEFFREY D. LEBENBURGER, DO, University of Alabama at Birmingham, Birmingham, AL

Diversity, Equity, and Inclusion

TAMARA J. DUNN, MD, Stanford University, Stanford, CA,

Malignant Hematology

BRIAN A. JONAS, MD, PhD, University of California, Davis, Sacramento, CA

Minority Medical Student Award Program (MMSAP)

PhD

ZE ZHENG, MBBS, PhD, Columbia University, Milwaukee, WI

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Quality Improvement

ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Research Training Award Fellows (RTAF)

ADAM YUH LIN, MD, PhD, Northwestern University, Chicago, IL

Sickle Cell Disease

JANE S. HANKINS, MD, MS, St. Jude Children's Research Hospital, Memphis, TN

Wellness

LAURA DE CASTRO, MD, MBBS, University of Pittsburgh Medical Center, Pittsburgh, PA

ASH Talk #2: The Resilient Trainee

Friday 2:10 p.m. – 2:30 p.m.
River City Ballroom, Mardi Gras World

Speaker:

ATHALIA PYZER, MD, PhD, University of Chicago Medicine, Chicago, IL

Blood Drops

Friday 2:40 p.m. – 3:00 p.m.,
3:00 p.m. – 3:10 p.m.
River City Ballroom, Mardi Gras World

ASH-Harold Amos Medical Faculty Development Program (AMFDP)

JUSTIN TAYLOR, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

Diversity, Equity, and Inclusion

TIFFANY LIN LUCAS, MD, University of California, San Francisco, San Francisco, CA

Hematology Opportunities for the Next Generation (HONORS)

GEORGIOS E. CHRISTAKOPOULOS, MD, University of Minnesota Medical School, Masonic Children's Hospital, Memphis, TN

Malignant Hematology

WENDY STOCK, MD, University of Chicago, Chicago, IL

PhD

WEI TONG, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Quality Improvement

ELIZABETH J. SHPALL, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

ASH-Harold Amos Medical Faculty Development Program (AMFDP)

JUSTIN TAYLOR, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL

Sickle Cell Disease

SOPHIE M. LANZKRON, MD, Johns Hopkins Medicine, Baltimore, MD

Translational Research Training in Hematology (TRTH)

ANDRES CHANG, MD, PhD, Emory University, Atlanta, GA

Wellness

PAUL A. S. FISHKIN, MD, Illinois Cancer Care, Peoria, IL

Blood Drops

Friday 4:35 p.m. – 4:45 p.m.,
4:50 p.m. – 5:00 p.m.
River City Ballroom, Mardi Gras World

SCHOLAR

SHANNON ELE, PhD, Division of Biological Sciences, The University of Chicago, Chicago, IL

ASH Medical Educators Institute (ASH MEI)

SRIKANTH NAGALLA, MD, MS, UT Southwestern, Dallas, TX

Diversity, Equity, and Inclusion

ALAN E. MAST, MD, PhD, Versiti (Blood Center of Wisconsin), Milwaukee, WI

Malignant Hematology

ALLISON WALKER, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

PhD

Physician-Scientist Award (Phy-Sci)

ALEXANDER F. M. CRAIG, MPhil, Stanford University Medical Center, Stanford, CA

Quality Improvement

DONALD M. ARNOLD, MD, MSc, McMaster University, Hamilton, ON, Canada

Sickle Cell Disease

Wellness

PETER A. KOUIDES, MD, Rochester General Hospital, Rochester, NY

Trainee Welcome Reception

Friday 5:00 p.m. – 7:00 p.m.
Float Den, Mardi Gras World

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

SATURDAY

Career Development Lunch 

Saturday 11:15 a.m. – 12:15 p.m.
St. Charles Ballroom, Hilton New Orleans Riverside

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

A boxed lunch is provided. There will be one hematology leader, assigned with a topic, at a table where trainees are welcome to eat lunch and chat about that topic.

Adult and Pediatric BMT

MOHAMED A. KHARFAN-DABAJA, MD, MBA, Division of Hematology/Oncology and Blood and Marrow Transplantation and Cellular Therapy, Mayo Clinic, Jacksonville, FL

LORI MUFFLY, MD, Division of BMT and Cellular Therapy, Stanford University, Stanford, CA

RACHEL PHELAN, MD, MPH, Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

Adult Clinical Classical Hematology

SHRUTI CHATURVEDI, MBBS, Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

ANJLEE MAHAJAN, MD, UC Davis Comprehensive Cancer Center, Sacramento, CA

STEPHAN MOLL, MD, Division of Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, NC

ANITA RAJASEKHAR, MD, University of Florida - Shands Hospital, Gainesville, FL

Adult Clinical Malignant Hematology

KAREN CARLSON, MD, PhD, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

HETTY E. CARRAWAY, MD, MBA, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH

COURTNEY D. DiNARDO, MD, MSCE, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

ANTHONY R. MATO, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY

Clinical Careers in Hematology (Private Practice
Careers)

PETER A. KOUIDES, MD, Department of Medicine, Mary M. Gooley Hemophilia Center, Rochester, NY

Global Hematology

EUGENIA VICKY VICKY ASARE, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana

ALI BAZARBACHI, MD, PhD, Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

ADLETTE INATI, MD, FAAP, Lebanese American University, School of Medicine, Byblos, Lebanon

RUSSELL E. WARE, MD, PhD, Division of Hematology, Children's Hospital Medical Center, Cincinnati, OH

Industry Careers

GREGORY J. KATO, MD, Heart, Lung and Blood Vascular Medicine Institute/Division of Hematology-Oncology/Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

WEILI SUN, MD, PhD, Department of Pediatrics, City of Hope Medical Center, Duarte, CA

Laboratory and Translational Hematology

OLGA A. GURYANOVA, MD, PhD, University of Florida, Gainesville, FL

ANDREW VOLK, PhD, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

ALISA S. WOLBERG, PhD, UNC Blood Research Center, University of North Carolina At Chapel Hill, Chapel Hill, NC

Medical Educators in Hematology

NADIA D. ALI, MD, Section of Hematology, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

ANDREW RW O'BRIEN, MD, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN

PhD Careers

MARGARET A. GOODELL, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX

COURTNEY L. JONES, PhD, University of Toronto, Toronto, ON, Canada

ZE ZHENG, MBBS, PhD, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Systems-Based Hematology

DAVID A. GARCIA, MD, Division of Hematology, University of Washington, Seattle, WA

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

COLLEEN MORTON, MD, Vanderbilt University Medical Center, Nashville, TN

RAKHI P. P. NAIK, MD, Division of Hematology, Johns Hopkins University, Baltimore, MD

SUNDAY – MONDAY

Trainee Didactic Sessions

Offered during lunch on Sunday and Monday, the Trainee Didactic Sessions are designed to offer trainees an overview of timely and relevant career-oriented issues.

Trainee Didactic Session: How to Transition from Trainee to Faculty

Sunday 11:15 a.m. – 12:15 p.m.
220-222

Chair:

JULIAN SPRAGUE, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:

ANDREW VOLK, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

LACHELLE D. WEEKS, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Trainee Didactic Session: Writing a Good CV, Portfolio, and Biosketch

Sunday 11:15 a.m. – 12:15 p.m.
217-219

Chair:

JULIAN SPRAGUE, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:

LESLIE R. ELLIS, MD, MSHPEd, FACP, Wake Forest University School of Medicine, Winston Salem, NC

ANDRES GOMEZ DE LEON, Hospital Universitario, Mexico City, Mexico

SHANNON MCKINNEY-FREEMAN, PhD, St. Jude Children's Research Hospital, Memphis, TN

Trainee Didactic Session: Entrepreneurship

Monday 12:15 p.m. – 1:15 p.m.
217-219

Chair:

JULIAN SPRAGUE, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:

TERRY J. FRY, MD, CCR, National Cancer Institute, National Institutes of Health, Aurora, CO

AJAY MAJOR, MD, MBA, University of Colorado, Denver, CO

Trainee Didactic Session: Giving A Scientific Presentation

Monday 12:15 p.m. – 1:15 p.m.
220-222

Chair:

JULIAN SPRAGUE, MD, PhD, Vermont Cancer Center, Burlington, VT

Speakers:

JULIA E. MAXSON, Oregon Health & Science University, Portland, OR

SONALI M. SMITH, MD, University of Chicago, Chicago, IL

Consider Investigational Trials
for Patients with

Multiple Types of Hematologic Malignancies.



MK-2140-003

- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), in combination with chemotherapy, for relapsed/refractory **diffuse large B-cell lymphoma (DLBCL)**

MK-2140-004

- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC) for patients with relapsed/refractory **diffuse large B-cell lymphoma (DLBCL)** who have not responded to other treatment options

MK-2140-006

- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), as a monotherapy and in combination for participants with aggressive and indolent **B-cell malignancies**

MK-1026-003

- Evaluating MK-1026, an investigational inhibitor of Bruton's tyrosine kinase (BTK), in multiple relapsed/refractory hematologic malignancies (including **CLL/SLL, Richter's transformation, marginal zone lymphoma [MZL], MCL, FL, and Waldenström's macroglobulinemia [WM]**)

MK-1026-008

- Evaluating MK-1026, an investigational inhibitor of Bruton's tyrosine kinase (BTK), versus chemoimmunotherapy for previously untreated **chronic lymphocytic leukemia/small lymphocytic lymphoma** without TP53 aberrations

MK-1026-010

- Evaluating MK-1026 (an investigational inhibitor of Bruton's tyrosine kinase [BTK]) plus venetoclax, versus venetoclax plus rituximab, in participants with relapsed/refractory **chronic lymphocytic leukemia/small lymphocytic lymphoma** following at least 1 prior therapy

MK-3475-667

- Evaluating pembrolizumab in children and young adults with newly diagnosed **classical Hodgkin lymphoma** with inadequate (slow early) response to frontline chemotherapy

MK-4280-003

- Evaluating a combination of MK-4280, an investigational lymphocyte activation gene-3 (LAG3) inhibitor, and pembrolizumab in participants with **hematologic malignancies**

MK-4280A-008

- Evaluating MK-4280A, an investigational coformulation of MK-4280 (an investigational lymphocyte activation gene-3 [LAG3] inhibitor) plus pembrolizumab versus physician's choice chemotherapy in PD-(L)1-refractory, relapsed, or refractory **classical Hodgkin lymphoma**



For more information and to see
if your patients may qualify, visit

[MerckClinicalTrials.com/Oncology](https://www.MerckClinicalTrials.com/Oncology)

© 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.



EDUCATION PROGRAM

EDUCATION SESSIONS

The Education Program will be held from Saturday, December 10, through Monday, December 12. A question-and-answer period will occur at the end of each individual speaker presentation. Chapters based on these sessions will be published in *Hematology 2022*, the ASH Education Program.

Education Program Co-Chairs:

DAVID A. GARCIA, MD, University of Washington, Seattle, WA

OLATOYOSI ODENIKE, MD, University of Chicago, Chicago, IL

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Autoimmune Hemolytic Anemias (AIHA)

Saturday 9:30 a.m. – 10:45 a.m.
291-292

Chair:

DAVID J. KUTER, MD, DPHIL, Massachusetts General Hospital, Boston, MA

Speakers:

DAVID J. KUTER, MD, DPHIL, Massachusetts General Hospital, Boston, MA
Warm AIHA and the Best Treatment Strategies

CATHERINE BROOME, MD, Georgetown Hospital, Washington, DC

SUE T. JOHNSON, MSTM, MLS(ASCP)SBB, Blood Center of Wisconsin, Milwaukee, WI
Evaluate the Difficulties of Evaluating AIHA Patients in the Reference Lab of the Blood Bank and the Best Transfusion Management Strategies

Controversies in Aggressive NHL

Saturday 9:30 a.m. – 10:45 a.m.
Hall E

Chair:

CHRISTOPHER R. FLOWERS, MD, MD Anderson Cancer Center, Houston, TX

Speakers:

KATE CWCYNARSKI, MBBS, PhD, FRCP, FRCPATH, University College London Hospitals, London, England, United Kingdom
CNS Prophylaxis in Aggressive B-Cell Lymphoma

CHRISTOPHER R. FLOWERS, MD, MD Anderson Cancer Center, Houston, TX
Sequencing Therapy in Relapsed DLBCL

ANITA KUMAR, MD, Memorial Sloan Kettering Cancer Center, New York City, NY
What Is the Role of Upfront Autologous Stem Cell Transplant in Mantle Cell Lymphoma?

JAK/STAT Inhibition and Beyond in Ph Negative MPNs

Saturday 9:30 a.m. – 10:45 a.m.
293-294

Chair:

KRISTEN M. PETTIT, MD, University of Michigan, Ann Arbor, MI

Speakers:

ALESSANDRO VANNUCCHI, MD, University of Florence, Firenze, Italy
Molecular Prognostication in Ph Negative MPNs in 2022

KRISTEN M. PETTIT, MD, University of Michigan, Ann Arbor, MI
New Approaches to Tackle Cytopenic Myelofibrosis

RAAJIT RAMPAL, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY
Management of Accelerated and Blast Phase MPN

Multiple Myeloma: Assessing the Patient and the Disease

Saturday 9:30 a.m. – 10:45 a.m.
Great Hall A/D

Chair:

NATALIE CALLANDER, MD, University of Wisconsin, Madison, WI

Speakers:

CIARA L. FREEMAN, MSc, FRCPATH, MBBChir, MRCP, BC Cancer, Tampa, FL
Fitness and Frailty in Myeloma

TIMOTHY MARTIN SCHMIDT, MD, Emory University/Winship Cancer Institute, Madison, WI
High or Low? Assessing Disease Risk in Multiple Myeloma

TAXIARCHIS KOURELIS, MD, Mayo Clinic, Rochester, MN
The Burden of Myeloma: Novel Approaches to Disease Assessment

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Late Effects of Curative Therapy for Sickle Cell Disease

Saturday 2:00 p.m. – 3:15 p.m.
Hall E

Chair:

COURTNEY D. FITZHUGH, MD, National Institutes of Health (Hematology), Bethesda, MD

Speakers:

COURTNEY D. FITZHUGH, MD, National Institutes of Health (Hematology), Bethesda, MD
Knowledge to Date on Secondary Malignancy

SHALINI SHENOY, MD, Washington University Medical Center, St. Louis, MO
Organ Function Indications and Potential Improvements

DEBRA FRIEDMAN, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN
Long-term health effects of curative therapies for SCD

Prophylactic Platelet Transfusions

Saturday 2:00 p.m. – 3:15 p.m.
243-245

Chair:

MONICA B. PAGANO, MD, University of Washington, Seattle, WA

Speakers:

ZBIGNIEW MACDONALD SZCZEPKOWSKI, MD, PhD, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Evaluate how hospitals are approaching the recent FDA guidance to reduce the risk of bacterial contamination, including pathogen reduction technology and large volume delayed sampling

JOHN D. ROBACK, MD, PhD, Emory University Hospital Blood Bank, Atlanta, GA
Donor Pool

DANA V. DEVINE, PhD, Canadian Blood Services UBC Centre for Blood Research, Vancouver, British Columbia, Canada
Assess New Alternatives for Platelets, including cold (4o) platelets

Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

Saturday 2:00 p.m. – 3:15 p.m.
Great Hall A/D

Chair:

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

Speakers:

BETHANY T. SAMUELSON BANNOW, MD, Oregon Health & Science University, Portland, OR
Anticoagulant Therapy for Women

PANTEP ANGCHAIKUSIRI, MD, Ramathibodi Hospital, Bangkok, Thailand
Thrombosis and Anticoagulation: Clinical Issues of Special Importance to Hematologists Who Practice in Asia

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT
Thrombosis Questions from the Inpatient Wards

von Willebrand Disease

Saturday 2:00 p.m. – 3:15 p.m.
208-210

Chair:

PAULA D. JAMES, MD, FRCPC, Queen's University, Kingston, Ontario, Canada

Speakers:

MICHELLE LAVIN, MB, PhD, FRCATH, Haemostasis Research Lab, Dublin, Ireland
Diagnostic Pitfalls and Conundrums

PAULA D. JAMES, MD, FRCPC, Queen's University, Kingston, Ontario, Canada
Special Considerations in GI Bleeding

MICHELLE SHOLZBERG, MD, St. Michael's Hospital, Toronto, Ontario, Canada
What Have We Learned About the Patient's Experience with von Willebrand Disease?

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Where Are We Headed in Hodgkin Lymphoma?

Saturday 2:00 p.m. – 3:15 p.m.
New Orleans Theater AB

Chair:

ALISON J. MOSKOWITZ, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

ALEX F. HERRERA, MD, City of Hope, Duarte, CA
Incorporating Novel Agents in Frontline Treatment of HL

SVEN BORCHMANN, MD, Uniklinik Köln, Cologne, Germany
Management of Nodular Lymphocyte Predominant HL

ALISON J. MOSKOWITZ, MD, Memorial Sloan Kettering Cancer Center, New York City, NY
Do All Patients with Primary Refractory/First Relapse of HL Need Autologous Stem Cell Transplant?

Anxiety Provoking Consultations: Mast Cells and Eosinophils

Saturday 4:00 p.m. – 5:15 p.m.
295-296

Chair:

JASON GOTLIB, MD, MS, Stanford Cancer Center, Stanford, CA

Speakers:

CEM AKIN, MD, University of Michigan, Ann Arbor, MI
How to Evaluate the Patient with a Suspected Mast Cell Disorder and How/When to Manage Symptoms

AMY D KLION, MD, National Institutes of Health, Bethesda, MD
How to Evaluate the Patient with a Suspected Eosinophil Disorder and How/When to Manage Symptoms

JASON GOTLIB, MD, MS, Stanford Cancer Center, Stanford, CA
Available and Emerging Therapies for Bona Fide Advanced Systemic Mastocytosis and Primary Eosinophilic Neoplasms

Immunotherapy in Multiple Myeloma

Saturday 4:00 p.m. – 5:15 p.m.
Hall E

Chair:

SUZANNE TRUDEL, MSc, MD, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada

Speakers:

PAULA RODRIGUEZ OTERO, MD, PhD, Clinica Universidad de Navarra, Pamplona, Spain
Cellular Therapy for Multiple Myeloma: What's Now and What's Next

SUZANNE TRUDEL, MSc, MD, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada
Antibodies and Bispecifics for Multiple Myeloma: Effective Effector Therapy

SARAH A. HOLSTEIN, MD, PhD, Nebraska Medical Center, Omaha, NE
Beyond the Cell: Novel Non-Cellular Immunotherapy Approaches to Multiple Myeloma

Managing Thrombocytopenia in Challenging Situations

Saturday 4:00 p.m. – 5:15 p.m.
243-245

Chair:

HANNY AL-SAMKARI, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA

Speakers:

HANNY AL-SAMKARI, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA
Chemotherapy-Induced Thrombocytopenia

ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA
Thrombocytopenia in Liver Disease

ALLYSON M. PISHKO, MD, Hospital of University of Pennsylvania, Bryn Mawr, PA
Thrombocytopenia in Pregnancy

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Novel Approaches in MDS

Saturday 4:00 p.m. – 5:15 p.m.
288-290

Chair:

UMA BORATE, MD, The Ohio State University, Columbus, OH

Speakers:

MARIO CAZZOLA, MD, University of Pavia, Pavia, Italy
Risk Stratifying MDS in the Time of Precision Medicine

AMIT VERMA, MD, Albert Einstein College of Medicine, Bronx, NY
Targeting Inflammation in Lower Risk MDS

UMA BORATE, MD, The Ohio State University, Columbus, OH
New Investigational Combinations For Higher-Risk MDS

Update in Hemophilia

Saturday 4:00 p.m. – 5:15 p.m.
291-292

Chair:

REBECCA KRUSE-JARRES, MD, MPH, University of Washington, Seattle, WA

Speakers:

MARILYN J MANCO-JOHNSON, MD, Mountain State Regional Hemophilia & Thrombosis Center, Aurora, CO
Long-Term Prophylaxis - What Are Our Options and How to Define Success?

REBECCA KRUSE-JARRES, MD, MPH, University of Washington, Seattle, WA
Peri-Operative Hemostasis

AMIT C. NATHWANI, MD, PhD, University College London, London, England, United Kingdom
Gene Therapy

Are Alternative Donors Now Mainstream in Allogeneic Transplant?

Saturday 4:00 p.m. – 5:15 p.m.
Great Hall B/C

Chair:

MONZR M. AL MALKI, MD, City of Hope, Duarte, CA

Speakers:

MONZR M. AL MALKI, MD, City of Hope, Duarte, CA
New Strategies for Mismatched Unrelated Donors

STEPHEN R. SPELLMAN, National Marrow Donor Program, Minneapolis, MN
What Is Complete HLA Match in 2022?

ARNON NAGLER, MD, Chaim Sheba Medical Center, Tel Hashomer, Israel
In 2022, Which is Preferred: Haploidentical or Cord Transplant?

Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets

Sunday 9:30 a.m. – 10:45 a.m.
Great Hall B/C

Chair:

ALICE S. MIMS, MD, The Ohio State University, Columbus, OH

Speakers:

CHRISTOPHER S. HOURIGAN, MD, DPHIL, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Achieving MRD Negativity in AML: How Important Is This and How Do We Get There?

KEITH W. PRATZ, MD, Johns Hopkins University, Baltimore, MD
Optimizing Outcomes in Secondary AML

ALICE S. MIMS, MD, The Ohio State University, Columbus, OH
Novel Investigational Approaches for High-Risk Molecular Subsets: TP53, MLL, FLT3

Maximizing Outcomes in CLL

Sunday 9:30 a.m. – 10:45 a.m.
265-268

Chair:

JENNIFER R. BROWN, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Speakers:

JENNIFER R. BROWN, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Selecting Initial Therapy in CLL

LYDIA SCARFÒ, MD, Ospedale San Raffaele, Milano, Italy
Novel Therapies and Combinations in CLL Refractory to BTK Inhibitors and Venetoclax

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

TANYA SIDDIQI, MD, City of Hope National Medical Center, Duarte, CA
Treatment of Richter's Syndrome

Reproductive and Sexual Health in Sickle Cell Disease

Sunday 9:30 a.m. – 10:45 a.m.
R06-R09

Chair:

IBRAHIM MUSA IDRIS, MBBS, MPH, FMCPATH, Aminu Kano Teaching Hospital, Kano, Nigeria

Speakers:

IBRAHIM MUSA IDRIS, MBBS, MPH, FMCPATH, Aminu Kano Teaching Hospital, Kano, Nigeria
Epidemiology and Treatment of Priapism in Sickle Cell Disease

LYDIA H. PECKER, MD, MHS, Johns Hopkins University, Baltimore, MD
Fertility of Women with Sickle Cell Disease

LILLIAN R. MEACHAM, MD, Children's Healthcare of Atlanta, Decatur, GA
Decision Making for Reproductive Health in Sickle Cell Disease

Beyond Routine Frontline Therapy of CML

Sunday 4:30 p.m. – 5:45 p.m.
La Nouvelle Orleans Ballroom C

Chair:

TIMOTHY P. HUGHES, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute, Adelaide, Australia

Speakers:

TIMOTHY P. HUGHES, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute, Adelaide, Australia
Treatment of TKI resistant chronic phase CML

NICOLAUS KROEGER, MD, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Transplantation in CML in the TKI Era: Who, When, How?

JANE F. APPERLEY, FRCP, FRCPATH, MB, Hammersmith Hospital, Imperial College, London, England, United Kingdom
Treatment of CML in Pregnancy

Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries

Sunday 4:30 p.m. – 5:45 p.m.
243-245

Chair:

EUGENIA VICKY ASARE, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana

Speakers:

EUGENIA VICKY ASARE, BSc, Ghana Institute of Clinical Genetics, Accra, Ghana
Epidemiology of Obstetric Complications Among women with Sickle Cell Disease

BOSEDE AFOLABI, DM, University of Lagos College of Medicine, Idi-Araba, Lagos, Nigeria
Evidence-Based Obstetric Management of Women with Sickle Cell Disease in Low Income Countries

EUGENE OTENG-NTIM, PhD, MBBS, Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom
Evidence-Based Management of Pregnant Women with Sickle Cell Disease in High Income Countries

What's New in Indolent Lymphoma

Sunday 4:30 p.m. – 5:45 p.m.
Great Hall B/C

Chair:

TYCEL J. PHILLIPS, MD, University of Michigan, Ann Arbor, MI

Speakers:

TYCEL J. PHILLIPS, MD, University of Michigan, Ann Arbor, MI
Management of Early Relapsed Follicular Lymphoma

JESSICA OKOSUN, MB BChir PhD, Barts Hospital, London, England, United Kingdom
Pathogenesis of Follicular Lymphoma

LUCA ARCAINI, MD, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Management of Marginal Zone Lymphoma

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Improving Outcomes in ALL

Monday 10:30 a.m. – 11:45 a.m.
R02-R05

Chair:

MATTHEW J. WIEDUWILT, MD, PhD, University of California—San Diego, San Diego, CA

Speakers:

NICOLAS BOISSEL, MD, PhD, Hôpital St. Louis /
Université Paris, Paris, France
New Developments in ALL in AYA

KRISTEN M. O'DWYER, MD, University of Rochester
Medical Center, Rochester, NY
Optimal Approach to T-Cell ALL

MATTHEW J. WIEDUWILT, MD, PhD, University of
California—San Diego, San Diego, CA
Ph+ ALL in 2022: Is There an Optimal Approach?

Treatment Approaches for the Multiple Myeloma Patient in 2022

Monday 2:45 p.m. – 4:00 p.m.
Great Hall A/D

Chair:

YVONNE A. EFEBERA, MD, MPH, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Speakers:

SIGRUN THORSTEINSDOTTIR, MD, PhD, Rigshospitalet,
Copenhagen, Denmark
The Consultant's Guide to Smoldering Multiple Myeloma

CAITLIN COSTELLO, MD, University of California—San
Diego, San Diego, CA
Newly Diagnosed Multiple Myeloma: Making Sense of the Menu

YVONNE A. EFEBERA, MD, MPH, The Ohio State
University Comprehensive Cancer Center,
Columbus, OH
The First Relapse in Multiple Myeloma – How to Pick the Next Best Thing

Updates in Targeted Therapy in Pediatric Leukemia

Monday 2:45 p.m. – 4:00 p.m.
343-345

Chair:

SARAH K. TASIAN, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

SARAH K. TASIAN, MD, Children's Hospital of
Philadelphia, Philadelphia, PA
Clinical Screening for Ph-like ALL and the Developing Role of TKIs

KATHERINE TARLOCK, MD, University of Washington,
Seattle, WA
The Evolution of Targeted Therapy in Pediatric AML: Small Molecule Inhibitors and Immunotherapeutic Strategies

RISHI SURY KOTECHA, PhD, FRACP, MBBSCHIR, MRCP,
University of Western Australia, Perth, WA,
Australia
Updates in Infant Leukemia and the Potential for Targeted Therapy

What is New in Classical Bone Marrow Failure Syndromes? (focus on management)

Monday 2:45 p.m. – 4:00 p.m.
260-262

Chair:

SHARON A. SAVAGE, MD, National Cancer Institute,
National Institutes of Health, Bethesda, MD

Speakers:

JEAN DONADIEU, MD, PhD, Hospital Trousseau, Paris,
France
Severe Congenital Neutropenia

CARLO DUFOUR, G. Gaslini Children's Hospital,
Genova, Italy
Fanconi Anemia

SHARON A. SAVAGE, MD, National Cancer Institute,
National Institutes of Health, Bethesda, MD
Dyskeratosis Congenita & Telomere Biology Disorders

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Thrombosis Prevention and Treatment

Monday 4:30 p.m. – 5:45 p.m.
R02-R05

Chair:

TZU-FEI WANG, MD, MPH, The University of Ottawa, Ottawa, Ontario, Canada

Speakers:

TZU-FEI WANG, MD, MPH, The University of Ottawa, Ottawa, Ontario, Canada
The 5 Most-Frequently-Asked Questions About Fxa Inhibitors

ALEX C. SPYROPOULOS, MD, Northwell, West Harrison, NY
Controversies in VTE Prevention for Medical Inpatients

WALTER AGENO, MD, University of Insubria, Varese, Italy
Coming Soon to a Pharmacy Near You? FXIa Inhibitors and Other Novel Strategies to Prevent or Treat Venous Thromboembolism

Junior Faculty Career Development Education Session

Monday 4:30 p.m. – 5:45 p.m.
New Orleans Theater AB

Chair:

YVONNE A. EFEBERA, MD, MPH, Ohio Health, Columbus, OH

Speakers:

ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA
Negotiation, It's More Than Just the Money

CECELIA CALHOUN, MD, MBA, MPH, Washington University School of Medicine in St. Louis, St. Louis, MO
Negotiation, It's More Than Just the Money

PALLAWI TORKA, MD, Roswell Park Cancer Institute, Buffalo, NY

URSHILA DURANI, MD, MPH, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Pasadena, CA
Should I Stay or Should I Go?

Late Effects Monitoring for Survivors of Pediatric Hematologic Malignancies

Monday 4:30 p.m. – 5:45 p.m.
288-290

Chair:

ERIC J. CHOW, MD, MPH, Seattle Children's, Seattle, WA

Speakers:

ERIC J. CHOW, MD, MPH, Seattle Children's, Seattle, WA
Mitigating, Monitoring, and Managing Long-Term Chemotherapy- and Radiation-Induced Cardiac Toxicity

KEVIN R. KRULL, PhD, St. Jude Children's Research Hospital, Memphis, TN
Risk Factors and Screening for Neurocognitive Impacts of Therapy

SMITA BHATIA, MD, MPH, University of Alabama at Birmingham, Birmingham, AL
Germ Line Risk Factors for Second Malignant Neoplasms After Treatment for Pediatric Hematologic Malignancies

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease

Monday 4:30 p.m. – 5:45 p.m.
343-345

Chair:

COLEMAN LINDSLEY, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Speakers:

DANIEL J. WEISDORF, MD, University of Minnesota, Minneapolis, MN
Transplant in Those with High-Burden Disease: Refractory AML and High-Risk MDS

CHARLES CRADDOCK, FRCP, FRCPATH, CBE, PHIL, Queen Elizabeth Hospital, Birmingham, England, United Kingdom
Transplant in AML with Measurable Residual Disease: Proceed or Defer?



blood advances[®]

Transforming the Conversation

INVITES YOU TO ATTEND

How to Peer Review a Scientific Paper



FEATURING (recorded):

Catherine Bollard, MD

Editor-in-Chief,
Blood Advances
Children's National Hospital
Washington, DC

The *Blood Advances* Editor-in-Chief, Dr. Catherine Bollard will lead a panel discussion with editors, Dr. Leslie Kean and Dr. Andrew Weyrich as panelists on *How to Peer Review a Scientific Paper*. The session will provide valuable information on the best practices of peer review from the editorial perspective for both basic and clinically relevant manuscripts. There are professional benefits to becoming a reviewer. It allows the hematologist to stay current on research and developments in the field and can help in patient care, both in the lab and classroom. The reviewer also can get recognized by their colleagues and demonstrate professional development with their institution.

ASH[®] 2022 Annual Meeting in New Orleans

Sunday December 11, 2022 • In-Person

11:15am - 12:15pm CST

Ernest N. Morial Convention Center Room 252-254

Annual Meeting Virtual Platform/Webcast

Requires ASH 2022 registration or webcast purchase

► **Register to attend this session in-person, or via
the Virtual Platform/Webcast**

hematology.org/annual-meeting



PANELIST (in-person):
LESLIE KEAN, MD, PhD
Boston Children's
Hospital
Boston, MA



PANELIST (in-person):
Andrew Weyrich, PhD
Oklahoma Medical
Research Foundation
Oklahoma City, OK

EDUCATION SPOTLIGHT SESSIONS

Education Spotlight Sessions are intended to provide an in-depth review on specific scientific topics. This year, speakers will discuss current challenges and controversies in eight exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 75-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Bone Marrow Failure Syndromes: Diagnostic Principles in 2022

Sunday 4:30 p.m. - 5:45 p.m.
260-262

CHAIR:

JEFFERY KILCO, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

MARK D. FLEMING, MD, DPHIL, Boston Children's Hospital, Boston, MA
Pathology vs molecular genetics: comprehensive microscopic evaluation will remain the essential initial step

SARA LEWIS, MS, St. Jude Children's Research Hospital, Memphis, TN
Genetic Counseling: Ethical Considerations during the Diagnostic Process and How to Avoid Confusing Situations

New Horizons for Histiocyte Disorders

Sunday 4:30 p.m. - 5:45 p.m.
275-277

Chair:

PAUL C. HENDRIE, MD, PhD, University of Washington, Seattle, WA

Speakers:

ELI L DIAMOND, MD, Memorial Sloan Kettering Cancer Center, New York, NY
How and When to Incorporate Targeted Therapy into the Treatment of Histiocytic Disorders

CARL E. ALLEN, MD, Texas Children's Cancer Center, Houston, TX
Updates on Genetic Drivers of Histiocyte Disorders

Survivorship In Adult Patients With Lymphoma

Sunday 4:30 p.m. - 5:45 p.m.
Great Hall A/D

Chair:

JAVID J. MOSLEHI, MD, Vanderbilt School of Medicine, San Francisco, CA

Speakers:

JAVID J. MOSLEHI, MD, Vanderbilt School of Medicine, San Francisco, CA
Prevention, screening, and treatment of treatment related cardiomyopathy

CARRIE A. THOMPSON, MD, Mayo Clinic, Rochester, MN
Screening for Radiation and Chemotherapy Late Effects (except cardiac)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MONDAY

Debate: Most/All Patients With Acquired (Immune) Thrombotic Thrombocytopenic Purpura (Ttp) Receive Caplacizumab

Monday 10:30 a.m. - 11:45 a.m.
295-296

Chair:

MARK CROWTHER, MD, St. Joseph's Hospital, Hamilton, ON, Canada

Speakers:

CAMILA MASIAS, MD, MPH, Miami Cancer Institute, Miami, FL
FOR (All/most patients should receive caplacizumab)

GEORGE GOSHUA, MD, MSc, Yale School of Medicine, New Haven, CT
AGAINST (most/all patients with Acquired TTP should receive caplacizumab)

Underrepresented Minorities In Clinical Trials For Hematologic Malignancies: What's The Data On The Data?

Monday 10:30 a.m. - 11:45 a.m.
R06-R09

Chair:

KENNETH C. ANDERSON, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

Speakers:

LUCIANO J. COSTA, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
Discuss historical percentages of URM enrollment in clinical trials and theories for this data

SIKANDER AILAWADHI, MD, Mayo Clinic, Jacksonville, FL
Discuss approaches to improve enrollment and outcomes

RAYNE H. ROUCE, MD, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Discuss approaches to increase the proportion of underrepresented minorities in the clinical investigator/clinical research pathway.

Immunotherapies For Myeloid Neoplasms: Are We Ready For Primetime?

Monday 2:45 p.m. - 4:00 p.m.
New Orleans Theater AB

Chair:

HONGTAO LIU, MD, PhD, University of Chicago, Chicago, IL

Speakers:

SARIT ASSOULINE, MD, MSc, FRCPC, McGill University Jewish General Hospital, Montreal, Quebec, Canada
BITEs, immune checkpoint molecules, macrophage checkpoint molecules for AML and high grade MDS-

SAAR GILL, MD, PhD, University of Pennsylvania, Philadelphia, PA
CAR-T therapy for high grade myeloid neoplasms- what are the barriers and how do we overcome?

Point/Counterpoint: The Case For/Against Thrombophilia Testing In Many/Most Adults With Unprovoked Thrombosis.

Monday 2:45 p.m. - 4:00 p.m.
288-290

Chair:

WENDY LIM, MD, MSc, McMaster University, Hamilton, Ontario, Canada

Speakers:

STEPHAN MOLL, MD, University of North Carolina School of Medicine, Chapel Hill, NC
Point/Counterpoint: There case FOR thrombophilia testing in many/most adults with unprovoked thrombosis.

DEBORAH M. SIEGAL, MD MSc FRCPC, Thrombosis Clinic, Juravinski Hospital, Ottawa, Ontario, Canada
Point/Counterpoint: There case AGAINST thrombophilia testing in many/most adults with unprovoked thrombosis

HOW I TREAT: BRINGING SCIENCE TO CLINICAL DILEMMAS

These sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed lunch will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 8, at the Ticketed Sessions Counter in the Great Hall Pre-Function.

Ticket Prices (per session)

Active or International Member	\$75
Non-Member	\$75
Associate, International Associate, Resident, or Graduate/Medical Student, or Honorary/Emeritus Member	\$50
Non-Member in Training	\$50
Allied Health Professional	\$50

Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Can We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes

Saturday 8:30 a.m. – 9:30 a.m.
Marlborough A, Hilton New Orleans Riverside

SPEAKER:

OLATOYOSI ODENIKE, MD, University of Chicago, Chicago, IL

ITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday

Saturday 8:30 a.m. – 9:30 a.m.
Camp, Hilton New Orleans Riverside

Speaker:

HANNY AL-SAMKARI, MD, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA

Sickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape

Saturday 8:30 a.m. – 9:30 a.m.
Commerce, Hilton New Orleans Riverside

Speaker:

COURTNEY D. FITZHUGH, MD, National Institutes of Health (Hematology), Bethesda, MD

The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML.

Saturday 8:30 a.m. – 9:30 a.m.
Canal, Hilton New Orleans Riverside

Speaker:

CHRISTOPHER S. HOURIGAN, MD, National Heart, Lung, and Blood Institute, Bethesda, MD

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia

Sunday 8:30 a.m. – 9:30 a.m.
Marlborough A, Hilton New Orleans Riverside

Speaker:

STEPHAN MOLL, MD, University of North Carolina School of Medicine, Chapel Hill, NC

Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes.

Sunday 8:30 a.m. – 9:30 a.m.
Camp, Hilton New Orleans Riverside

Speaker:

JASON GOTLIB, MD, MS, Stanford Cancer Center, San Carlos, CA

vWD and Other Bleeding Disorders – Diagnostic Pitfalls and Special Situations

Sunday 8:30 a.m. – 9:30 a.m.
Canal, Hilton New Orleans Riverside

Speaker:

MICHELLE SHOLZBERG, MDCM, MSc, St. Michael's Hospital, Toronto, Ontario, Canada



American Society of Hematology

Helping hematologists conquer blood diseases worldwide



blood® INVITES YOU TO ATTEND



CHAIR:

Nancy Berliner, MD

Editor-in-Chief, *Blood*
Brigham and Women's
Hospital
Boston, MA



PANELIST:

**Andrew Roberts,
MBBS, PhD**

Deputy Editor, *Blood*
Peter MacCallum
Cancer Centre
Melbourne, Australia

How to Get Published in a Peer-Reviewed Journal

The ability to communicate one's work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. Dr. Berliner will lead a panel discussion that will provide insight into the elements of a high-quality manuscript worthy of publication in *Blood* and tips on avoiding common errors that might result in rejection.

ASH® 2022 Annual Meeting in New Orleans

Saturday, December 10, 2022 • In-Person

11:15am - 12:15pm CST

Ernest N. Morial Convention Center, Room 243-245

Annual Meeting Virtual Platform/Webcast

Requires ASH 2022 registration or webcast purchase

► **Register to attend this session in-person, or via the Virtual Platform/Webcast**

hematology.org/annual-meeting



Visit Booth 2243



FOR MYELOFIBROSIS PATIENTS, ONE SIZE DOES NOT FIT ALL

Myelofibrosis (MF) presents with substantial heterogeneity in patients' symptoms and course of disease.¹
An unmet need remains in understanding the pathogenesis of anemia in MF.²

TO LEARN MORE, VISIT [MYELOFIBROSISINSIGHTS.COM](https://myelofibrosisinsights.com)



References: 1. Verstovsek S, Yu J, Kish JK, et al. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. *Ann Hematol.* 2020;99(11):2555-2564. doi:10.1007/s00277-020-04055-w 2. Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. *Hemasphere.* 2017;1(1):e1. doi:10.1097/HS9.0000000000000001

Trademarks are owned by or licensed to the GSK group of companies.



©2022 GSK or licensor.
MMLJRNA220004 October 2022
Produced in USA.

SCIENTIFIC PROGRAM



SCIENTIFIC SESSIONS

The Scientific Program will be held Saturday, December 10, through Monday, December 12. There will be a panel discussion at the end of the session during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

Scientific Program Co-Chairs:

DAVID M. BODINE, PhD, National Institutes of Health, Bethesda, MD

CATHERINE J. WU, MD, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Boston, MA

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Aplastic Anemia, Dysimmunity and Mutant Clones

Saturday 9:30 a.m. – 10:45 a.m.
288-290

Scientific Committee on Bone Marrow Failure

Chair:

JEAN SOULIER, MD, PhD, Hospital Saint-Louis, Centre Hayem, Paris, France

Speakers:

NEAL S. YOUNG, MD, National Institutes of Health, Bethesda, MD

Immune Deregulation in Aplastic Anemia

DARIA V. BABUSHOK, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

HLA-restricted Attack and Clonal Evolution in Aplastic Anemia

AUSTIN KULASEKARARAJ, MD, MBBS, King's College Hospital, London, England, United Kingdom
New Biological Insights on Clonal Evolution in the Eltrombopag Era

Emerging Technologies in Hemostasis

Saturday 9:30 a.m. – 10:45 a.m.
265-268

Scientific Committee on Hemostasis

Chair:

KEITH B. NEEVES, PhD, University of Colorado—Denver, Denver, CO

Speakers:

CHRISTIAN J. KASTRUP, PhD, University of British Columbia, Vancouver, BC, Canada

Gene Therapies to Enhance the Hemostatic Function of Platelets

ASHLEY BROWN, PhD, North Carolina State University, Raleigh, NC
Engineered Biomaterials for Hemostasis

DAVID BARK, PhD, Washington University, St. Louis, MO

Microsystems Based Technologies to Measure and Model Hemostasis

Overcoming T-cell Burnout and Exhaustion

Saturday 2:00 p.m. – 3:15 p.m.
271-273

Scientific Committee on Immunology and Host Defense

Chair:

LESLIE S. KEAN, MD, PhD, Boston Children's Hospital, Boston, MA

Speakers:

ANDREA SCHIETINGER, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY
T-Cell Exhaustion: Molecular Mechanisms in CAR-T and Beyond

EVAN WEBER, PhD, Stanford University, Stanford, CA
An Integrated View of T-Cell Exhaustion

GIEDRE KRENCIUTE, PhD, St. Jude Children's Research Hospital, Memphis, TN
CAR-T Cell Dysfunction: Revitalizing the Living Drug

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Joint Session: New Tools to Optimize Platelet Transfusion Therapy

Saturday 4:00 p.m. – 5:35 p.m.
252-254

Scientific Committee on Megakaryocytes and Platelets & Scientific Committee on Transfusion Medicine

Co-Chairs:

MAUREANE HOFFMAN, MD, PhD, Durham VA Medical Center, Durham, NC

KELLIE MACHLUS, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Speakers:

MARIE ALICE HOLLENHORST, MD, PhD, Stanford University, Stanford, CA
Glycan Regulation of Immune and Hemostasis Function in Platelet Biology and Transfusion Speakers

DIANNE EVERTDINA VAN DER WAL, PhD, The Australian Red Cross, Alexandria/Sydney, New South Wales, Australia
Platelet Clearance by Direct and Indirect Mechanisms: Implications for Platelet Transfusion and Treatment of Different Pathologic Conditions Speakers

MARTIN SCHREIBER, MD, Oregon Health & Science University, Portland, OR
Platelets in Whole Blood Transfusion, Cold Stored Platelets

MARTHA SOLA-VISNER, MD, Children's Hospital Boston, Boston, MA
Platelet Transfusion Outcomes in the Preterm Infant – The Intersection Between Hemostatic Efficacy and Immune/Inflammatory Modulation of Platelets

Joint Session: Seed and Soil: The Role of Inflammation in Myeloid Malignancies

Saturday 4:00 p.m. – 5:35 p.m.
R02-R05

Scientific Committee on Myeloid Biology & Scientific Committee on Myeloid Neoplasia

Co-Chairs:

KIMBERLY STEGMAIER, MD, Dana-Farber Cancer Institute, Boston, MA

FABIOLA TRAINA, MD, PhD, University of Sao Paulo at Ribeirão Preto Medical School, Ribeirão Preto, Brazil

Speakers:

KATHERINE Y. KING, MD, PhD, Baylor College of Medicine, Houston, TX
Inflammatory Signaling and Clonal Hematopoiesis

CRISTINA LO CELSO, PhD, Imperial College London, London, England, United Kingdom
Contribution of the Bone Marrow Microenvironment to Leukemogenesis

ERIC PIETRAS, PhD, University of Colorado, Aurora, CO
Dysregulated Inflammatory Signaling in the Pathogenesis of Myeloid Malignancies

DANIEL T. STARCZYNOWSKI, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Therapeutic Implications of Inflammatory Signaling in Myeloid Malignancies

Joint Session: Cell Competition and Clonal Hematopoiesis

Sunday 9:30 a.m. – 11:05 a.m.
New Orleans Theater AB

Scientific Committee on Hematopoiesis & Scientific Committee on Stem Cells and Regenerative Medicine

Co-Chairs:

FERNANDO D. CAMARGO, PhD, Harvard Stem Cell Institute, Boston, MA

LOUISE E. PURTON, PhD, St. Vincent's Institute, Fitzroy, Victoria, Australia

Speakers:

LAURA A. JOHNSTON, PhD, Columbia University, New York City, New York
Cell Competition and Fitness Concept

ALEJO E. RODRIGUEZ-FRATICELLI, PhD, IRB Barcelona, Barcelona, Spain
HSC Heterogeneity

ANN MULLALLY, MD, Brigham and Women's Hospital, Boston, MA
MPNs as a Paradigm for Clonal Dominance and Myeloid Transformation

DOMIQUE BONNET, PhD, Francis Crick Institute, London, England, United Kingdom
Cell Competition in the Hematopoietic Niches

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Joint Session: The Lymphoma Microenvironment and Its Impact on Therapy

Sunday 9:30 a.m. – 11:05 a.m.
R02-R05

Scientific Committee on Lymphoid Neoplasia & Scientific Committee on Transplantation Biology & Cellular Therapies

Co-Chairs:

MICHAEL R. GREEN, PhD, MD Anderson Medical Center, Houston, TX

KELLI MACDONALD, PhD, Queensland Institute of Medical Research, Brisbane, Queensland, Australia

Speakers:

MAHER K. GANDHI, PhD, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
Ecotypes in Lymphoma

LEANDRO CERCHIETTI, MD, Weill Cornell Medical College, New York City, NY
Stromal Cells in Lymphoma

FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL
Mapping Effects of the Tumour Microenvironment on CAR T Responses in NHL

SAAD S. KENDERIAN, MD, Mayo Clinic, Rochester, MN
Cellular and Cytokine Modulation of the Tumour Microenvironment

New Therapeutic Targets for Thrombosis That Do Not Cause Bleeding

Sunday 4:30 p.m. – 5:45 p.m.
293-294

Scientific Committee on Thrombosis and Vascular Biology

Chair:

WILBUR A. LAM, MD, PhD, Emory University/Georgia Tech, Atlanta, GA

Speakers:

HELEN PHILLIPOU, PhD, University of Leeds, Leeds, England, United Kingdom
FXII Inhibition in Prevention of Thrombosis Without Causing Bleeding

CRISTINA PUY, PhD, Oregon Health & Science University, Portland, OR
FXI Inhibition in Prevention of Thrombosis Without Causing Bleeding

ELLIOT L. CHAIKOF, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Inhibition of P-selectin to Target Thrombosis

Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias

Monday 10:30 a.m. – 11:45 a.m.
343-345

Scientific Committee on Blood Disorders in Childhood

Chair:

IRENE ROBERTS, MD, Weatherall Institute of Molecular Medicine, Oxford, England, United Kingdom

Speakers:

DEENA ISKANDER, MD, PhD, Imperial College London, London, England, United Kingdom
Dissecting Heterogeneity in Diamond-Blackfan Anemia: Insight from Single Cell Studies and Clinical Findings

WILBUR A. LAM, MD, PhD, Emory University/Georgia Tech, Atlanta, GA
New Technologies for Assessment of Anemia and Other Hematologic Disorders in Resource Limited Settings

JULIE MAKANI, MD, PhD, Muhimbili University, Dar es Salaam, Tanzania
Managing Severe Sickle Cell Disease- How Can We Deliver Novel Therapies in Resource-Poor Settings?

Plasma Cell Dyscrasias: Resistance to Immunotherapy: Mechanisms and Monitoring

Monday 10:30 a.m. – 11:45 a.m.
New Orleans Theater AB

Scientific Committee on Plasma Cell Neoplasia

Chair:

RAVI VIJ, MD, MBBS, Washington University School of Medicine at St. Louis, St. Louis, MO

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

FLAVIA PICHIORRI, PhD, City of Hope, Duarte, CA
Resistance to CD38 and BCMA Targeted Therapies

SARAH GOODING, MD, PhD, University of Oxford, Oxford, England, United Kingdom
Resistance to Immunomodulatory Drugs

JENS G. LOHR, MD, PhD, Harvard Medical School, Boston, MA
Cell Free DNA Analysis

Histone Modifications and Chromatin Programs in Clonal Selection and Cancer Emergence

Monday 2:45 p.m. – 4:00 p.m.
275-277

Scientific Committee on Epigenetics and Genomics

Chair:

JENNIFER J. TROWBRIDGE, PhD, The Jackson Laboratory, Bar Harbor, ME

Speakers:

GABRIELLA FICZ, PhD, Cancer Research UK Barts Centre, London, England, United Kingdom
Histone Programs Regulate Human Hematopoietic Stem Cell State

CRISTINA PINA, MD, DPHIL, Brunel University London, London, England, United Kingdom
Histone Programs Drive Clonal Diversification in Pre-Leukemia

ELISA ORICCHIO, PhD, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
Histone Acetylation as a Driver of Oncogenic Transformation

Morphology in a Genomic World

Monday 2:45 p.m. – 4:00 p.m.
208-210

Scientific Committee on Hematopathology and Clinical Laboratory Hematology

Chair:

KEITH R. LOEB, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

Speakers:

PETER KARL SORGER, PhD, Harvard University, Boston, MA
Spatial Landscape of Progression and Immunoediting in Solid Tumors

SIMON HAAS, PhD, HI-STEM Ggmbh, Heidelberg, Germany
Spatial Transcriptomic Analysis of Bone Marrow or Lymphoma

Iron and Red Cells: A Co-Dependent Relationship

Monday 2:45 p.m. – 4:00 p.m.
265-268

Scientific Committee on Iron and Heme

Chair:

TOMAS GANZ, MD, PhD, University of California—Los Angeles, Los Angeles, CA

Speakers:

SHANG MA, PhD, Scripps Research, San Diego, CA
Piezo1 in Anemia and Iron Overload

ROBIN VAN BRUGGEN, MD, PhD, Sanguin, Amsterdam, Netherlands
Iron Recycling in the Spleen

SARAH H. ATKINSON, MD, London School of Hygiene & Tropical Medicine, London, England, United Kingdom
Anemia and Iron Homeostasis in Malaria

Metabolic Regulation and Implications for Red Cells

Monday 4:30 p.m. – 5:45 p.m.
275-277

Scientific Committee on Red Cell Biology

Chair:

VIJAY G. SANKARAN, MD, PhD, Boston Children's Hospital, Boston, MA

Speakers:

NAVDEEP S. CHANDEL, PhD, Northwestern University, Chicago, IL
Overview of Metabolic Regulation

LEONARD I. ZON, MD, Harvard University, Boston, MA
Regulation of Metabolism in Hematopoietic Differentiation

JIAN XU, PhD, Children's Research Institute at UT Southwestern Medical Center, Dallas, TX
Regulation of Erythroid Metabolism

SCIENTIFIC SYMPOSIA

The Scientific Symposia feature transformative basic, translational, and clinical research poised to advance the field of hematology. There will be a panel discussion at the end of each session during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Biology and Translation of NK Cells

Saturday 2:00 p.m. – 3:15 p.m.
293-294

Chair:

KATY REZVANI, MD, The University of Texas M D Anderson Cancer Center, Houston, TX

Speakers:

RIZWAN ROMEE, MD, Dana Farber Cancer Institute, Boston, MA
Fundamentals of NK Cell Biology

KATY REZVANI, MD, The University of Texas M D Anderson Cancer Center, Houston, TX
NK Cell Engineering: The Next Frontier in Cancer Immunotherapy

JEFFREY S. MILLER, MD, University of Minnesota, Minneapolis, MN
Novel Immunomodulatory Agents to Harness NK Cell Mediated Anti-Tumor Responses

Genetic and Functional Heterogeneity in Megakaryocytes and Platelets

Saturday 2:00 p.m. – 3:15 p.m.
252-254

Chair:

KELLIE R. MACHLUS, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Speakers:

DIANE S. KRAUSE, MD, PhD, Yale University, New Haven, CT

Differentiation of Bipotent Progenitors to the Megakaryocytic versus Erythroid Lineages

ALASTAIR W. POOLE, VET.MB, MA, PhD, School of Medical Sciences, Bristol, United Kingdom
Highly Efficient In Vitro Platelet Generation in Lung Vasculature Reproduced by Microfluidics

ANANDI KRISHNAN, PhD, Stanford University School of Medicine, Stanford, CA
Genetic Heterogeneity in Platelets - Towards Personalized Medicine

SUNDAY

Building Dietary Evidence for Hematologic Malignancies - Mechanistic Insights

Sunday 9:30 a.m. – 10:45 a.m.
217-219

Chair:

URVI A. SHAH, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

CATHERINE R. MARINAC, PhD, Dana-Farber Cancer Institute, Boston, MA
Nutrition Metabolism Connection (Epidemiologic Focus)

MATTEO BELLONE, MD, Istituto Scientifico H. San Raffaele, Milan, MI, Italy
Nutrition Gut Microbiome Connection (Translational Focus)

IRIT AVIVI, MD, Tel Aviv University, Tel Aviv, Israel
Nutrition Immune Connection (Clinical Focus)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Targeting Endogenous Retroelements and Viral Mimicry in Therapy of Hematologic Malignancies

Sunday 9:30 a.m. – 10:45 a.m.
288-290

Chair:

MEGAN E. McNERNEY, MD, PhD, University of Chicago, Chicago, IL

Speakers:

GABRIEL K. GRIFFIN, MD, Brigham and Women's Hospital, Boston, MA
Introduction to Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy

DANIEL B. LIPKA, MD, German Cancer Research Center (DKFZ), Heidelberg, Germany
Viral Mimicry Induced by Hypomethylating Agents in Acute Myeloid Leukemia

KATHERINE CHIAPPINELLI, PhD, George Washington University School of Medicine and Health Sciences, Washington, DC
New Therapeutic Approaches to Engage Viral Mimicry Response

MONDAY

Special Symposium on the Basic Science of Hemostasis and Thrombosis

Monday 4:30 p.m. – 6:05 p.m.
208-210

Co-Chairs:

KELLIE R. MACHLUS, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

KEITH B. NEEVES, PhD, University of Colorado Denver, Aurora, CO

WILBUR A. LAM, MD, PhD, Emory University/Georgia Tech, Atlanta, GA

Speakers:

JULIE RAYES, PhD, Institute of Cardiovascular Science, University of Birmingham, Birmingham, United Kingdom
Coordinated Platelet Activation and Netosis Drive Thrombo-Inflammation during Sepsis

EVI X. STAVROU, MD, Case Western Reserve University, Cleveland, OH
Role of Factor XII in Sepsis

ROBERT FLAUMENHAFT, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA
Targeting the Endothelium to Prevent Thrombus Formation in Sepsis

SEAN QUINN, PhD, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA
Abstract 397: An Antibody Targeting Human FV Promotes Thrombin Generation and Reduces Bleeding in a Hemophilic Mouse Model

SCIENTIFIC SPOTLIGHT SESSIONS

Scientific Spotlight Sessions are intended to cover niche topic areas that are of interest to special researchers in hematology.

Each 75-minute session will be presented once in a small-venue format on either Sunday or

Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)

Sunday 4:30 p.m. - 5:45 p.m.
291-292

Co-Chairs:

VIVIEN CHEN, PhD, MBBS, Concord Hospital, Sydney, New South Wales, Australia

JONATHAN M. COUTINHO, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

Speakers:

VIVIEN CHEN, PhD, MBBS, Concord Hospital, Sydney, New South Wales, Australia
PF4 Autoantibodies and Thrombosis

JONATHAN M. COUTINHO, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

Cerebral Venous Sinus Thrombosis: Risk Factors and Biology

MONDAY

Sowing the Seeds of Leukemia Before Birth

Monday 2:45 p.m. - 4:00 p.m.
271-273

Co-Chairs:

ANINDITA ROY, MD, PhD, University of Oxford, Oxford, England, United Kingdom

JYOTI NANGALIA, MBBS, PhD, Wellcome Sanger Institute, Saffron Walden, England, United Kingdom

Speakers:

ANINDITA ROY, MD, PhD, University of Oxford, Oxford, England, United Kingdom
Acute Lymphoblastic Leukemia: How Fetal-Specific Gene Expression Programs Cooperate with MLL-AF4 to Initiate and Maintain Leukemia

JYOTI NANGALIA, MBBS, PhD, Wellcome Sanger Institute, Saffron Walden, England, United Kingdom


Myeloproliferative Neoplasms: Adult Diseases with a Fetal Origin?



ASH | Image Bank

OVER 2,000 Images!

The American Society of Hematology Image Bank
is a peer-reviewed web-based image library and free resource*
that offers a comprehensive collection of images
relating to a wide range of hematologic topics.



*Commercial use requires a copyright license from Copyright Clearance Center

imagebank.hematology.org

SCIENTIFIC WORKSHOPS

The Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology. Please check this page closer to the meeting for additional information about each workshop program.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Scientific Workshop on Advancing Decentralized Clinical Trials in Hematology

non-CME

2:00 p.m. – 5:00 p.m.
275-277

Chairs:

KAMI J. MADDOCKS, MD, Ohio State University Hospital, Columbus, OH

FANGXIN HONG, PhD, Dana-Farber Cancer Institute, Boston, MA

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 2:23 p.m.	Keynote Address: What is a Decentralization of Clinical Trials? – Overview
2:23 p.m. – 3:15 p.m.	Decentralized Clinical Trials in Hematology – Why and How
3:15 p.m. – 4:10 p.m.	Decentralization of Clinical Trials – Innovative Approaches and Technologies
4:10 p.m. – 4:55 p.m.	Decentralization of Clinical Trials - Moving Forward
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS

non-CME

2:00 p.m. – 5:00 p.m.
271-273

Chairs:

NIRALI N. SHAH, MD, National Cancer Institute/NIH, Bethesda, MD

FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL

FABIANA PERNA, MD, Indiana University, Indianapolis, IN

MELODY SMITH, MD, MS, Memorial Sloan-Kettering Cancer Center, Stanford, CA

2:00 p.m. – 2:10 p.m.	Opening Remarks
2:10 p.m. – 3:00 p.m.	Rare and Unique Presentations of ICANS and On-Target/Off-Tumor Toxicity Considerations
3:00 p.m. – 4:00 p.m.	CAR T-cell Toxicities and Associations with Cytokine Profiling and the Gut Microbiome
4:00 p.m. – 4:50 p.m.	CAR T-cell Associated Coagulopathies and Cytopenias
4:50 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Gene Editing in Hematology: Here to Stay

non-CME

2:00 p.m. – 5:00 p.m.
288-290

Chairs:

MATTHEW H. PORTEUS, MD, PhD, Stanford Medical School, Stanford, CA

PAULA RIO, PhD, CIEMAT-Hematopoietic Innovative Therapies, Madrid, Spain

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:20 p.m.	Introduction to the Genome Editing Toolbox
2:20 p.m. – 3:10 p.m.	Targeting HSCs by Gene Editing Moves to the Clinic
3:10 p.m. – 4:00 p.m.	Gene Editing in Immunotherapy
4:00 p.m. – 4:55 p.m.	Genome Editing of the Blood: Safety and Toxicology Evaluations for the Clinic
4:55 p.m. – 5:00 p.m.	Closing Remarks

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

2:00 p.m. – 5:00 p.m.
291-292

Chairs:

LUCY A. GODLEY, MD, PhD, Univ. of Chicago Med. Ctr., Chicago, IL

MARCIN W. WŁODARSKI, MD, PhD, University Medical Center Freiburg, Freiburg, Germany

2:00 p.m. – 2:02 p.m.	Opening Remarks
2:03 p.m. – 2:43 p.m.	Models and Mechanistic Insights
2:44 p.m. – 3:32 p.m.	Clonal Hematopoiesis and Inflammation in Patients with Germline Predisposition Syndromes
3:33 p.m. – 4:25 p.m.	New Insights in Established Syndromes
4:26 p.m. – 4:58 p.m.	Discoveries of New Predisposition Disorders/Genes
4:58 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Hematology and Aging

2:00 p.m. – 5:00 p.m.
278-282

Chairs:

HEIDI KLEPIN, MD, MS, Wake Forest University School of Medicine, Winston Salem, NC

ASHLEY E. ROSKO, MD, The Ohio State University, Columbus, OH

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:45 p.m.	Hematopoietic Stem Cell Mechanisms of Aging
2:45 p.m. – 3:25 p.m.	Implications of the Aging Microenvironment
3:25 p.m. – 4:15 p.m.	Emerging Science from Emerging Investigators in Hematology and Aging
4:15 p.m. – 4:55 p.m.	Thrombosis and Aging
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Interplay between Coagulation and Malignancy

2:00 p.m. – 5:00 p.m.
295-296

Chairs:

LISA BAUMANN KREUZIGER, MD, Bloodcenter of Wisconsin, Menomonee Falls, WI

JEFFREY I. ZWICKER, MD, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:50 p.m.	Platelets and Tumor Growth
2:50 p.m. – 3:50 p.m.	Extracellular Vesicles and Cancer
3:50 p.m. – 4:55 p.m.	Thrombosis in Patients with Myeloproliferative Neoplasms
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Leveraging Digital Technology to Modernize and Enhance Observational Studies

2:00 p.m. – 5:00 p.m.
283-285

Chairs:

WENDY COZEN, DO, MPH, Univ. of Southern California Norris Cancer Ctr., Manhattan Beach, CA

JAMES R. CERHAN, MD, PhD, Mayo Clinic, Rochester, MN

JAMES M. FORAN, MD, Mayo Clinic Florida, Jacksonville, FL

NEIL ZAKAI, Fletcher Allen Health Care, University of Vermont, Burlington, VT

2:00 p.m. – 2:02 p.m.	Opening Remarks
2:02 p.m. – 3:24 p.m.	Using Natural Language and Artificial Intelligence to Enhance Observational Studies in Hematology.
3:24 p.m. – 4:22 p.m.	Use of Electronic Health Records in Observational Studies of Benign and Malignant Hematology.
4:22 p.m. – 4:59 p.m.	New Digital Tools and Technology to Enhance Observational Studies of Benign and Malignant Hematology
4:59 p.m. – 5:00 p.m.	Closing Remarks

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Scientific Workshop on Myeloid Development

 non-CME

2:00 p.m. – 5:00 p.m.
New Orleans Theater AB

Chairs:

PATRICIA ERNST, PhD, University of Colorado Denver, Aurora, CO

ROSS L. LEVINE, MD, Memorial Sloan Kettering Cancer Center, New York, NY

2:00 p.m. – 2:01 p.m.	Opening Remarks
2:02 p.m. – 2:42 p.m.	Myeloid Malignancies
2:42 p.m. – 3:35 p.m.	Stem Cells
3:35 p.m. – 4:15 p.m.	Signaling and Developmental Hematopoiesis
4:15 p.m. – 4:55 p.m.	Transcription Factors
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Thrombotic Microangiopathies

2:00 p.m. – 5:00 p.m.
293-294

Chairs:

SHRUTI CHATURVEDI, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD

SPERO CATALAND, MD, Ohio State University Medical Center, Columbus, OH

MARIE SCULLY, MD, University College London, London, ENG, United Kingdom

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 3:10 p.m.	New Insights into the Pathogenesis of Thrombotic Thrombocytopenic Purpura
3:10 p.m. – 4:15 p.m.	Treatment of Thrombotic Microangiopathy
4:15 p.m. – 4:58 p.m.	Long Term Outcomes of Thrombotic Microangiopathy
4:58 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Translational Molecular Diagnostics: Genomic Reclassification of Blood Cancer

2:00 p.m. – 5:00 p.m.
298-299

Chairs:

PIERS BLOMBERY, MBBS, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia


TORSTEN HAFERLACH, MD, MLL Munchner Leukamie Labor Gmbh, Munchen, Germany

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 2:47 p.m.	New Tools and Approaches for Genomic Classification of Blood Cancer
2:47 p.m. – 3:31 p.m.	Novel Genomic Blood Cancer Entities - Part 1
3:31 p.m. – 4:15 p.m.	New Classifications Systems in Blood Cancer
4:15 p.m. – 4:59 p.m.	Novel Genomic Blood Cancer Entities - Part 2
4:59 p.m. – 5:00 p.m.	Closing Remarks



American Society of Hematology

Helping hematologists conquer blood diseases worldwide



BLOOD AND BEYOND

The Pandemic of the Past and Present in Context of the History of American Medicine

THE GREAT INFLUENZA/
COVID-19

ASH® 2022 Annual Meeting in New Orleans

Sunday December 11, 2022 • In-Person

4:30 PM – 6:00 PM

Ernest N. Morial Convention Center Room 265-268

Annual Meeting Virtual Platform/Webcast

Requires ASH 2022 registration or webcast purchase

► Register to attend this session in-person, or via the Virtual Platform/Webcast

hematology.org/annual-meeting



SPEAKER:

John M. Barry

Author

The Influenza

Pandemic of 1918



CHAIR:

Nancy Berliner, MD

Editor-in-Chief, *Blood*

Brigham & Women's

Hospital

John M. Barry has had considerable influence on both pandemic policy and flood protection. Both the Bush and Obama administrations sought his advice on influenza preparedness and response, and he was a member of the original team which developed plans for non-pharmaceutical interventions to mitigate a pandemic. Barry has served on advisory boards at M.I.T.'s Center for Engineering Systems Fundamentals and the Johns Hopkins Bloomberg School of Public Health as well as on the board of the Society of American Historians. John M. Barry is Distinguished Scholar at both the Tulane University School of Public Health and Tropical Medicine and Tulane's Bywater Institute. Barry concludes in *The Great Influenza* that "The final lesson of 1918, a simple one yet one most difficult to execute, is that...those in authority must retain the public's trust. The way to do that is to distort nothing, to put the best face on nothing, to try to manipulate no one. Lincoln said that first, and best. A leader must make whatever horror exists concrete. Only then will people be able to break it apart."

ASH POSTER WALKS

Check the mobile app or the ASH annual meeting website for a detailed list of posters that will be discussed and the most up-to-date scheduling information.

The ASH Poster Walks are curated groups of poster presentations selected by ASH Committees, Task Forces, and volunteers, which focus on a specific disease state or scientific research topic. These sessions will provide an opportunity to view up to six pre-selected poster presentations accompanied by a moderated discussion with the authors and key opinion leaders in the field. These

sessions will be held Wednesday, December 14, through Thursday, December 15.

ASH Poster Walks are not offered for CME credit.

DATES/TIMES to be announced. Please check the mobile app or the ASH Annual Meeting website for more information.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WEDNESDAY AND THURSDAY

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:

WARREN FINGRUT, MD, Harvard T.H. Chan School of Public Health, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY

Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:

KLAUS METZELER, MD, University Hospital Leipzig, Leipzig, Germany

Platelets from Bench to Bedside

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:

MARIE HOLLENHORST, MD, Stanford University, Palo Alto, CA

The Spectrum of Hemostasis and Thrombosis Research

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:

LISA BAUMANN KREUZIGER, MD, Versiti, Blood Research Institute, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI

What's Hot in Sickle Cell Disease Research 2022

Please check the mobile app for the date and time.
VIRTUAL PROGRAM

Organizer:

ELIZABETH KLINGS, MD, Boston University School of Medicine, Boston University, Boston, MA

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed lunch will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 8, at the Ticketed Sessions Counter in the Great Hall Pre-Function.

Ticket Prices (per session)

Active or International Member	\$75
Non-Member	\$75
Associate, International Associate, Resident, or Graduate/Medical Student, or Honorary/Emeritus Member	\$50
Non-Member in Training	\$50
Allied Health Professional	\$50
Attention Trainees!	

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Acute Myeloid Leukemia Genomics

Saturday 8:00 a.m. – 9:00 a.m.
Jackson, Hilton New Orleans Riverside

Speaker:

TIMOTHY J. LEY, MD, Washington University in St. Louis, Saint Louis, MO
Acute Myeloid Leukemia Genomics

Clonal Analysis of Dnmt3a-mutant Premalignant Hematopoiesis

Saturday 8:00 a.m. – 9:00 a.m.
Magazine, Hilton New Orleans Riverside

Speaker:

ALEJO E. RODRIGUEZ-FRATICELLI, PhD, Boston Children's Hospital, Barcelona, Spain
Clonal Analysis of Dnmt3a-mutant Premalignant Hematopoiesis

Hemoglobin Switching

Saturday 8:00 a.m. – 9:00 a.m.
Prince of Wales, Hilton New Orleans Riverside

Speaker:

VIJAY G. SANKARAN, MD, PhD, Boston Children's Hospital, Boston, MA
Hemoglobin Switching

T Cell Exhaustion

Saturday 8:00 a.m. – 9:00 a.m.
Royal, Hilton New Orleans Riverside

Speaker:

ANDREA SCHIETINGER, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
T Cell Exhaustion

SUNDAY

CAR -T Cell Analysis and Lymphoma Genomics

Sunday 8:00 a.m. – 9:00 a.m.
Marlborough B, Hilton New Orleans
Riverside

Speaker:

MICHAEL R. GREEN, PhD, University of Texas MD
 Anderson Cancer Center, Friendswood, TX
CAR -T Cell Analysis and Lymphoma Genomics

Hematopoietic Cell Competition

Sunday 8:00 a.m. – 9:00 a.m.
Jackson, Hilton New Orleans Riverside

Speaker:

LAURA A. JOHNSTON, PhD, Columbia University, New
 York, NY
Hematopoietic Cell Competition

Multiple Myeloma

Sunday 8:00 a.m. – 9:00 a.m.
Prince of Wales, Hilton New Orleans
Riverside

Speaker:

KATHERINE Y. KING, MD, PhD, Baylor College of
 Medicine, Houston, TX
Multiple Myeloma

Tumor Cell Imaging

Sunday 8:00 a.m. – 9:00 a.m.
Magazine, Hilton New Orleans Riverside

Speaker:

PETER K. SORGER, PhD, Harvard University, Harvard,
 MA
Tumor Cell Imaging Wednesday



SECURE
TRANSFUSION
SOLUTIONS

Platelet Supply Problem?

If your hospital has experienced a platelet supply shortage in the last year, you are not alone. In a recent survey of 481 US hospitals, over 22% of the institutions surveyed reported shortages at least once per month or more, with nearly half of the high-volume transfusion facilities reporting the same.*

Secure Transfusion Solutions (STS) can help

STS owns and operates commercial blood centers under the name **Trusting Heart Blood Center**. Our goal is to provide a safe, reliable additional source of pathogen-reduced apheresis platelets to hospitals throughout the country.



Our innovative approach utilizes:

- + **100% pathogen-reduced components.** STS utilizes the Cerus INTERCEPT® system on all collected platelet units
- + **Best in class safety standards.** STS performs infectious disease testing on all donors on two separate occasions
- + **World class donor experience.** Our spa-like donor centers deliver an enjoyable and relaxing donor experience while attracting a younger donor demographic
- + **Responsible compensated donor model.** STS taps into a dedicated, pre-screened donor base

Platelet Donation Center locations:

Edina, Minnesota
Raleigh, North Carolina
Beaverton, Oregon


Additional sites in 2023-24.

Learn more

To learn more, or to schedule an introductory call, email
info@securetransfusion.com

* Source: Pandey S, et al. A survey of US hospitals on platelet inventory management, transfusion practice, and platelet availability. *Transfusion*. 2021; 61:2611-2620.

ABSTRACT SESSIONS



2022 SCIENTIFIC CATEGORIES

For the 2022 64th Annual Meeting, abstracts were submitted in 65 different categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number.

Oral Sessions' titles begin with the category number and name. They are listed in the Program at a Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.

100s—Red Cell Physiology and Disorders

- 101 Red Cells and Erythropoiesis, Excluding Iron
- 102 Iron Homeostasis and Biology
- 112 Thalassemia and Globin Gene Regulation
- 113 Hemoglobinopathies, Excluding Thalassemia: Basic and Translational
- 114 Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological

200s—Leukocytes, Inflammation, and Immunology

- 201 Granulocytes, Monocytes, and Macrophages
- 203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s—Hemostasis, Thrombosis, and Vascular Wall Biology

- 301 Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
- 311 Disorders of Platelet Number or Function: Clinical and Epidemiological
- 321 Coagulation and Fibrinolysis: Basic and Translational
- 322 Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
- 331 Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological
- 332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s—Transfusion Medicine

- 401 Blood Transfusion

500s—Hematopoiesis

- 501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
- 503 Clonal Hematopoiesis, Aging and Inflammation
- 506 Bone Marrow Microenvironment
- 508 Bone Marrow Failure: Acquired
- 509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s—Hematologic Malignancy

- 602 Myeloid Oncogenesis: Basic
- 603 Lymphoid Oncogenesis: Basic
- 604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
- 605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
- 612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
- 613 Acute Myeloid Leukemias: Clinical and Epidemiological
- 614 Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
- 615 Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
- 616 Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
- 617 Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

- 618 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
- 621 Lymphomas: Translational—Molecular and Genetic
- 622 Lymphomas: Translational—Non-Genetic
- 623 Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
- 624 Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
- 626 Aggressive Lymphomas: Prospective Therapeutic Trials
- 627 Aggressive Lymphomas: Clinical and Epidemiological
- 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
- 632 Chronic Myeloid Leukemia: Clinical and Epidemiological
- 634 Myeloproliferative Syndromes: Clinical and Epidemiological
- 636 Myelodysplastic Syndromes—Basic and Translational
- 637 Myelodysplastic Syndromes—Clinical and Epidemiological
- 641 Chronic Lymphocytic Leukemias: Basic and Translational
- 642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological
- 651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
- 652 Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological
- 653 Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials
- 700s—Transplantation and Adoptive Cell Therapies**
- 701 Experimental Transplantation: Basic and Translational
- 703 Cellular Immunotherapies: Basic and Translational
- 704 Cellular Immunotherapies: Early Phase and Investigational Therapies
- 705 Cellular Immunotherapies: Late Phase and Commercially Available Therapies
- 711 Cell Collection and Processing
- 721 Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
- 722 Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
- 723 Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence
- 731 Autologous Transplantation: Clinical and Epidemiological
- 732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
- 800s—Gene Therapies, Chemical Biology, and Emerging Diagnostics**
- 801 Gene Therapies
- 802 Chemical Biology and Experimental Therapeutics
- 803 Emerging Tools, Techniques and Artificial Intelligence in Hematology
- 900s—Health Services and Outcomes Research**
- 901 Health Services and Quality—Non-Malignant Conditions
- 902 Health Services and Quality—Lymphoid Malignancies
- 903 Health Services and Quality—Myeloid Malignancies
- 904 Outcomes Research—Non-Malignant Conditions
- 905 Outcomes Research—Lymphoid Malignancies
- 906 Outcomes Research—Myeloid Malignancies


ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 10, through Monday, December 12. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter. The Plenary

Scientific Session will be held Sunday, September 11, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY


9:30 a.m. – 11:00 a.m. Oral Abstract Sessions 

- | | |
|---|--|
| <p>114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies (7–12)
391-392</p> <p>201. Granulocytes, Monocytes, and Macrophages II (13–18)
295-296</p> <p>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Special Populations and Long-term Outcomes in ITP (19–24)
275-277</p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders (25–30)
271-273</p> <p>401. Blood Transfusion: Molecular Mechanisms and Novel Therapies (31–36)
393-396</p> <p>602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies (37–42)
353-355</p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Vulnerabilities Triggering Mechanisms of Drug Resistance and Sensitivity in Myeloid Neoplasms (43–48)
343-345</p> <p>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups (49–54)
243-245</p> <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia (55–60)
208-210</p> <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML (61–66)
220-222</p> <p>622. Lymphomas: Translational–Non-Genetic: Tumor Microenvironment in Lymphoid Malignancies: Composition, Biology, and Prognostic Significance (67–72)
New Orleans Theater C</p> | <p>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I (73–78)
La Nouvelle Orleans Ballroom C</p> <p>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents (79–84)
217-219</p> <p>636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies (85–90)
260-262</p> <p>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations (91–96)
La Nouvelle Orleans Ballroom AB</p> <p>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational (97–102)
R06-R09</p> <p>652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma (103–108)
R02-R05</p> <p>722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT (109–114)
252-254</p> <p>731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP (115–120)
278-282</p> <p>801. Gene Therapies: Addressing Challenges & Opportunities in Pre-clinical Settings (121–126)
Great Hall B/C</p> <p>903. Health Services and Quality—Myeloid Malignancies I (127–132)
388-390</p> |
|---|--|

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.


12:00 p.m. – 1:30 p.m. Oral Abstract Sessions 

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological I (133–138)
Great Hall A/D
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Controversies in Anticoagulation and Venous Thromboembolism (139–144)
Great Hall B/C
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Transcription, Translation, and Epigenetics (145–150)
288-290
627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment of CNS Lymphoma, Neurologic Toxicities, and Relapsed/Refractory DLBCL (151–156)
New Orleans Theater C
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma (157–162)
R02-R05
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma (163–168)
La Nouvelle Orleans Ballroom AB
905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant (169–174)
243-245

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions 

113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models (175–180)
275-277
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment (181–186)
278-282
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Looking Forward: Novel Therapies and Diagnostic Modalities for Bleeding Disorders (187–192)
288-290
508. Bone Marrow Failure: Acquired: Biology (193–198)
260-262
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms (199–204)
343-345
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK (205–210)
388-390
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials (211–216)
265-268
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML (217–222)
Great Hall B/C
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications (223–228)
291-292
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III (229–234)
New Orleans Theater C
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis (235–240)
217-219
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational (241–246)
R06-R09
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM) (247–252)
R02-R05
703. Cellular Immunotherapies: Basic and Translational I (253–258)
La Nouvelle Orleans Ballroom C
705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies (259–264)
La Nouvelle Orleans Ballroom AB
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses (265–270)
391-392
802. Chemical Biology and Experimental Therapeutics I (271–276)
353-355
906. Outcomes Research—Myeloid Malignancies II (277–282)
220-222

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

4:00 p.m. – 5:30 p.m. Oral Abstract Sessions 

- | | |
|---|--|
| <p>101. Red Cells and Erythropoiesis, Excluding Iron I (283–288)
391-392</p> <p>508. Bone Marrow Failure: Acquired: Clinical Studies (289–294)
260-262</p> <p>602. Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism (295–300)
293-294</p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML (301–306)
388-390</p> <p>621. Lymphomas: Translational—Molecular and Genetic: Single Cell, Microenvironment, and Treatment Resistance (307–312)
La Nouvelle Orleans Ballroom C</p> <p>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma (313–318)
278-282</p> <p>627. Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL (319–324)
New Orleans Theater AB</p> <p>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel Therapeutic Targets in MPN and CML (325–330)
275-277</p> <p>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Disease (331–336)
265-268</p> | <p>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Avant-garde and Traditional Prognostic and Response Assessment in MPNs (337–342)
217-219</p> <p>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter's Transformation (343–348)
R06-R09</p> <p>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational (349–354)
New Orleans Theater C</p> <p>703. Cellular Immunotherapies: Basic and Translational II (355–360)
393-396</p> <p>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT (361–366)
Great Hall A/D</p> <p>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III (367–372)
343-345</p> <p>723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II (373–378)
353-355</p> <p>905. Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies (379–384)
208-210</p> <p>906. Outcomes Research—Myeloid Malignancies I (385–390)
220-222</p> |
|---|--|

SUNDAY

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions 

- | | |
|--|--|
| <p>113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease (391–396)
343-345</p> <p>321. Coagulation and Fibrinolysis: Basic and Translational (397–402)
293-294</p> <p>503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models (403–408)
271-273</p> <p>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics (409–414)
260-262</p> <p>603. Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis (415–420)
393-396</p> | <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia (421–426)
278-282</p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Treatment-related Biomarkers (427–432)
Hall E</p> <p>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies (433–438)
Great Hall A/D</p> <p>626. Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma (439–444)
La Nouvelle Orleans Ballroom AB</p> |
|--|--|

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

627. Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations (445–450)
La Nouvelle Orleans Ballroom C
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations (451–456)
275-277
637. Myelodysplastic Syndromes – Clinical and Epidemiological III (463–468)
252-254
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM) (469–474)
New Orleans Theater C
701. Experimental Transplantation: Basic and Translational: Novel Mechanisms of Acute and Chronic Graft-versus-Host Disease (475–480)
391-392
703. Cellular Immunotherapies: Basic and Translational IV (481–486)
388-390
731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis (487–492)
220-222
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology (493–498)
208-210
901. Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias (499–504)
291-292
904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras (505–510)
295-296

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions 

101. Red Cells and Erythropoiesis, Excluding Iron II (511–516)
243-245
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment (517–522)
291-292
506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment (523–528)
260-262
602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation (529–534)
275-277
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia (535–540)
271-273
621. Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication (541–546)
Great Hall B/C
622. Lymphomas: Translational–Non-Genetic: Translational Research in Lymphoma: Prognostic Biomarkers and Novel Therapeutic Vulnerabilities (547–552)
Great Hall A/D
627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL (553–558)
R02-R05
637. Myelodysplastic Syndromes – Clinical and Epidemiological IV (559–564)
265-268
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma (565–570)
New Orleans Theater C
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Critical Advances in GVHD Management (571–576)
208-210
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes (577–582)
R06-R09

2:00 p.m. – 4:00 p.m. Oral Abstract Sessions 

Plenary Scientific Session (1–6)
Hall E

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions 

- | | |
|--|---|
| <p>201. Granulocytes, Monocytes, and Macrophages I (583–588)
391-392</p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Von Willebrand Disease and Other Congenital and Acquired Bleeding Disorders (589–594)
288-290</p> <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia (595–600)
353-355</p> <p>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Outcomes and New Treatment Strategies in Genetically Adverse Risk and MRD-positive AML (601–606)
343-345</p> <p>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological IV (607–612)
278-282</p> <p>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T-cell Malignancies: Clinical and Epidemiological (613–618)
393-396</p> <p>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TFR, Pregnancy, and Disparities (619–624)
388-390</p> <p>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative</p> | <p>Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs (625–630)
217-219</p> <p>637. Myelodysplastic Syndromes – Clinical and Epidemiological II (457–462)
R06-R09</p> <p>641. Chronic Lymphocytic Leukemias: Basic and Translational: Pathogenesis and Transformation (631–636)
R02-R05</p> <p>651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response (637–642)
New Orleans Theater AB</p> <p>652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma (643–648)
New Orleans Theater C</p> <p>701. Experimental Transplantation: Basic and Translational: Novel Translational Approaches in Transplantation (649–654)
208-210</p> <p>705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas (655–660)
Hall E</p> <p>711. Cell Collection and Processing I (661–666)
220-222</p> <p>901. Health Services and Quality—Non-Malignant Conditions: Better, Faster, Stronger: Innovations in Care Delivery, Care Cost, and Healthcare Teams in Classical Hematology (667–672)
295-296</p> |
|--|---|

MONDAY

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions 

- | | |
|--|---|
| <p>114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Organ Function (673–678)
353-355</p> <p>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans (679–684)
278-282</p> <p>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium (685–690)
293-294</p> <p>321. Coagulation and Fibrinolysis: Basic and Translational (691–696)
291-292</p> <p>506. Bone Marrow Microenvironment: Extrinsic Regulators of Hematopoiesis (697–702)
260-262</p> <p>603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis (703–708)
208-210</p> | <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance (709–714)
275-277</p> <p>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: High-risk T-ALL and Prognostic Biomarkers (715–720)
Great Hall B/C</p> <p>621. Lymphomas: Translational—Molecular and Genetic: Genomic Characterization (721–726)
271-273</p> <p>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Hodgkin Lymphoma: Retrospective Analyses and Prospective Trials (727–732)
265-268</p> <p>626. Aggressive Lymphomas: Prospective Therapeutic Trials: Frontline Treatment of Large B-cell Lymphoma (733–738)
La Nouvelle Orleans Ballroom C</p> |
|--|---|

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies and Surrogate Endpoints in ET and PV (739–744)
217-219
641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers (745–750)
La Nouvelle Orleans Ballroom AB
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Therapeutic Impact in Multiple Myeloma (751–756)
New Orleans Theater C
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions (757–762)
288-290
705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy (763–768)
393-396
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease (769–774)
252-254
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence I (775–780)
243-245
801. Gene Therapies: Advances in Clinical Gene Therapy for Hematological Disorders (781–786)
220-222
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Clinical Implication of Artificial Intelligence in Precision Hematology (787–792)
391-392
905. Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma (793–798)
388-390

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions 

112. Thalassemia and Globin Gene Regulation I (799–804)
220-222
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues (805–810)
278-282
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies (811–816)
353-355
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental (817–822)
252-254
602. Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution (823–828)
293-294
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML (829–834)
R02-R05
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Reponse to Treatment in AML (835–840)
295-296
621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology (841–846)
388-390
627. Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome (847–852)
La Nouvelle Orleans Ballroom C
637. Myelodysplastic Syndromes – Clinical and Epidemiological I (853–858)
243-245
651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences (859–864)
Hall E
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: New Approaches to MRD Assessment (865–870)
Great Hall B/C
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II (871–876)
393-396
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Results of Large Prospective Studies (877–882)
391-392
901. Health Services and Quality—Non-Malignant Conditions: Level Up! Taking Quality Care to the Next Level in Sickle Cell Disease (883–888)
New Orleans Theater C
902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care (889–894)
La Nouvelle Orleans Ballroom AB
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Care Across the Lifespan (895–900)
R06-R09
905. Outcomes Research—Lymphoid Malignancies: Outcomes in Childhood Leukemia/Lymphoma (901–906)
291-292

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions 

102. Iron Homeostasis and Biology I (907–912)
388-390
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP (913–918)
220-222


All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging (919–924)
393-396
503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts And Biosamples (925–930)
252-254
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms (931–936)
353-355
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics (937–942)
391-392
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations (943–948)
New Orleans Theater C
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II (949–954)
R06-R09
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T- and NK-cell Lymphomas: Prospective Trials and a Retrospective Analysis (955–960)
271-273
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19 (961–966)
243-245
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring (967–972)
278-282
703. Cellular Immunotherapies: Basic and Translational III (973–978)
La Nouvelle Orleans Ballroom C
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma (979–984)
Hall E
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I (985–990)
260-262
902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities (991–996)
La Nouvelle Orleans Ballroom AB
905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation (997–1002)
291-292



blood advances[®]

Transforming the Conversation



Blood Advances is a semimonthly medical journal published by the American Society of Hematology. It is a peer-reviewed, online-only open access journal.

Blood Advances covers all aspects of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology.



Editor-in-Chief

Catherine M. Bollard, MBChB, MD, FRACP, FRCPA

Children's National Research Institute, Washington, DC

FEATURING



Blood Advances Talks (BATs): Articles featuring podcast reviews



Point-Counterpoint: Debate based articles presenting contradicting opinions



Clinical Guidelines: Includes recommendations based on a high level of evidence relevant to patient care



Health Services & Health Outcomes: Articles analyzing systems of health care



Drug Advances: Covers both the preclinical development and clinical applications of a new drug or indication relevant to hematology



Original Research: Articles describing basic laboratory, translational, and clinical investigations in hematology



JOIN THE CONVERSATION TODAY

bloodadvances.org



POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the Ernest N. Morial Convention Center, Hall D. Presenters will stand beside their posters during the evening Presentation times.

Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Central time) each day, as well as access posters from previous days.

The Poster Hall hours are as follows:

Saturday, December 10 9:00 a.m. – 7:30 p.m.

Sunday, December 11 9:00 a.m. – 8:00 p.m.

Monday, December 12 9:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY, DECEMBER 10, 2022

9:00 a.m. – 7:30 p.m. **Poster Session I – Viewing** 

5:30 p.m. – 7:30 p.m. **Poster Session I – Presentations** 

Hall D, Ernest N. Morial Convention Center

- | | |
|---|--|
| <p>101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1003–1017)</p> <p>102. Iron Homeostasis and Biology: Poster I (1018–1028)</p> <p>112. Thalassemia and Globin Gene Regulation: Poster I (1029–1036)</p> <p>113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I (1037–1054)</p> <p>114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster I (1055–1083)</p> <p>201. Granulocytes, Monocytes, and Macrophages: Poster I (1084–1098)</p> <p>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1099–1107)</p> <p>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1108–1126)</p> <p>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1127–1138)</p> <p>321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1139–1146)</p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1147–1171)</p> <p>331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I (1172–1181)</p> <p>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1182–1200)</p> <p>401. Blood Transfusion: Poster I (1201–1208)</p> <p>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1209–1221)</p> <p>503. Clonal Hematopoiesis, Aging and Inflammation: Poster I (1222–1233)</p> | <p>506. Bone Marrow Microenvironment: Poster I (1234–1244)</p> <p>508. Bone Marrow Failure: Acquired: Poster I (1245–1257)</p> <p>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1258–1266)</p> <p>602. Myeloid Oncogenesis: Basic: Poster I (1267–1299)</p> <p>603. Lymphoid Oncogenesis: Basic: Poster I (1300–1314)</p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1315–1340)</p> <p>605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1341–1366)</p> <p>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1367–1380)</p> <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1381–1408)</p> <p>614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1409–1419)</p> <p>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1420–1439)</p> <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1440–1460)</p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1461–1500)</p> <p>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1501–1516)</p> <p>621. Lymphomas: Translational—Molecular and Genetic: Poster I (1517–1543)</p> <p>622. Lymphomas: Translational—Non-Genetic: Poster I (1544–1562)</p> |
|---|--|

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1563–1590)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I (1591–1617)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I (1618–1637)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I (1638–1672)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1673–1688)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1689–1708)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1709–1740)
636. Myelodysplastic Syndromes—Basic and Translational: Poster I (1741–1754)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I (1755–1783)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1784–1796)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (1797–1817)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1818–1855)
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (1856–1914)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I (1915–1940)
701. Experimental Transplantation: Basic and Translational: Poster I (1941–1960)
703. Cellular Immunotherapies: Basic and Translational: Poster I (1961–1992)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I (1993–2021)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I (2022–2043)
711. Cell Collection and Processing: Poster I (2044–2050)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I (2051–2072)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I (2073–2094)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I (2095–2108)
731. Autologous Transplantation: Clinical and Epidemiological: Poster I (2109–2119)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2120–2136)
801. Gene Therapies: Poster I (2137–2151)
802. Chemical Biology and Experimental Therapeutics: Poster I (2152–2165)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I (2166–2183)
901. Health Services and Quality—Non-Malignant Conditions: Poster I (2184–2207)
902. Health Services and Quality—Lymphoid Malignancies: Poster I (2208–2225)
903. Health Services and Quality—Myeloid Malignancies: Poster I (2226–2236)
904. Outcomes Research—Non-Malignant Conditions: Poster I (2237–2259)
905. Outcomes Research—Lymphoid Malignancies: Poster I (2260–2301)
906. Outcomes Research—Myeloid Malignancies: Poster I (2302–2321)

SUNDAY, DECEMBER 11, 2022

9:00 a.m. – 8:00 p.m. **Poster Session II – Viewing** 

6:00 p.m. – 8:00 p.m. **Poster Session II – Presentations** 

Hall D, Ernest N. Morial Convention Center

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2322–2336)
102. Iron Homeostasis and Biology: Poster II (2337–2347)
112. Thalassemia and Globin Gene Regulation: Poster II (2348–2355)
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II (2356–2372)
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster II (2373–2400)
201. Granulocytes, Monocytes, and Macrophages: Poster II (2401–2415)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2416–2424)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II (2425–2442)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2443–2454)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (2455–2462)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II (2463–2487)
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II (2488–2497)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2498–2517)
401. Blood Transfusion: Poster II (2518–2526)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2527–2538)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster II (2539–2550)
506. Bone Marrow Microenvironment: Poster II (2551–2562)
508. Bone Marrow Failure: Acquired: Poster II (2563–2575)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2576–2584)
602. Myeloid Oncogenesis: Basic: Poster II (2585–2616)
603. Lymphoid Oncogenesis: Basic: Poster II (2617–2631)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2632–2656)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2657–2682)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2683–2696)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2697–2723)
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2724–2734)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2735–2755)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2756–2776)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2777–2817)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2818–2834)
621. Lymphomas: Translational—Molecular and Genetic: Poster II (2835–2862)
622. Lymphomas: Translational–Non-Genetic: Poster II (2863–2881)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (2882–2908)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II (2909–2935)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II (2936–2956)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (2957–2991)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (2992–3007)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3008–3027)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3028–3059)
636. Myelodysplastic Syndromes—Basic and Translational: Poster II (3060–3072)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II (3073–3100)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II (3101–3113)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3114–3134)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3135–3172)
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3173–3231)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II (3232–3257)
701. Experimental Transplantation: Basic and Translational: Poster II (3258–3276)
703. Cellular Immunotherapies: Basic and Translational: Poster II (3277–3309)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II (3310–3339)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II (3340–3360)
711. Cell Collection and Processing: Poster II (3361–3367)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II (3368–3390)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II (3391–3412)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II (3413–3426)
731. Autologous Transplantation: Clinical and Epidemiological: Poster II (3427–3437)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3438–3455)
801. Gene Therapies: Poster II (3456–3470)
802. Chemical Biology and Experimental Therapeutics: Poster II (3471–3483)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II (3484–3502)
901. Health Services and Quality—Non-Malignant Conditions: Poster II (3503–3526)
902. Health Services and Quality—Lymphoid Malignancies: Poster II (3527–3544)
903. Health Services and Quality—Myeloid Malignancies: Poster II (3545–3554)
904. Outcomes Research—Non-Malignant Conditions: Poster II (3555–3577)
905. Outcomes Research—Lymphoid Malignancies: Poster II (3578–3619)
906. Outcomes Research—Myeloid Malignancies: Poster II (3620–3638)

MONDAY, DECEMBER 12, 2022

9:00 a.m. – 8:00 p.m. **Poster Session III – Viewing** 

6:00 p.m. – 8:00 p.m. **Poster Session III – Presentations** 

Hall D, Ernest N. Morial Convention Center

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3639–3653)
102. Iron Homeostasis and Biology: Poster III (3654–3664)
112. Thalassemia and Globin Gene Regulation: Poster III (3665–3672)
113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III (3673–3690)
114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III (3691–3719)
201. Granulocytes, Monocytes, and Macrophages: Poster III (3720–3733)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3734–3742)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III (3743–3760)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3761–3773)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3774–3781)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III (3782–3806)
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III (3807–3816)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (3817–3836)
401. Blood Transfusion: Poster III (3837–3845)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (3846–3858)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster III (3859–3870)
506. Bone Marrow Microenvironment: Poster III (3871–3881)
508. Bone Marrow Failure: Acquired: Poster III (3882–3894)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (3895–3902)
602. Myeloid Oncogenesis: Basic: Poster III (3903–3935)
603. Lymphoid Oncogenesis: Basic: Poster III (3936–3950)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (3951–3976)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (3977–4002)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4003–4015)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4016–4042)
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4043–4053)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4054–4073)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4074–4094)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4095–4134)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4135–4151)
621. Lymphomas: Translational—Molecular and Genetic: Poster III (4152–4178)
622. Lymphomas: Translational–Non-Genetic: Poster III (4179–4197)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4198–4224)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III (4225–4250)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III (4251–4270)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4271–4306)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4307–4323)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4324–4343)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4344–4376)
636. Myelodysplastic Syndromes—Basic and Translational: Poster III (4377–4389)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III (4390–4417)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III (4418–4430)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4431–4451)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4452–4489)
652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4490–4549)
653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III (4550–4575)
701. Experimental Transplantation: Basic and Translational: Poster III (4576–4594)
703. Cellular Immunotherapies: Basic and Translational: Poster III (4595–4626)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4627–4656)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4657–4678)
711. Cell Collection and Processing: Poster III (4679–4685)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III (4686–4707)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4708–4728)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4729–4742)
731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4743–4754)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4755–4772)
801. Gene Therapies: Poster III (4773–4787)
802. Chemical Biology and Experimental Therapeutics: Poster III (4788–4801)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (4802–4819)
901. Health Services and Quality—Non-Malignant Conditions: Poster III (4820–4843)
902. Health Services and Quality—Lymphoid Malignancies: Poster III (4844–4861)
903. Health Services and Quality—Myeloid Malignancies: Poster III (4862–4872)
904. Outcomes Research—Non-Malignant Conditions: Poster III (4873–4895)
905. Outcomes Research—Lymphoid Malignancies: Poster III (4896–4937)
906. Outcomes Research—Myeloid Malignancies: Poster III (4938–4956)

SATELLITE SYMPOSIA

Satellite Symposia will take place on Friday, December 9, 2022, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in this program. The Society values its partnerships and the supportive role that members of the community play in an effort to provide hematologists with quality educational programs. Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FRIDAY MORNING SYMPOSIA

7:00 A.M. – 10:00 A.M.

A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies

7:00 a.m. – 10:00 a.m.

VIRTUAL PROGRAM

This program is provided by Cleveland Clinic and supported by Cleveland Clinic and AAMDSIF.

CHAIR:

SUDIPTO MUKHERJEE, MD, PhD, MPH, Cleveland Clinic
Taussig Cancer Institute, Cleveland, OH

Speakers:

RODRIGO T. CALADO, MD, PhD, Hospital das Clínicas de Ribeirão Preto, São Paulo, Brazil
GABRIELA S. HOBBS, MD, Massachusetts General Hospital, Boston, MA
BHUMIKA J. PATEL, MD, Prisma Health, University Medical Group, University of South Carolina School of Medicine Greenville, Greenville, SC
GUILLERMO SANZ, MD, PhD, Hospital Universitario La Fe, Valencia, Spain
CRAIG S. SAUTER, MD, Cleveland Clinic, Cleveland, OH
ROLAND B. WALTER, MS, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

Contact: Kristin Bower
Email: bowerk@ccf.org

Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

7:00 a.m. – 10:00 a.m.

Celestin EFGH
Hyatt Regency New Orleans

This program is provided by National Comprehensive Cancer Network and supported by educational grants from Astellas, Daiichi Sankyo, Servier, and Syndax Pharmaceuticals Inc., and an independent educational grant from Gilead Sciences, Inc. Provided by NCCN in partnership with Clinical Care Options, LLC.

Chair:

DANIEL A. POLLYEA, MD, MS, University of Colorado, Aurora, CO

Speakers:

COURTNEY D. DiNARDO, MD, MSCE, MD Anderson Cancer Center, Houston, TX
EYTAN STEIN, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Kristin Hasson
Email: hasson@nccn.org

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies

7:00 a.m. – 10:00 a.m.

Elite B
Hyatt Regency New Orleans

This program is provided by National Comprehensive Cancer Network and supported by educational grants from AstraZeneca, BeiGene, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by NCCN in partnership with Clinical Care Options, LLC.

Chair:

JENNIFER A. WOYACH, MD, The Ohio State University, Columbus, OH

Speakers:

BRIAN T. HILL, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH
DEBORAH M. STEPHENS, DO, Huntsman Cancer Institute, Salt Lake City, UT

Contact: Kristin Hasson
Email: hasson@nccn.org

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

7:00 a.m. – 10:00 a.m.

Grand Ballroom A/B
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Sanofi.

Chairs:

SIGBJØRN BERENTSEN, MD, PhD, Haugesund Hospital, Haugesund, Norway
ILENE C. WEITZ, MD, University of Southern California, Los Angeles, CA

Contact: Margaret Walker
Email: margaret.walker@peerview.com

Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management

7:00 a.m. – 10:00 a.m.

Empire CD
Hyatt Regency New Orleans

This program is provided by PeerView Institute for Medical Education and supported by AstraZeneca and Lilly.

Chair:

TOBY A. EYRE, MChB, DipMedEd, MRCP, FRCPath, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom

Speakers:

JIA RUAN, MD, PhD, The New York and Presbyterian Hospital, New York City, NY
PAOLO STRATI, MD, MD Anderson Cancer Center, Houston, TX

Contact: Margaret Walker
Email: margaret.walker@peerview.com

Maintaining 'Intensity' for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

7:00 a.m. – 10:00 a.m.

Napoleon B 1-3 + Corridor A/B
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Jazz Pharmaceuticals.

Chair:

GAIL J. ROBOZ, MD, Weill Cornell Medicine and The New York Presbyterian Hospital, New York City, NY

Speaker:

HARRY P. ERBA, MD, PhD, Duke University Medical Center, Durham, N
TAPAN KADIA, MD, MD Anderson Cancer Center, Houston, TX C

Contact: Margaret Walker
Email: margaret.walker@peerview.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Myelodysplastic Syndromes 2022: Today and Tomorrow

7:00 a.m. – 10:00 a.m.

La Nouvelle Orleans Ballroom AB

This program is provided and supported by MDS Foundation, Inc.

Co-Chairs:

MOSHE MITTELMAN, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

VALERIA SANTINI, MD, AOU Careggi-University of Florence, Florence, Italy

Speakers:

RAFAEL BEJAR, MD, PhD, University of California, San Diego, La Jolla, CA

RENA BUCKSTEIN, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada

JANE CHURPEK, MD, University of Wisconsin Madison, Madison, WI

THEO M DE WITTE, MD, Radboud University Medical Centre, Nijmegen, Netherlands

PETER C. GRAYSON, MD, MSc, Tenure Track Investigator, National Institutes of Health, Bethesda, MD

ELIZABETH A. GRIFFITHS, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

YASUSHI MIYAZAKI, MD, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

SOPHIE PARK, MD, PhD, CHU Centre hospitalo-universitaire (CHU) Grenoble Alpes, Grenoble, France

LEWIS R. SILVERMAN, MD, Icahn School of Medicine at Mount Sinai, Director Translational Research Center for the Myelodysplastic Syndrome, Tisch Cancer Institute, New York City, NY

Contact: Lea Harrison

Email: lharrison@mds-foundation.org

Navigating the Frontier of Hematologic Malignancy Therapies

7:00 a.m. – 10:00 a.m.

Great Hall A/D

For In-Person Participants Only

This program is jointly provided by RMEI Medical Education LLC and The Leukemia & Lymphoma Society, and is supported by AstraZeneca Pharmaceuticals LP and The Leukemia & Lymphoma Society.

Chair:

HELEN E. HESLOP, MD, DSc (HON), Baylor College of Medicine, Houston, TX

Speakers:

KATHERINE DONOVAN, PhD, Dana-Farber Cancer Institute, Boston, MA

SOHEIL MESHINCHI, M.D., Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA

MARK ROSCHEWSKI, MD, National Cancer Institute, Bethesda, MD

SAAD Z. USMANI, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Cherie Haley

Email: chaley@rmei.com

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

7:00 a.m. – 10:00 a.m.

VIRTUAL PROGRAM

This program is provided by RedMedEd and supported by The Multiple Myeloma Research Foundation with funding provided by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Legend Biotech USA Inc.

Co-Chairs:

HEARN J. CHO, MD, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, Icahn School of Medicine at Mount Sinai, New York, NY

PAUL G. RICHARDSON, MD, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

KEITH STEWART, MChB, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Speakers:

AMRITA Y. KRISHNAN, MD, FACP, City of Hope Medical Center, Duarte, CA

SUZANNE LENTZSCH, MD, PhD, Columbia University, New York City, NY

Contact: Karen Tenaglia

Email: ktenaglia@redmeded.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms into Patient Care

7:00 a.m. – 10:00 a.m.
Rhythms Ballroom
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Incyte Corporation and MorphoSys US Inc.

Chair:

GRZEGORZ (GREG) NOWAKOWSKI, MD, Mayo Clinic, Rochester, MN

Speaker:

PAOLO F. CAIMI, MD, Cleveland Clinic Lerner College of Medicine, Case Comprehensive Cancer Center, Cleveland, OH

Contact: Margaret Walker
Email: margaret.walker@peerview.com

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

7:00 a.m. – 10:00 a.m.
Empire B
Hyatt Regency New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Bristol Myers Squibb and Kite, a Gilead Company.

Chair:

JASON WESTIN, MD, MD Anderson Cancer Center, Houston, TX

Speakers:

SATTVA S. NEELAPU, MD, MD Anderson Cancer Center, Houston, TX
ALISON R. SEHGAL, MD, UPMC Hillman Cancer Center, Pittsburgh, PA

Contact: Margaret Walker
Email: margaret.walker@peerview.com

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

7:00 a.m. – 10:00 a.m.
Grand Ballroom C
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education, and supported by AbbVie, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

Chair:

NIKHIL C. MUNSHI, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Speakers:

NIZAR JACQUES BAHLIS, MD, University of Calgary, Calgary, Alberta, Canada
IRENE GHOBRIAL, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Margaret Walker
Email: margaret.walker@peerview.com

The Sequel to the Targeted Therapy Era in CML: Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans

7:00 a.m. – 10:00 a.m.
Napoleon C 1-3 + Corridor C/D
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Novartis Pharmaceuticals Corporation.

Chair:

JERALD P. RADICH, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

Speakers:

MICHAEL MAURO, MD, Memorial Sloan Kettering Cancer Center, New York City, NY
KENDRA SWEET, MD, Moffitt Cancer Center, Tampa, FL

Contact: Margaret Walker
Email: margaret.walker@peerview.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

**The Winning Way with BTK Inhibitors in CLL:
Evidence-Informed Choices on Treatment
Selection, Safety, and Therapeutic Sequencing**

7:00 a.m. – 10:00 a.m.

**Empire A
Hyatt Regency New Orleans**

This program is provided by PeerView Institute for Medical Education and supported by Astra-Zeneca.

Chair:

JOHN C. BYRD, MD, University of Cincinnati College of Medicine, Cincinnati, OH

Speakers:

JACQUELINE C. BARRIENTOS, MD, MS, Zucker School of Medicine at Hofstra/Northwell Feinstein Institutes for Medical Research, Mount Sinai Medical Center, Comprehensive Cancer Center, Miami, FL
NICOLE LAMANNA, MD, Columbia University Medical Center, New York City, NY

Contact: Margaret Walker

Email: margaret.walker@peerview.com

**FRIDAY EARLY AFTERNOON SYMPOSIA
11:00 A.M. – 2:00 P.M.**

**A Conversation With the Myeloma Experts:
Making Sense of the Evolving Treatment
Landscape**

11:00 a.m. – 2:00 p.m.

**Elite B
Hyatt Regency New Orleans**

This program is provided by Clinical Care Options, LLC and supported by educational grants from Amgen, Janssen Biotech, Inc., Karyopharm Therapeutics Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Chair:

BRIAN G.M. DURIE, MD, Cedars Sinai Cancer Center, Los Angeles, CA

Speakers:

SHAJI K. KUMAR, MD, Mayo Clinic, Rochester, MN
THOMAS MARTIN, MD, University of California, San Francisco, CA
PHILIPPE MOREAU, MD, University Hospital Hôtel-Dieu, Nantes, France
S. VINCENT RAJKUMAR, MD, Mayo Clinic, Rochester, MN
JESÚS SAN-MIGUEL, MD, PhD, Clínica Universidad De Navarra, Pamplona, Spain

Contact: Patience Merullo

Email: customersupport@cealliance.com

**Acute Lymphoblastic Leukemia Data and Case
Discussion on the Use of Asparaginase Therapy
in Young and Older Adults**

11:00 a.m. – 2:00 p.m.

**Napoleon C 1-3 + Corridor C/D
Sheraton New Orleans**

This program is provided by Clinical Care Options, LLC and supported by an educational grant from Jazz Pharmaceuticals.

Chair:

DANIEL J. DEANGELO, MD, PhD, Harvard Medical School, Boston, MA

Speakers:

KJELD SCHMIEGELOW, MD, DMSc, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
EMILY K. CURRAN, MD, University of Cincinnati Cancer Center, Cincinnati, OH

Contact: Patience Merullo

Email: customersupport@cealliance.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)

11:00 a.m. – 2:00 p.m.

Celestin ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC.

Chair:

NEIL LOVE, MD, Research To Practice, Miami, FL

Speakers:

ALEXEY DANILOV, MD, PhD, City of Hope National
MATTHEW S. DAVIDS, MD, Dana-Farber/Boston
Children's Cancer and Blood Disorders Center,
Boston, MA
ARNON P. KATER, MD, PhD, Academic Medical Center,
Amsterdam Zuidoost, NH, Netherlands
Medical Center, Duarte, CA
LINDSEY E. ROEKER, MD, Memorial Sloan Kettering
Cancer Center, New York City, NY
PHILIP A. THOMPSON, MBBS, MD Anderson Cancer
Center, Houston, TX

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion

11:00 a.m. – 2:00 p.m.

Rhythms Ballroom
Sheraton New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Daiichi Sankyo, Inc., Kyowa Kirin, Inc., and Seagen.

Chair:

STEVEN M. HORWITZ, MD, Memorial Sloan Kettering
Cancer Center, New York City, NY

Speakers:

PAMELA B. ALLEN, MD, Emory University, Decatur, GA
KERRY J. SAVAGE, MD, MSc, FRCPC, University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada

Contact: Patience Merullo
Email: customersupport@cealliance.com

Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias

11:00 a.m. – 2:00 p.m.
243-245

This program is provided by Physicians' Education Resource, LLC and supported by Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Rigel Pharmaceuticals.

Chair:

CARLOS M. DE CASTRO, MD, Duke University, Durham, NC

Speakers:

ARA METJIAN, MD, University of Colorado, Anschutz School of Medicine, Aurora, CO
CAROLINE I. PIATEK, MD, University of Southern California / LAC+USC Medical Center, Santa Monica, CA
JENNIFER A. ROTHMAN, MD, Duke University Medical Center, Durham, NC
PHILLIP SCHEINBERG, MD, Hospital A Beneficência Portuguesa, São Paulo, Brazil

Contact: Dayna Kleinstein
Email: info@gotoper.com

An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

11:00 a.m. – 2:00 p.m.
Napoleon B 1-3 + Corridor A/B
Sheraton New Orleans

This program is provided and provided by Clinical Care Options, LLC and supported by educational grants from Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics Inc., and Novartis Pharmaceuticals Corporation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Chair:

RAMI S. KOMROKJI, H. Lee Moffitt Cancer Center, Tampa, FL

Speakers:

MARÍA DIEZ-CAMPELO, MD, PhD, Hematology Service, University Hospital of Salamanca and IBSAL, Salamanca, Spain

AMER M. ZEIDAN, MD, Yale University and Yale Cancer Center, East Haven, CT

Contact: Patience Merullo

Email: customersupport@cealliance.com

Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow

11:00 a.m. – 2:00 p.m.

VIRTUAL PROGRAM

This program is provided by Physicians' Education Resource, LLC and supported by Genmab.

Chair:

ANDRE H. GOY, MD, MS, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

Speakers:

LORENZO FALCHI, MD, Columbia University Medical Center, New York City, NY

LORI LESLIE, MD, Hackensack Meridian School of Medicine, Hackensack, NJ

Contact: Dayna Kleinstein

Email: info@gotoper.com

Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA

11:00 a.m. – 2:00 p.m.

Empire B**Hyatt Regency New Orleans**

This program is provided by Medscape LLC and supported by Alexion Pharmaceuticals, Inc.

Chair:

JEFF SZER, MBBS, FRACP, Royal Melbourne Hospital, Melbourne, Victoria, Australia

Speakers:

FADI FAKHOURI, MD, PhD, Universite de Lausanne, Lausanne, Switzerland

SONATA JODELE, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Elevating Equity in Caring For Patients With Hematologic Malignancies

11:00 a.m. – 2:00 p.m.

Celestin EFGH**Hyatt Regency New Orleans**

This program is provided by Medscape LLC and supported by AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Pharmacyclics, Regeneron, Gilead Sciences, Inc., and Lilly.

Chair:

ADRIENNE A. PHILLIPS, MD, MPH, Weill Cornell Medicine, New York City, NY

Speakers:

LAURA ORTIZ-RAVICK, MA, The Leukemia & Lymphoma Society, Rye Brook, NY

AMBER THOMASSEN, APRN-BC, AOCNP, University of Miami, Miami, FL

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Expert Illustrations & Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease

11:00 a.m. – 2:00 p.m.

217-219

This program is provided by Physicians' Education Resource, LLC and supported by GlaxoSmithKline.

Chair:

STEVEN FISHBANE, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

ELLIE KELEPOURIS, MD, FACP, FAHA, University of Pennsylvania, Philadelphia, PA
 NUPUR UPPAL, MD, Northwell Health Physician Partners Kidney and Hypertension Specialists at Great Neck, Great Neck, NY
 JAY WISH, MD, Indiana University School of Medicine, Indianapolis, IN

Contact: Dayna Kleinstein
 Email: info@gotoper.com

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/ Refractory Disease?

11:00 a.m. – 2:00 p.m.
 Great Hall B/C

This program is provided by RMEI Medical Education, LLC and supported by Regeneron Pharmaceuticals, Inc.

Chair:

SUNDAR JAGANNATH, Mount Sinai Medical Center, New York City, NY

Speakers:

JAMES E. HOFFMAN, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
 MARIA-VICTORIA MATEOS, MD, University Hospital of Salamanca, Salamanca, Spain

Contact: Steph Kielt
 Email: skielt@rmei.com

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

11:00 a.m. – 2:00 p.m.
 Empire A
 Hyatt Regency New Orleans

This program is provided by PeerView Institute for Medical Education and supported by AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Lilly, Merck & Co., Inc., and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Chair:

PROF. JOHN G. GRIBBEN, MD, DSc, Barts Cancer Institute, London, England, United Kingdom

Speakers:

PROF. DR. MED. BARBARA EICHHORST, University Hospital Cologne, Cologne, Germany
 NITIN JAIN, MD, MD Anderson Cancer Center, Houston, TX
 ANTHONY R. MATO, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Margaret Walker
 Email: margaret.walker@peerview.com

How We Do It™: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow

11:00 a.m. – 2:00 p.m.
 Grand Ballroom DE
 Sheraton New Orleans

This program is provided by Physicians' Education Resource, LLC and supported by Incyte Corporation, Protagonist Therapeutics, SDP Oncology, and PharmaEssentia USA.

Speakers:

ANDREW KUYKENDALL, MD, H. Lee Mofitt Cancer Center, Tampa, FL
 LUCIA MASAROVA, MD, MD Anderson Cancer Center, Houston, TX

Contact: Dayna Kleinstein
 Email: info@gotoper.com

Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult

11:00 a.m. – 2:00 p.m.
 La Nouvelle Orleans Ballroom C

This program is provided by Physicians' Education Resource, LLC and supported by Amgen, Inc., Jazz Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceuticals USA, Inc.

Chair:

ELIAS JABBOUR, MD, University of Texas, MD Anderson Cancer Center, Houston, TX

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

SABINA CHIARETTI, MD, PhD, AOU Policlinico, Umberto I - Rome, Rome, Italy
 HAGOP KANTARJIAN, MD, MD Anderson Cancer Center, Houston, TX
 ROB PIETERS, PROF. MD. PhD, Princess Maxima Center Pediatric Oncology, Utrecht, Netherlands
 BIJAL D. SHAH, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Contact: Dayna Kleinstein
 Email: info@gotoper.com

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

11:00 a.m. – 2:00 p.m.
 343-345

This program is provided by Physicians' Education Resource, LLC and supported by AbbVie, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi.

Speakers:

OLA LANDGREN, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
 AARON C. LOGAN, MD, PhD, University of California—San Francisco, San Francisco, CA

Contact: Dayna Kleinstein
 Email: info@gotoper.com

Navigating a Changing Landscape Together: Gene Therapy for Hemophilia

11:00 a.m. – 2:00 p.m.
 393-396

This program is provided by The France Foundation and supported by BioMarin Pharmaceutical Inc., CSL Behring, and Spark Therapeutics, Inc.

Chair:

MICHAEL RECHT, MD, PhD, MBA, Yale University School of Medicine, New Haven, CT

Speakers:

JENNIFER MAAHS, NP, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
 LUKE PEMBROKE, Haemnet, London, England, United Kingdom
 GUY YOUNG, MD, Children's Hospital Los Angeles, Los Angeles, CA

Contact: Amanda Noe
 Email: ANoe@francefoundation.com

Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Integrating Novel Treatment Strategies in the Clinic

11:00 a.m. – 2:00 p.m.
 Grand Ballroom C
 Sheraton New Orleans

This program is provided by Medscape LLC and supported by ADC Therapeutics America, Inc., Genmab, and Gilead Sciences, Inc.

Chair:

JULIE M. VOSE, MD, MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:

SCOTT F. HUNTINGTON, MD, MPH, Yale School of Medicine, New Haven, CT
 CARON A. JACOBSON, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Vikki Chavis
 Email: vchavis@medscapealive.com

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

11:00 a.m. – 2:00 p.m.
 Empire CD
 Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb, Janssen Biotech, Inc., GlaxoSmithKline, Karyopharm Therapeutics, and Sanofi.

Chair:

AJAI CHARI, MD, Mt. Sinai School of Medicine, New York City, NY

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

AJAY K. NOOKA, MD, MPH, FACP, Winship Cancer Institute of Emory University, Atlanta, GA
KRINA PATEL, MD, MSc, MD Anderson Cancer Center, Houston, TX

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

State-of-the-Art CMV Care: Experts' Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections

11:00 a.m. – 2:00 p.m.
La Nouvelle Orleans Ballroom AB

This program is provided by Physicians' Education Resource, LLC and supported by Merck & Co., Inc. and Takeda Pharmaceuticals, U.S.A., Inc.

Chair:

GENOVEFA A. PAPANICOLAOU, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

ROY CHEMALY, MD, MPH, MD Anderson Cancer Center, Houston, TX
SANJEET S. DADWAL, MD, City of Hope National Medical Center, Duarte, CA
GUENTHER KOEHNE, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Dayna Kleinstein
Email: info@gotoper.com

Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT

11:00 a.m. – 2:00 p.m.
Great Hall A/D
For In-Person Participants Only

This program is provided and supported by RMEI Medical Education, LLC and supported by CSL Behring LLC.

Chair:

MIGUEL-ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

NELSON J. CHAO, MD, MBA, Duke University Medical Center, Durham, NC
SUNG W. CHOI, MD, MS, University of Michigan Health System, Ann Arbor, MI

Contact: Elizabeth Gray
Email: egrays@rmei.com

Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient's Lifespan

11:00 a.m. – 2:00 p.m.
208-210

This program is provided by Physicians' Education Resource, LLC and supported by Agios Pharmaceuticals, Inc., Chiesi USA, Vertex Pharmaceuticals, and Forma Therapeutics.

Chair:

BIREE ANDEMARIAM, MD, University of Connecticut Health Center, West Hartford, CT

Speakers:

RAFFAELLA COLOMBATTI, MD, PhD, University of Padova, Padova, Italy
MODUPE IDOWU, MD, University of Texas—Houston, Houston, TX
NIRMISH SHAH, MD, Duke University Health System, Durham, NC

Contact: Dayna Kleinstein
Email: info@gotoper.com

Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis

11:00 a.m. – 2:00 p.m.
Grand Ballroom A/B
Sheraton New Orleans

This program is provided by Medscape LLC and supported by CTI BioPharma Corp.

Chair:

JOHN MASCARENHAS, MD, Icahn School of Medicine at Mount Sinai, New York City, NY

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

JEAN-JACQUES KILADJIAN, MD, Hôpital Saint-Louis
STEPHEN T. OH, MD, PhD, Washington University
School of Medicine, Saint Louis, MO

Contact: Vikki Chavis

Email: vchavis@medscapelite.com

FRIDAY LATE AFTERNOON SYMPOSIA

3:00 P.M. – 6:00 P.M.

**A Light at the End of the Treatment Tunnel –
Exploring the Potential Role for Gene Therapy in
Hemophilia B**

3:00 p.m. – 6:00 p.m.
217-219

This program is provided by Physicians' Education Resource, LLC and supported by CSL Behring LLC.

Chair:

CHRISTINE L. KEMPTON, MD, MSc, Emory University,
Atlanta, GA

Speakers:

ANDREW D. LEAVITT, MD, University of California—
San Francisco, San Francisco, CA
STEVEN W. PIPE, MD, University of Michigan, Ann
Arbor, MI
ANNETTE VON DRYGALSKI, MD, PHARM D, University of
California—San Diego Health, San Diego, CA

Contact: Dayna Kleinstein

Email: info@gotoper.com

**A Review of Next-Generation Therapeutics and
Contemporary Management of Myelofibrosis**

3:00 p.m. – 6:00 p.m.
Rhythms Ballroom
Sheraton New Orleans

This program is provided and provided by Clinical Care Options, LLC and supported by educational grants from AbbVie and CTI Biopharma.

Chair:

SRDAN VERSTOVSEK, MD, PhD, MD Anderson Cancer
Center, Houston, TX

Speakers:

BRADY L. STEIN, MD, MHS, Northwestern University,
Chicago, IL
ABDULRAHEEM YACOUB, MD, University of Kansas,
Leawood, KS

Contact: Patience Merullo

Email: customersupport@cealliance.com

**Addressing Current Questions and
Controversies in the Management of Hodgkin
and Non-Hodgkin Lymphoma - What Clinicians
Want to Know (Part 2 of a 3-part CME-
accredited Symposia Series)**

3:00 p.m. – 6:00 p.m.
Celestin ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, a Gilead Company, MEI Pharma Inc., Novartis, and Seagen Inc.

Chair:

NEIL LOVE, MD, Research To Practice, Miami, FL

Speakers:

JONATHAN W. FRIEDBERG, MD, MMSc, University of
Rochester, Rochester, NY
BRAD S. KAHL, MD, Washington University School of
Medicine in St. Louis, Saint Louis, MO
DAVID G. MALONEY, MD, PhD, Fred Hutchinson
LORETTA J. NASTOUPIL, MD, MD Anderson Cancer
Center, Houston, TX
Cancer Research Center, Seattle, WA
SONALI M. SMITH, MD, University of Chicago,
Chicago, IL

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies

3:00 p.m. – 6:00 p.m.
Napoleon B 1-3 + Corridor A/B
Sheraton New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Bristol Myers Squibb, Genmab US, Inc., AbbVie, Karyopharm Therapeutics Inc., and Regeneron Pharmaceuticals, Inc.

Chair:

JOHN P. LEONARD, MD, Weill Cornell Medical College, Pelham Manor, NY

Speakers:

JOHN N. ALLAN, MD, Weill Cornell Medicine, New York City, NY

LAURIE H. SEHN, MD, MPH, British Columbia Cancer Centre, Vancouver, British Columbia, Canada

Contact: Patience Merullo
Email: customersupport@cealliance.com

AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

3:00 p.m. – 6:00 p.m.
Elite B
Hyatt Regency New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from Alexion Pharmaceuticals and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Chair:

ANGELA DISPENZIERI, MD, Mayo Clinic, Rochester, MN

Speakers:

ANITA D'SOUZA, MD, MS, The Medical College of Wisconsin Inc., Milwaukee, WI

JEFFREY A. ZONDER, MD, Karmanos Cancer Institute, Detroit, MI

Contact: Patience Merullo
Email: customersupport@cealliance.com

Blazing the Trail to Better Patient Outcomes: Erythroid Maturation Agents in β -Thalassemia

3:00 p.m. – 6:00 p.m.
La Nouvelle Orleans Ballroom C
For In-Person Participants Only

This program is provided by Answers in CME Inc. and supported by an educational grant from Bristol Myers Squibb.

Chair:

ASHUTOSH LAL, MD, UCSF Benioff Children's Hospital, Oakland, CA

Speaker:

SUJIT SHETH, MD, Cornell University, New York City, NY

Contact: Answers In CME Inc
Email: aubrie.rudnick@answersincme.com

Challenging Cases in Relapsed/Refractory Follicular Lymphoma

3:00 p.m. – 6:00 p.m.
Empire A
Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb and Epizyme, Inc.

Chair:

CARLA CASULO, MD, James P. Wilmot Cancer Center, Rochester, NY

Speakers:

JEREMY S. ABRAMSON, MD, MMSc, Massachusetts General Hospital Cancer Center, Boston, MA

GILLES SALLES, MD, PhD, Memorial Kettering Cancer Center, New York City, NY

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective

3:00 p.m. – 6:00 p.m.
Grand Ballroom C
Sheraton New Orleans

This program is provided by Physicians' Education Resource, LLC and supported by Sanofi.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Chair:

PRAMOD K. MISTRY, MD, PhD, FRCP, Yale University, New Haven, CT

Speaker:

NICHOLA COOPER, MD, Imperial College, London, England, United Kingdom
ELI MUCHTAR, MD, Mayo Clinic College of Medicine and Science, Rochester, MN

Contact: Dayna Kleinstein
Email: info@gotoper.com

Experts Under the Microscope: Evaluating the Role of Maintenance Therapy in Long-Term Management of AML

3:00 p.m. – 6:00 p.m.

343-345

For In-Person Participants Only

This program is provided by Haymarket Medical Education and supported by Haymarket Medical Education and Bristol Myers Squibb.

Chair:

AMIR T. FATHI, MD, Massachusetts General Hospital Cancer Center, Cambridge, MA

Speakers:

MAXIMILIAN F. STAHL, MD, Instructor of Medicine Harvard Medical School, Boston, MA
ANDREW H. WEI, MBBS, PhD, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Contact: Beth Kurdock
Email: beth.kurdock@haymarketmedical.com

JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy

3:00 p.m. – 6:00 p.m.

Empire B

Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Bristol Myers Squibb and Sierra Oncology, a GlaxoSmithKline company.

Chair:

RUBEN MESA, MD, FACP, UT Health San Antonio Cancer Center, San Antonio, TX

Speakers:

CLAIRE HARRISON, DM, FRCP, FRCPath, Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom
NIKOLAI A. PODOLTSEV, MD, PhD, Yale University School of Medicine, New Haven, CT

Contact: Vikki Chavis
Email: vchavis@medscapealive.com

Let's Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls

3:00 p.m. – 6:00 p.m.

Empire CD

Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by Global Blood Therapeutics, Inc.

Chair:

MAUREEN M. ACHEBE, MD, MPH, Hematology Division, Brigham and Women's Hospital, Boston, MA

MADHAV VISSA, MD, UCSF Benioff Children's Hospitals, Oakland, CA

Speakers:

JULIE KANTER, MD, University of Alabama at Birmingham, Birmingham, AL

Contact: Vikki Chavis
Email: vchavis@medscapealive.com

Let's Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome

3:00 p.m. – 6:00 p.m.

Celestin EFGH

Hyatt Regency New Orleans

This program is provided by Medscape LLC and supported by AbbVie, Actinium Pharmaceuticals, BioMea Fusion, Gilead Sciences, Inc., and Glyco-Mimetics, Inc.

Chair:

NAVAL DAVER, MD, MD Anderson Cancer Center, Houston, TX

Speakers:

DAVID A. SALLMAN, MD, H. Lee Moffitt Cancer Center, Tampa, FL

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

RORY MICHAEL SHALLIS, MD, Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
EUNICE S. WANG, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Contact: Vikki Chavis
Email: vchavis@medscapelive.com

Speakers:

MONICA L. GUZMAN, PhD, Weill Cornell Medical College Division of Hematology/Oncology, New York City, NY
MARINA KONOPLEVA, MD, PhD, MD Anderson Cancer Center, Houston, TX
ANDREW A. LANE, MD, PhD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

Contact: Dayna Kleinstein
Email: info@gotoper.com

Navigating New Terrain in Chemotherapy-Induced Anemia: Hem/Onc Perspectives and Evidence-Supported Strategies for Improving Care with Intravenous Iron

3:00 p.m. – 6:00 p.m.
393-396

This program is provided by Creative Educational Concepts and supported by American Regent.

Chair:

GEORGE M. RODGERS, MD, PhD, University of Utah Medical Center, Salt Lake City, UT

Speakers:

MICHAEL AUERBACH, MD, Auerbach Hem-Onc Associates, Inc., Baltimore, MD
PATRICIA A. FORD, MD, University Of Pennsylvania, Penn Medicine, Philadelphia, PA
DAVID H. HENRY, MD, Abramson Cancer Center, Philadelphia, PA
JOSEPH D. KHOURY, MD, FCAP, University of Nebraska Medical Center, Omaha, NE
MICHAEL R. SAVONA, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Jessica Hall
Email: jhall@ceconcepts.com

Medical Crossfire® Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings

3:00 p.m. – 6:00 p.m.
208-210

This program is provided by Physicians' Education Resource, LLC and supported by Seagen Inc., Takeda Pharmaceuticals U.S.A., Inc.

Chair:

DAVID J. STRAUS, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

SHARON M. CASTELLINO, MD, MSc, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
JOSEPH M. CONNORS, MD, FRCPC, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada
DORIS M. PONCE, MD, Associate Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
PIER LUIGI ZINZANI, Istituto Di Ematologia, Bologna, Italy

Contact: Dayna Kleinstein
Email: info@gotoper.com

Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

3:00 p.m. – 6:00 p.m.
243-245

This program is provided by Physicians' Education Resource, LLC and supported by ImmunoGen, Inc., Menarini-Stemline, and Mustang Bio, Inc.

Chair:

NAVEEN PEMMARAJU, MD, MD Anderson Cancer Center, Department of Leukemia, Houston, TX

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management

3:00 p.m. – 6:00 p.m.
Grand Ballroom A/B
Sheraton New Orleans

This program is provided by PeerView Institute for Medical Education and supported by Geron and Gilead Sciences, Inc.

Chair:

GUILLERMO GARCIA-MANERO, MD, MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Speakers:

JOSEPH D. KHOURY, MD, FCAP, University of Nebraska Medical Center, Omaha, NE

MICHAEL R. SAVONA, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Margaret Walker

Email: margaret.walker@peerview.com

FRIDAY EVENING SYMPOSIA

7:00 P.M. – 10:00 P.M.

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)

7:00 p.m. – 10:00 p.m.
Celestin ABCD
Hyatt Regency New Orleans

This program is provided by Research To Practice and supported by educational grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi.

Chair:

NEIL LOVE, MD, Research To Practice, Miami, FL

Speakers:

JESUS G. BERDEJA, MD, Sarah Cannon Research Institute, Nashville, TN

RAFAEL FONSECA, Mayo Clinic, Phoenix, AZ

SAGAR LONIAL, MD, Emory University School of Medicine, Atlanta, GA

ROBERT Z. ORLOWSKI, MD, PhD, MD Anderson Cancer Center, Houston, TX

NOOPUR RAJE, MD, Mass General Hospital Cancer Center, Boston, MA

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration

7:00 p.m. – 10:00 p.m.
Elite B
Hyatt Regency New Orleans

This program is provided by Clinical Care Options, LLC and supported by educational grants from BeiGene and Lilly.

Chair:

JEFF P. SHARMAN, MD, US Oncology Research, Eugene, OR

Speakers:

IAN W. FLINN, MD PhD, Sarah Cannon Research Institute, Nashville, TN

SUSAN O'BRIEN, MD, UCI Cancer Center, Orange, CA

Contact: Patience Merullo

Email: customersupport@cealliance.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?

7:00 p.m. – 10:00 p.m.

Grand Ballroom DE
Sheraton New Orleans

This program is provided by Physicians' Education Resource, LLC and supported by Incyte Corporation, Orca Bio, Pharmacyclics, and ST Shared Services, LLC, a Mallinckrodt Company.

Chair:

COREY CUTLER, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA

Speakers:

SERGIO A. GIRALT, MD, FACP, FASTCT, Memorial Sloan Kettering Cancer Center, New York City, NY

CATHERINE J. LEE, MD, University of Utah, Salt Lake City, UT

DORIS M. PONCE, MD, Associate Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY

Contact: Dayna Kleinstein
Email: info@gotoper.com

Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes

7:00 p.m. – 10:00 p.m.

VIRTUAL PROGRAM

This program is provided by Physicians' Education Resource, LLC and supported by Chiesi USA.

Chair:

TRISHA E. WONG, MD, MS, Division of Hematology and Oncology, School of Medicine, Oregon Health & Sciences University, Portland, OR

Contact: Dayna Kleinstein
Email: info@gotoper.com

PRODUCT THEATERS

Product Theaters as of October 22, 2022.

Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

SATURDAY

Sponsored by Novo Nordisk

Are Higher Factor Levels a Rising Consideration When Selecting a Hemophilia Treatment?

 non-CME

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 6

For in-person participants only

Speakers:

STEPHANIE SEREMETIS, MD, NOVO Nordisk
ADAM R. WUFUS, PhD, NOVO Nordisk

Sponsored by AbbVie

Data Worth Stopping For: New 5-year Follow-Up Data for an Oral-Based CLL Regimen with a Fixed Treatment Duration

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

AHMED KOTB, MD, AbbVie

Sponsored by Apellis Pharmaceuticals, Inc.

Evolving Treatment Expectations in PNH

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 2

For in-person participants only

Speakers:

PETER HILLMEN, MB ChB, PhD, Apellis Pharmaceuticals, Inc.
STEPHANIE MONCRIEFF, BSN, RN, Apellis Pharmaceuticals, Inc.

Sponsored by Bristol Myers Squibb

Treatment Options in Relapsed/Refractory Multiple Myeloma: Clinical Studies and Patient Cases

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 4

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

UNICEL-ANNE FLORES, PHARM D, Bristol Myers Squibb

SUNDAY

Sponsored by Bristol Myers Squibb

A Treatment Option for Patients with Myelodysplastic Syndromes 

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 7

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

CHRISTINA HUGHES, PhD, Bristol Myers Squibb

Sponsored by Global Blood Therapeutics/Pfizer, Inc

Discussion on the Treatment of Sickle Cell Disease, Moving Beyond Pain as a Primary Target 

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 4

For in-person participants only

Speaker:

CLARK BROWN, MD, Global Blood Therapeutics / Pfizer, Inc

Sponsored by CSL Behring

Gene Therapy for Hemophilia B: A Look Into New Advancements 


Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 2

For in-person participants only

Speaker:

DEBBIE BENSEN-KENNEDY, MD, CSL Behring

Sponsored by Genentech

Pivotal Phase 3 data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms 

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

MELISSA MONTEZ, PHARM D, Genentech

Sponsored by Genentech

Genentech Lymphoma Product Presentation



Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 4

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

GINNA LAPORT, Genentech

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Sponsored by Adaptive Bio Therapeutics

The Clinical Actionability of ClonoSEQ MRD Assessment in Lymphoid Malignancies

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

ALLISON JACOB, MS, Adaptive Bio Therapeutics

Sponsored by Kite, a Gilead Company

Kite, The Leader in Cell Therapy: Leading the Way in Large B-Cell Lymphoma Care

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 7

For in-person participants only

Speakers:

WARNER BIDDLE, Gilead Sciences, Inc.
FRANK NEUMANN, MD, PhD, Gilead Sciences, Inc.
CHRISTOPHER McDONALD, MBA, Gilead Sciences, Inc.

Sponsored by Bristol Myers Squibb

Treatment Option in AML

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

SARAH CHITTENDEN, RN, MSN, FNP-C, Bristol Myers Squibb

Sponsored by Janssen Biotech, Inc.

What's Next for Patients with Relapsed or Refractory Multiple Myeloma after Multiple Lines of Therapy?

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speakers:

JESSICA FOWLER, PhD, Janssen Biotech, Inc.
THOMAS LIN, MD, PhD, Janssen Biotech, Inc.
SAURABH PATEL, MD, Janssen Biotech, Inc.

MONDAY

Sponsored by Sanofi

A Breakthrough for Patients: Complement inhibition in Cold Agglutinin Disease

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees

Speaker:

MATIAS CORDOBA, MD, Sanofi

Sponsored by Takeda Pharmaceuticals

First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More

Monday 8:00 a.m. - 9:00 a.m.
Hall J - Theater 2
For in-person participants only

Speaker:

PETER L. TURECEK, Baxalta Innovations GmbH, part of Takeda

Sponsored by Pharmacyclics LLC and Janssen Biotech, Inc.

Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies

Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 7

For in-person participants only

Speakers:

JAMES P. DEAN, MD, PhD, Pharmacyclics LLC, an AbbVie Company
CHRISTOPHER CAMPEN, PHARM D, Janssen Biotech, Inc.
SANDRA KNIGHT, MN, BC-APN, CNS, AOCN, Pharmacyclics LLC, an AbbVie Company

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Sponsored by Janssen Pharmaceuticals, Inc.

Perspectives on the Treatment of DVT/PE and Reduction in the Risk of Recurrent DVT/PE, Including Patients with Obesity and/or Cancer

 non-CME

**Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 5**

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

KETURAH REID ROBINSON, PHARM.D, BCPS, LSSBB, The Janssen Pharmaceutical Companies of Johnson & Johnson

Sponsored by ADC Therapeutics

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL  non-CME

**Monday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 4**

This presentation is intended for U.S. based registered meeting attendees

Speaker:

JOSEPH CAMARDO, MD, ADC Therapeutics, Inc.

Sponsored by Sanofi

An Innovative Treatment Option for Appropriate Patients With cGVHD  non-CME

**Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 7**

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

KATHY MARSHALL, RN, MSN, APRN, AOCNS, Sanofi

Sponsored by Janssen Biotech, Inc.

Darzalex & Darzalex Faspro: A Frontline Treatment Approach for a Variety of Newly Diagnosed Multiple Myeloma Patient Types

 non-CME

**Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 5**

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

ANNELORE CORTOOS, MD, Janssen Biotech, Inc.

Sponsored by Genentech

DLBCL Treatment Landscape Overview for Fellows and APPs  non-CME

**Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 2**

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

INDUSTRY THEATERS

Industry Theaters as of October 22, 2022.
Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

SATURDAY

Sponsored by AstraZeneca

Emerging AstraZeneca Hematology Pipeline

 non-CME

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 5

For in-person participants only

Speakers:

ROBERT CHEN, MD, AstraZeneca
RAOUL TIBES, MD, AstraZeneca
NINA SHAH, MD, AstraZeneca
ANAS YOUNES, MD, AstraZeneca

Sponsored by Gilead Sciences

Investigating the Biological Mechanisms of HR-MDS: Role of the Immune System During Disease

 non-CME

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 3

For in-person participants only

Speaker:

CAROL O'HEAR, MD, PhD, Gilead Sciences Inc

Sponsored by Pfizer Inc.

Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients with Hematologic Malignancies

 non-CME

Saturday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 7

Speakers:

SUNEET VARMA, MBA, Pfizer Inc.
DANY HABR, MD, Pfizer Inc.
SRIRAM KRISHNASWAMI, PhD, Pfizer Inc.

SUNDAY

Sponsored by Vertex Pharmaceuticals

Gene Therapy for the Hemoglobinopathies: Translating Complex Science to Inform the Physician-Patient Dialogue

 non-CME

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speakers:

MARK MOGUL, MD, Vertex Pharmaceuticals
TONY E. BOITANO, PhD, Vertex Pharmaceuticals
MARJORIE DEJOIE-BREWER, MD, Vertex Pharmaceuticals

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Sponsored by Sanofi

Sanofi Hematology Clinical Pipeline

Sunday 8:00 a.m. – 9:00 a.m.
Hall J - Theater 5

Speakers:

KARIN KNOBE, MD, PhD, Sanofi
CRAIG BENSON, MD, Sanofi
MICHELLE LEE, MD, Sanofi

Sponsored by Karyopharm Therapeutics, Inc.

Investigating the Function of Tumor Suppressor Proteins in Myelofibrosis (MF) and Myelodysplastic Neoplasms (MDS)

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 5

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

RESHMA RANGWALA, MD, PhD, Karyopharm Therapeutics, Inc.

MONDAY

Sponsored by Rigel Pharmaceuticals

A Clinical Overview of Olutasidenib: An Investigational Therapy, Currently Under FDA Review, For the Potential Treatment of Patients with Relapsed/Refractory mIDH1 AML

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 4

Speakers:

AARON SHEPPARD, PhD, Rigel Pharmaceuticals
PATRICK KELLY, MD, PhD, Rigel Pharmaceuticals

Sponsored by AstraZeneca

Protection Onboard: A Clinical Approach to Preventing COVID-19 in At-Risk Patients

Sunday 11:30 a.m. – 12:30 p.m.
Hall J - Theater 3

Speaker:

MARK ESSER, PhD, AstraZeneca

Sponsored by Cytiva

From Science Fiction to Standard of Care: Developing the next wave of Genomic Medicines for Hematology

Monday 12:15 p.m. – 1:15 p.m.
Hall J - Theater 6

For in-person participants only

Speaker:

SADIK KASSIM, PhD, Danaher Genomic Medicines

COMPANY SHOWCASES

Company Showcases as of October 22, 2022.

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies' services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Labcorp Oncology

Powering Better Decisions: A Comprehensive Hematopathology Analysis Case Study 

Saturday 1:30 p.m. – 1:45 p.m.
Hall J - Theater 6

For in-person participants only

Speaker:

ERIC A. SEVERSON, MD, PhD, MMSc, Labcorp Oncology

Sponsored by TwinStrand Biosciences

Ultra-low Frequency Variant Detection in AML with Duplex Sequencing Technology 

Saturday 3:30 p.m. – 3:45 p.m.
Hall J - Theater 6

For in-person participants only

Speakers:

CLINT VALENTINE, MSc, TwinStrand Biosciences
JACOB HIGGINS, PhD, TwinStrand Biosciences

SUNDAY

Sponsored by Mission Bio

AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility 

Sunday 4:00 p.m. – 4:15 p.m.
Hall J - Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Speaker:

AARON LLANSO, Mission Bio

MONDAY

Sponsored by Karius

**PICKUP Study: Pneumonia in the
ImmunoCompromised – Use of the Karius Test®
for the Detection of Undiagnosed Pathogens**

 non-CME

**Monday 10:15 a.m. – 10:30 a.m.
Hall J - Theater 6**

**This presentation is intended for U.S. based registered
meeting attendees**

For in-person participants only

Speaker:

DAVID M. BERMAN, DO, FAAP, FPIDS, Karius

EXHIBITORS

Participating Exhibitors as of October 19, 2022

2seventy bio

Booth: 1928

<https://www.2seventybio.com>

Our name, 2seventy bio™, is inspired by the maximum speed of translating human thought into action – 270 miles per hour. At 2seventy, we think in the language of time. It's about time we outmaneuver cancer so the people we serve can have MORE...more time building stories with families and friends, experiencing their passions, and living their best lives in the big and small moments. Too many have lost time to cancer and we are wildly impatient to change that.

AbbVie

Booth: 2825, Virtual

<https://www.abbvie.com>

Cancer/Chemotherapy, Oncology Pharmaceuticals, Pharmaceuticals

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

ABHH - Brazilian Association of Hematology, Hemotherapy and Cellular Therapy

Booth: 2722

<http://www.abhh.org.br>

Association, Educational, Immunotherapy, Non Profit, Other
The Brazilian Association of Hematology, Hemotherapy and Cellular Therapy -ABHH - is a nonprofit that started in 2008. The outcome of the merger of the Brazilian Society of Hematology and Hemotherapy and the Brazilian Collegiate of Hematology, ABHH gathers years of expertise on the field. We annually hold the largest Brazilian Congress of Hematology, Hemotherapy, and Cell Therapy - HEMO. The Congress includes 4200 participants, 1200 scientific works, and 80 exhibitors in a 4-day event.

Abiosciences, Inc.

Booth: 2842

<http://www.abiosciences.com>

Cancer/Chemotherapy, Immunotherapy, New Exhibitor, Oncology Pharmaceuticals, Software

Abiosciences, Inc. is a therapeutic discovery company harnessing the power of single-cell multi-omics and bioinformatics to gain molecular insights into human diseases. Our mission is to accelerate the development of novel therapeutics. Guided by science and data, the company generates new knowledge and gains insight into the identification and validation of novel drug targets and biomarkers, leading to next-generation breakthrough therapeutics and diagnostics.

Acrotech Biopharma

Booth: 2015

<https://acrotechbiopharma.com/news-events/>

Biotechnology, Oncology Pharmaceuticals, Pharmaceuticals

Acrotech Biopharma Inc. is a pharmaceutical company built as global platform to develop and commercialize innovative proprietary medications, starting with the US market. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients first as well as all healthcare stakeholders. Acrotech Biopharma Inc. aspires to be a patient-focused, research-based organization that strives to launch treatments which are accessible to the patients that need them.

Actinium Pharmaceuticals

Booth: 1829

<https://www.actiniumpharma.com/>

Biotechnology, Bone Marrow Products, Clinical Research, Monoclonal Antibodies, Oncology Pharmaceuticals

Actinium is a late-stage clinical pharma company developing targeted radiotherapies to deliver cancer-killing radiation with cell-level precision to treat patients with high unmet needs. Our pipeline is led by radiotherapies for targeted conditioning to selectively deplete disease or cancer and certain immune cells prior to a BMT, gene, or cell therapy (e.g., CAR-T) to enable engraftment of transplanted cells with minimal toxicities. The goal is to improve outcomes and access to curative treatments by reducing the non-targeted chemotherapy standardly used for conditioning.

Adaptive Biotechnologies Corporation Booth: 930**<https://www.clonoseq.com/congress/>***Biotechnology, Diagnostic Services/Testing*

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive's goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

ADC Therapeutics Booth: 2533, Virtual**<https://www.adctherapeutics.com>***Biotechnology, Clinical Research, Oncology Pharmaceuticals, Patient Education Materials, Pharmaceuticals*

Confronting cancer with the full potential of our science. ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Advanced Instruments Booth: 1921**<http://www.aicompanies.com>***Cell Counters, Hematology Analyzers*

Advanced Instruments is trusted in laboratories worldwide. Chemistry labs depend on our easy-to-use osmometers that provide accurate and precise results with secure and efficient electronic data management. Microbiology labs have confidence in our Advanced™ Anoxomat® III anaerobic jar system because it efficiently achieves desired environments in just a few minutes. Hematology labs rely on the GloCyte® Automated Cell Counter System as the only CSF counter that is FDA cleared to count down to 0

Agios Pharmaceuticals Booth: 2433**<https://www.agios.com>***Biotechnology, Genetic Testing, Pharmaceuticals*

Agios is passionately committed to applying our leadership in the field of cellular metabolism to create life-changing therapies for people living with genetically defined diseases. The bonds we build with patient communities, healthcare professionals, partners and colleagues help elevate our thinking and propel our science to new heights. These connections, combined with our cellular metabolism expertise, have fueled the development of our first-in-class pyruvate kinase (PK) activator, mitapivat, as well as other investigational therapies.

Allogene Therapeutics Booth: 1222, 3713**<https://allogenevirtualexperience.com/>***Biotechnology, Immunotherapy*

Allogene Therapeutics is a clinical-stage biotechnology company developing a pipeline of “off-the-shelf” CAR T cell therapy candidates (AlloCAR T™) with the goal of delivering readily available cell therapy faster, more reliably and at greater scale.

Alnylam Pharmaceuticals Booth: 1919, 1923**<https://www.alnylam.com>***Biotechnology, Pharmaceuticals*

Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is headquartered in Cambridge, MA. For more information visit www.alnylam.com.

American Association for Cancer Research**Booth: 2615****<https://www.aacr.org>***Association, Cancer/Chemotherapy, Clinical Research, Publisher, Research Grants*

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

American Porphyria Foundation Booth: 2429**<http://www.porphyrifoundation.org>***Educational, Non Profit, Patient Education Materials, Patient Services, Registry*

Our mission is to improve the health and well-being of all individuals and families impacted by Porphyria. We have maintained a relentless focus on education, advocacy, support services and research for the prevention, treatment, and cure of the Porphyrias.

American Society of Hematology Booth: 1333, Virtual<http://hematology.org>

Association, Biologicals, Biotechnology, Bleeding/Clotting Tests, Bone Marrow Products, Bone Marrow Transplantation Research, Books/Journals, Cancer/Chemotherapy, CD-ROM, Cell Counters, Cell Culture, Cell Separators, Clinical Research, Coagulation Products, Coagulation Testing, Contract Research Organization, Cord Blood Banking, Cytogenics, Diagnostic Assay Kits, Diagnostic Reagents, Diagnostic Services/Testing, Digital Imaging Systems, DNA Probes, Educational, Flow Cytometry, Genetic Testing, Hematology Analyzers, Hematology Cytocentrifuge, Hemostasis Diagnostic Instruments, Human Biologicals, Immunotherapy, Leukemia/Lymphoma Detection, Market Research, Molecular Biology, Monoclonal Antibodies, Non Profit, Oncology Pharmaceuticals, Other, Patient Education Materials, Patient Services, Pharmaceuticals, Physician Recruitment, Plasma Derivatives, Plasma Therapy Devices, Platelet Aggregation Reagents and Instruments, Point-of-Care Testing, Publisher, Registry, Research Affairs, Research Grants, Research Immunochemicals, Research Reagents, Self-Assessment Program, Software, Specimen Collection/Transport

The Society's mission is to foster high quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders.

American Society of Pediatric Hematology Oncology (ASPHO) Booth: 2525<http://www.aspho.org>

Association, Educational, Market Research, Non Profit

The American Society of Pediatric Hematology/Oncology (ASPHO) is the professional organization for nearly 2,000 member physicians and other healthcare professionals dedicated to promoting the optimal care of children, adolescents and young adults with blood disorders and cancer by advancing research, education, treatment, and professional practice. ASPHO sponsors educational and professional development programs. ASPHO's diversity statement welcomes diverse and inclusive participation within the profession and the Society's membership.

Amgen Booth: 943<http://www.amgenoncology.com>

Biotechnology, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amyloidosis Research Consortium (ARC) Booth: 2618<https://www.arci.org>

Educational, Non Profit, Patient Education Materials, Patient Services, Research Affairs

The Amyloidosis Research Consortium (ARC) is a patient-focused nonprofit, harnessing the power of collaboration and innovation to advance science and both improve and extend the lives of those with amyloidosis.

Amyloidosis Support Groups Booth: 2417<http://www.amyloidosisupport.org>

Educational, Non Profit, Patient Education Materials, Patient Services, Registry

The Amyloidosis Support Groups is dedicated to providing peer group support to patients, caregivers, families and friends of those touched by all types of amyloidosis. We host meetings in 33 cities across the US. Additionally, we provide online support groups and live webinars that offer disease education to patients around the globe. An educational booklet and video are available on our website at https://www.amyloidosisupport.org/amyloid_aware.html.

Anucell Biosystems Booth: 400<http://www.anucellbio.com>

Biotechnology, Cell Separators, Immunotherapy, New Exhibitor, Startup (Organization is less than 5 years old and has 10 or fewer employees)

Anucell Biosystems is a company focused on providing novel solutions to emerging difficulties in cell processing: mitigating the impacts of over-processing of primary cells for treatments including CAR-T therapies. We employ a proprietary technology to enable true bead-free enrichments of T-cells from PBMC or Leukopak inputs without need to add additional chemistries or exchange cells from their culture media. Enriched T-cells are functionally fit and ready for downstream processing with no requirement for bead removal or media exchange following enrichment.

Apellis Pharmaceuticals Booth: 501, 601, 700, Virtual<https://www.apellis.com>

Biotechnology, Immunotherapy, Pharmaceuticals

At Apellis, we are committed to developing therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body's immune system.

Aplastic Anemia and MDS International Foundation, Inc. **Booth: 1642**

<http://www.aamds.org>

Non Profit, Patient Education Materials

The Aplastic Anemia and MDS International Foundation (AAMDSIF) is the world's leading non-profit health organization dedicated to supporting patients and their families who are living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and related bone marrow failure diseases. Founded in 1983, AAMDSIF provides patient education resources, professional education programs, research grants and advocacy for bone marrow failure disease research funding.

AplusA **Booth: 1428**

<https://www.aplusaresearch.com/>

Cancer/Chemotherapy, Oncology Pharmaceuticals, Other, Registry

argenx **Booth: 543**

<http://www.argenx.com>

Pharmaceuticals

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan and the EU. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, Instagram and Facebook.

ARUP Laboratories **Booth: 3629**

<http://www.aruplab.com>

Ascentage Pharma **Booth: 2318**

<https://www.ascentage.com/>

ASCO **Booth: 2425**

<https://www.asco.org>

Non Profit

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary oncology organizations representing nearly 45,000 members from every cancer specialty. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

ASH Research Collaborative **Booth: Virtual**
<http://ashresearchcollaborative.org>

Association, Biologicals, Biotechnology, Bleeding/Clotting Tests, Bone Marrow Products, Bone Marrow Transplantation Research, Books/Journals, Cancer/Chemotherapy, CD-ROM, Cell Counters, Cell Culture, Cell Separators, Clinical Research, Coagulation Products, Coagulation Testing, Contract Research Organization, Cord Blood Banking, Cytogenics, Diagnostic Assay Kits, Diagnostic Reagents, Diagnostic Services/Testing, Digital Imaging Systems, DNA Probes, Educational, Flow Cytometry, Genetic Testing, Hematology Analyzers, Hematology Cytocentrifuge, Hemostasis Diagnostic Instruments, Human Biologicals, Immunotherapy, Leukemia/Lymphoma Detection, Market Research, Molecular Biology, Monoclonal Antibodies, Non Profit, Oncology Pharmaceuticals, Other, Patient Education Materials, Patient Services, Pharmaceuticals, Physician Recruitment, Plasma Derivatives, Plasma Therapy Devices, Platelet Aggregation Reagents and Instruments, Point-of-Care Testing, Publisher, Registry, Research Affairs, Research Grants, Research Immunochemicals, Research Reagents, Self-Assessment Program, Software, Specimen Collection/Transport

The ASH Research Collaborative (ASH RC) is a non-profit organization established by the American Society of Hematology in 2018 to foster collaborative partnerships that accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. The foundation of the ASH RC is its Data Hub and Clinical Trials Network. The Data Hub is a technology platform that facilitates the exchange of information by aggregating research-grade data on hematologic diseases. As a major initiative within the ASH RC, the Data Hub aims to create the largest shared information resource within the global hematology community. The Sickle Cell Disease Clinical Trials Network is designed to accelerate the development and evaluation of therapies in a large proportion of the United States population affected by SCD. Through the Data Hub, the SCD Clinical Trials Network, and projects still to come, the ASH RC will transform research and practice in classical (nonmalignant) and malignant hematologic diseases throughout the world, for the benefit of patients and the hematology community. Visit the ASH RC kiosk located within ASH Central to learn more.

Associates of Cape Cod, Inc. **Booth: 404**
<http://www.acciusa.com>

Biotechnology

Associates of Cape Cod, Inc. (ACC) is a global biopharmaceutical company specializing in endotoxin and glucan detection. ACC was the first company licensed by the FDA to manufacture LAL for use as a quality control test for endotoxin in the pharmaceutical and medical device industry. ACC also operates a contract testing service.

**ASTCT | American Society for Transplantation
and Cellular Therapy**

Booth: 2518

<https://www.astct.org>

Association, Non Profit

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field.

Astellas Pharma US, Inc.

Booth: 1234

<https://www.astellasoncology.com>

Pharmaceuticals

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world. 075-0155-PM 11/2021.

Astex Pharmaceuticals, Inc.

Booth: 343

<https://www.astx.com>

Oncology Pharmaceuticals, Pharmaceuticals

Astex Pharmaceuticals, Inc. ("Astex") is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. Astex is a member of the Otsuka group of pharmaceutical companies. The group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex's products will be commercialized in the US and Canada by Taiho subsidiaries, and the rest of the world by Otsuka subsidiaries.

AstraZeneca

Booth: 619, Virtual

<http://www.astrazeneca-us.com>

Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca-us.com.

Atara Biotherapeutics, Inc.

Booth: 646

<http://www.atarabio.com>

Bone Marrow Transplantation Research, Immunotherapy

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara's pipeline includes tacecleucel for EBV-driven post-transplant lymphoproliferative disease (PTLD) and other EBV-associated diseases, next-generation CAR T therapies for cancers, and ATA188 for Multiple Sclerosis.

AVM Biotechnology LLC

Booth: 504

<https://avmbiotech.com>

Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

AVM Biotechnology, a clinical-stage company, advancing AVM0703 for expeditious FDA approval in patients with relapsed/refractory Non-Hodgkin's Lymphoma/Leukemia. AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific $\gamma\delta$ TCR+ invariant TCR+ NKT-like cells by a glucocorticoid-receptor-independent mechanism and potentiates chemotherapy and CAR-T response in pre-clinical models. Durable clinical responses achieved with strong safety profile. Ph 2/3 actively enrolling. Seeking additional trial sites & strategic partners for commercial launch in 2024.

AXON

Booth: 549

<http://www.axon-com.com>

AXON is a global healthcare communications agency that ignites change in healthcare. Through the power of life-changing communications, we contribute to medical advances that improve lives. We specialize in advising clients on medical affairs, clinical studies, real-world evidence, marketing, advocacy, and communications, all underpinned by insights and creative strategy. AXON has an international reach, with offices in Copenhagen, London, New York, and Toronto, and a worldwide affiliate network. AXON is proudly an AVE-NIR GLOBAL company.

Bayer

Booth: 1529

<https://pharma.bayer.com>

Coagulation Products, Oncology Pharmaceuticals

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.

Beckman Coulter Life Sciences Booth: 2018
<https://www.beckman.com/>

Cell Separators, Clinical Research, Diagnostic Reagents, Flow Cytometry, Research Reagents

Life sciences. Research. Precision manufacturing. If your life's calling is in any of these or related fields, you need to know Beckman Coulter Life Sciences. Our mission is to empower those seeking answers to life's important scientific and healthcare questions. For more details, visit beckman.com.

BeiGene Booth: 2543, Virtual
<https://www.beigene.com>

Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,000 colleagues across five continents.

Binding Site, Inc. Booth: 2119
<https://www.bindingsite.com/>

Coagulation Products, Diagnostic Assay Kits, Diagnostic Reagents, Research Immunochemicals

Binding Site is a world leader in providing specialized diagnostic products to clinicians and laboratory professionals worldwide. Our market-leading Freelite(R) serum free light chain tests are used as an aid in the diagnosis and monitoring of Multiple Myeloma and related plasma cell disorders. We are dedicated to improving patient lives, delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders.

Bio Products Laboratory USA, Inc. Booth: 843
<https://www.coagadex.com/hcp>

Coagulation Products, Plasma Derivatives

Bio Products Laboratory (BPL) is committed to providing a continuous and reliable supply of high quality, plasma-based products to the patients, healthcare professionals, and customers we serve.

Biomea Fusion, Inc Booth: 3342
<https://biomeafusion.com/>

Biotechnology, New Exhibitor

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Our mission is to revolutionize medicine by creating therapies that cure patients of their disease.

Blue Spark Technologies, Inc. Booth: 1543
<https://www.temptraq.healthcare>

Bone Marrow Transplantation Research, Cancer/Chemotherapy, Diagnostic Services/Testing, Immunotherapy, Point-of-Care Testing

TempTraq®, is the only clinically tested, disposable Bluetooth®, wearable temperature monitor in the form of a soft, comfortable patch that continuously, safely and comfortably monitors body temperature for up to 72 hours and sends notifications to Apple® or Android™ compatible mobile devices. TempTraq Connect is the HIPAA-compliant cloud service supported by Google Healthcare Cloud Platform that enables patients and caregivers to monitor body temperature from anywhere. The system is FDA, CE, Health Canada and TGA cleared.

bluebird bio Booth: 1228
<https://www.bluebirdbio.com/>

Biologicals, Biotechnology, Clinical Research

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β -thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Blueprint Medicines Booth: 1655
<https://www.blueprintmedicines.com>

Oncology Pharmaceuticals, Pharmaceuticals

Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and blood disorders.

BMS/Pfizer**Booth: 1515****<https://bmstpifizercongressresources.com/show/booth>***Pharmaceuticals*

The Bristol Myers Squibb and Pfizer alliance is a worldwide collaboration bringing together two leading companies focused on cardiovascular disease with a shared vision to reduce NVAf-related stroke and treat DVT/pulmonary embolism events.

BostonGene**Booth: 2214****<https://www.bostongene.com/>***Immunotherapy, Software*

BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

BPS Bioscience**Booth: 2428****<https://www.bpsbioscience.com/>***Cancer/Chemotherapy, Cell Culture, Immunotherapy, New Exhibitor, Research Reagents*

BPS Bioscience's purpose is to advance new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, coronavirus, CRISPR, cell signaling, and others, providing 4500+ high quality recombinant cell lines, lentiviruses, proteins and biochemical and cell-based assay kits. As a primary manufacturer, we can supply products in large-scale bulk quantities, as well as custom manufacturing. Our biochemical and cell-based screening services are also available to accelerate your research.

Bristol Myers Squibb**Booth: 1615, Virtual****<https://www.bmsvirtualcongress.com/ASH2022>***Biologicals, Cancer/Chemotherapy, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals*

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.

Calithera Biosciences**Booth: 2229****<https://www.calithera.com>***Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals*

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies for biomarker-specific patient populations. Calithera is advancing a pipeline of investigational small molecules targeting genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers with a high unmet need. The oral SYK inhibitor, mivavotinib, is being studied in R/R non-GCB DLBCL. Sapanisertib, an oral mTORC1/2 inhibitor, is being evaluated in R/R NRF2m sqNSCLC.

Cancer Science Institute of Singapore (CSI Singapore)**Booth: 2725****<https://www.csi.nus.edu.sg>***Cancer/Chemotherapy, Educational, Non Profit*

The Cancer Science Institute of Singapore (CSI Singapore) is hosted by the National University of Singapore (NUS), a globally leading, research-intensive University. Our mission is to better understand the causes of human cancer across Asia, and thereby improve its detection, treatment and prevention. Our outstanding researchers and exceptional facilities create an energetic environment for ground-breaking science and world-class training. Extensive cancer research ranging from basic cancer studies to experimental therapeutics are conducted to improve cancer treatment.

Cardinal Health**Booth: 401****<http://www.cardinalhealth.com>**

Cardinal Health Specialty Solutions partners with physicians to help them deliver cost effective care to patients managing complex diseases. We provide reliable, cost-effective access to specialty medications and innovative tools to help physicians run more efficient practices. We work to ensure physicians get fairly reimbursed for delivering quality care to patients.

CellPoint**Booth: 800****<https://www.cellpoint.bio>***Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Point-of-Care Testing*

CellPoint (a Galapagos company) believes the future of cell therapy is at the point-of-care, near the patient. The company is developing point-of-care candidate CAR-T therapies that could potentially solve unmet needs of patients with hematological cancer and offer the potential for more rapidly available, affordable treatments. Phase I/II clinical trials with CellPoint candidate CAR-T constructs are currently ongoing in various haematological malignancies.

Cellworks**Booth: 605**<https://www.cellworks.life/>*Biotechnology, Cancer/Chemotherapy, Clinical Research, Oncology Pharmaceuticals, Software*

Cellworks is a leader in Precision Biosimulation Services for Personalized Oncology and Drug Development. Using OMICs modeling, computational biosimulation and AI heuristics, Cellworks provides biopharma companies with biosimulation services that accelerate drug development and clinicians with patient-specific therapy predictions. Precision Biosimulation improves patient outcomes by accelerating the availability of new drugs and personalizing therapy selection. www.cellworks.life

Cepheid**Booth: 2859**<http://www.cepheid.com>*Diagnostic Reagents, Genetic Testing, Leukemia/Lymphoma Detection, Molecular Biology*

Cepheid is the leading innovator in the field of molecular diagnostics. The Company is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use systems and tests. By automating highly complex procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular testing that can dramatically enhance the management of cancer and infectious diseases.

Certara**Booth: 200**<https://www.certara.com/>*New Exhibitor, Software*

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Champions Oncology**Booth: 323**<https://www.championsoncology.com/>*Biotechnology, Cancer/Chemotherapy, Clinical Research, Contract Research Organization, Flow Cytometry*

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharma-co-pheno-multiomic integration. For more information, please visit www.championsoncology.com

Chiesi Global Rare Diseases**Booth: 125, 223**<https://chiesirarediseases.com/>*Pharmaceuticals*

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focuses on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders to patient advocacy, research and patient care.

Children's Hospital of Philadelphia **Booth: 2424**<https://www.chop.edu/>*Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Non Profit*

The Cancer Center at Children's Hospital of Philadelphia is internationally recognized for its expert staff and game-changing innovations. Our pediatric oncologists treat patients using an evidence-based approach backed by the latest research. We offer a range of therapies, from standard treatment protocols to groundbreaking clinical trials available only at CHOP. Our care is comprehensive, including extensive psychosocial support, programs for cancer predisposition and survivorship, and more.

CIBMTR (Center for International Blood & Marrow Transplant Research)**Booth: 2521**<https://www.cibmtr.org>*Bone Marrow Transplantation Research, Clinical Research, Registry*

The CIBMTR facilitates critical cellular therapy research through a clinical database with >600,000 patients from >350 centers worldwide and a biospecimen repository with >195,000 samples. Collaborate with us on one of our ~225 current studies. Visit www.cibmtr.org.

City of Hope Comprehensive Cancer Center**Booth: 1547**<http://www.cityofhope.org/ash22>*Bone Marrow Transplantation Research, Cancer/Chemotherapy, Genetic Testing, Immunotherapy, Leukemia/Lymphoma Detection*

City of Hope is an NCI-designated comprehensive cancer center and a global pioneer in breakthrough treatments for hematologic cancers, having performed over 17,000 bone marrow transplants to date with exceptional survival rates, according to the Center for International Blood & Marrow Transplant Research. We are also home to one of the most comprehensive CAR T

cell programs in the world, with nearly 1,000 patients treated in immune effector cell trials. With our acquisition of Cancer Treatment Centers of America, City of Hope now serves approximately 115,000 patients every year.

Cleveland Clinic Taussig Cancer Institute Booth: 810

<https://my.clevelandclinic.org/>

Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Leukemia/Lymphoma Detection, Non Profit

Cleveland Clinic Cancer Center provides comprehensive care enhanced by innovative research. Our more than 700 caregivers treat thousands of cancer patients yearly and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Center unites clinicians and researchers in Taussig Cancer Institute and Cleveland Clinic's 25 other institutes, as well as cancer specialists at our regional hospitals, health centers and Cleveland Clinic Florida.

Clinical Advances in Hematology and Oncology Booth: 2021

<http://www.hematologyandoncology.net>

Books/Journals

CAH&O is an independent PubMed-indexed peer-reviewed journal reaching over 26,000 hem/onc clinicians on a monthly basis. CAH&O also published high quality industry-supported educational supplements and clinical monographs.

Cogent Biosciences Booth: 642

<https://www.cogentbio.com/>

Biotechnology, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients. We have ongoing clinical research programs in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).

College of American Pathologists Booth: 2516

<https://www.cap.org>

Association, Books/Journals, Non Profit

The College of American Pathologists offers two monthly publications: CAP TODAY and the Archives of Pathology & Laboratory Medicine. CAP TODAY brings monthly business and medical news in the clinical laboratory. The Archives of Pathology & Laboratory Medicine is one of the best-read journals among pathologists and laboratory directors. Samples are available.

Cooley's Anemia Foundation Booth: 2614

<https://www.thalassemia.org/>

Non Profit, Research Grants

Cooley's Anemia Foundation advances the treatment and cure for thalassemia, enhances quality of life of patients and educates the medical profession, trait carriers & the public about thalassemia. The Foundation funds fellowships & medical research.

Correspondances en Onco-hematologie Booth: 322

<http://www.edimark.fr/correspondances-onco-hematologie>

Books/Journals, Publisher

Correspondances en Onco-hematologie is a French bimonthly publication specialized in oncology, which editor in chief is Pr Noel Milpied. The readership is composed of hematologists, oncologists, geriatrists. Correspondances en onco-hematologie is published in 4500 copies.

CRISPR Therapeutics Booth: 315

<https://www.crisprtx.com>

Biotechnology, Bone Marrow Transplantation Research, Cancer/Chemotherapy, Immunotherapy, Oncology Pharmaceuticals

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary gene editing technology allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Cryoport Systems Booth: 229

<https://www.cryoport.com/integrated-supply-chain-platform>

Human Biologicals, New Exhibitor

Cryoport and BioLife Cellular Therapy Services, part of the global biopharma company, Takeda Pharmaceutical Company, have joined forces in a strategic relationship to establish an integrated supply chain platform to offer standardized cell therapy collection, processing, storage, and distribution services. The platform will provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. The relationship aims to shorten processing & logistics time and standardize collections to accelerate cell therapy programs.

CSL Behring**Booth: 3519**<https://www.cslbehring.com>*Biotechnology, Coagulation Products*

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients' needs using the latest technologies to develop and deliver innovative therapies. The company offers a broad range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and chronic inflammatory demyelinating polyneuropathy (CIDP). CSL Behring's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CTI BioPharma Corp.**Booth: 351**<http://www.ctibiopharma.com>*Biotechnology, Cancer/Chemotherapy, Oncology Pharmaceuticals*

CTI Biopharma is a Seattle based biopharmaceutical company focused on acquisition, development, and commercialization of novel targeted therapies for blood-related cancers that offer options to patients and healthcare providers. CTI has one FDA-approved product VONJO® (pacritinib). See full prescribing information at www.VONJO.com. Contact: 3010 Western Avenue, #800 Seattle, WA 98121 800-215-2355

Curis, Inc.**Booth: 604**<https://www.curis.com>*Biotechnology, Cancer/Chemotherapy, Clinical Research, Monoclonal Antibodies*

Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for cancer, with a pipeline of differentiated small molecule hematology and oncology drug candidates. Currently Curis has two drugs candidates in development; CA-4948 an orally available small molecule inhibitor of IRAK4 kinase in non-Hodgkin's lymphoma and leukemia (AML/MDS), and CI-8993 a clinical-stage human IgG1 kappa monoclonal antibody designed to antagonize the VISTA signaling pathway in advance solid tumors.

Cytiva**Booth: 2259**<https://www.cytiva.com>*Biologicals, Cell Culture, Cell Separators, Molecular Biology, Specimen Collection/Transport*

At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That's why our 10,000+ associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We're driven by their desire to achieve better

flexibility, capacity, and efficiency in all facets of their work – all the way from idea to injection. Learn more at cytiva.com.

Daiichi Sankyo – Medical**Booth: 2633**<https://www.dsvirtualexhibit.com/medical>*Oncology Pharmaceuticals, Pharmaceuticals*

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

Dana-Farber Cancer Institute**Booth: 2419**<https://www.dana-farber.org/>*Cancer/Chemotherapy, Clinical Research, Immunotherapy*

Dana-Farber Cancer Institute is committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Located in Boston, MA, Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center, an NCI designated Comprehensive Cancer Center. Dana-Farber is the nation's top academic recipient of grant funding from the NCI and offers more than 1,100 clinical trials. Visit us at booth #2419 to learn more.

DAVA Oncology**Booth: 2659**<http://www.davaonc.com>*Clinical Research, Market Research, Other*

DAVA Oncology is the leading provider of clinical trial acceleration services and oncology drug development consulting products designed to accelerate research and development timelines. DAVA's primary focus is to accelerate the successful completion of cancer clinical trials through the deployment of experienced medical oncologists.

Diagenode, Inc.**Booth: 411**<http://www.diagenode.com>*Biotechnology, Molecular Biology, Research Reagents*

Diagenode provides complete solutions for epigenetics research in immuno-oncology, neuroscience, and more. Our comprehensive approach to gain insights into RNA, DNA, and chromatin analysis from solid tumor to liquid biopsy samples with experimentally-validated, easy-to-use solutions and services give researchers the success to move from research to translational and clinical applications.

Diamond Blackfan Anemia Canada Booth: 2717**<http://www.dbacanada.com>***Association, Educational, Non Profit, Patient Education Materials, Patient Services*

Diamond Blackfan Anemia Canada's mission is to provide education, support, and resources to Canadian families and individuals affected by Diamond Blackfan Anemia. Additionally, in collaboration with the Diamond Blackfan Anemia Foundation, we fund much needed research into this rare disorder.

Diamond Blackfan Anemia Foundation Booth: 2715**<http://www.dbafoundation.org>***Non Profit, Patient Education Materials, Patient Services, Registry, Research Grants*

The mission of the Diamond Blackfan Anemia Foundation is to advance research initiatives that promote a better understanding, therapeutic strategies and a cure for this rare bone marrow failure syndrome. We are dedicated to providing patient advocacy, support and education services to individuals, families and medical professionals resulting in improvements in the diagnosis, clinical treatment and management of the disorder, while enhancing the quality of life of affected families worldwide.

Doximity Booth: 410**<http://www.doximity.com>***Educational, Other*

Doximity is the largest social network for healthcare professionals, with over 1 million members on our platform. Our free app offers services such as referrals, HIPAA secure faxing and messaging, colleguing, CME, privately calling patients from your cell phone, and more. Over 80% of all US physicians are a part of Doximity - using our services to connect, communicate, and help improve patient care.

ECD Global Alliance Booth: 2619**<https://www.erdheim-chester.org/>***Cancer/Chemotherapy, Non Profit, Patient Education Materials, Patient Services, Research Grants*

The ECD Global Alliance is dedicated to the awareness, support, education, and research related to Erdheim-Chester Disease (ECD). ECD is an ultra-rare type of blood cancer that is difficult to diagnose and can manifest in a variety of complex ways. Hematologists, together with other clinicians, pathologists, and radiologists, play a vital role in identifying ECD. There are viable FDA-approved and off-label treatments available to improve the quality of life and slow the progression of the life-threatening disease. The key to a successful or more positive outcome is early diagnosis.

Editas Medicine Booth: 1918**<https://www.editasmedicine.com/>***Biotechnology, Cancer/Chemotherapy*

Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into treatments for people living with serious diseases around the world.

Eli Lilly and Company Booth: 3014, 3513, Virtual**<https://www.LillyLoxoOncologyPipeline.com/>***Oncology Pharmaceuticals, Pharmaceuticals*

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

Elsevier Booth: 2242**<http://Us.elsevierhealth.com>***Books/Journals, Clinical Research*

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care.

Emmaus Medical, Inc. Booth: 555**<http://www.emmausmedical.com>***Pharmaceuticals*

Emmaus Medical, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. We are currently focused on sickle cell disease (SCD), a genetic disorder with a significant unmet medical need. Our lead product, Endari® (L-glutamine oral powder), received FDA approval on July 7, 2017. With this approval, Endari® is available to reduce the acute complications of sickle cell disease in adults and children 5 years and older. For more information, please read the Full Prescribing Information for Endari® at <http://www.EndariRx.com>.

Enable Injections Booth: 3450**<https://www.enableinjections.com/>***Biotechnology, Other, Pharmaceuticals*

Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable's body-worn enFuse® delivers high-volume

pharmaceutical and biologic therapeutics via subcutaneous administration with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. Enable Injections is redefining drug delivery for the benefit of patients, providers, payers and partners.

EpigenDx

Booth: 3322

<https://labs.epigendx.com/>

Biotechnology, Clinical Research, Diagnostic Assay Kits, Diagnostic Services/Testing, Genetic Testing

With 15+ years of experience in genetic & epigenetic clinical research, EpigenDx offers high quality products & laboratory services focused on DNA methylation analysis, gene expression profiling, & mutation analysis. Our scientific teams carefully evaluate each project & establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, & GeneChip Microarray. Our popular services include Line-1 global methylation tests & Foxp3-TSDR analysis.

Eurasian Hematology Oncology Group **Booth: 2524**

<http://www.ehog.net/>

Association, Educational

Hematology Specialist Association taking it as a mission, has been working to protect rights of medical doctors who became Specialists in Hematology and have been working in this area for a long time period. Further, the mission is also to introduce Turkish Hematology in all around the world and practice and develop hematology related applications of all kinds.

European Hematology Association **Booth: 2822**

<http://www.ehaweb.org>

Association, Educational

THE EUROPEAN HEMATOLOGY ASSOCIATION PROMOTES EXCELLENCE IN PATIENT CARE, RESEARCH, AND EDUCATION IN HEMATOLOGY. We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology.

EUSA Pharma

Booth: 1553

<https://www.eusaexhibit.com/en-us>

Monoclonal Antibodies, Oncology Pharmaceuticals

EUSA Pharma is a global biopharmaceutical company committed to transforming the lives of people affected by cancer or rare disease. We Change Lives, Patient by Patient.

Evident

Booth: 611

<http://www.olympus-ossa.com>

Olympus is an int'l precision technology leader operating in industrial, medical, academic, and consumer markets, specializing in optics, electronics, and precision engineering. Olympus Corporation of Americas' core product lineup comprises clinical, educational, and research microscopes, nondestructive testing equipment, and analytical instruments, all designed with an unwavering commitment to enhancing people's lives every day.

Exelixis, Inc. - Medical Affairs

Booth: 1057

<https://www.exelixismedicalaffairs.com/>

Oncology Pharmaceuticals

Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new products for difficult-to-treat cancers. Our efforts have resulted in four approved products available to patients worldwide. Our clinical development program focuses on our pipeline products as well as evaluation of cabozantinib in new tumor types and combinations. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

Fidelis Research AD

Booth: 1115

<http://www.fidelis-research.com>

Bone Marrow Products, Cell Culture, Flow Cytometry, Plasma Derivatives, Specimen Collection/Transport

Fully custom offerings that meet your needs for bio-specimen collections, processing, preparation and shipping. Fidelis is specialized in the procurement of high-quality human biological specimens and value-adding ancillary services. We support researchers globally by collecting and processing a broad range of disease-state and healthy control samples accompanied by comprehensive annotated data. Our goal is to accelerate research and innovation that help our partner's translational science.

Flow Contract Site Laboratory

Booth: 202

<https://www.fcslaboratory.com>

Clinical Research, Contract Research Organization, Flow Cytometry, Immunotherapy, New Exhibitor

Flow Contract Site Laboratory is a specialized CRO offering flow cytometry services for research, nonclinical and clinical drug development. Our capabilities include multi-color antibody panels for immunophenotyping, receptor occupancy, intracellular cytokine and phospho-protein detection and cellular functional assays. We are proficient in processing a multitude of specimen types including whole blood, tissue, frozen PBMCs and tumors for pre-clinical model systems and human clinical trials.

Follicular Lymphoma Foundation Booth: 2729**<https://www.theflf.org/>***Immunotherapy, Non Profit, Patient Education Materials, Patient Services, Research Grants*

The Follicular Lymphoma Foundation is the only lymphoma charity dedicated to finding a cure for Follicular Lymphoma (FL) – and finding it fast. Incurable is not good enough. All our programmes aim to accelerate a transformative change in FL scientific research, putting patients at the heart of everything we do. We aim to link research and clinical communities, together with patients, to help ensure their views and experiences are part of the development process for new treatments and a cure.

Forma Therapeutics Booth: 143**<https://www.formatherapeutics.com/>***Biotechnology, Pharmaceuticals*

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our work has generated a broad, proprietary portfolio of programs with the potential to provide profound patient benefit, including our sickle cell disease program, etavopivat (FT-4202), and our metastatic, castration-resistant prostate cancer program, FT-7051. Click the link above to visit our corporate website or visit us in person at booth #143.

Foundation for Sickle Cell Disease Research**Booth: 2623****<http://www.fscdr.org>***Clinical Research, Patient Services*

We are a Non-Profit Organization with a Mission to tirelessly research, inform, hear, respect, treat and support all individuals living with Sickle Cell Disease. We are driven to make this disorder a livable, non-threatening condition.

Foundation for the Accreditation of Cellular Therapy (FACT) Booth: 2714**<https://www.factglobal.org/>***Bone Marrow Transplantation Research, Cord Blood Banking, Educational, Non Profit, Self-Assessment Program*

FACT is a non-profit corporation founded for the purpose of voluntary inspection and accreditation in the field of cellular therapy, cord blood banking, and regenerative medicine. The objective of FACT is to improve the quality of cellular therapy through peer-developed standards, education and accreditation for the benefits of patients. FACT is the standards setting and accreditation arm of the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT).

Fred Hutchinson Cancer Center Booth: 2622**<http://www.fredhutch.org>***Bone Marrow Transplantation Research, Clinical Research, Immunotherapy, Patient Services*

Fred Hutchinson Cancer Center unites comprehensive care and advanced research to provide the latest cancer treatment options and accelerate discoveries that prevent, treat and defeat cancer and infectious diseases worldwide. Based in Seattle, Fred Hutch is an independent, nonprofit organization and is the only National Cancer Institute-designated cancer center in Washington.

Fresenius Kabi Booth: 510**<http://www.fresenius-kabi.us>***Biologicals, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals*

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, and we supply the US oncology market with one of the largest injectable oncology portfolios in the industry. We're now committed to launching a range of biosimilars in the U.S. with our BioSpecialized approach to health care. From the collaborative way we work with health care professionals to how we manufacture and deliver our products, we are committed to going beyond medicines to support patient care.

Fulgent Oncology Booth: 2328**<https://www.fulgentoncology.com/>***Biotechnology, Clinical Research, Diagnostic Services/Testing, Genetic Testing*

Fulgent Oncology offers expert-driven analysis coupled with individually-curated reports, giving you the insights you need for optimizing patient care. Reports provide guidance for appropriate therapeutic considerations, including immunotherapy and clinical trials eligibility. The Lumera™ Xpanded Profile, our flagship pan-cancer NGS solid tumor profile, offers the unique advantage of a comprehensive summary report that includes pathology consultation and case review.

Gamida Cell Booth: 1823**<https://www.gamida-cell.com>***Bone Marrow Transplantation Research, Immunotherapy*

Gamida Cell is the leader in pioneering NAM-enabled cell therapies designed as a curative approach for patients with blood cancers and other serious diseases. We are harnessing the power of our proprietary NAM-enabled technology to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create cell therapy candidates with potential to redefine standards of care and significantly improve patient outcomes and health equity.

Geisinger**Booth: 243****<http://www.geisinger.org/careers>***Non Profit, Patient Services, Physician Recruitment*

Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes ten hospital campuses, a 550,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With nearly 24,000 employees and more than 1,600 employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually.

GemPharmatech**Booth: 804****<https://www.gempharmatech.us/en/>***Contract Research Organization, Immunotherapy, Molecular Biology, Startup (Organization is less than 5 years old and has 10 or fewer employees)*

GemPharmatech is a leading provider of animal models and services to global preclinical R&D communities. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of conditional knockout/knockout mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, and customized breeding.

Genentech USA, Inc.**Booth: 2843****<http://www.gene.com>***Biotechnology, Clinical Research, Coagulation Products, Oncology Pharmaceuticals, Pharmaceuticals*

Every person with a blood disease has their own story; and each unique story shapes ours, fueling our dedication to pursue science and bring the best care to each individual. Our power is in discovering innovative medicines and personalizing patient care. For more than 40 years, we've been following the science and seeking solutions to unmet medical needs. Building on our legacy as the pioneer in blood cancer innovation, Genentech, a proud member of the Roche Group, has the opportunity to revolutionize new approaches to a spectrum of blood diseases.

Genmab**Booth: 1242, Virtual****<https://www.genmab.com>***Biotechnology, Cancer/Chemotherapy, Immunotherapy, Monoclonal Antibodies, Oncology Pharmaceuticals*

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. Founded in 1999, Genmab utilizes its next-gen antibody technologies to create novel therapies.

Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. For more information, please visit Genmab.com

Genomic Testing Cooperative**Booth: 205****<https://www.genomictestingcooperative.com>***Diagnostic Reagents, Diagnostic Services/Testing, Genetic Testing, Immunotherapy, Leukemia/Lymphoma Detection*

GTC offers advanced genomic profiling of DNA/RNA for hematologic cancers. We have a fast TAT of 5-10 days and a QNS rate of <1%. We are excited to introduce Liquid Trace, a comprehensive liquid biopsy analyzing cfDNA and cfRNA that will reduce the need for bone marrow biopsies. Our co-op model allows us to support labs to internalize NGS testing, while providing bioinformatics and reporting. In addition we do all of the R&D work to keep the assays up to date with the science and disperse that innovation to our co-op lab members. GTC also can operate as traditional reference lab.

GenPath**Booth: 305****<https://www.genpathdiagnostics.com/>***Coagulation Testing, Cytogenetics, Diagnostic Services/Testing, Flow Cytometry, Genetic Testing*

GenPath®, a division of BioReference, is a leading expert in cancer diagnostics, offering a comprehensive portfolio to support the continuum of care of cancer patients— from risk assessment to treatment planning. Backed by a team of specialized pathologists, GenPath delivers cutting-edge solutions that meet the unique needs of oncologists and pathologists, ranging from routine clinical and special coagulation to complex genomic testing for tumor sequencing and hereditary cancer syndromes.

Geron Inc.**Booth: 405****<http://www.geron.com>**

Geron Corporation 149 Commonwealth Drive Menlo Park, CA 94025 USA Tel: 650-473-7700 Fax: 650-473-7750 Email: info@geron.com

Gilead and Kite Oncology**Booth: 919****<https://www.gilead.com/science-and-medicine/medicines>***Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals*

Gilead and Kite Oncology are creating the future of oncology. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our R&D programs and partnerships are creating possibilities for people with overlooked, underserved and difficult-to-treat cancers. We are focused on helping to bring

more life to people with cancer and changing the way cancer is treated.

Global Blood Therapeutics Booth: 135, Virtual

<https://www.gbtvirtual.com>

Biotechnology, Pharmaceuticals

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease.

Global Pediatric MDS Initiative Booth: 2720

<https://www.pediatricmds.org>

GRAIL, LLC Booth: 551

<https://www.galleri.com/>

Diagnostic Services/Testing

GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured and is focused on saving lives and improving health by pioneering new technologies for early cancer detection. Their first product, the Galleri® multi-cancer early detection test, complements guideline-recommended screenings, and can detect a cancer signal across more than 50 types of cancer through a routine blood draw for adults with elevated risk, such as aged 50 or older. When cancer is detected, the Galleri test can predict the cancer signal origin.

Grifols Laboratory Solutions, Inc. Booth: 2420

<http://www.grifols.com/en/web/eeuu>

Pharmaceuticals

Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.

GSK Booth: 2243, 2749, Virtual

<https://www.gsk.com/>

Cancer/Chemotherapy, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

GSK is focused on maximizing patient survival through transformational medicines. GSK's pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. NX-GBL-ON-OGM-210034. December 2021.

Gundersen Health System Booth: 505

<https://www.gundersenhealth.org/careers>

Physician Recruitment

Gundersen Health System is a top-rated healthcare organization based in La Crosse, Wis. Gundersen offers top-quality primary and specialty healthcare usually found only in larger metropolitan areas. We are anchored by one of the largest multi-specialty group practices linking us with our regional clinics and affiliated hospitals via telemedicine, distance learning, digital imaging and other services. Our system serves the western Wisconsin, southeastern Minnesota and northeastern Iowa areas.

Harborside Booth: 942

<http://www.harborsidenexus.com>

Books/Journals, Educational, Oncology Pharmaceuticals, Pharmaceuticals, Publisher

Harborside is a medical communications company and publisher of The ASCO Post, Journal of Oncology Practice, Journal of the Advanced Practitioner in Oncology (JADPRO), and JNCCN-Journal of the National Comprehensive Cancer Network. The company also manages the advertising sales for ASCO's suite of publications, including the Journal of Clinical Oncology (JCO), the Journal of Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology. In addition, Harborside also produces live events for practicing nurse practitioners, PA's, and pharmacists.

Haymarket Oncology Booth: 3637

<https://www.cancertherapyadvisor.com/>

Publisher

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.

HealthTree Foundation Booth: 2628

<https://www.healthtree.org>

Cancer/Chemotherapy, Clinical Research, Non Profit, Patient Education Materials, Patient Services

The HealthTree Foundation (formerly Myeloma Crowd) puts patients first, builds trusted patient communities, accelerates research, and drives to a cure. We currently support myeloma, AML, MDS, and Kidney disease patients with a suite of tools such as free coaching, attending an educational event, finding a disease specialist, or learning in HealthTree University. In Cure Hub find your genetic twin and see personalized treatment options or clinical trials. Data is merged into a

collective network with other patient data that provides validated real-world data for research.

HealthWell Foundation

Booth: 2828

<http://www.healthwellfoundation.org>

Non Profit

The HealthWell Foundation is an independent non-profit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can't afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org.

HEMA Biologics

Booth: 2455

<https://www.hemabio.com/>

Biologicals, Coagulation Products

HEMA Biologics is a privately held biopharmaceutical company focused on the rarest bleeding disorders. We aspire to support patients living with these disorders, partner with the broader community that cares for them, and bring meaningful treatments and services to help better their daily lives.

HematoLogics, Inc.

Booth: 1214

<https://www.hematologics.com>

Bone Marrow Transplantation Research, Cytogenetics, Flow Cytometry, Genetic Testing, Leukemia/Lymphoma Detection

HematoLogics, Inc. is a privately owned laboratory with a focus on medicine and scientific discovery. We have an international reputation for our study of myelodysplasia, MRD detection, and the integration of technologies to detect and monitor treatment of hematopoietic diseases. Our approaches are validated through international collaborations and clinical trials. Our experience ensures these innovative techniques support a service oriented hematopathology referral group.

Hemophilia Federation of America (HFA) Booth: 2528

<http://www.hemophiliafed.org>

Association, Educational, Non Profit, Patient Education Materials, Patient Services

HFA is a national non-profit organization serving the needs of the bleeding disorders community. Through programming and listening to their needs, we work to advance patients' rights and access to care, be a resource to patients and their families, and to provide educational opportunities to give patients the tools they need to advocate for themselves. We aim to improve the care and quality of life for those with bleeding disorders by removing barriers to diagnosis, treatment, and cure.

Ichnos Sciences

Booth: 3127

<https://www.ichnosciences.com/>

Biotechnology, Human Biologicals, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals

Ichnos Sciences has a mission to provide breakthrough therapies that will extend and improve lives. A clinical-stage biotech with the spirit of a start-up, Ichnos aims to shift the way the world thinks about innovation through its research and development of transformative bi/multispecific antibody therapies in oncology. Headquartered in New York, N.Y., Ichnos is using its patented BEAT® technology platform to advance a pipeline of drug candidates to treat hematologic cancers and solid tumors.

ICON

Booth: 2023

<https://www.ICONplc.com>

Biotechnology, Clinical Research, Contract Research Organization, Hematology Cytochemistry, Oncology Pharmaceuticals

PRA Health Sciences is now an ICON plc company. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON operates from 150 locations in 47 countries and has approximately 38,000 employees.

Imaging Endpoints II, LLC

Booth: 2059

<https://www.imagingendpoints.com/>

Clinical Research, Contract Research Organization, Digital Imaging Systems, New Exhibitor, Oncology Pharmaceuticals

Imaging Endpoints (IE) is the largest oncology-focused imaging CRO globally and is widely recognized for conducting the industry's largest, most complex, and most successful imaging trials for both solid and liquid tumor indications. IE is based in Scottsdale, AZ with offices around the world including Cambridge, MA; London, United Kingdom; Basel, Switzerland; Leiden, Netherlands; Hyderabad, India; and Shanghai, China. Visit imagingendpoints.com to learn more!

Imago Biosciences

Booth: 2559

<https://www.imagobio.com/>

Biotechnology, Clinical Research, New Exhibitor, Oncology Pharmaceuticals, Pharmaceuticals

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecules that target lysine-specific demethylase 1 (LSD1), an essential enzyme in the production of blood cells in the bone marrow. Bomedemstat, is an orally available LSD1 inhibitor discovered by Imago being

tested in clinical studies as a potentially disease-modifying therapy for myeloproliferative neoplasms (MPNs), a family of chronic cancers of the bone marrow, including essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV).

ImmunoGen, Inc.

Booth: 3320

<https://www.immunogen.com>

Biotechnology, Clinical Research

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™. Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Incyte Corporation

Booth: 1343

<http://www.incyte.com>

Clinical Research, Immunotherapy, Oncology Pharmaceuticals

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. We are advancing a growing portfolio of medicines across oncology and inflammation & autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information visit incyte.com and follow @incyte.

Intermountain Healthcare

Booth: 201

<https://intermountainhealthcare.org/careers/explore-careers/physician-jobs>

Non Profit

Intermountain Healthcare is a team of nearly 60,000 caregivers who serve the healthcare needs of people across the Intermountain West, primarily in Utah, Idaho, Nevada, Colorado, Montana, Wyoming, and Kansas. We are an integrated, non-profit health system based in Salt Lake City, with clinics, a medical group, affiliate networks, hospitals, homecare, telehealth, health insurance plans, and other services, along with wholly owned subsidiaries including SelectHealth, Saltzer Health, Castell, Tellica, and Classic Air Medical.

International Myeloma Society

Booth: 2415

<https://www.myelomasociety.org/>

Association, Cancer/Chemotherapy, Clinical Research, Molecular Biology, Other

The International Myeloma Society (IMS) promotes education, research and clinical care globally by

building a global myeloma community, educating for today and the future, fostering clinical and translational research in myeloma and assuring clinical excellence worldwide.

International Society on Thrombosis and Haemostasis (ISTH)

Booth: 2529

<http://www.isth.org>

Books/Journals, Non Profit

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

Interpace Pharma Solutions

Booth: 1015

<http://www.flagshipbio.com>

Clinical Research, Contract Research Organization, Cytogenetics, Flow Cytometry, Genetic Testing

Flagship Biosciences is a leader in spatial biology and biomarker analytics specializing in histology, advanced molecular biomarker solutions, flow cytometry, cytogenetics, and bioinformatics solutions. Our team of experts in pathology, molecular sciences, and regulatory strategy offers advanced end-to-end biomarker and analytics services to support drug trials, biomarker discovery, and clinical diagnostics.

Intrinsic LifeSciences

Booth: 342

<http://www.intrinsiclifesciences.com>

Biotechnology, Clinical Research, Diagnostic Reagents, Diagnostic Services/Testing, Research Reagents

Intrinsic LifeSciences LLC provides superior, innovative & patent-protected research test kits and certified diagnostics & clinical research CLIA services for hepcidin and erythroferrone (ERFE), the key indicators of anemia, inflammation and pregnancy disorders. Our CAP accredited clinical lab, IntrinsicDx™, offers the Intrinsic Hepcidin IDx™ Test service. We also provide RUO immunoassay testing for other related biomarkers. To learn more visit www.intrinsicdx.com, www.intrinsiclifesciences.com.

Invivoscribe, Inc.

Booth: 3813

<https://www.invivoscribe.com/>

Diagnostic Assay Kits, Diagnostic Services/Testing, Flow Cytometry, Leukemia/Lymphoma Detection, Software

Invivoscribe is a global leader in hemato-oncology diagnostics. Our flow & molecular assays, reagents, controls, bioinformatics & services focus on actionable biomarkers supporting therapeutic decisions, MRD testing, stratification & CDx development.

Ipsen**Booth: 1815****<https://www.ipsenus.com>***Biotechnology, Clinical Research, Oncology Pharmaceuticals, Pharmaceuticals*

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Our North American operations are located in Cambridge, Massachusetts, one of the company's three global hubs. For more information please visit www.ipsenus.com.

IQVIA Biotech**Booth: 704****<http://www.iqviabiotech.com>***Biotechnology, Clinical Research, Contract Research Organization, Immunotherapy, Oncology Pharmaceuticals*

IQVIA Biotech delivers flexible clinical solutions designed to help biotech and emerging biopharma companies get treatments to patients. When you partner with our clinical development team, you gain expertise from two decades of planning and executing clinical trials exclusively for biotech companies. With more than 500 oncology studies in the last five years, and a focus on hematologic oncology and cell therapy, our dedicated teams have the experience to support your clinical trial.

IsoPlexis**Booth: 507****<https://www.isoplexis.com>***Biotechnology, Diagnostic Services/Testing, Immunotherapy, Monoclonal Antibodies, Oncology Pharmaceuticals*

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit www.isoplexis.com to learn more.

JAMA Network**Booth: 500****<https://www.jamanetwork.com>***Books/Journals, Publisher*

JAMA Network advances the science and practice of hematology with high-impact journals including JAMA, JAMA Oncology, and JAMA Network Open. We publish research, reviews, and opinions shaping

the future of medicine. Explore booth #500 at ASH to read the latest hematology articles from our journals and learn more about publishing with the JAMA Network. Learn more at <https://www.jamanetwork.com>.

Janssen Biotech, Inc.**Booth: 429****<https://www.janssen.com>***Pharmaceuticals*

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS.

Janssen Biotech, Inc. – Medical Affairs **Booth: 2215****<http://www.janssen.com>***Pharmaceuticals*

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.

Janssen Pharmaceuticals Inc.**Booth: 443****<https://www.janssen.com>***Pharmaceuticals*

About the Janssen Pharmaceutical Companies of Johnson & Johnson - At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Jazz Pharmaceuticals, Inc.**Booth: 3131****<http://www.jazzpharma.com>***Cancer/Chemotherapy, Pharmaceuticals*

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.

John Theurer Cancer Center**Booth: 710****<http://www.jtcancercenter.org/>***Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Genetic Testing, Immunotherapy*

John Theurer Cancer Center at Hackensack University Medical Center is among the nation's top 50 U.S. News and World Report Best Hospitals — the highest ranked in New Jersey. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Karius**Booth: 1256****<http://www.kariusdx.com>***Diagnostic Services/Testing, Genetic Testing*

Karius is a life science company focused on advancing diagnostic science and technology for infectious disease. The Karius Test® is a liquid biopsy for infectious diseases that, from a single blood sample, can non-invasively and rapidly detect over 1000 pathogens causing both deep-seated and bloodstream infections. The Karius Test helps clinicians avoid invasive, low-yield, and sequential diagnostic tests that can delay treatment for the most vulnerable hospitalized patients.

Karyopharm Therapeutics Inc.**Booth: 2233****<https://www.karyopharm.com>***Biotechnology, Oncology Pharmaceuticals, Pharmaceuticals*

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Kedrion Biopharma Inc.**Booth: 701****<http://www.kedrionusa.com/>***Biologicals, Biotechnology, Coagulation Products, Human Biologicals, Pharmaceuticals*

Kedrion Biopharma is a leading international biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders, and conditions such as immune system deficiencies and coagulation disorders. Kedrion has special expertise in the treatment of rare diseases and the manufacture of hyper-immune products such as anti-hepatitis B, anti-tetanus, and RhoGAM® for prophylaxis against Rh sensitization and subsequent hemolytic disease of the fetus and newborn.

Kronos Bio**Booth: 325****<http://www.kronosbio.com>***Biotechnology, Clinical Research, Leukemia/Lymphoma Detection, New Exhibitor, Oncology Pharmaceuticals*

Kronos Bio is advancing three investigational compounds in clinical trials for patients with cancer. The company's lead compound, the SYK inhibitor entospletinib, is being evaluated in the registrational Phase 3 AGILITY trial for newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The company is also developing the CDK9 inhibitor, KB-0742, and lanraplenib, a next-generation SYK inhibitor. Kronos Bio's scientific focus is the dysregulated transcription that is the hallmark of cancer.

Kura Oncology**Booth: 2959****<http://kuraoncology.com>***Biotechnology, Oncology Pharmaceuticals, Pharmaceuticals*

Kura Oncology is a clinical-stage biopharmaceutical company whose mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. We are advancing a number of precision medicines for the treatment of solid tumors and hematologic malignancies including ziftomenib (KO-539), a menin inhibitor, which is being studied in genetically defined subsets of patients that includes NPM1 mutant and KMT2A-rearranged acute myeloid leukemia.

Kyowa Kirin, Inc.**Booth: 957****<https://www.kkna.kyowakirin.com>***Biologicals, Monoclonal Antibodies, Oncology Pharmaceuticals*

Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Bedminster, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and well-being of people through innovative and state-of-the-art technologies in various

therapeutic areas including oncology, neurology, nephrology, and immunology. For additional information, you can visit us at www.kkna.kyowakirin.com.

Labcorp Oncology

Booth: 2322

<https://oncology.labcorp.com/>

Cancer/Chemotherapy, Clinical Research

Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization- using a biomarker-driven strategy throughout the entire process. <https://oncology.labcorp.com/>

Legend Biotech

Booth: 914

<https://experiencelegendbiotech.com>

Biotechnology, Clinical Research, Immunotherapy

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the US, China and Europe, along with our differentiated technology, global development, and manufacturing expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need.

Lymphoma Coalition

Booth: 2728

<http://www.lymphomacoalition.org>

Non Profit, Patient Education Materials, Patient Services

Lymphoma Coalition, a worldwide network of patient groups with a full or partial focus on providing support to patients with lymphoma, was formed in 2002 and incorporated as a not for profit organisation in 2010. Today, there are over 80 member organisations from over 50 countries. LC's current strategy is focused on ensuring impact within two pillars: information and advocacy. VISION: EQUITY IN LYMPHOMA OUTCOMES ACROSS BORDERS. MISSION: ENABLING GLOBAL IMPACT BY FOSTERING A LYMPHOMA ECOSYSTEM THAT ENSURES LOCAL CHANGE AND EVIDENCE-BASED ACTION.

M2GEN

Booth: 3628

<https://www.m2gen.com>

Biotechnology, Clinical Research, Immunotherapy, Oncology Pharmaceuticals, Other

M2GEN is an oncology-focused informatics solutions company advancing precision medicine and transforming cancer care through linked clinical and deep

molecular data. In collaboration with leading academic cancer centers, biopharmaceutical companies and patients, we have developed a unique data-driven ecosystem to provide cancer researchers and clinicians with insights to make informed decisions faster. We focus on the areas of greatest unmet need in oncology, including hematological malignancies. For more information, visit www.M2GEN.com.

Machaon Diagnostics, Inc.

Booth: 610

<http://www.machaondiagnosics.com>

Bleeding/Clotting Tests, Clinical Research, Coagulation Testing, Diagnostic Services/Testing, Genetic Testing

Machaon Diagnostics specializes in the diagnosis of bleeding and clotting disorders, as well as rare disease genetics. Headquartered in Oakland, California, we also operate Louisiana Coagulation in New Orleans, LA. We provide the highest quality and fastest turnaround times for testing of platelets, thrombosis, hemostasis and rare disease genetics for both our hospital and pharmaceutical company clients. Machaon Diagnostics can offer courier services and interface options.

Mayo Clinic Referring Provider Office

Booth: 2220

2220

<https://www.mayoclinic.org/medical-professionals>

Cancer/Chemotherapy, Diagnostic Services/Testing, Genetic Testing, Non Profit, Patient Services

More than 150,000 people with cancer come to Mayo Clinic each year. They find experts with extensive experience in the diagnosis and treatment of virtually every kind of cancer and the resources to provide excellent care tailored to their needs. A multispecialty cancer team and Mayo Clinic's clinical expertise drives strong collaboration with referring physicians throughout their patient's care. Visit Mayo Clinic at booth #2220 to learn more.

MD Anderson Cancer Center

Booth: 2219

<http://www.mdanderson.org>

Biologicals, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Physician Recruitment

MD Anderson is renowned for breakthrough discoveries and exceptional patient care. We're proud to be ranked No. 1 in cancer care by U.S. News & World Report. Our research enterprise is rooted in interdisciplinary collaboration, benefiting patients faster than ever through our expansive clinical trials program. Our work has led to new treatments like CAR T cell therapy, eliminated the need for chemotherapy for some leukemia patients and improved outcomes for stem cell transplant patients. Visit booth 2219 to meet our experts, discuss clinical trials and learn about open positions.

MDoutlook**Booth: 2329****<http://www.mdoutlook.com>***Educational, Market Research, Physician Recruitment*

MDoutlook is a leading disease intelligence organization, headquartered since 2008 in Atlanta, GA. Our solutions include disease insight, ThoughtLeader and physician identification, targeting and engagement. Clients are life sciences companies and service providers. Governed by top ThoughtLeaders and driven by in-house medical experts, MDoutlook® is the largest, single global intelligence source directly accessing 85,000+ validated and verified cancer treaters.

Med Learning Group**Booth: 855****<https://www.medlearninggroup.com/>***Cancer/Chemotherapy, Clinical Research, Educational, Leukemia/Lymphoma Detection, Patient Education Materials*

This Virtual Reality Room invites learners to experience a virtual world illustrating the pathogenesis and mechanisms therapies targeting novel pathways in hematologic malignancies. Through this sensory-immersive experience, a series of virtual reality animations will allow learners to visualize the pathophysiology underlying hematologic malignancies, identify therapeutics mechanisms, and recognize both existing and novel therapies in development to diversify the range of treatment options available to patients.

Medexus Pharma**Booth: 2315****https://www.medexus.com/en_US/divisions/medexus-pharma-usa***Bone Marrow Products, Bone Marrow Transplantation Research, Coagulation Products, Pharmaceuticals*

Medexus Pharma is a wholly owned subsidiary of Medexus Pharmaceuticals, Inc. Based in Chicago, Illinois, Medexus Pharma focuses on the development and commercialization of novel treatments and near market opportunities.

Medidata, a Dassault Systèmes company**Booth: 2159****<https://www.medidata.com/>***Clinical Research, Software*

Medidata AI, a Dassault Systèmes company, combines data, technology, and deep expertise to help life sciences companies deliver actionable insights.

Medpace Inc.**Booth: 3314****<http://www.medpace.com>***Clinical Research, Contract Research Organization, Immunotherapy, Oncology Pharmaceuticals, Research Affairs*

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device

industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including hematology and oncology.

Medscape Oncology & Hematology**Booth: 3153****<https://www.medscape.com/oncology>***Educational, Market Research, Patient Education Materials, Publisher, Research Reagents*

Medscape Oncology is a leading source of oncology & hematology news and information for physicians and other healthcare professionals worldwide. We offer medical news, including practice guidelines, FDA announcements, journal articles, conference news, and thought leader perspectives; point-of-care clinical reference tools; and continuing medical education in a variety of engaging formats. [medscape.com/oncology](https://www.medscape.com/oncology)

MEI Pharma, Inc.**Booth: 3247****<https://www.meipharma.com/>***Clinical Research, Oncology Pharmaceuticals*

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing new therapies for cancer. MEI Pharma's portfolio of clinical stage drug candidates includes the lead candidate zandelisib (ME-401), an oral PI3Kdi differentiated by its unique dosing schedule currently under evaluation for R/R FL and MZL in Phase 2 (NCT03768505) and Phase 3 (NCT04745832) clinical trials intended to support market authorization applications, as well as voruciclib, an oral CDK9 inhibitor currently evaluated in a Phase 1 (NCT03547115) clinical trial for R/R B-cell malignancies and AML.

Menarini Silicon Biosystems**Booth: 3633****<https://www.siliconbiosystems.com/en-us/>***Biotechnology, Cell Counters, Clinical Research*

Menarini Silicon Biosystems' new Circulating Multiple Myeloma Cell (CMMC) Enumeration assay directly measures levels of plasma cells in peripheral blood. This test provides complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.

Menarini Stemline**Booth: 3321****<http://www.menarini.com>**

Menarini/Stemline are committed to make a difference in cancer patients lives. We invest in the development

of precision medicine through our pipeline of investigational drugs, which includes small molecules & biologics in hematologic & solid tumors.

Merck & Co., Inc.
<https://www.merck.com>

Booth: 3333

Clinical Research, Oncology Pharmaceuticals

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

Miltenyi Biotec
<http://www.miltenyibiotec.com>

Booth: 3355

Cell Separators, Clinical Research

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. We are committed to supporting clinical innovators, physicians, and cell manufacturers with solutions that enable scalable clinical translation of novel cell and gene therapies and engineered grafts for hematopoietic stem cell transplant. Visit our web page and discover a selection of useful resources to enhance your development of advanced therapies.

Mission Bio
<https://www.missionbio.com/>

Booth: 2014

Clinical Research, Genetic Testing, Research Reagents

Mission Bio is a life sciences company that accelerates discoveries and cures by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to precision therapies. With the Tapestri Platform, the only commercialized platform capable of analyzing DNA and protein simultaneously with single-cell resolution, Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health.

MJH Life Sciences
<https://www.mjhlifesciences.com/>

Booth: 2118

Books/Journals, Educational, Other, Publisher

MJH Life Sciences is home to iconic health care brands across hematology and oncology. We are dedicated to providing health care professionals with the resources and education needed to optimize patient outcomes and improve care. Our hematology-focused brands include OncLive®, Targeted Oncology™, CURE®, CancerNetwork®, HCPLive®, CGTLive™ and Physician's Education Resource®, all offering unparalleled multimedia access to recent data, insights, and thought leadership, and committed to helping provide the most

relevant information to health care providers and patients.

MLM Medical Labs
<https://www.mlm-labs.com/>

Booth: 2323

Clinical Research, Coagulation Testing, Flow Cytometry, Molecular Biology

MLM Medical Labs is an industry-leading specialty and central laboratory with comprehensive standard and fully customizable biological research services and analytical capabilities across a wide spectrum of therapeutic areas. Our strong reputation for scientific expertise, passionate customer care, and quality data adds value at every stage of the product development process, empowering our customers to reach confident clinical decisions that improve patient lives. Our expertise includes biomarkers, assay development, immunoncology, coagulation, and platelets.

Moffitt Cancer Center
<https://www.Moffitt.org>

Booth: 1922

Cancer/Chemotherapy, Clinical Research, Immunotherapy, Non Profit

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of \$2.4 billion.

MorphoSys
<https://www.morphosys.com/>

Booth: 3115

Biotechnology, Immunotherapy, Oncology Pharmaceuticals

At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn.

MPLT Healthcare
<https://www.mplthealthcare.com>

Booth: 2320

MPLT Healthcare specializes in placing highly qualified physicians and advanced practice clinicians in locum, locum-to-perm and direct hire staff positions. We will always be people helping people, striving to earn the loyalty of our clients, providers and employees

through selfless service, relentless focus on quality and a culture of excellence.

Multiple Myeloma Research Foundation **Booth: 2629**

<https://themmrf.org/>

Clinical Research, Educational, Non Profit, Patient Education Materials

The Multiple Myeloma Research Foundation (MMRF) leads the way in accelerating a cure for each and every myeloma patient. One important initiative is the MMRF CureCloud®. This longitudinal IRB-approved research study includes the first at-home genomic testing program for multiple myeloma patients. Our goal: harness a vast amount of genomic, clinical—and eventually—patient immune and other kinds of data—to accelerate research into smarter treatments for every patient. Ultimately, this research study will inform personalized treatment options to consider with your patients.

National Blood Clot Alliance

Booth: 2620

<http://www.stoptheclot.org>

Educational, Non Profit, Patient Education Materials

The National Blood Clot Alliance (NBCA) is a 501(c)(3), non-profit, voluntary health organization dedicated to advancing the prevention, early diagnosis and successful treatment of life-threatening blood clots such as deep vein thrombosis, pulmonary embolism, and clot-provoked stroke. NBCA works on behalf of people who may be susceptible to blood clots, including, but not limited to, people with clotting disorders, atrial fibrillation, cancer, traumatic injury, and risks related to surgery, lengthy immobility, childbirth and birth control.

National Cancer Institute

Booth: 2616

<https://www.cancer.gov>

Cancer/Chemotherapy, Research Grants

NCI is the federal government's principal agency for cancer research and training. NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.

National Comprehensive Cancer Network (NCCN)

Booth: 2716

<https://www.nccn.org/>

Cancer/Chemotherapy, Clinical Research, Educational, Non Profit, Patient Education Materials

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 32 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Through the

leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.

National Heart, Lung, and Blood Institute **Booth: 2314**

<http://www.nhlbi.nih.gov>

Clinical Research, Research Grants

The National Heart, Lung, and Blood Institute (NHLBI) plans and directs research in the development and evaluation of prevention, treatment, and rehabilitation of patients suffering from diseases of the heart, blood vessels, lung, and blood, obesity, and sleep disorders. NHLBI conducts educational activities, including development and dissemination of materials in the above areas. Contact NHLBI by email: nhlbiinfo@nhlbi.nih.gov or phone: 301-592-8573.

NEJM Group

Booth: 600

<https://www.nejmgroup.org/>

Books/Journals, Educational, Publisher

NEJM Group creates high-quality medical resources for research, learning, practice and professional development designed to meet the demand for essential medical knowledge among academic researchers and teachers, physicians, clinicians, executives and others in medicine and health care. NEJM Group brings together the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch, NEJM Knowledge+, NEJM Resident 360, NEJM Healer, NEJM 医学前沿, and NEJM CareerCenter. For more information visit www.nejmgroup.org.

NeoGenomics Laboratories

Booth: 3415

<https://www.neogenomics.com>

Clinical Research, Diagnostic Services/Testing, Flow Cytometry, Immunotherapy, Registry

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. >600 tests including molecular profiling in myeloid disorders and leukemias, cfDNA/RNA assays for biopsy-free evaluation of hematologic cancers, and >20 HemeFISH™ panels. Our Pharma Services division serves pharmaceutical clients in clinical trials and drug development from biomarker discovery thru CDx validation and commercialization.

NMDP/Be The Match

Booth: 2517

<https://bethematchclinical.org/>

Bone Marrow Products, Bone Marrow Transplantation Research

The National Marrow Donor Program (NMDP)/Be The Match manages the most diverse registry of potential

unrelated blood stem donors and cord blood and partners to provide cures to patients with life-threatening blood disorders. They support therapy development and delivery through Be The Match BioTherapies and are also a leader in research through the CIBMTR (Center for International Blood and Marrow Transplant Research)—investing in and managing studies to help patient outcomes.

Northside Hospital

Booth: 1114

<http://www.northside.com>

Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Immunotherapy, Leukemia/Lymphoma Detection

The Blood and Marrow Transplant, Leukemia and Immunotherapy Programs at Northside Hospital, Atlanta GA, strives to be the premier blood cancer treatment center in the Southeast by achieving outstanding patient outcomes and satisfaction. We are dedicated to providing patient-focused care through research, leading edge treatments and clinical excellence. Our patients and their families are at the center of our program, and we are committed to treating each individual with respect, dignity and compassion while providing them with the clinical and ongoing support they need.

Notable Labs

Booth: 2022

<http://www.notablelabs.com>

Biotechnology, Cancer/Chemotherapy, Flow Cytometry, New Exhibitor, Oncology Pharmaceuticals

Notable a clinical-stage platform therapeutics, & drug development company featuring revolutionary predictive precision medicine platform that matches individual cancer patients responses to therapies with up to 100% accuracy based on results of 4 clinical validation studies. A team of highly collaborative medical & technology visionaries have harnessed a combination of therapeutics, diagnostics, software, engineering, machine learning & automation, to develop proprietary, platform that bio-simulates patient's cancer treatment with high fidelity to actual treatment.

Novartis

Booth: 1931

<https://www.hcp.novartis.com/>

Cancer/Chemotherapy, Immunotherapy, Oncology Pharmaceuticals, Patient Services, Pharmaceuticals

Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients' hopes for the future. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines.

Novo Nordisk

Booth: 3143

<https://www.novonordisk-us.com/>

Coagulation Products, Pharmaceuticals

Novo Nordisk, a global health care company, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations. We're working toward a future where fewer people get chronic diseases, everyone is diagnosed, and all patients receive adequate treatment.

Nucleus Biologics

Booth: 1959

<https://nucleusbiologics.com/>

Cell Culture, Clinical Research, New Exhibitor, Research Reagents

Nucleus Biologics, The Cell Performance Company™, is the leading provider of custom cell-growth media, tools, and technologies for cell and gene therapy. Its mission is to speed the time from scientific discovery to cure by delivering innovative, transparent, and cGMP products and services. From design to delivery, we offer an entire ecosystem of cell culture media solutions that seamlessly interface with one another, facilitating easy formulation, configuration, ordering, and manufacture of media, while addressing the environmental impacts of cell culture media fulfillment.

NuProbe USA, Inc.

Booth: 1157

<https://www.nuprobe.com>

Biotechnology, Clinical Research, Diagnostic Assay Kits, Molecular Biology

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe's vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.

Omeros Corporation

Booth: 2149

<https://eisthreat.com/>

Biotechnology

Endothelial injury syndromes (EIS) resulting from hematopoietic stem cell transplant (HSCT) encompass numerous serious and potentially fatal complications. Endothelial injury, including HSCT-TMA, can occur prior to, during, and after HSCT.

ONO Pharma USA, Inc. Booth: 249, Virtual
<https://www.ono-usa.com/>

Cancer/Chemotherapy, Pharmaceuticals

ONO PHARMA USA, INC. is pursuing the clinical development of new drug candidates and aiming to commercialize in the US. ONO PHARMA USA, INC. was established as a US subsidiary of Ono Pharmaceutical Co., Ltd. (ONO) in 1998. ONO was founded in Osaka, Japan, in 1717. ONO is an R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, like nivolumab, an anti-PD-1 antibody drug, focusing on oncology, immunology, neurology, and specialty research.

OPIS Booth: 3226
<https://opisresearch.com/>

Clinical Research

OPIS is an international CRO (Contract Research Organization), with 23 years of experience in conducting more than 1400 Phase I-IV clinical trials, including non-interventional, medical devices and nutraceutical studies on an international level. With 10 offices across Europe and more locations growing overseas worldwide, OPIS offers a full range of integrated clinical research services as scientific advice, medical writing, trial start-up, monitoring, study management, data management, statistics, pharmacovigilance as well as quality assurance and training.

OPTOLANE Technologies, Inc. Booth: 1942
<http://www.optolane.com>

Cancer/Chemotherapy, Diagnostic Assay Kits, Genetic Testing, Leukemia/Lymphoma Detection, Molecular Biology

Optolane is a digital real-time PCR platform manufacturing company. Utilizing the high sensitivity of digital PCR, we have been developing liquid biopsy products for cancer starting from the BCR-ABL1 Major Kit which can detect the BCR-ABL1 transcript up to MR5.3. We continue to develop diagnostic tools for the fast and proper treatment of cancer. We also provide digital PCR cartridges for research use for extensive utilization of our platform. Our platform is applicable for use in absolute quantification, CNV, SNP/mutation/methylation detection, and NGS library analysis.

OrganaBio Booth: 2143
<https://www.organabio.com/>

Biotechnology, Cell Culture, Human Biologicals, Immunotherapy, Other

OrganaBio's unique, flexible model combines proprietary and scalable tissue sourcing with advanced processed and highly characterized perinatal and adult tissues (including umbilical cord blood and leukopaks). With the ability to tailor products and services to a customers' evolving needs, OrganaBio rapidly

manufactures a variety of isolated cells such as CD34+ HSCs, T, B & NK Cells, and macrophages from tissues for pre-clinical research use as well as in the manufacturing of clinical-grade cell therapies.

Parexel International Booth: 149
<https://www.parexel.com/experience/therapeutic-expertise/oncology-study-experience>

Clinical Research, Contract Research Organization

As a leading global CRO, Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. What we do, we do With Heart™.

Pfizer (MM) Booth: 1833
<https://www.pfizeroncologycongresshub.com/ASH2022>

Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Pfizer (Oncology) Booth: 1215, Virtual
<https://www.pfizeroncologycongresshub.com/ASH2022>

Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Pfizer (Rare Disease) Booth: 648
<https://www.pfizer.com>

Biotechnology, Clinical Research, Pharmaceuticals

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly

improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Pfizer, Inc.

Booth: 206, 4114

<http://www.pfizer.com>

About Pfizer: Breakthroughs That Change Patients' Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Pharmacosmos Therapeutics Inc.

Booth: 847

<https://www.monoferric.com>

Oncology Pharmaceuticals, Pharmaceuticals

Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferic® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.

Pharmacyclics LLC, An AbbVie Company **Booth: 415**

<http://www.abbvie.com>

Biotechnology, Oncology Pharmaceuticals

Pharmacyclics is an AbbVie Company in South San Francisco, California, developing and commercializing small-molecule medicines for which there is great unmet medical need.

PharmaEssentia Corporation

Booth: 235

<http://www.pharmaessentia.com/>

Biotechnology, Bone Marrow Products, Cancer/Chemotherapy, Molecular Biology, Oncology Pharmaceuticals

PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations the U.S., Japan, China and Korea. Visit our website to learn more.

Pharming Healthcare, Inc.

Booth: 3529

<https://www.pharming.com>

Pharming Healthcare, Inc. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

PicnicHealth

Booth: 321

<https://www.picnichealth.com/>

New Exhibitor, Registry, Software

PicnicHealth is building deep real-world datasets to fuel cutting-edge research while giving patients control of their own medical records. These complete, clinically-rich datasets produce unique insights to ultimately get the right treatments into patients' hands faster. We do this by working directly with patients and leveraging human-assisted machine learning to transform messy medical records into structured research-ready datasets. To date, we've helped tens of thousands of patients securely access their records and contribute to research that impacts their lives.

Platelet Disorder Support Association **Booth: 2514**

<https://www.pdsa.org>

Association, Non Profit, Patient Services

The Platelet Disorder Support Association, patient-founded in 1998, is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support.

PlatformQ Health

Booth: 547

<http://www.PlatformQ.com>

New Exhibitor

PlatformQ Health is the leading provider of interactive digital medical education for clinicians, patients, and caregivers. To improve patient care, PlatformQ Health Education creates video-first educational modules with premier partners, so learners can better understand conditions, available treatment options, and the latest research. The company's proprietary platform allows participants to engage in real-time discussion with scientific, research, and patient care experts.

Precision for Medicine

Booth: 420

<https://www.precisionformedicine.com/>

Clinical Research, Contract Research Organization

Premier Research**Booth: 2414****<https://www.premier-research.com>***Clinical Research, Contract Research Organization*

Premier Research, a product development company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.

Protagonist Therapeutics, Inc Booth: 713, Virtual**<https://www.protagonist-inc.com>***Biotechnology, Clinical Research, Pharmaceuticals*

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide, PN-943, and PN-235 in different stages of clinical development, all derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate. VERIFY, the global Phase 3 registration study of rusfertide in polycythemia vera, is currently underway.

Prothena**Booth: 3059****<http://www.prothena.com>***Biologicals, Clinical Research, Monoclonal Antibodies*

Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases.

Q2 Solutions**Booth: 2542****<https://www.q2labsolutions.com>***Clinical Research, Contract Research Organization, Flow Cytometry, Molecular Biology*

Q Squared Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines, and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery.

Rapid Novor Inc.**Booth: 2743****<https://www.byopsy.com>***Flow Cytometry, Genetic Testing*

Rapid Novor Inc is developing a sensitive and non-invasive blood based liquid biopsy (EasyM) to monitor the minimal residue disease and detect early relapse for Multiple Myeloma. EasyM is sensitive enough to determine MM relapse 6-8 months earlier than traditional tests.

Regeneron Pharmaceuticals**Booth: 1847****<http://www.regeneron.com>***Monoclonal Antibodies, Oncology Pharmaceuticals*

Regeneron is a leading biotechnology company that invents life-transforming medicines for serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies. Visit www.Regeneron.com to learn more.

Rigel Pharmaceuticals**Booth: 2815****<http://www.rigel.com>***Biotechnology, Oncology Pharmaceuticals*

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the development and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist. Rigel's first FDA approved product TAVALISSE® (fostatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Rutgers Cancer Institute of New Jersey/**RWJBarnabas Health****Booth: 311****<https://www.cinj.org>***Clinical Research, Immunotherapy, New Exhibitor, Patient Services, Physician Recruitment*

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers innovative cancer treatment including CAR-T cell therapy, stem cell transplant, proton therapy, clinical trials, and immunotherapy. More than 230 faculty in interdisciplinary programs, including pediatric hematology/oncology, focus on basic, clinical, translational, and population research that drives outstanding contributions towards reducing cancer incidence and improving patient outcomes.

S. Karger Publishers, Inc.**Booth: 2418**<https://www.karger.com/>*Educational, Patient Education Materials, Publisher*

Karger Publishers, headquartered in Basel, Switzerland, is an independent, globally active publishing house in health sciences. Committed to Connecting and Advancing Health Sciences, the emphasis is on providing customized solutions for all industry partners. Among Karger's compelling advantages are access to key opinion leaders, leading medical societies, and a global community of healthcare professionals. Karger builds a strong global alliance through its engagement with these communities.

Sampled**Booth: 204**<https://sampled.com/>

Sampled is a next-generation laboratory that unlocks the valuable data in any biological sample. Through our integrated "SMART Lab" services, we can Store, Manage, Analyze, Research and Transport biological materials, offering partners a seamless solution for all research samples. Our vision is a world where we make it faster and easier for health innovators to improve human health, with a mission to be the SMART Lab behind every transformative health innovation.

Sanius Health**Booth: 300**<http://www.saniushealth.com>*New Exhibitor, Software, Startup (Organization is less than 5 years old and has 10 or fewer employees)*

Sanius Health is focused on accelerating personalised medicine, drug discovery and clinical research on sickle cell disease and other rare conditions. People with rare diseases spend 99% of their lives outside of the hospital, yet their care is based solely on what's seen in appointments. Sanius Health goes beyond hospital data so that clinical decisions can be based upon the full picture, not just 1% of it. We partner with passionate patients, treatment centres, researchers, and developers of therapeutics in advancing outcomes for patients.

Sanofi**Booth: 643, Virtual**<https://www.sanofi.us>*Biotechnology, Monoclonal Antibodies, Oncology Pharmaceuticals, Pharmaceuticals*

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanyou Biopharmaceuticals Co. Ltd**Booth: 2058**www.sanyoubio.com**Sarah Cannon Research Institute****Booth: 1914**<http://www.sarahcannon.com>*Bone Marrow Transplantation Research, Cancer/Chemotherapy, Clinical Research, Contract Research Organization, Immunotherapy*

Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the US and UK. Sarah Cannon's cancer programs include individualized patient navigation provided by oncology-trained nurses - 1,400 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities.

Saudi Society of Blood & Marrow**Transplantation (SSBMT)****Booth: 2723**<http://www.ssbmt.org.sa>*Association, Non Profit, Registry*

The Saudi Scientific Society of Blood and Marrow Transplantation (SS BMT) is a professional non-for-profit organization, aims to promote and enhance science, research and proper practice with the vision to be a high-standard resource for healthcare workers, patients and the public in the field of specialization. Scope of Specialization: • Stem Cell Transplantation & other stem cell applications • Blood disorders and cancers • Hematopathology and related specialties and technologies

Scientific Education Support**Booth: 301**<https://scientificeducationsupport.com/>*Educational, Patient Education Materials, Publisher*

Scientific Education Support (SES) is a medical education provider, building healthcare professional and patient networks that facilitate open access, science-driven, unbiased disease education through multichannel communications.

Seagen**Booth: 1943, Virtual**<https://www.seagen.com>*Biotechnology, Clinical Research, Pharmaceuticals*

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.

Secura Bio Inc.**Booth: 1415**<https://www.securabio.com>*Biotechnology, Oncology Pharmaceuticals*

Secura Bio is an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. For more information, please visit www.securabio.com.

Secure Transfusion Solutions**Booth: 613**<http://securetransfusion.com>*New Exhibitor, Other*

Secure Transfusion Solutions (STS) owns and operates commercial blood centers under the name Trusting Heart Blood Center. Our goal is to help hospitals around the country build a robust, resilient supply of pathogen-reduced apheresis platelets to meet patient needs.

Servier Pharmaceuticals**Booth: 1735**<https://www.servier.us/>*Clinical Research, Oncology Pharmaceuticals, Patient Education Materials*

Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier's global portfolio and seeking acquisitions, licensing deals and partnerships.

Shwachman-Diamond Syndrome Foundation**Booth: 2814**<https://www.shwachman-diamond.org>*Bone Marrow Transplantation Research, Non Profit, Patient Services, Registry, Research Grants*

Shwachman-Diamond Syndrome Foundation has educated medical professionals and the public about this ultra rare disease since 1994. We have provided education, answers, support and hope to SDS patients and their families. We advocate for and fund research to improve treatment and curative therapies. We reach our families and medical professionals through our website, Facebook page, newsletters, and medical conferences.

Singleron Biotechnologies GmbH**Booth: 3351**<https://www.singleron.bio/>*Biotechnology, Clinical Research, Molecular Biology, New Exhibitor, Research Reagents*

SingleronBiotechnologiesdevelopsandcommercializes

single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 1,600 laboratories in hospitals, research institutes, and pharmaceutical companies.

siParadigm Diagnostic Informatics**Booth: 2422**<https://www.siparadigm.com/>*Cytogenetics, Diagnostic Services/Testing, Flow Cytometry, Genetic Testing, Molecular Biology*

siParadigm Laboratories is a leading cancer diagnostic reference laboratory with unsurpassed expertise in Hematopathology and latest Oncology Diagnostics working with physicians, clinicians, patients, and providers, to inform timely and appropriate patient CARE through Communication, Accuracy and Reliability. Our areas of expertise include cancer cytogenetics with industry-leading turnaround times (TAT); hematologic and solid tumor testing. siParadigm has earned national accreditation by both CLIA and CAP, in addition to receiving local licensing in several states.

Sobi, Inc.**Booth: 3343**<https://sobi-northamerica.com/>*Bone Marrow Transplantation Research, Clinical Research, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals*

As the North America affiliate of biopharmaceutical company Sobi™, our team is committed to Sobi's vision of bringing innovative therapies and services to make a difference in the lives of those affected by a rare disease, from the patient to their families and caregivers. We bring a rare strength to our work – a superior focus, commanding agility and the power of the people we are dedicated to serving. Our key therapeutic areas include rare diseases in hematology and immunology, as well as a portfolio of specialty care products.

Society for Immunotherapy of Cancer (SITC)**Booth: 2515**<https://www.sitcancer.org>*Educational, Immunotherapy, Non Profit*

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of more than 4,650 influential research scientists, physician scientists, clinicians and more dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Society of Hematologic Oncology Booth: 2816**<https://www.sohoonline.org>***Association, Non Profit*

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. SOHO represents physicians and other health care professionals from all corners of the world. The SOHO global network supports and is supported by members from more than 110 countries, who are leading the vital efforts to further treatments for those afflicted by these diseases.

SOPHiA GENETICS**Booth: 1915****<https://www.sophiagenetics.com>***Biotechnology, Diagnostic Services/Testing, Genetic Testing, Software*

SOPHiA GENETICS (Nasdaq: SOPH) is a health care technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multi-modal data sets and different diagnostic modalities.

Spark Therapeutics, Inc.**Booth: 511****<https://www.sparktx.com>***Clinical Research, Human Biologicals*

At Spark Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research is hemophilia A, an inherited bleeding disorder caused by mutations in the F8 gene that encodes coagulation factor VIII. Led by researchers and clinicians with long-standing commitment to the hemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community. Spark Therapeutics is a member of the Roche Group.

SpringWorks Therapeutics**Booth: 2359****STEMCELL Technologies****Booth: 705****<https://www.stemcell.com>***Cell Culture, Research Reagents*

STEMCELL Technologies Inc. is committed to providing specialized cell isolation products, standardized cell culture media and accessory tools for your cell biology research. Driven by science and a passion for quality, STEMCELL supports the advancement of scientific research around the world with our catalog of more than 2000 cell biology research tools. To learn more, visit www.STEMCELL.com.

Studio ER Congressi s.r.l.**Booth: 2443****<http://www.ercongressi.it>***Educational, Other*

Studio E.R. Congressi has a vast experience in the area of medical meetings, especially in the Hematology and Oncology field, organizing national and international congresses. It is also a provider of the national Continuing Education in Medicine program and it is the organizing secretariat of the Italian Society of Hematology. The Italian Society of Hematology has about 1,500 members and its aim is to improve the knowledge of the hematologists organizing and supporting educational activities.

Syndax Pharmaceuticals**Booth: 1819****<https://www.syndax.com/>***Biotechnology, Oncology Pharmaceuticals*

Syndax is determined to realize a future in which people with cancer live longer and better than ever before. Syndax's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, in development for the treatment of patients with MLLr or mNPM1 acute leukemias, and axatilimab, an investigational monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, in development for the treatment of patients with chronic Graft versus Host Disease.

Syneos Health**Booth: 3643****<https://www.syneoshealth.com/therapeutic-expertise/therapeutic-areas/oncology-and-hematology>***Biotechnology, Clinical Research, Contract Research Organization, Immunotherapy, Oncology Pharmaceuticals*

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Syros**Booth: 4112****<https://www.syros.com>***Biotechnology, Oncology Pharmaceuticals*

Syros is a clinical-stage biopharmaceutical company redefining the power of small molecules to control the expression of genes, to provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.

Taiho**Booth: 1423, 1523****<http://www.taihooncology.com>***Pharmaceuticals*

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho Oncology has an oral oncology pipeline consisting of selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It's our work; it's our passion; it's our legacy.

Takeda Hematology**Booth: 1535****<https://www.takeda.com>***Biotechnology, Pharmaceuticals*

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. www.takeda.com

Takeda Oncology**Booth: 1643****<https://takedaoncologyvirtualexperience.com/>***Immunotherapy, Oncology Pharmaceuticals, Pharmaceuticals*

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide. For more information, visit www.takedaoncology.com.

Takeda Pharmaceuticals - LSD Division**Booth: 1329****<http://www.takeda.com>**

Millennium Pharmaceuticals wants to be the drug company for the new millennium. Operating as Millennium: The Takeda Oncology Company, it's a subsidiary of Japan's Takeda Pharmaceutical. The company's cancer drug Velcade is approved as a treatment for multiple myeloma (a blood cancer) and mantle cell lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). Millennium boasts more than a

dozen other drug candidates in the pipeline, most of them cancer-related. Its oncology-focused sales force, in partnership with Johnson & Johnson, markets the drug, with Millennium handling sales in the US and various J&J subsidiaries handling sales in Europe and most other countries where Velcade is approved.

Team Telomere**Booth: 2724****<http://teamtelomere.org>***Genetic Testing, Non Profit, Patient Education Materials, Registry, Research Grants*

Team Telomere is a 501(c)3 registered disease advocacy group that spreads awareness & encouragement to those affected by Dyskeratosis Congenita & Telomere Biology Disorders by providing medical information, advocating on the patient/caregiver's behalf, and focusing on outreach programs to better the lives of those affected by DC/TBD. Team Telomere aims to improve diagnosis by educating providers and influence research by working alongside researchers/scientists.

Telo Genomics**Booth: 3243****<https://www.telodx.com>***Leukemia/Lymphoma Detection*

Telo Genomics pioneers the most comprehensive 3-dimensional telomere analytics platform to assess risk of progression, treatment outcome or active monitoring of multiple myeloma patients and other cancers. TeloView®, the company's ground-breaking single-cell analysis platform, utilizes a proprietary algorithm to quantify genomic disease signals enabling dynamic assessment of genomic changes and empowering precision medicine treatment decisions. TeloView technology is applicable to liquid biopsy.

Tempus**Booth: 2114****<http://www.tempus.com>***Clinical Research, Diagnostic Services/Testing, Genetic Testing, Molecular Biology, Patient Services*

Data-driven precision medicine. Bringing the power of data and artificial intelligence to healthcare.

The MDS Foundation, Inc.**Booth: 2522****<https://www.mds-foundation.org/>***Clinical Research, Non Profit*

The MDS Foundation, Inc. is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases. The Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.

Theradex Oncology
<http://www.theradex.com/>
 Contract Research Organization

Booth: 3913

a specialized MBA degree completed in two years in a hybrid format.

ThermoFisher
<http://www.oncomine.com>
 Genetic Testing, Research Reagents

Booth: 3542

Thermo Fisher Scientific is the world leader in serving science. We offer leading next-generation sequencing (NGS) solutions for the study of myeloid and lymphoid malignancy samples. Our portfolio of assays enable a range of applications, including genomic profiling and clonality detection. Using our latest platform, you can have sequencing results in as fast as 1 day. To learn how you can see us during the meeting visit: www.oncomine.com/ash2022

ThinkCyte, Inc
<https://thinkcyte.com/>

Booth: 1843

Biotechnology, Cell Separators, Flow Cytometry, Immunotherapy, New Exhibitor

ThinkCyte has pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology with partners in major global biopharmaceutical companies and leading academic research institutes. www.thinkcyte.com. Our system provides researchers with a powerful tool to study solid tumor and hematological cancers, isolate live cells with defined phenotypes such as non-exhausted or activated T-cells, and characterize subtle phenotypes that aren't detectable by current approaches.

TwinStrand Biosciences

Booth: 1224

<https://twinstrandbio.com/applications/aml-mrd/>

TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company's highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields on a faster timescale, where actions are most impactful.

United Porphyrias Association
<https://www.porphyrria.org/>

Booth: 2718

University of Colorado Denver
<http://www.ucdenver.edu/education>

Booth: 2721

The Executive MBA in Health Administration program provides healthcare Professionals and leaders the knowledge and tools to manage complex issues within the healthcare industry. Accelerate your career with

Vaniam Group

Booth: 2757

<https://www.vaniamgroup.com>

Biotechnology, Educational, Market Research, Oncology Pharmaceuticals, Pharmaceuticals

A premier network of independent communications agencies, we help biopharma companies realize the full potential of their oncology and hematology discoveries -- through early asset planning, insights gathering, clinical trial optimization, scientific content development, publications, and market access strategies. For more than 15 years, we've studied the evolving treatment landscape, championed meaningful collaboration between the scientific and medical communities, and communicated data with clarity. Ultimately, we hope our work has helped improve patients' lives.

Vertex Pharmaceuticals Inc. Booth: 1854, 2447, Virtual

<https://www.vrtx.com/>

Biotechnology, Bone Marrow Transplantation Research, Pharmaceuticals

Vertex Pharmaceuticals and CRISPR Therapeutics are researching the use of CRISPR/Cas9 gene editing to develop potential new treatments aimed at the underlying genetic causes of human disease, including transfusion-dependent β -thalassemia and severe sickle cell disease.

Viatrix

Booth: 304

<http://www.VIATRIS.com>

Pharmaceuticals

VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatrix brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities.

Waldenstrom's Macroglobulinemia Foundation

Booth: 2621

<https://www.iwmf.com>

Educational, Non Profit, Patient Education Materials, Publisher, Research Grants

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven international nonprofit organization with a simple but compelling vision and mission. OUR VISION: A world without WM (Waldenstrom's macroglobulinemia) OUR MISSION: Support and educate everyone affected by Waldenstrom's macroglobulinemia

(WM) while advancing the search for a cure. The IWWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWWMF has invested over \$21 million in WM research projects throughout the world.

WellSpan Health

Booth: 2719

<http://www.joinwellspan.org/oncology>

New Exhibitor, Non Profit

At WellSpan, the work we do makes a difference because our patients are at the forefront of everything that we do. As part of our cancer program, we have an expanded collaboration with Johns Hopkins Medicine providing access to clinical trials, cancer subspecialists for second opinions, and improved genomics capabilities. Our goal is to provide high-quality, seamless, advanced cancer care for our patients who trust us with their cancer journey.

Wolters Kluwer

Booth: 711

<https://shop.lww.com>

Books/Journals, Publisher

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, and the next generation of healthcare providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effective decision-making and consistent outcomes across the continuum of care. Visit us at booth 711 or online at <https://shop.lww.com>. Save 25% with promo code WNA022AA at checkout. Exclusions apply.

Worldwide Clinical Trials

Booth: 2224

<http://www.worldwide.com>

Biotechnology, Clinical Research, Contract Research Organization, Oncology Pharmaceuticals, Pharmaceuticals

Worldwide Clinical Trials is a global, midsize contract research organization that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries. Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval, and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology, and rare diseases.

X4 Pharmaceuticals

Booth: 2115

<https://www.x4pharma.com/>

Biotechnology, Clinical Research, Genetic Testing, Other

X4 is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4's pipeline is comprised of a first-in-class, oral, small molecule antagonist of chemokine receptor CXCR4, which has the potential to treat a broad range of rare diseases resulting from dysfunction of the CXCR4 receptor pathway, including primary immunodeficiencies, neutropenia, and certain cancers.

X4 Pharmaceuticals (Commercial) Booth: 2321

<http://www.x4pharma.com>

Clinical Research, Genetic Testing

X4 is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4's pipeline is comprised of a first-in-class, oral, small molecule antagonist of chemokine receptor CXCR4, which has the potential to treat a broad range of rare diseases resulting from dysfunction of the CXCR4 receptor pathway, including primary immunodeficiencies, neutropenia, and certain cancers.



blood[®]

Podcast Series



Listen on

Apple Podcasts



LISTEN ON



Listen on

Google Podcasts



Blood[®] Podcast

Weekly highlights of select articles in each issue



SUBSCRIBE TODAY



SAVE THE DATE
December 9-12, 2023
San Diego, CA



65th ASH[®] Annual Meeting and Exposition

ELEVATE YOUR KNOWLEDGE

View head-to-head and ~5-year data*¹
at **Booth #619** during the 2022 ASH
Annual Meeting



See more information
at calquencehcp.com
or scan QR code


CALQUENCE[®]
acalabrutinib 100 mg tablets

**NEW TABLET
FORMULATION**

*At median 58.2-month follow-up (range: 0.0-72.0 months).¹

Reference: 1. Sharman JP, Egyed M, Jurczak W, et al. Poster presented at ASCO Annual Meeting; June 3-7, 2022. Abs 7539.



CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2022 AstraZeneca. All rights reserved. US-69037 9/22